U.S. patent application number 10/884707 was filed with the patent office on 2005-04-28 for dual nk1/nk3 receptor antagonists.
Invention is credited to Hoffmann, Torsten, Koblet, Andreas, Peters, Jens-Uwe, Schnider, Patrick, Sleight, Andrew, Stadler, Heinz.
Application Number | 20050090533 10/884707 |
Document ID | / |
Family ID | 33560750 |
Filed Date | 2005-04-28 |
United States Patent
Application |
20050090533 |
Kind Code |
A1 |
Hoffmann, Torsten ; et
al. |
April 28, 2005 |
Dual NK1/NK3 receptor antagonists
Abstract
The present invention provides a method for the treatment of
schizophrenia which comprises administering a compound of formula 1
wherein the substituents are as described herein or a
pharmaceutically active acid-addition salt thereof. In particular,
the invention provides methods for treating both positive and
negative symptoms of schizophrenia through dual inhibition of NK1
and NK3 receptors. The invention also provides novel compounds with
formula I and methods for preparing compounds of the invention.
Inventors: |
Hoffmann, Torsten; (Weil am
Rhein, DE) ; Koblet, Andreas; (Binningen, CH)
; Peters, Jens-Uwe; (Grenzach-Wyhlen, DE) ;
Schnider, Patrick; (Oberwil, CH) ; Sleight,
Andrew; (Riedisheim, FR) ; Stadler, Heinz;
(Rheinfelden, CH) |
Correspondence
Address: |
HOFFMANN-LA ROCHE INC.
PATENT LAW DEPARTMENT
340 KINGSLAND STREET
NUTLEY
NJ
07110
|
Family ID: |
33560750 |
Appl. No.: |
10/884707 |
Filed: |
July 2, 2004 |
Current U.S.
Class: |
514/352 |
Current CPC
Class: |
A61K 31/46 20130101;
C07D 495/10 20130101; A61K 31/4439 20130101; A61K 31/444 20130101;
A61K 31/547 20130101; C07D 213/75 20130101; A61K 31/4418 20130101;
A61K 31/4995 20130101; A61K 31/496 20130101; C07D 491/10 20130101;
A61P 25/18 20180101; A61K 31/551 20130101; C07D 413/04 20130101;
C07D 419/04 20130101; C07D 513/08 20130101; C07D 451/04 20130101;
C07D 487/08 20130101; C07D 417/04 20130101; A61K 31/5377 20130101;
A61K 31/44 20130101; A61P 25/00 20180101; A61K 31/5386 20130101;
C07D 401/04 20130101; C07D 497/10 20130101; A61K 31/554 20130101;
A61K 31/541 20130101; A61K 31/4427 20130101 |
Class at
Publication: |
514/352 |
International
Class: |
A61K 031/44 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 3, 2003 |
EP |
03014513.0 |
Claims
1. A method of treating schizophrenia comprising administering to
an individual an effective amount of a compound of formula I
475wherein R.sup.1 is aryl, unsubstituted or substituted by one or
more substituents selected from the group consisting of alkyl,
alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl,
and --NR'S(O).sub.2-alkyl, or is heteroaryl, selected from the
group consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl,
each of which is unsubstituted or substituted by alkyl, halogen or
alkoxy; R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3; R.sup.4 and R.sup.5 are each independently hydrogen,
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").su- b.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl, wherein R' and
R" on each carbon atom may be the same or different from each
other, --C.sub.b-alkyl, --C(O)H, --(CH.sub.2).sub.dcycloalkyl,
unsubstituted or substituted by hydroxy, --(CH.sub.2).sub.cNR'R",
--(CH.sub.2).sub.cNR'C(O)-alkyl,
--(CH.sub.2).sub.cNR'S(O).sub.2-alkyl,
--(CH.sub.2).sub.dS(O)-alkyl, --(CH.sub.2).sub.dS-alkyl,
--(CH.sub.2).sub.dS(O).sub.2-alkyl, or
--(CH.sub.2).sub.dS(O).sub.2--NR'- R"; R' is hydrogen, alkyl,
--(CH.sub.2).sub.oOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl, R" is hydrogen or alkyl; or
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.e-, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
--(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.c--, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, halogen, CF.sub.3,
--(CR'R").sub.dOH, .dbd.O, --CHO, and --NR'R", wherein R' and R"
are as described above or may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; or with
--(CH.sub.2).sub.2--S(O).sub.2N(CH.sub.3)--CH.sub.2- , or with
--S(O)--O--(CH.sub.2).sub.2,3--; or --NR.sup.4R.sup.5 is 476a is 0
or 1; b is 1 or 2; c is 1, 2, or 3; d is 0, 1, 2, or 3; e is 3, 4,
or 5; and f is 0, 1, or 2; or a pharmaceutically active
acid-addition salt thereof.
2. The method of claim 1, wherein the compound of formula I is a
compound of formula IA 477wherein R.sup.1 is phenyl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl, and --NR'S(O).sub.2-alkyl; R.sup.2 and
R.sup.3 are each independently hydrogen, halogen, alkyl, alkoxy,
OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3; R.sup.4 and R.sup.5
are each independently hydrogen,
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH, or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl, wherein R' and
R" on each carbon atom may be the same or different from each other
and are hydrogen, or C.sub.b-alkyl; R' is hydrogen, alkyl,
--(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl, R" is hydrogen or alkyl; a
is 0 or 1; b is 1 or 2; and d is 0, 1, 2 or 3; or a
pharmaceutically acceptable acid addition salt thereof.
3. The method of claim 1, wherein the compound of formula I is a
compound of formula IB 478wherein R.sup.1 is phenyl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl, and --NR'S(O).sub.2-alkyl; R.sup.2 and
R.sup.3 are each independently hydrogen, halogen, alkyl, alkoxy,
OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3; R.sup.4 and R.sup.5
are each independently hydrogen, --(CH.sub.2).sub.2SCH.sub.3,
--(CH.sub.2).sub.2S(O).sub.2CH.sub.3,
--(CH.sub.2).sub.2S(O).sub.2NHCH.sub.3, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.2NHS(O).sub.2CH.sub.3, or
--(CH.sub.2).sub.2NHC(O)CH.sub- .3; R' is hydrogen, alkyl,
--(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl; R" is hydrogen or alkyl; b
is 1 or 2; and d is 0, 1, 2, or 3; or a pharmaceutically active
acid-addition salt thereof.
4. The method of claim 1, wherein the compound of formula I is a
compound of formula IC 479wherein R.sup.1 is phenyl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl and --NR'S(O).sub.2-alkyl; R.sup.2 and
R.sup.3 are each independently hydrogen, halogen, alkyl, alkoxy,
OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3; R.sup.4 is hydrogen;
R.sup.5 is --(CH.sub.2).sub.0-cycloalkyl, unsubstituted or
substituted by hydroxy; R' is hydrogen, alkyl,
--(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl; R" is hydrogen or alkyl; b
is 1 or 2; and d is 0, 1, 2, or 3; or a pharmaceutically active
acid-addition salt thereof.
5. The method of claim 1, wherein the compound of formula I is a
compound of formula ID 480wherein R.sup.1 is phenyl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl and --NR'S(O).sub.2-alkyl; R.sup.2 and
R.sup.3 are each independently hydrogen, halogen, alkyl, alkoxy,
OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3; R.sup.4 and R.sup.5
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e-, which is unsubstituted or substituted by
one or more substituents selected from the group consisting of
--(CR'R").sub.dOH; R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH,
--C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl; R" is hydrogen or alkyl; b is 1 or 2; d
is 0, 1, 2, or 3; and e is 3, 4, or 5; or a pharmaceutically active
acid-addition salt thereof.
6. The method of claim 1, wherein the compound of formula I is a
compound of formula IE 481wherein R.sup.1 is phenyl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl and --NR'S(O).sub.2-alkyl; R.sup.2 and
R.sup.3 are each independently hydrogen, halogen, alkyl, alkoxy,
OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3; R.sup.4 and R.sup.5
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of lower alkyl, halogen,
--(CR'R").sub.dOH, .dbd.O, and --NR'R", wherein R' and R" may form
together with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; R' is hydrogen,
alkyl, --(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl,
--C(O)-cycloalkyl, --S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl,
--S(O)-alkyl, --S-alkyl or --S(O).sub.2--N-di-alkyl; R" is hydrogen
or alkyl; b is 1 or 2; c is 1, 2, or 3; d is 0, 1, 2, or 3; and e
is 3, 4, or 5; or a pharmaceutically active acid-addition salt
thereof.
7. The method of claim 1, wherein the compound of formula I is a
compound of formula IF 482wherein R.sup.1 is phenyl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl, and --NR'S(O).sub.2-alkyl, or is
heteroaryl selected from the group consisting of pyridin-2-or 3-yl,
imidazolyl and oxazolyl, each of which is unsubstituted or
substituted by alkyl, halogen or alkoxy; R.sup.2 and R.sup.3 are
each independently hydrogen, halogen, alkyl, alkoxy, OCHF.sub.2,
OCH.sub.2F, OCF.sub.3 or CF.sub.3; and R.sup.4 and R.sup.5 form
together with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; R' is hydrogen,
alkyl, --(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl,
--C(O)-cycloalkyl, --S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl,
--S(O)-alkyl, --S-alkyl or --S(O).sub.2--N-di-alkyl; R" is hydrogen
or alkyl; b is 1 or 2; c is 1, 2, or 3; d is 0, 1, 2, or 3; and e
is 3, 4, or 5; or a pharmaceutically active acid-addition salt
thereof.
8. The method of claim 1, wherein the compound of formula I is a
compound of formula IG 483wherein R.sup.1 is phenyl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl and --NR'S(O).sub.2-alkyl; R.sup.2 and
R.sup.3 are each independently hydrogen, halogen, alkyl, alkoxy,
OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3; R.sup.4 and R.sup.5
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.- 2--, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of lower alkyl, halogen,
--(CR'R").sub.dOH, .dbd.O, and --NR'R", wherein R' and R" may form
together with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.d, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; R' is hydrogen,
alkyl, --(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl,
--C(O)-cycloalkyl, --S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl,
--S(O)-alkyl, --S-alkyl or --S(O).sub.2--N-di-alkyl; R" is hydrogen
or alkyl; b is 1 or 2; c is 1, 2, or 3; d is 0, 1, 2, 3 or 4; e is
3, 4, or 5; and f is 0, 1, or 2; or a pharmaceutically active
acid-addition salt thereof.
9. The method of claim 1, wherein the compound of formula I is a
compound of formula IH 484wherein R.sup.1 is heteroaryl selected
from the group consisting of pyridin-2-or 3-yl, imidazolyl and
oxazolyl, each of which is unsubstituted or substituted by alkyl,
halogen or alkoxy; R.sup.2 and R.sup.3 are each independently
hydrogen, halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3
or CF.sub.3; R.sup.4 and R.sup.5 are each independently hydrogen,
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").su- b.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-- alkyl, wherein R'
and R" on each carbon atom may be the same or different from each
other, --C.sub.b-alkyl, --C(O)H, --(CH.sub.2).sub.dcycloalkyl,
unsubstituted or substituted by hydroxy, --(CH.sub.2).sub.cNR'R",
--(CH.sub.2).sub.cNR'C(O)-alkyl,
--(CH.sub.2).sub.cNR'S(O).sub.2-alkyl,
--(CH.sub.2).sub.dS(O)-alkyl, --(CH.sub.2).sub.dS-alkyl,
--(CH.sub.2).sub.dS(O).sub.2-alkyl, or
--(CH.sub.2).sub.dS(O).sub.2--NR'- R"; R' is hydrogen, alkyl,
--(CH.sub.2).sub.oOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl, R" is hydrogen or alkyl; or
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.c--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
--(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.c--, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, halogen, CF.sub.3,
--(CR'R").sub.dOH, .dbd.O, --CHO, and --NR'R", wherein R' and R"
are as described above or may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; or with
--(CH.sub.2).sub.2--S(O).sub.2N(CH.sub.3)--CH.sub.2- , or with
--S(O)--O--(CH.sub.2).sub.2,3--; or --NR.sup.4R.sup.5 is 485a is 0
or 1; b is 1 or 2; c is 1, 2, or 3; d iso, 1, 2, or 3; e is 3, 4,
or 5; and f is 0, 1, or 2; or a pharmaceutically active
acid-addition salt thereof.
10. The method of claim 1, wherein the compound of formula I is a
compound of formula I J, 486wherein R.sup.1 is aryl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl, and --NR'S(O).sub.2-alkyl, or is
heteroaryl, selected from the group, consisting of pyridin-2-or
3-yl, imidazolyl and oxazolyl, each of which is unsubstituted or
substituted by alkyl, halogen or alkoxy; R.sup.2 and R.sup.3 are
each independently hydrogen, halogen, alkyl, alkoxy, OCHF.sub.2,
OCH.sub.2F, OCF.sub.3 or CF.sub.3; --NR.sup.4R.sup.5 are 487R' is
hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl,
--C(O)-cycloalkyl, --S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl,
--S(O)-alkyl, --S-alkyl or --S(O).sub.2--N-di-alkyl, R" is hydrogen
or alkyl; b is 1 or 2; d is 0, 1, 2, or 3; and f is 0, 1, or 2; or
a pharmaceutically active acid-addition salt thereof.
11. The method of claim 1, wherein the compound of formula I is a
compound of formula I-1 488wherein R.sup.1 is aryl, unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, alkoxy, halogen, --(CH.sub.2).sub.dOH,
--C(O)H, CF.sub.3, CN, S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R",
--NR'R", --NR'C(O)-alkyl, and --NR'S(O).sub.2-alkyl, or is
heteroaryl, selected from the groups consisting of pyridin-2-or
3-yl, imidazolyl or oxazolyl, each of which is unsubstituted or
substituted by alkyl, halogen or alkoxy; R.sup.2 and R.sup.3 are
each independently hydrogen, halogen, lower alkyl, lower alkoxy,
OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3; R.sup.4 and R.sup.5
are each independently hydrogen, --(CR'R").sub.l--(C+R'R").sub.-
l--(CR'R").sub.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-lowe- r alkyl,
wherein R' and R" on each carbon atom may be the same or different
from each other, --C.sub.b-alkyl, --C(O)H,
--(CH.sub.2).sub.dcycloalkyl, unsubstituted or substituted by
hydroxy, --(CH.sub.2).sub.cNR'C(O)-lower alkyl,
--(CH.sub.2).sub.cNR'S(O).sub.2-l- ower alkyl, or
--(CH.sub.2).sub.dS(O).sub.2-lower alkyl; R' is hydrogen, lower
alkyl, --(CH.sub.2).sub.oOH, --C(O)H, --C(O)-lower alkyl,
--C(O)-cycloalkyl, --S(O).sub.2-lower alkyl; R" is hydrogen or
lower alkyl; or R.sup.4 and R.sup.5 form together with the N-atom
to which they are attached a ring with --(CH.sub.2).sub.e-, which
is unsubstituted or substituted by one or more substituents
selected from the group consisting of lower alkyl, halogen,
CF.sub.3, --(CR'R").sub.dOH, .dbd.O, and --NR'R", wherein R' and R"
may form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-lower
alkyl, --(CH.sub.2).sub.d--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidin- yl, or --C(O)NR'R", or with
--(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" may form together with the
N-atom to which they are attached a ring with --(CH.sub.2).sub.e,
or by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl- ,
--(CH.sub.2).sub.dOC(O)NR'R", --(CH.sub.2).sub.d--S(O).sub.2-lower
alkyl, --(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-loewr alkyl,
--(CH.sub.2).sub.d-pyrrolidin- yl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub- .c-, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of lower alkyl, halogen,
--(CR'R").sub.dOH, .dbd.O, and --NR'R", wherein R' and R" may form
together with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl- ,
--(CH.sub.2).sub.dOC(O)NR'R", --(CH.sub.2).sub.d--S(O).sub.2-lower
alkyl, --(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl- ,
--(CH.sub.2).sub.dOC(O)NR'R", --(CH.sub.2).sub.d--S(O).sub.2-lower
alkyl, --(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; a is 0 or 1;
b is 1 or 2; c is 1, 2, or 3; d is 0, 1, 2, or 3; e is 3, 4, or 5;
and f is 0, 1, or 2; or a pharmaceutically active acid-addition
salt thereof.
12. A compound selected from the group consisting of
N-[6-(2-acetylamino-ethylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5--
bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,5-dich-
loro-phenyl)-N-methyl-isobutyramide,
2-(3,5-dichloro-phenyl)-N-[4-(4-fluor-
o-2-methyl-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hy-
droxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[ethyl-(2-hyd-
roxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-e-
thyl)-propyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifuoromethyl-phenyl)-N-[6-[butyl-(2-hydroxy-ethyl)-amino]-4--
(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2,3-di-
hydroxy-propyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(1-hydrox-
ymethyl-3-methyl-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy--
ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(2-hydroxy-ethylamino)-pyridi-
n-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
,4-dichloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobut-
yramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-
-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydrox-
y-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydrox-
y-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydro-
xy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-2--
methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-bu-
tylamino)-pyrin-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dih-
ydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydrox-
y-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydrox-
y-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1--
hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-
,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-{6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-bis-tri-
fluoromethyl-phenyl)-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-a-
mino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethy-
l-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]--
pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-
-(2,4-dichloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N--
methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3,4-dichloro-p-
henyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyra-
mide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-
-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-[(2-hydroxy-e-
thyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-amino]-4-
-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxyethyl)-amino]-4--
o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-[(2-hydroxy-ethyl)-propyl-amino]-4-o-tolyl-pyridin-3-yl]-N-met-
hyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy--
propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-propyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-bis-tr-
ifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-meth-
yl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydro-
xy-propylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-propyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(-
3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihy-
droxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihy-
droxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl]-2-(3,5-bi-
s-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
N-[6-[bis-(2-hydroxy-eth-
yl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoro-
methyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-
-isobutyramide,
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyri-
din-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifuoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxy-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-1-hydroxymethyl-ethyla-
mino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxy-1'-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1R,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1S,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[hexyl-(2-hyd-
roxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-e-
thyl)-pentyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hydroxy-e-
thyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-t-
olyl-pyridin-3-yl]-N-methyl-isobutyramide, and
2-(3,5-bis-trifluoromethyl--
phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[(2-hydroxy-1-hydroxymethyl-ethy-
l)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide.
13. A composition comprising a compound of claim 12 and a
pharmaceutically acceptable carrier.
14. A compound of formula IB 489wherein R.sup.1 is phenyl,
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, alkoxy, halogen,
--(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN, S-alkyl,
--S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl, and
--NR'S(O).sub.2-alkyl; R and R.sup.3 are each independently
hydrogen, halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3
or CF.sub.3; R.sup.4 and R.sup.5 are each independently hydrogen,
--(CH.sub.2).sub.2SCH.sub.3, --(CH.sub.2).sub.2S(O).sub.2CH.sub-
.3, --(CH.sub.2).sub.2S(O).sub.2NHCH.sub.3,
--(CH.sub.2).sub.2NH.sub.2, --(CH.sub.2).sub.2NHS(O).sub.2CH.sub.3
or --(CH.sub.2).sub.2NHC(O)CH.sub.- 3; R' is hydrogen, alkyl,
--(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl; R" is hydrogen or alkyl; b
is 1 or 2; and d is 0, 1, 2, or 3; or a pharmaceutically active
acid-addition salt thereof.
15. A composition comprising a compound of claim 14 and a
pharmaceutically acceptable carrier.
16. A compound selected from the group consisting of
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydr-
oxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4--
hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydro-
xy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1RS,2RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide, and
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
17. A composition comprising a compound of claim 16 and a
pharmaceutically acceptable carrier.
18. A compound selected from the group consisting of
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3--
yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1--
yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3--
yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1--
yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyra-
mide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolid-
in-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrol
idin-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1--
yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-to-
lyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dichloro-phenyl)--
N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-
-methyl-isobutyramide,
(S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyrami-
de,
(2R,4S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-to-
lyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-difluoro-phenyl)--
N-[6-(4-hydroxy-2-hydroxymethyl-pyrrol
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-- N-methyl-isobutyramide,
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(2-hydroxym-
ethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-to-
lyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dimethyl-phenyl)--
N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-
-methyl-isobutyramide,
(S)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-
-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobut-
yramide,
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymet-
hyl-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-
-methyl-isobutyramide,
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymet-
hyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-i-
sobutyramide,
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phen-
yl)-isobutyramide,
(S)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
(2S,4R)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4--
hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
(S)-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydr-
oxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hyd-
roxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide,
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrr-
olidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxyme-
thyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl--
isobutyramide,
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl-
)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-
-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-
2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydrox-
y-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydrox-
y-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4--
dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4--
dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hy-
droxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4--
hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, and
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-ph-
enyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
19. A composition comprising a compound of claim 18 and a
pharmaceutically acceptable carrier.
20. A compound selected from the group consisting of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide-
,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(3-hy-
droxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phe-
nyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl--
isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichlo-
ro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-ch-
loro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-
-methyl-isobutyramide,
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2--
chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(-
2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)--
pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3R)-2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrol-
idin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-triflu-
oromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxyme-
thyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6--
[2-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isob-
utyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phe-
nyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl-
)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide-
,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin--
1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydro-
xymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4--
dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-
-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin-
-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-
-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobuty-
ramide,
(2S,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-
-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl--
isobutyramide,
(2R,5R)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-f-
luoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N--
methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-h-
ydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-i-
sobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-
-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyram-
ide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-dimethylamino--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-bromo-
-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-met-
hyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chlo-
ro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fl-
uoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-
-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,-
5-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-
-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N--
[4-(3,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4-(3-fluoro-4-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidi-
n-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoro-
methyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-4-fluoro-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
(2S,4R)-N-[4-(2-amino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2--
hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-hydroxy-phenyl)-pyridin-3-yl]-N-met-
hyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isob-
utyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hy-
droxymethyl-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hy-
droxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methanesulfonyl-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-[5-{[2-(3,5-bis-trifluoromethyl--
phenyl)-2-methyl-propionyl]-methyl-amino}-2-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-pyridin-4-yl]-benzamide,
(2S,4R)-2-(3,5-bis-trifluoromethyl--
phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-
-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluorom-
ethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hy-
droxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrol
idin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifl-
uoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-ph-
enyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro--
2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
-(3-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)--
pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin--
1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluorome-
thyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl--
pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-m-
ethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]--
N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-
-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide, and
(2S,4S)-2-(3,5-bis-trifluoromethyl--
phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
21. A composition comprising a compound of claim 20 and a
pharmaceutically acceptable carrier.
22. A compound selected from the group consisting of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(4-hy-
droxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymet-
hyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-
-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-cyano--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-
-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-met-
hyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobu-
tyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-meth-
yl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fl-
uoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridi-
n-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[4-(5-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-
-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluorom-
ethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrr-
olidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trif-
luoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrol
idin-1-yl)-pyridin-3-yl]-- N-methyl-isobutyramide,
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-met-
hyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N--
methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-f-
luoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]--
N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl--
isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-p-
henyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobut-
yramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phe-
nyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrol
idin-1-yl)-pyridin-3-yl]-N-methyl- -isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
(2R,3S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(2,5-di-
chloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(-
2,3-dichloro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)--
N-[4-(2-chloro-4-fluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1--
yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-py-
rrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl-
-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-met-
hyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluo-
ro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin--
3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[4-(5-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-N-methyl-isobutyramide,
(2R,3S)-2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[4-(2,5-difluoro-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolid-
in-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-
-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-
-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(2-hydrox-
ymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(2-hydrox-
ymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(2-hydrox-
ymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-
-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
(3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-pheny-
l)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide,
(3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-p-
henyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-meth-
yl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-met-
hyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-f-
luoro-2-methyl-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-
-methyl-isobutyramide,
(S)-2-(3,5-dimethoxy-phenyl)-N-[6-(2-hydroxymethyl--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolid-
in-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-
methyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide-
,
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hy-
droxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
(2S,4R)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-t-
olyl-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
and
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl--
pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isob-
utyramide.
23. A composition comprising a compound of claim 22 and a
pharmaceutically acceptable carrier.
24. A compound selected from the group consisting of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro--
phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide,
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(RS)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(2-chloro-phenyl)-py-
ridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-2-pyrro-
lidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-dimeth-
ylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-metha-
nesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-p-
henyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyra-
mide,
(R)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-meth-
yl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobu-
tyramide,
(S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)--
pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl-
)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-met-
hyl-isobutyramide,
(S)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl--
methanesulfonyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyrid-
in-3-yl]-N-methyl-isobutyramide,
(S)-N-[6-[3-(acetyl-methyl-amino)-pyrroli-
din-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluorom-
ethyl-phenyl)-N-methyl-isobutyramide,
(S)-N-[6-[3-(acetyl-ethyl-amino)-pyr-
rolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-triflu-
oromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-pheny-
l)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-bro-
mo-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobu-
tyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-o-
xo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymet-
hyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isob-
utyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide-
,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hy-
droxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramid-
e,
(S)-N-[6-[2-(acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl--
phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide, (S)-dimethyl-carbamic acid
1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl-
)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-
-yl]-pyrrolidin-2-ylmethyl ester,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)--
N-[4'-(2-chloro-phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl--
5'-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-
-chloro-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-
-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro--
phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-m-
ethyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chlo-
ro-phenyl)-2-(2-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'--
yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
N-[4-amino-4'-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridiny-
l-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methanesulfo-
nylamino-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyra-
mide,
N-[4-acetylamino-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-
-[1,2']bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isob-
utyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-
-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide, and
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-p-
henyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-me-
thyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-
-phenyl)-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N--
methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2--
methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-azetidin-1-yl)-4-
-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl--
phenyl)-N-(4-hydroxymethyl-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridi-
nyl-5'-yl)-N-methyl-isobutyramide,
(3R,5R)-2-(3,5-bis-trifluoromethyl-phen-
yl)-N-(3,5-dihydroxy-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-
-yl)-N-methyl-isobutyramide,
(3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N--
[4'-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridiny-
l-5'-yl]-N-methyl-isobutyramide,
(3S,5R)-5-bis-trifluoromethyl-phenyl)-N-[-
4'-(2-chloro-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-
-5'-yl]-N-methyl-isobutyramide,
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-pheny-
l)-N-(3,4-dihydroxy-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'--
yl)-N-methyl-isobutyramide,
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-(3,4-dihydroxy-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)--
N-methyl-isobutyramide,
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-
-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5-
'-yl]-N-methyl-isobutyramide,
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[4'-(2-chloro-phenyl)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyrid-
inyl-5'-yl]-N-methyl-isobutyramide,
(2RS,4SR)-2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[4'-(2-chloro-phenyl)-4-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydr-
o-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide,
(2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-2-hydroxymethyl-
-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobut-
yramide,
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydro-
xymethyl-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methy-
l-isobutyramide,
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-
-3-hydroxymethyl-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-
-N-methyl-isobutyramide,
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
'-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']-
bipyridinyl-5'-yl]-N-methyl-isobutyramide,
(3RS,4RS)-2-(3,5-bis-trifluorom-
ethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hydroxy-3-hydroxymethyl-3,4,5,6-te-
trahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide and
(2RS,3RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3-hy-
droxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-met-
hyl-isobutyramide.
25. A composition comprising a compound of claim 24 and a
pharmaceutically acceptable carrier.
26. A compound selected from the group consisting of
N-[6-(4-acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-b-
is-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cyclopropanecarbonyl-piperazin-1-y-
l)-pyridin-3-yl]-N-methyl-isobutyramide,
N-[6-(4-acetyl-[1,4]diazepan-1-yl-
)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-m-
ethyl-phenyl)-6-(5-oxo-[1,4]diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(3-methanesulfonyl-imidazolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
N-[6-(3-acetyl-imidazolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-
-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl-
)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
-(3-chloro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-
-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fl-
uoro-2-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-
-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-
-methyl-phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethanesulfonyl-
-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-chloromethanesulfonyl-
-piperazin-1-y)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-dimethylsulfamoyl-pipe-
razin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-met-
hyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-p-
henyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesul-
fonyl-2-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyram-
ide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(-4-methanesulfonyl-
-3-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
(2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
(2S,6R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(-
4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2,6-dimethyl-piperazin-1-yl-
)-pyridin-3-yl]-N-methyl-isobutyramide,
(3S,5R)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,5-dimethyl-
-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl--
isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-met-
hyl-phenyl)-6-(4-formyl-2-hydroxymethyl-piperazin-1-yl)-pyridin-3-yl]-N-me-
thyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-cyclopr-
opanecarbonyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-
-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-N-[6-(4-acetyl-2-hydroxymethyl--
piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trif-
luoromethyl-phenyl)-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[6-(4-ethyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methy-
l-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
(S)-2-(3,5-bis-trifluorome-
thyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanes-
ulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-4-methanesul-
fonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl--
isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N--
methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesu-
lfonyl-3,3-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobu-
tyramide,
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phe-
nyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-
-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanes-
ulfonyl-2,2-dimethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isob-
utyramide,
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-pip-
erazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-difluorometho-
xy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-piperazin-1-yl-pyridin-3-yl]--
N-methyl-isobutyramide,
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro--
phenyl)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tol-
yl-pyridin-3-yl)-isobutyramide, and
2-(3,5-bis-difluoromethoxy-phenyl)-N-[-
6-(4-methanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isob-
utyramide.
27. A composition comprising a compound of claim 26 and a
pharmaceutically acceptable carrier.
28. A compound selected from the group consisting of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morpholin-4-
-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-morpholin-4-
-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
morpholin-4-yl-pyridin-3-yl]-N-methyl-isobutyramide.
29. A composition comprising a compound of claim 28 and a
pharmaceutically acceptable carrier.
30. A compound selected from the group consisting of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-pyridin-3--
yl]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(-
3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-py-
ridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[-
4-(4-fluoro-2-methyl-phenyl)-6-thiazolidin-3-yl-pyridin-3-yl]-N-methyl-iso-
butyramide, (1RS,4RS)- or
(1RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[-
4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thia-
zolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide, (1RS,4SR)- or
(1RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolidin-3-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-
-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thia-
zolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
(+)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-l.-
quadrature..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-iso-
butyramide,
(-)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1-
,1-dioxo-l.quadrature..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-
-methyl-isobutyramide,
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-flu-
oro-2-methyl-phenyl)-6-(1-oxo-l.lambda..sup.4-[1,4]thiazepan-4-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,-
1-dioxo-l.lambda..sup.6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)--
pyridin-3-yl]-N-methyl-isobutyramide,
2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-(1,1-dioxo-l.lambda..sup.6-[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-p-
henyl)-pyridin-3-yl]-N-methyl-isobutyramide, and
(S)-2-(3,5-bis-trifluorom-
ethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-2,5-dihyd-
ro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
31. A composition comprising a compound of claim 30 and a
pharmaceutically acceptable carrier.
32. A compound of formula IH 490wherein R.sup.1 is heteroaryl
selected from the group consisting of pyridin-2-or 3-yl, imidazolyl
and oxazolyl, each of which is unsubstituted or substituted by
alkyl, halogen or alkoxy; R.sup.2 and R.sup.3 are each
independently hydrogen, halogen, alkyl, alkoxy, OCHF.sub.2,
OCH.sub.2F, OCF.sub.3 or CF.sub.3; R.sup.4 and R.sup.5 are each
independently hydrogen, --(CR'R").sub.l--(CR'R").sub.l-
--(CR'R").sub.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl- , wherein R'
and R" on each carbon atom may be the same or different from each
other, --C.sub.b-alkyl, --C(O)H, --(CH.sub.2).sub.dcycloalkyl,
unsubstituted or substituted by hydroxy, --(CH.sub.2).sub.cNR'R",
--(CH.sub.2).sub.cNR'C(O)-alkyl,
--(CH.sub.2).sub.cNR'S(O).sub.2-alkyl,
--(CH.sub.2).sub.dS(O)-alkyl, --(CH.sub.2).sub.dS-alkyl,
--(CH.sub.2).sub.dS(O).sub.2-alkyl;
--(CH.sub.2).sub.dS(O).sub.2--NR'R"R- ' is hydrogen, alkyl,
--(CH.sub.2).sub.cOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl, R" is hydrogen or alkyl; or
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.c--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
--(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.c--, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, halogen, CF.sub.3,
--(CR'R").sub.dOH, .dbd.O, --CHO, and --NR'R", wherein R' and R"
are as described above or may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; or with
--(CH.sub.2).sub.2--S(O).sub.2N(CH.sub.3)--CH.sub.2- , or with
--S(O)--O--(CH.sub.2).sub.2,3--; or --NR.sup.4R.sup.5 is 491a is 0
or 1; b is 1 or 2; c is 1, 2, or 3; d is 0, 1, 2, or 3; e is 3, 4,
or 5; f is 0, 1, or 2; or a pharmaceutically active acid-addition
salt thereof.
33. A composition comprising a compound of claim 32 and a
pharmaceutically acceptable carrier.
34. A compound of formula IJ, 492wherein R.sup.1 is aryl,
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, alkoxy, halogen,
--(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN, S-alkyl,
--S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl, and
--NR'S(O).sub.2-alkyl, or is heteroaryl, selected from the group,
consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of
which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R.sup.2 and R.sup.3 are each independently hydrogen, halogen,
alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3;
--NR.sup.4R.sup.5 are 493R' is hydrogen, alkyl,
--(CH.sub.2).sub.dOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl, R" is hydrogen or alkyl; b
is 1 or 2; d is 0, 1, 2, or 3; and f is 0, 1, or 2; or a
pharmaceutically active acid-addition salt thereof.
35. A composition comprising a compound of claim 34 and a
pharmaceutically acceptable carrier.
36. A process for preparing a compound of formula I 494wherein
R.sup.1 is aryl, unsubstituted or substituted by one or more
substituents selected from the group consisting of alkyl, alkoxy,
halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN, S-alkyl,
--S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl, and
--NR'S(O).sub.2-alkyl, or is heteroaryl, selected from the group
consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of
which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R.sup.2 and R.sup.3 are each independently hydrogen, halogen,
alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3;
R.sup.4 and R.sup.5 are each independently hydrogen,
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").su- b.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl, wherein R' and
R" on each carbon atom may be the same or different from each
other, --C.sub.b-alkyl, --C(O)H, --(CH.sub.2).sub.dcycloalkyl,
unsubstituted or substituted by hydroxy, --(CH.sub.2).sub.cNR'R",
--(CH.sub.2).sub.cNR'C(O)-alkyl,
--(CH.sub.2).sub.cNR'S(O).sub.2-alkyl,
--(CH.sub.2).sub.dS(O)-alkyl, --(CH.sub.2).sub.dS-alkyl,
--(CH.sub.2).sub.dS(O).sub.2-alkyl, or
--(CH.sub.2).sub.dS(O).sub.2--NR'- R"; R' is hydrogen, alkyl,
--(CH.sub.2).sub.cOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N-di-alkyl, R" is hydrogen or alkyl; or
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.e-, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
--(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.c-, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, halogen, CF.sub.3,
--(CR'R").sub.dOH, .dbd.O, --CHO, and --NR'R", wherein R' and R"
are as described above or may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; or with
--(CH.sub.2).sub.2--S(O).sub.2N(CH.sub.3)--CH.sub.2- , or with
--S(O)--O--(CH.sub.2).sub.2,3--; or --NR.sup.4R.sup.5 is 495a is 0
or 1; b is 1 or 2; c is 1, 2, or 3; d is 0, 1, 2, or 3; e is 3, 4,
or 5; and f is 0, 1, or 2; which process comprises reacting a
compound of formula 496 with a compound of formula NHR.sup.4R.sup.5
III to produce a compound of formula 497 wherein R.sup.1, R.sup.2,
R.sup.3, R.sup.4 and R.sup.5 are as defined above.
37. A process for preparing a compound of formula I 498wherein
R.sup.1 is aryl, unsubstituted or substituted by one or more
substituents selected from the group consisting of alkyl, alkoxy,
halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN, S-alkyl,
--S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl, and
--NR'S(O).sub.2-alkyl, or is heteroaryl, selected from the group
consisting of pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of
which is unsubstituted or substituted by alkyl, halogen or alkoxy;
R.sup.2 and R.sup.3 are each independently hydrogen, halogen,
alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or CF.sub.3;
R.sup.4 and R.sup.5 are each independently hydrogen,
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").su- b.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl, wherein R' and
R" on each carbon atom may be the same or different from each
other, C.sub.b-alkyl, --C(O)H, --(CH.sub.2).sub.dcycloalkyl,
unsubstituted or substituted by hydroxy, --(CH.sub.2).sub.cNR'R",
--(CH.sub.2).sub.cNR'C(O)-alkyl,
--(CH.sub.2).sub.cNR'S(O).sub.2-alkyl,
--(CH.sub.2).sub.dS(O)-alkyl, --(CH.sub.2).sub.dS-alkyl,
--(CH.sub.2).sub.dS(O).sub.2-alkyl; or
--(CH.sub.2).sub.dS(O).sub.2--NR'- R"; R' is hydrogen, alkyl,
--(CH.sub.2).sub.oOH, --C(O)H, --C(O)-alkyl, --C(O)-cycloalkyl,
--S(O).sub.2-alkyl, --S(O).sub.2-halogen-alkyl, --S(O)-alkyl,
--S-alkyl or --S(O).sub.2--N'-di-alkyl, R" is hydrogen or alkyl; or
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.e-, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
--(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.c-, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, halogen, CF.sub.3,
--(CR'R").sub.dOH, .dbd.O, --CHO, and --NR'R", wherein R' and R"
are as described above or may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O- )-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-cycloalk-
yl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
--CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; or with
--(CH.sub.2).sub.2--S(O).sub.2N(CH.sub.3)--CH.sub.2- , or with
--S(O)--O--(CH.sub.2).sub.2,3--; or --NR.sup.4R.sup.5 is 499a is 0
or 1; b is 1 or 2; c is 1, 2, or 3; d is 0, 1, 2, or 3; e is 3, 4,
or 5; and f is 0, 1, or 2; which process comprises reacting a
compound of formula 500 with a compound of formula
R.sup.1--B(OH).sub.2 or a compound of formula 501 or a compound of
formula R.sup.1--ZnCl to produce a compound of formula 502 wherein
R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined
above.
Description
BACKGROUND OF THE INVENTION
[0001] Schizophrenia is one of the major neuropsychiatric
disorders, characterized by severe and chronic mental impairment.
This devastating disease affects about 1% of the world's
population. Symptoms begin in early adulthood and are followed by a
period of interpersonal and social dysfunction. Schizophrenia
manifests as auditory and visual hallucinations, paranoia,
delusions (positive symptoms), blunted affect, depression,
anhedonia, poverty of speech, memory and attention deficits as well
as social withdrawal (negative symptoms).
[0002] For decades scientists and clinicians have made efforts with
the aim of discovering an ideal agent for the pharmacological
treatment of schizophrenia. However, the complexity of the
disorders, due to a wide array of symptoms, has hampered those
efforts. There are no specific focal characteristics for the
diagnosis of schizophrenia and no single symptom is consistently
present in all patients. Consequently, the diagnosis of
schizophrenia as a single disorder or as a variety of different
disorders has been discussed but not yet resolved. The major
difficulty in the development of a new drug for schizophrenia is
the lack of knowledge about the cause and nature of this disease.
Some neurochemical hypotheses have been proposed on the basis of
pharmacological studies to rationalize the development of a
corresponding therapy: the dopamine, the serotonin and the
glutamate hypotheses. But taking into account the complexity of
schizophrenia, an appropriate multireceptor affinity profile might
be required for efficacy against positive and negative signs and
symptoms. Furthermore, an ideal drug against schizophrenia would
preferably have a low dosage allowing once-per-day dosage, due to
the low adherence of schizophrenic patients.
[0003] In recent years clinical studies with selective NK1 and NK2
receptor antagonists appeared in the literature showing results for
the treatment of emesis, depression, anxiety, pain and migraine
(NK1) and asthma (NK2 and NK1). The most exciting data were
produced in the treatment of chemotherapy-induced emesis, nausea
and depression with NK1 and in asthma with NK2-receptor
antagonists. In contrast, no clinical data on NK3 receptor
antagonists have appeared in the literature until 2000. Osanetant
(SR 142,801) from Sanofi-Synthelabo was the first identified potent
and selective non-peptide antagonist described for the NK3
tachykinin receptor for the potential treatment of schizophrenia,
which was reported in the literature (Current Opinion in
Investigational Drugs, 2001, 2(7), 950-956 and Psychiatric
Disorders Study 4, Schizophrenia, June 2003, Decision Resources,
Inc., Waltham, Mass.). The proposed drug SR 142,801 has been shown
in a phase II trial as active on positive symptoms of
schizophrenia, such as altered behavior, delusion, hallucinations,
extreme emotions, excited motor activity and incoherent speech, but
inactive in the treatment of negative symptoms, which are
depression, anhedonia, social isolation or memory and attention
deficits.
[0004] The neurokinin-3 receptor antagonists have been described as
useful in pain or inflammation, as well as in schizophrenia, Exp.
Opinion. Ther. Patents (2000), 10(6), 939-960 and Current Opinion
in Investigational Drugs, 2001, 2(7), 950-956 956 and Psychiatric
Disorders Study 4, Schizophrenia, June 2003, Decision Resources,
Inc., Waltham, Mass.).
[0005] In addition, EP 1 192 952 describes a pharmaceutical
composition containing a combination of a NK3 receptor antagonist
and a CNS penetrant NK1 receptor antagonist for the treatment of
depression and anxiety.
[0006] Now it has been found that the combination of the
antidepressant, mood enhancing properties of NK1 receptor
antagonism and the antipsychotic symptoms of NK3 receptor
antagonism are suitable to treat both positive and negative
symptoms in schizophrenia.
[0007] This advantage may be realized in the administration of an
ideal drug against schizophrenia.
[0008] Some of the compounds of formula I are described in EP
1035115, WO 02/08232 or WO 02/16324.
[0009] They have been described as active at the NK1 receptor for
the treatment of diseases related to this receptor, such as
inflammatory conditions including migraine, rheumatoid arthritis,
asthma, and inflammatory bowel disease as well as mediation of the
emetic reflex and the modulation of central nervous system (CNS)
disorders such as Parkinson's disease, anxiety, pain, headache,
especially migraine, Alzheimer's disease, multiple sclerosis,
attenuation of morphine withdrawal, cardiovascular changes, oedema,
such as oedema caused by thermal injury, chronic inflammatory
diseases such as rheumatoid arthritis, asthma/bronchial
hyperreactivity and other respiratory diseases including allergic
rhinitis, inflammatory diseases of the gut including ulcerative
colitis and Crohn's disease, ocular injury and ocular inflammatory
diseases.
[0010] The neurokinin-1 receptor antagonists are further useful for
the treatment of motion sickness, for treatment induced vomiting or
for the treatment of psychoimmunologic or psychosomatic disorders,
see Neurosci. Res., 1996, 7, 187-214, Can. J. Phys., 1997, 75,
612-621, Science, 1998, 281, 1640-1645, Auton. Pharmacol., 13,
23-93, 1993, WO 95/16679, WO 95/18124 and WO 95/23798, The New
England Journal of Medicine, Vol. 340, No. 3 190-195, 1999, U.S.
Pat. No. 5,972,938.
SUMMARY OF THE INVENTION
[0011] The present invention relates to the use of compounds of
formula I and pharmaceutically acceptable salts thereof for the
treatment of positive and negative symptoms in schizophrenia, novel
compounds of formulas I, pharmaceutically active acid-addition
salts thereof, all sterioisomeric forms of the compounds of formula
I, including each of the individual enantiomers and mixtures
thereof, the preparation of the above-mentioned novel compounds,
medicaments containing them and their manufacture as well as the
use of the above-mentioned compounds in the control or prevention
of illnesses, especially of illnesses and disorders of the kind
referred to earlier or in the manufacture of corresponding
medicaments.
[0012] Thus, in one embodiment the invention provides a method of
treating schizophrenia which comprises administering a compound of
formula 2
[0013] wherein
[0014] R.sup.1 is aryl, unsubstituted or substituted by one or more
substituents selected from the group consisting of alkyl, alkoxy,
halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN, S-alkyl,
--S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl, and
--NR'S(O).sub.2-alkyl, or
[0015] is heteroaryl, selected from the group consisting of
pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is
unsubstituted or substituted by alkyl, halogen or alkoxy;
[0016] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[0017] R.sup.4 and R.sup.5 are each independently
[0018] hydrogen,
[0019] --(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl,
[0020] wherein R' and R" on each carbon atom may be the same or
different from each other,
[0021] --C.sub.b-alkyl,
[0022] --C(O)H,
[0023] --(CH.sub.2).sub.dcycloalkyl, unsubstituted or substituted
by hydroxy,
[0024] --(CH.sub.2).sub.cNR'R",
[0025] --(CH.sub.2).sub.cNR'C(O)-alkyl,
[0026] --(CH.sub.2).sub.cNR'S(O).sub.2-alkyl,
[0027] --(CH.sub.2).sub.dS(O)-alkyl,
[0028] --(CH.sub.2).sub.dS-alkyl,
[0029] --(CH.sub.2).sub.dS(O).sub.2-alkyl;
[0030] --(CH.sub.2).sub.dS(O).sub.2--NR'R"
[0031] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl;
[0032] R" is hydrogen or alkyl; or
[0033] R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring
[0034] with --(CH.sub.2).sub.e-, which is unsubstituted or
substituted
[0035] by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0036] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
[0037] --(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0038] by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0039] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0040] --(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0041] by one or more substituents, selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0042] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0043] --(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.c--, which is
unsubstituted or substituted
[0044] by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0045] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0046] --CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted
[0047] by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0048] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; or with
[0049] --(CH.sub.2).sub.2--S(O).sub.2N(CH.sub.3)--CH.sub.2, or
with
[0050] --S(O)--O--(CH.sub.2).sub.g-- or
[0051] --NR.sup.4R.sup.5 is 3
[0052] a is 0 or 1;
[0053] b is 1 or 2;
[0054] c is 1, 2, or 3;
[0055] d is 0, 1, 2, or 3;
[0056] e is 3, 4, or 5;
[0057] f is 0, 1, or 2; and
[0058] g is 2 or 3;
[0059] or a pharmaceutically active acid-addition salt thereof.
[0060] The compounds of formula I may contain some asymmetric
carbon atoms. Accordingly, the present invention includes all
stereioisomeric forms of the compounds of formula I, including each
of the individual enantiomers and mixtures thereof.
[0061] The compounds of formula I and their salts are characterized
by valuable therapeutic properties. It has surprisingly been found
that the compounds of formula I show a high affinity simultaneously
to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor
antagonists), useful in the treatment of schizophrenia.
DETAILED DESCRIPTION OF THE INVENTION
[0062] The following definitions of the general terms used in the
present description apply irrespective of whether the terms in
question appear alone or in combination.
[0063] As used herein, the term "lower alkyl" denotes a straight-
or branched-chain alkyl group containing from 1-4 carbon atoms, for
example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl,
t-butyl and the like. The term "alkyl" denotes a straight- or
branched-chain alkyl group containing from 1-7 carbon atoms.
[0064] The terms "lower alkoxy" and "alkoxy" denote a group wherein
the alkyl residues are as defined above, and which is attached via
an oxygen atom.
[0065] The term "halogen" denotes chlorine, iodine, fluorine and
bromine.
[0066] The term "cycloalkyl" denotes a saturated carbocyclic group
containing 3-6 carbon atoms.
[0067] The term "aryl" means a monovalent cyclic aromatic
hydrocarbon group consisting of one or more fused rings in which at
least one ring is aromatic in nature. Examples of aryl radicals
include, but are not limited to, phenyl, naphthyl, biphenyl,
indanyl, anthraquinolyl, and the like. The preferred aryl group is
phenyl.
[0068] "Heteroaryl" means a monovalent aromatic carbocyclic group
having one or more rings incorporating one, two, or three
heteroatoms within the ring wherein the heteroatoms are chosen from
nitrogen, oxygen, or sulfur. Examples of heteroaryl radicals
include, but are not limited to, imidazolyl, isoxazolyl, thiazolyl,
pyrazinyl, thiophenyl, furanyl, pyranyl, pyridinyl, quinolinyl,
isoquinolinyl, benzofuryl, benzothiophenyl, benzothiopyranyl,
benzimidazolyl, benzooxazolyl, benzothiazolyl, benzopyranyl,
indazolyl, indolyl, isoindolyl, naphtyridinyl, and the like.
Preferred heteroaryl groups are isoxazolyl and pyridinyl.
[0069] "Pharmaceutically acceptable," such as pharmaceutically
acceptable carrier, excipient, etc., means pharmacologically
acceptable and substantially non-toxic to the subject to which the
particular compound is administered.
[0070] The term "pharmaceutically acceptable acid addition salt"
embraces salts with inorganic and organic acids, such as
hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid,
citric acid, formic acid, fumaric acid, maleic acid, acetic acid,
succinic acid, tartaric acid, methanesulfonic acid,
p-toluenesulfonic acid and the like.
[0071] "Therapeutically effective amount" means an amount that is
effective to prevent, alleviate or ameliorate symptoms of disease
or prolong the survival of the subject being treated.
[0072] In one embodiment the invention provides a method of
treating schizophrenia which comprises administering a compound of
formula 4
[0073] wherein
[0074] R.sup.1 is aryl, unsubstituted or substituted by one or more
substituents selected from the group consisting of alkyl, alkoxy,
halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN, S-alkyl,
--S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl, and
--NR'S(O).sub.2-alkyl, or
[0075] is heteroaryl, selected from the group consisting of
pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is
unsubstituted or substituted by alkyl, halogen or alkoxy;
[0076] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[0077] R.sup.4 and R.sup.5 are each independently
[0078] hydrogen,
[0079] --(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl,
[0080] wherein R' and R" on each carbon atom may be the same or
different from each other,
[0081] --C.sub.b-alkyl,
[0082] --C(O)H,
[0083] --(CH.sub.2).sub.dcycloalkyl, unsubstituted or substituted
by hydroxy,
[0084] --(CH.sub.2).sub.cNR'R",
[0085] --(CH.sub.2).sub.cNR'C(O)-alkyl,
[0086] --(CH.sub.2).sub.cNR'S(O).sub.2-alkyl,
[0087] --(CH.sub.2).sub.dS(O)-alkyl,
[0088] --(CH.sub.2).sub.dS-alkyl,
[0089] --(CH.sub.2).sub.dS(O).sub.2-alkyl, or
[0090] --(CH.sub.2).sub.dS(O).sub.2--NR'R";
[0091] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl;
[0092] R" is hydrogen or alkyl; or
[0093] R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring
[0094] with --(CH.sub.2).sub.e-, which is unsubstituted or
substituted
[0095] by one or more substituents, selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0096] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
[0097] --(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0098] by one or more substituents, selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0099] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0100] --(CH.sub.2).sub.r--O--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0101] by one or more substituents, selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0102] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0103] --(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.c-, which is
unsubstituted or substituted
[0104] by one or more substituents, selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0105] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.cOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0106] --CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted
[0107] by one or more substituents, selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or
[0108] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R"; or with
--(CH.sub.2).sub.2--S(O).sub.2N(CH.sub.3)--CH.sub.2, or with
--S(O)--O--(CH.sub.2).sub.g--;
[0109] or --NR.sup.4R.sup.5 is 5
[0110] a is 0 or 1;
[0111] b is 1 or 2;
[0112] c is 1, 2, or 3;
[0113] d is 0, 1, 2, or 3;
[0114] e is 3, 4, or 5;
[0115] f is 0, 1, or 2; and
[0116] g is 2 or 3;
[0117] or a pharmaceutically active acid-addition salt thereof.
[0118] In another embodiment, the invention provides a method of
treating schizophrenia which comprises administering a compound of
1 formula 6
[0119] wherein
[0120] R.sup.1 is aryl, unsubstituted or substituted by one or more
substituents selected from the group consisting of lower alkyl,
lower alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-lower alkyl, --S(O).sub.2-lower alkyl, --C(O)NR'R", --NR'R",
--NR'C(O)-lower alkyl, and --NR'S(O).sub.2-lower alkyl, or
[0121] is heteroaryl, selected from the group consisting of
pyridin-2-or 3-yl, imidazolyl, and oxazolyl, each of which is
unsubstituted or substituted by lower alkyl, halogen or lower
alkoxy;
[0122] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, lower alkyl, lower alkoxy, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3 or CF.sub.3;
[0123] R.sup.4 and R.sup.5 are each independently
[0124] hydrogen,
[0125] --(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-lower alkyl, wherein
R' and R" on each carbon atom may be the same or different from
each other,
[0126] --C.sub.b-alkyl,
[0127] --C(O)H, --(CH.sub.2).sub.dcycloalkyl, unsubstituted or
substituted by hydroxy,
[0128] --(CH.sub.2).sub.cNR'C(O)-lower alkyl,
--(CH.sub.2).sub.cNR'S(O).s- ub.2-lower alkyl, or
[0129] --(CH.sub.2).sub.dS(O).sub.2-lower alkyl;
[0130] R' is hydrogen, lower alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-lower alkyl, --C(O)-cycloalkyl or S(O).sub.2-lower
alkyl;
[0131] R" is hydrogen or lower alkyl; or
[0132] R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with
[0133] --(CH.sub.2).sub.e-, which is unsubstituted or
substituted
[0134] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH,
.dbd.O, and --NR'R", wherein R' and R" may form together with the
N-atom to which they are attached a ring with --(CH.sub.2).sub.e,
or
[0135] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
[0136] --(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0137] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[0138] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0139] --(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0140] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[0141] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0142] --(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0143] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[0144] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0145] --CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted
[0146] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[0147] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R";
[0148] a is 0 or 1;
[0149] b is 1 or 2;
[0150] c is 1, 2, or 3;
[0151] d is 0, 1, 2, or 3;
[0152] e is 3, 4 or 5;
[0153] f is 0, 1, or 2; and
[0154] g is 2 or 3;
[0155] or a pharmaceutically active acid-addition salts thereof as
described above.
[0156] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.1, R.sup.4 and R.sup.5 have
the definitions as described in formula I-1 and R.sup.2 and R.sup.3
are both CF.sub.3.
[0157] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.e-, which is unsubstituted or substituted by one
or more substituents selected from the group consisting of lower
alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, --NR'R",
--(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-lower alkyl, --(CH.sub.2).sub.d--C(O)-cyc-
loalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lowe- r alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl, and --C(O)NR'R".
[0158] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.4--, wherein the ring is mono substituted by
--CH.sub.2OH or disubstituted by hydroxy and --CH.sub.2OH. Examples
of such compounds include
[0159]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0160]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0161]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0162]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0163]
(2R,3S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0164]
(2S,4S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0165]
(2R,3S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0166]
(2R,3R)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0167]
(2S,4R)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0168]
(S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0169]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0170]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0171]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0172]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0173]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0174]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
[0175]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0176]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0177]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0178]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0179]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0180]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0181]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0182]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0183]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0184]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0185]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0186]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0187]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0188]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
[0189]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
[0190] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.4--, wherein the ring is disubstituted by
NHC(O)CH.sub.3 and --CH.sub.2OH. An example of such compounds
is
[0191]
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-c-
hloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide.
[0192] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.4--, wherein the ring is disubstituted by .dbd.O
and --CH.sub.2OH. Examples of such compounds are
[0193]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
and
[0194]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobu-
tyramide.
[0195] In another embodiment of the invention, the method employs a
compound of formula I-1 wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.4--, wherein the ring is di- or tri-substituted by
halogen and --CH.sub.2OH. Examples of such compounds are
[0196]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0197]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
[0198]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0199]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide and
[0200]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
[0201] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 are each
independently hydrogen,
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-lower alkyl, wherein
R' and R" on each carbon atom may be the same or different from
each other, or are --C.sub.b-alkyl, --C(O)H,
--(CH.sub.2).sub.dcycloalkyl which is unsubstituted or substituted
by hydroxy,
[0202] --(CH.sub.2).sub.cNR'C(O)-lower alkyl,
--(CH.sub.2).sub.cNR'S(O).su- b.2-lower alkyl,
--(CH.sub.2).sub.dS(O).sub.2-lower alkyl,
[0203] C(O)(CH.sub.2).sub.dOH; R' is hydrogen, lower alkyl,
--(CH.sub.2).sub.dOH, --C(O)-lower alkyl, --C(O)-cycloalkyl or
S(O).sub.2-lower alkyl; and R" is hydrogen or lower alkyl.
[0204] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 are each
independently hydrogen, --CH(CH.sub.2OH)CH.sub.2OH or
--(CH.sub.2).sub.cOH. Examples of such compounds are
[0205]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0206]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0207]
N-{6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl}-2-(3,5-b-
is-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0208]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0209]
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)--
6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl}-N-methyl-isob-
utyramide,
[0210]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0211]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0212]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-
-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0213]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide and
[0214]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-meth-
yl-isobutyramide.
[0215] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.c--O--- (CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O,
--NR'R", --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-lower alkyl, --(CH.sub.2).sub.d--C(O)-cyc-
loalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lowe- r alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl and --C(O)NR'R".
[0216] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.2--O--- (CH.sub.2).sub.2--, wherein the ring is
substituted by --CH.sub.2OH.
[0217] Examples of such compounds are
[0218]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e and
[0219]
(R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morph-
olin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
[0220] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2)C--S(O).sub- .f--(CH.sub.2).sub.2--, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of lower alkyl, halogen,
--(CR'R").sub.dOH, .dbd.O, --NR'R", --(CH.sub.2).sub.dNR'--C(O)--
lower alkyl, --(CH.sub.2).sub.d--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-cycloalkyl,
--(CH.sub.2).sub.dOC(O)NR'R", --(CH.sub.2).sub.d--S(O).sub.2-
-lower alkyl, --(CH.sub.2).sub.d-pyrrolidinyl and --C(O)NR'R".
[0221] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.2--S(O- ).sub.2--(CH.sub.2).sub.2--, wherein the
ring is mono-substituted by --CH.sub.2OH. Examples of such
compounds are
[0222]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide and
[0223]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-d-
ioxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl--
isobutyramide.
[0224] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.1, R.sup.4 and R.sup.5 have
the definitions as described above and R.sup.2 and R.sup.3 are
other than di-CF.sub.3.
[0225] In another embodiment of the invention, the method employs a
compound of formula I-1, wherein R.sup.4 and R.sup.5 form together
with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.4-- wherein the ring is mono substituted by
--CH.sub.2OH or disubstituted by OH and
[0226] --CH.sub.2OH. Examples of such compounds are
[0227]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
[0228]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[0229]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-h-
ydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0230]
(S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)--
4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0231]
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0232]
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0233]
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide,
[0234]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide,
[0235]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0236]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
[0237]
(2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
and
[0238]
(2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide.
[0239] In another embodiment, the invention provides a compound of
formula 7
[0240] wherein
[0241] R.sup.1 is aryl, unsubstituted or substituted by one or more
substituents selected from the group consisting of lower alkyl,
lower alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-lower alkyl, --S(O).sub.2-lower alkyl, --C(O)NR'R", --NR'R",
--NR'C(O)-lower alkyl, and --NR'S(O).sub.2-lower alkyl, or
[0242] is heteroaryl, selected from the group consisting of
pyridin-2-or 3-yl, imidazolyl, and oxazolyl, each of which is
unsubstituted or substituted by lower alkyl, halogen or lower
alkoxy;
[0243] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, lower alkyl, lower alkoxy, OCHF.sub.2, OCH.sub.2F,
OCF.sub.3 or CF.sub.3;
[0244] R.sup.4 and R.sup.5 are each independently
[0245] hydrogen,
[0246] --(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-lower alkyl, wherein
R' and R" on each carbon atom may be the same or different from
each other,
[0247] --C.sub.b-alkyl,
[0248] --C(O)H, --(CH.sub.2).sub.dcycloalkyl, unsubstituted or
substituted by hydroxy,
[0249] --(CH.sub.2).sub.cNR'C(O)-lower alkyl,
--(CH.sub.2).sub.cNR'S(O).s- ub.2-lower alkyl, or
[0250] --(CH.sub.2).sub.dS(O).sub.2-lower alkyl;
[0251] R' is hydrogen, lower alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-lower alkyl, --C(O)-cycloalkyl or S(O).sub.2-lower
alkyl;
[0252] R" is hydrogen or lower alkyl; or
[0253] R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with
[0254] --(CH.sub.2).sub.e-, which is unsubstituted or
substituted
[0255] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH,
.dbd.O, and --NR'R", wherein R' and R" may form together with the
N-atom to which they are attached a ring with --(CH.sub.2).sub.e,
or
[0256] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl, or --C(O)NR'R", or with
[0257] --(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0258] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[0259] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0260] --(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0261] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[0262] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alky,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)-
NR'R", --(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrr- olidinyl or --C(O)NR'R", or with
[0263] --(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[0264] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[0265] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R", or with
[0266] --CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
substituted
[0267] by one or more substituents, selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[0268] by --(CH.sub.2).sub.dNR'--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O- )-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R";
[0269] a is 0 or 1;
[0270] b is 1 or 2;
[0271] c is 1, 2, or 3;
[0272] d is 0, 1, 2, or 3;
[0273] e is 3, 4 or 5;
[0274] f is 0, 1, or 2; and
[0275] g is 2 or 3;
[0276] or a pharmaceutically active acid-addition salts thereof as
described above.
[0277] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted phenyl
and R.sup.4 and R.sup.5 are each independently hydrogen,
[0278] --(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH, or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-lower alkyl, wherein
R' and R" on each carbon atom may be the same or different from
each other, or are C.sub.b-alkyl. Examples of these compounds
are
[0279]
N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,-
5-dichloro-phenyl)-N-methyl-isobutyramide,
[0280]
2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydrox-
y-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0281]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hyd-
roxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0282]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[ethyl--
(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0283]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hyd-
roxy-ethyl)-propyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0284]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[butyl-(2-hydroxy-ethyl)-am-
ino]-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0285]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(-
2,3-dihydroxy-propyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0286]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(1--
hydroxymethyl-3-methyl-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0287]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0288]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0289]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2--
hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0290]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-
-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0291]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0292]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0293]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-
-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0294]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-2-methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0295]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0296]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0297]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-
,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0298]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0299]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0300]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0301]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0302]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-b-
is-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0303]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0304]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isob-
utyramide,
[0305]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2,4-dichloro-phenyl)-pyridin--
3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0306]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3,4-dichloro-phenyl)-pyridin--
3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0307]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0308]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-[(2-hyd-
roxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0309]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-am-
ino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0310]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-am-
ino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0311]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[(2-hydroxy-ethyl)-propyl-a-
mino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0312]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0313]
N-[6-[bis-(2-hydroxy-propyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5--
bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0314]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylam-
ino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0315]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylam-
ino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0316]
N-[6-[bis-(2-hydroxy-propyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-y-
l]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0317]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,-
3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0318]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,-
3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0319]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0320]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0321]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-h-
ydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0322]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-
-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0323]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0324]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-1-hydroxymethyl--
ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0325]
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0326]
(1R,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0327]
(1S,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0328]
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0329]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[hexyl--
(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0330]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hyd-
roxy-ethyl)-pentyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0331]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hyd-
roxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide-
,
[0332]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
[0333]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-[(2-hydroxy-1-hydroxymethyl-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl--
isobutyramide.
[0334] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted
phenyl, R.sup.4 is hydrogen and R.sup.5 is
--(CH.sub.2).sub.d-cycloalkyl, unsubstituted or substituted by
hydroxy. Examples of these compounds are
[0335]
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-
4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0336]
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-
-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0337]
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-ph-
enyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0338]
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-
-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0339]
(1RS,2RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-
-6-(2-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0340]
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0341]
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
and
[0342]
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e.
[0343] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted
phenyl, R.sup.4 is hydrogen and R.sup.5 is
--(CH.sub.2).sub.cNR'C(O)-lower alkyl or
--(CH.sub.2).sub.dS(O).sub.2-lower alkyl. Examples of such
compounds are
[0344]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-meth-
anesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
and
[0345]
N-[6-(2-acetylamino-ethylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-
-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
[0346] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted phenyl
and R.sup.4 and R.sup.5 form together with the N-atom to which they
are attached a ring with --(CH.sub.2).sub.4--, which ring is
substituted by one or two groups --(CR'R").sub.dOH. Examples of
such compounds are
[0347]
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
[0348]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
[0349]
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0350]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[0351]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide,
[0352]
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydro-
xymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0353]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-h-
ydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0354]
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
[0355]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
[0356]
(S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)--
4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0357]
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0358]
(S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0359]
(2R,4S)-2-(3-fluoro-5'-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hy-
droxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramid-
e,
[0360]
(S)-2-(3,5-difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)--
4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0361]
(2S,4R)-2-(3,5-difluoro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0362]
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin--
1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0363]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0364]
(S)-2-(3,5-dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)--
4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0365]
(2S,4R)-2-(3,5-dimethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0366]
(S)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0367]
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0368]
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide,
[0369]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide,
[0370]
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide,
[0371]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-iso-
butyramide,
[0372]
(S)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0373]
(2S,4R)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0374]
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0375]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0376]
(S)-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydr-
oxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0377]
(2S,4R)-2-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0378]
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6--
(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0379]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
[0380]
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0381]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide-
,
[0382]
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0383]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[0384]
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-c-
hloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide,
[0385]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0386]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0387]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3--
hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0388]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3--
hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0389]
(3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0390]
(3R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0391]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0392]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0393]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0394]
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0395]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0396]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0397]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0398]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0399]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0400]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0401]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0402]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-pheny-
l)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0403]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0404]
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0405]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0406]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0407]
(2R,3R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0408]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0409]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phen-
yl)-6-[2-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methy-
l-isobutyramide,
[0410]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0411]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0412]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0413]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0414]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-
-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0415]
(3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0416]
(3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrr-
olidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0417]
(3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrr-
olidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0418]
(2R,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide,
[0419]
(2S,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide,
[0420]
(2R,5R)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide,
[0421]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0422]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0423]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0424]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0425]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-dimethylamino-ph-
enyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
[0426]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0427]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0428]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0429]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0430]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0431]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-4-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0432]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0433]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0434]
(2S,4R)-N-[4-(2-amino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolid-
in-1-yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobuty-
ramide,
[0435]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[0436]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[0437]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0438]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
[0439]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methanesulfonyl-phenyl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0440]
(2S,4R)-2-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propiony-
l]-methyl-amino}-2-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-y-
l]-benzamide,
[0441]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0442]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0443]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0444]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0445]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0446]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
[0447]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0448]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0449]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0450]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0451]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0452]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0453]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0454]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0455]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0456]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0457]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0458]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0459]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0460]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[0461]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-cyano-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0462]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0463]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0464]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0465]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0466]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0467]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0468]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0469]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0470]
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0471]
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0472]
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0473]
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0474]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0475]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0476]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[0477]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0478]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0479]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0480]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0481]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-pheny-
l)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0482]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0483]
(2R,3S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phen-
yl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0484]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-pheny-
l)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0485]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0486]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0487]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0488]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0489]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0490]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-difluoro-pheny-
l)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0491]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0492]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0493]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0494]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0495]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0496]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0497]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0498]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0499]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0500]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
and
[0501]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide.
[0502] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted phenyl
and R.sup.4 and R.sup.5 form together with the N-atom to which they
are attached a ring with --(CH.sub.2).sub.4--, which ring is
substituted by one to three substituents selected from the group
consisting of --NR'R", --(CH.sub.2).sub.d--C(O)-lower alkyl,
[0503] CH.sub.2OH, --(CH.sub.2).sub.d-pyrrolidinyl,
--(CH.sub.2).sub.d--S(O).sub.2-lower alkyl, .dbd.O, halogen and
--(CH.sub.2).sub.dOC(O)NR'R". Examples of such compounds are
[0504]
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-c-
hloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide,
[0505]
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0506]
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0507]
(RS)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(2-chloro-phen-
yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramid-
e,
[0508]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-2-
-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0509]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3--
dimethylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0510]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-
-methanesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0511]
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide-
,
[0512]
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide-
,
[0513]
(R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-me-
thyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[0514]
(R)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-met-
hyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isob-
utyramide,
[0515]
(S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0516]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide,
[0517]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phen-
yl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-m-
ethyl-isobutyramide,
[0518]
(S)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfo-
nyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[0519]
(S)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-me-
thyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[0520]
(S)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-met-
hyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isob-
utyramide,
[0521]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(3-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0522]
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-bromo-phenyl)-pyridin-
-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0523]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0524]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[0525]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0526]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
[0527]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0528]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
[0529]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0530]
(S)-N-[6-[2-(acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-met-
hyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isob-
utyramide or
[0531] (S)-dimethyl-carbamic acid
1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl-
)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-
-yl]-pyrrolidin-2-ylmethyl ester.
[0532] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted phenyl
and R.sup.4 and R.sup.5 form together with the N-atom to which they
are attached a ring with --(CH.sub.2).sub.h--, which ring is mono-
or di-substituted by --(CH.sub.2).sub.dOH or --NR'R", wherein h is
3 or 5. Examples of such compounds are
[0533]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3-h-
ydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyrami-
de,
[0534]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hydrox-
y-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide,
[0535]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hydrox-
ymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyram-
ide,
[0536]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-(-
2-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide,
[0537]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydr-
oxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0538]
N-[4-amino-4'-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrid-
inyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0539]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methan-
esulfonylamino-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-iso-
butyramide,
[0540]
N-[4-acetylamino-4'(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-
-[1,2']bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isob-
utyramide,
[0541]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-h-
ydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobu-
tyramide,
[0542]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-hy-
droxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobut-
yramide,
[0543]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-hy-
droxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobut-
yramide,
[0544]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0545]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-azetidin-1-yl)-4-
-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0546]
2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxymethyl-4'-o-tolyl-3,-
4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramide,
[0547]
(3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,5-dihydroxy-4'-o-to-
lyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramide,
[0548]
(3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)--
3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isob-
utyramide,
[0549]
(3S,5R)-5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3,5-d-
ihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyra-
mide,
[0550]
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4'-o--
tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramid-
e,
[0551]
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4'-o--
tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramid-
e,
[0552]
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-is-
obutyramide,
[0553]
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-is-
obutyramide,
[0554]
(2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-4-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide,
[0555]
(2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-2-hydroxy-
methyl-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl--
isobutyramide,
[0556]
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxy-
methyl-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl--
isobutyramide,
[0557]
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxy-
methyl-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl--
isobutyramide,
[0558]
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide,
[0559]
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide and
[0560]
(2RS,3RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-3-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide.
[0561] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted phenyl
and R.sup.4 and R.sup.5 form together with the N-atom to which they
are attached a ring with
[0562] --(CH.sub.2).sub.g--NR'--(CH.sub.2).sub.2--, which is
unsubstituted or mono-or di-substituted by
--(CH.sub.2).sub.d--C(O)-lower alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --NR'R" or .dbd.O. Examples of
such compounds are
[0563]
N-[6-(4-acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2--
(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0564]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cycl-
opropanecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0565]
N-[6-(4-acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide and
[0566]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(5-oxo-diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
[0567] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted phenyl
and R.sup.4 and R.sup.5 form together with the N-atom to which they
are attached a ring with --(CH.sub.2).sub.2,
--O--(CH.sub.2).sub.2--, which is unsubstituted or mono- or
-di-substituted by --(CR'R").sub.dOH. Examples of such compounds
are
[0568]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
[0569]
(R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morph-
olin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
[0570]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-morph-
olin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
[0571] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted phenyl
and R.sup.4 and R.sup.5 form together with the N-atom to which they
are attached a ring with
--(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.2--, which is
unsubstituted or mono-or di-substituted by --(CR'R").sub.dOH
Examples of such compounds are
[0572]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide and
[0573]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-d-
ioxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl--
isobutyramide.
[0574] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted phenyl
as described above and R.sup.4 and R.sup.5 form together with the
N-atom to which they are attached a ring with
--CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
mono-substituted by, --(CR'R").sub.dOH. One such compound is
[0575]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide.
[0576] In another embodiment, the invention is a compound of
formula I-1, wherein R.sup.1 is unsubstituted or substituted
heteroaryl as described above. Examples of such compounds are
[0577]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-dimethyl-isoxa-
zol-4-yl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-me-
thyl-isobutyramide,
[0578]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-2,6-dimethoxy-[3,4']bipyridinyl-3'-yl]-N-methyl--
isobutyramide,
[0579]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-chloro-6'-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[0580]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[0581]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6'-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[0582]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-chloro-6'-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[0583]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[0584]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6'-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[0585]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(3-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[0586]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(2-hydroxymethyl-pyrro-
lidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramide,
[0587]
N-{6'-[bis-(2-hydroxy-ethyl)-amino]-2-methyl-[3,4']bipyridinyl-3'-y-
l}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0588]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(2-hydroxymethyl-pyrro-
lidin-1-yl)-4-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramide,
[0589]
N-{6'-[bis-(2-hydroxy-ethyl)-amino]-4-methyl-[3,4']bipyridinyl-3'-y-
l}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
and
[0590]
2-(3,5-bis-trifluoromethyl-phenyl)-N-{6'-[(2-hydroxy-ethyl)-methyl--
amino]-4-methyl-[3,4']bipyridinyl-3'-yl}-N-methyl-isobutyramide.
[0591] Preferred is the use of compounds of formula I, wherein
R.sup.1, R.sup.4 and R.sup.5 have the definitions as described
above and R.sup.2 and R.sup.3 are both CF.sub.3.
[0592] Further preferred is the use of compounds of formula I,
wherein R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with --(CH.sub.2).sub.e--, which ring is
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, halogen, CF.sub.3,
--(CR'R").sub.dOH, .dbd.O, and --NR'R", wherein R' and R" may form
together with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.e, or substituted by
--(CH.sub.2).sub.dNR'--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R".
[0593] Preferred is also the use of compounds of formula I, wherein
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.e-, wherein the ring is mono
or di-substituted by hydroxy, --CH.sub.2OH or --C(O)H. Examples of
such compounds are
[0594]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0595]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0596]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0597]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0598]
(2R,3S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0599]
(2S,4S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0600]
(2R,3S)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0601]
(2R,3R)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0602]
(2S,4R)-2-(3,5-,is-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0603]
(S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0604]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0605]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0606]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0607]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0608]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0609]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
[0610]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0611]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0612]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0613]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0614]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0615]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0616]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0617]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0618]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0619]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0620]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[0621]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0622]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0623]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0624]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0625]
(3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-
-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-me-
thyl-isobutyramide,
[0626]
(3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)--
3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isob-
utyramide,
[0627]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-formyl-pyrrolidin-1--
yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0628]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-
-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide,
[0629]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0630]
(S)-2-(3,5-dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0631]
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-py-
rrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0632]
(S)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0633]
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0634]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide,
[0635]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0636]
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0637]
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0638]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0639]
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0640]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0641]
(2S,4R)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl--
pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
and
[0642]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-is-
obutyramide.
[0643] Preferred are further compounds of formula I, wherein
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.e--, wherein the ring is mono
or di-substituted by NH.sub.2, NHS(O).sub.2CH.sub.3,
NCH.sub.3S(O).sub.2CH.sub.3, N(CH.sub.2CH.sub.3)S(O).sub.2CH.sub.3,
NHC(O)CH.sub.3 and --CH.sub.2OH. Examples of such compounds are
[0644]
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-c-
hloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide,
[0645]
(R)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0646]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide,
[0647]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phen-
yl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-m-
ethyl-isobutyramide,
[0648]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfon-
yl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-me-
thyl-isobutyramide,
[0649]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-
-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-m-
ethyl-isobutyramide,
[0650]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-
-4-(methanesulfonyl-methyl-amino)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl--
5'-yl]-N-methyl-isobutyramide and
[0651]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(ethyl-methanesulfonyl-amin-
o)-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5-
'-yl]-N-methyl-isobutyramide.
[0652] A further preferred group of compounds are further those,
wherein R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with --(CH.sub.2).sub.4-- and wherein the
ring is disubstituted by .dbd.O and --CH.sub.2OH, for example the
following compounds:
[0653]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
and
[0654]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobu-
tyramide.
[0655] Compounds of formula I, wherein R.sup.4 and R.sup.5 form
together with the N-atom to which they are attached a ring with
--(CH.sub.2).sub.4--, wherein the ring is di- or tri-substituted by
halogen and --CH.sub.2OH, are also preferred. The following
compounds relate to this group:
[0656]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0657]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
[0658]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0659]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide and
[0660]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
[0661] A further preferred group of compounds are those, wherein
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.e--, wherein the ring is
substituted by CH.sub.2S(O).sub.2CH.sub.3, CH.sub.2SCH.sub.3 or
CH.sub.2S(O)CH.sub.3. Examples of such compounds are
[0662]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
[0663]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-
-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-m-
ethyl-isobutyramide,
[0664]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-ph-
enyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-y-
l]-N-methyl-isobutyramide,
[0665]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-
-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N--
methyl-isobutyramide,
[0666]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-methylsulfanylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
[0667]
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)--
6-[(RS)-3-((RS)-methanesulfinylmethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-me-
thyl-isobutyramide and
[0668]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide.
[0669] Other preferred compounds of formula 1 are those, wherein
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.e-, wherein the ring is
substituted by S(O).sub.2CH.sub.3, SCH.sub.3, S(O)CH.sub.3 or
S(O).sub.2N(CH.sub.3).sub.- 2, for example the following
compounds:
[0670]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0671]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-ph-
enyl)-3-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-m-
ethyl-isobutyramide,
[0672]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-
-4-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-
-isobutyramide,
[0673]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-dimethylsulfamoyl-4'-(4-flu-
oro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-meth-
yl-isobutyramide,
[0674]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methyl-
sulfanyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyra-
mide,
[0675]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-m-
ethanesulfinyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-iso-
butyramide and
[0676]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methan-
esulfonyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyr-
amide.
[0677] Compounds, wherein --NR.sup.4R.sup.5 is 8
[0678] and R' is as described in claim 1, are further preferred,
which compounds are
[0679]
(1S,3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0680]
(1R,3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0681]
(rac)-(1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridi-
n-3-yl]-N-methyl-isobutyramide,
[0682]
(1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(3-methanesulfonyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide,
[0683]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide,
[0684]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-dioxo-1-oxa-4.lambda..-
sup.6-thia-8-aza-spiro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin--
3-yl]-N-methyl-isobutyramide,
[0685]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1-oxa-5-thia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0686]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(5,5-dioxo-1-oxa-5.lambda..-
sup.6-thia-9-aza-spiro
[5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyrid-
in-3-yl]-N-methyl-isobutyramide,
[0687]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1,1,4,4-tetraoxo-l.lambda..sup.6,4.lambda..sup.6-dithia-8-aza-spiro[4.5-
]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0688]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1,1,5,5-tetraoxo-l.lambda..sup.6,4.lambda..sup.6-dithia-9-aza-spiro[5.5-
]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0689]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1-oxa-8-aza-spiro
[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0690]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[(1S,5R)-4-(4-fluoro-2-methyl--
phenyl)-6-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0691]
(1S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(8,8-dioxo-8%-thia--
3-aza-bicyclo
[3.2.1]oct-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]--
N-methyl-isobutyramide,
[0692]
(1S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-((1S,4S)-5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-py-
ridin-3-yl]-N-methyl-isobutyramide and
[0693]
(1R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(8-methanesulfonyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide.
[0694] Another group of preferred compounds of formula I are those
wherein R.sup.4 and R.sup.5 are each independently hydrogen;
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl, wherein R' and
R" on each carbon atom may be the same or different from each
other; --C.sub.b-alkyl; --C(O)H; --(CH.sub.2).sub.dcycloalkyl,
unsubstituted or substituted by hydroxy; or is
--(CH.sub.2).sub.cNR'R", --(CH.sub.2).sub.cNR'C(O)-alkyl,
--(CH.sub.2).sub.cNR'S(O).sub.2-alkyl,
--(CH.sub.2).sub.dS(O)-alkyl, --(CH.sub.2).sub.dS-alkyl,
--(CH.sub.2).sub.fS(O).sub.2-alkyl or
--(CH.sub.2).sub.dS(O).sub.2--NR'R"- .
[0695] Especially preferred compounds from this group are those,
wherein R.sup.4 and R.sup.5 are each independently hydrogen,
--CH(CH.sub.2OH)CH.sub.2OH or --(CH.sub.2).sub.cOH, for
example,
[0696]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0697]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0698]
N-{6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl}-2-(3,5-b-
is-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0699]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0700]
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)--
6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl}-N-methyl-isob-
utyramide,
[0701]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0702]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0703]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-
-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0704]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0705]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0706]
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-c-
hloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide,
[0707]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxy-ethylamino)-4-o--
tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0708]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
and
[0709]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
[0710] Compounds of formula I, wherein R.sup.4 and R.sup.5 are each
independently hydrogen, (CH.sub.2).sub.2SCH.sub.3,
(CH.sub.2).sub.2S(O).sub.2CH.sub.3 or
(CH.sub.2).sub.2S(O).sub.2NHCH.sub.- 3 are also preferred. Examples
of such compounds are
[0711]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0712]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
and
[0713]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-meth-
ylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
[0714] Other preferred compounds are those, wherein R.sup.4 and
R.sup.5 are each independently hydrogen, (CH.sub.2).sub.2NH.sub.2,
(CH.sub.2).sub.2NHS(O).sub.2CH.sub.3 or
(CH.sub.2).sub.2NHC(O)CH.sub.3, for example,
[0715]
N-[6-(2-amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0716]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-methanesulfonylamino-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
and
[0717]
N-[6-(2-acetylamino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridi-
n-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
[0718] Preferred are further compounds of formula I, wherein
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with
[0719] --(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is
unsubstituted or substituted by one or more substituent selected
from the group consisting of alkyl, halogen, CF.sub.3,
--(CR'R").sub.dOH, .dbd.O, --CHO, and --NR'R", wherein R' and R"
are as described above or may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R".
[0720] To this group relate compounds, wherein R.sup.4 and R.sup.5
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.2--O--(CH.sub.2).sub.2--, wherein the ring is
unsubstituted or substituted by --CH.sub.2OH, for example,
[0721]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
[0722]
(R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morph-
olin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0723]
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide and
[0724]
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-morpholin-4-yl-pyridin-3-yl]-N-methyl-isobutyramide.
[0725] Another preferred group are compounds of formula I, wherein
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with
--(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.v--, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of alkyl, halogen, CF.sub.3,
--(CR'R").sub.dOH, .dbd.O, --CHO, and --NR'R", wherein R' and R"
are as described above or may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or by
--(CH.sub.2).sub.dNR'--C(O)-alkyl, --(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R".
[0726] Especially preferred compounds from this group are those
wherein R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with
--(CH.sub.2).sub.2--S(O).sub.2--(CH.sub.2).sub.2--, wherein the
ring is unsubstituted or substituted by --CH.sub.2OH or methyl.
Examples of such compounds are
[0727]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide,
[0728]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-d-
ioxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl--
isobutyramide,
[0729]
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-thiazolidin-3-yl-pyridin-3-yl]-N-methyl-isobutyramide,
[0730] (1RS,4RS)- or
(1RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4--
fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolid-
in-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric
racemate of Example 349),
[0731] (1RS,4SR)- or
(1RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4--
fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolid-
in-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric
racemate of Example 348),
[0732]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(4-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiazolidin-3-yl)-pyridi-
n-3-yl]-N-methyl-isobutyramide,
[0733]
(+)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-di-
oxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0734]
(-)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-di-
oxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0735]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(1-oxo-l.lambda..sup.4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl--
isobutyramide,
[0736]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6--
[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0737]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6--
[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide and
[0738]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-meth-
yl-1,1-dioxo-1%6-[1,2,4]thiadiazinan-4-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide.
[0739] Preferred are also compounds wherein R.sup.1, R.sup.4 and
R.sup.5 have the definitions as describe above and R.sup.2 and
R.sup.3 are other than di-CF.sub.3. Examples of such compounds
are
[0740]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
[0741]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[0742]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-h-
ydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0743]
(S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)--
4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0744]
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0745]
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0746]
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide,
[0747]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide,
[0748]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0749]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
[0750]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide-
,
[0751]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[0752]
(S)-2-(3,5-dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0753]
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-py-
rrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0754]
2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydro-
xy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0755]
(S)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0756]
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0757]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide,
[0758]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxy-ethylamino)-4-o--
tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0759]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0760]
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0761]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0762]
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0763]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0764]
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0765]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0766]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[0767]
(2S,4R)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl--
pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide,
[0768]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-is-
obutyramide,
[0769]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperaz-
in-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
[0770]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
[0771]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-meth-
anesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0772]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0773]
2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-
-tolyl-pyridin-3-yl)-isobutyramide and
[0774]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazi-
n-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
[0775] A preferred group of compounds of formula I are compounds
wherein R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with
--(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is unsubstituted
or substituted by one or more substituents selected from the group
consisting of alkyl, halogen, CF.sub.3, --(CR'R").sub.dOH, .dbd.O,
--CHO, and --NR'R", wherein R' and R" are as described above or may
form together with the N-atom to which they are attached a ring
with --(CH.sub.2).sub.e, or by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d--S(O)-alkyl, --(CH.sub.2).sub.d--S-alkyl,
--(CH.sub.2).sub.d--S(O).sub.2--NR'R",
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R".
[0776] Preferred from this group are those compounds wherein
R.sup.4 and R.sup.5 form together with the N-atom to which they are
attached a ring with --(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--,
and wherein R' on the N-atom is hydrogen, lower alkyl, C(O)H,
C(O)CH.sub.3, C(O)-cyclopropyl,
[0777] S(O).sub.2-alkyl, S(O).sub.2--CH.sub.2C1 or
S(O).sub.2--N(CH.sub.3)- .sub.2. Examples of such compounds are
[0778]
N-[6-(4-acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2--
(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0779]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cycl-
opropanecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0780]
N-[6-(4-acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0781]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(5-oxo-diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0782]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(3-methanesulfonyl-imidazolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0783]
N-[6-(3-acetyl-imidazolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyri-
din-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0784]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazi-
n-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0785]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-meth-
anesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0786]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0787]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0788]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0789]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethanesulfonyl-piperazin-
-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0790]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-chloromethanesulfonyl-pi-
perazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0791]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-dimethylsulfamoyl-pipera-
zin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
[0792]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0793]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0794]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4--
methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0795]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2-me-
thyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0796]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0797]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-4-
-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide,
[0798]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(-4-methanesulfonyl-3-m-
ethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0799]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0800]
(2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methy-
l-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]--
N-methyl-isobutyramide,
[0801]
(2S,6R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-methanesulfonyl-2,6-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N--
methyl-isobutyramide,
[0802]
(3S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-methanesulfonyl-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N--
methyl-isobutyramide,
[0803]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[0804]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-formyl-2-hydroxymethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
[0805]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-cyclopropanecarbonyl-
-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl-
]-N-methyl-isobutyramide,
[0806]
(S)-N-[6-(4-acetyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-me-
thyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[0807]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxymethy-
l-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isob-
utyramide,
[0808]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[0809]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-4-meth-
anesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide-
,
[0810]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[0811]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0812]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-3,3-dime-
thyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0813]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl-
)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0814]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[0815]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2,2-dime-
thyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0816]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperaz-
in-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
[0817]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
[0818]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-meth-
anesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0819]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0820]
2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-
-tolyl-pyridin-3-yl)-isobutyramide and
[0821]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazi-
n-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
[0822] The following compounds of formulas IA to IJ, are novel.
[0823] Encompassed by formula I are compounds of formula IA 9
[0824] wherein
[0825] R.sup.1 is phenyl, unsubstituted or substituted by one or
more substituents selected from the group consisting of alkyl,
alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl,
and --NR'S(O).sub.2-alkyl;
[0826] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[0827] R.sup.4 and R.sup.5 are each independently
[0828] hydrogen,
[0829] --(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a--OH, or
--(CR'R").sub.l--(CR'R").sub.l--(CR'R").sub.a-alkyl, wherein R' and
R" on each carbon atom may be the same or different from each other
and are hydrogen
[0830] or C.sub.b-alkyl;
[0831] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl,
[0832] R" is hydrogen or alkyl;
[0833] a is 0 or 1;
[0834] b is 1 or 2; and
[0835] d is 0, 1, 2 or 3;
[0836] or a pharmaceutically active acid-addition salt thereof.
[0837] Some specific compounds of formula IA are
[0838]
N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,-
5-dichloro-phenyl)-N-methyl-isobutyramide,
[0839]
2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydrox-
y-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0840]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hyd-
roxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0841]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[ethyl--
(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0842]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hyd-
roxy-ethyl)-propyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0843]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[butyl-(2-hydroxy-ethyl)-am-
ino]-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0844]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(-
2,3-dihydroxy-propyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0845]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(1--
hydroxymethyl-3-methyl-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0846]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0847]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0848]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2--
hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0849]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-
-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0850]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0851]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0852]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-
-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0853]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-2-methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0854]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0855]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0856]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-
,3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0857]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0858]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxy-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0859]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0860]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0861]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5-b-
is-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0862]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0863]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-[(2-hydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isob-
utyramide,
[0864]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2,4-dichloro-phenyl)-pyridin--
3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0865]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3,4-dichloro-phenyl)-pyridin--
3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0866]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0867]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-[(2-hyd-
roxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0868]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-am-
ino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0869]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-am-
ino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0870]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[(2-hydroxy-ethyl)-propyl-a-
mino]-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0871]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0872]
N-[6-[bis-(2-hydroxy-propyl)-amino]-4-o-tolyl-pyridin-3-yl]-2-(3,5--
bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0873]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylam-
ino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0874]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylam-
ino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0875]
N-[6-[bis-(2-hydroxy-propyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-y-
l]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0876]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,-
3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0877]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,-
3-dihydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0878]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0879]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0880]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-h-
ydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0881]
N-[6-[bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-
-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0882]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0883]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-1-hydroxymethyl--
ethylamino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0884]
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0885]
(1R,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0886]
(1S,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0887]
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[0888]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[hexyl--
(2-hydroxy-ethyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0889]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hyd-
roxy-ethyl)-pentyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide,
[0890]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-[(2-hyd-
roxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl]-N-methyl-isobutyramide-
,
[0891]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and
[0892]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-[(2-hydroxy-1-hydroxymethyl-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl--
isobutyramide.
[0893] Other compounds of formula I are compounds of formula IB
10
[0894] wherein
[0895] R.sup.1 is phenyl, unsubstituted or substituted by one or
more substituents selected from the group consisting of alkyl,
alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl,
and --NR'S(O).sub.2-alkyl;
[0896] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[0897] R.sup.4 and R.sup.5 are each independently hydrogen,
--(CH.sub.2).sub.2SCH.sub.3, --(CH.sub.2).sub.2S(O).sub.2CH.sub.3,
--(CH.sub.2).sub.2S(O).sub.2NHCH.sub.3, --(CH.sub.2).sub.2NH.sub.2,
--(CH.sub.2).sub.2NHS(O).sub.2CH.sub.3 or
--(CH.sub.2).sub.2NHC(O)CH.sub.- 3;
[0898] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl;
[0899] R" is hydrogen or alkyl;
[0900] b is 1 or 2; and
[0901] d is 0, 1, 2, or 3;
[0902] or a pharmaceutically active acid-addition salt thereof.
[0903] Some specific compounds of formula IB are
[0904]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-meth-
anesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0905]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0906]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0907]
N-[6-(2-amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0908]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-methanesulfonylamino-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
and
[0909]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-meth-
ylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
[0910] Also encompassed by formula I are compounds of formula IC
11
[0911] wherein
[0912] R.sup.1 is phenyl, unsubstituted or substituted by one or
more substituents selected from the group consisting of alkyl,
alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl
and --NR'S(O).sub.2-alkyl;
[0913] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[0914] R.sup.4 is hydrogen;
[0915] R.sup.5 is --(CH.sub.2).sub.0-cycloalkyl, unsubstituted or
substituted by hydroxy;
[0916] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl;
[0917] R" is hydrogen or alkyl;
[0918] b is 1 or 2; and
[0919] d is 0, 1, 2, or 3;
[0920] or a pharmaceutically active acid-addition salt thereof.
[0921] Some compounds of formula IC are
trans-2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]--
N-methyl-isobutyramide,
[0922]
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-
-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0923]
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-ph-
enyl)-6-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0924]
trans-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-
-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0925]
(1RS,2RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-
-6-(2-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0926]
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide,
[0927]
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
and
[0928]
(1S,2S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e.
[0929] Other compounds encompassed by formula I are compounds of
formula-ID 12
[0930] wherein
[0931] R.sup.1 is phenyl, unsubstituted or substituted by one or
more substituents selected from the group consisting of alkyl,
alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl
and --NR'S(O).sub.2-alkyl;
[0932] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[0933] R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with --(CH.sub.2).sub.e-, which is
unsubstituted or substituted by one or more substituents selected
from the group consisting of --(CR'R").sub.dOH;
[0934] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl;
[0935] R" is hydrogen or alkyl;
[0936] b is 1 or 2;
[0937] d is 0, 1, 2, or 3; and
[0938] e is 3, 4, or 5;
[0939] or a pharmaceutically active acid-addition salt thereof.
[0940] Examples of compounds of formula ID are
[0941] wherein the compounds are selected from the group consisting
of
[0942]
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
[0943]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide,
[0944]
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[0945]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[0946]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide,
[0947]
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(27-chloro-phenyl)-6-(2-hydr-
oxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0948]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-h-
ydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0949]
(S)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
[0950]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide,
[0951]
(S)-2-(3,5-dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)--
4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0952]
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0953]
(S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0954]
(2R,4S)-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide-
,
[0955]
(S)-2-(3,5-difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)--
4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0956]
(2S,4R)-2-(3,5-difluoro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0957]
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin--
1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0958]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0959]
(S)-2-(3,5-dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)--
4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0960]
(2S,4R)-2-(3,5-dimethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0961]
(S)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0962]
(2S,4R)-2-(3,5-dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0963]
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide,
[0964]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide,
[0965]
(S)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide,
[0966]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-iso-
butyramide,
[0967]
(S)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0968]
(2S,4R)-2-(3,5-difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0969]
(S)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0970]
(2S,4R)-2-(3-chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0971]
(S)-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydr-
oxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0972]
(2S,4R)-2-(3,5-dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0973]
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6--
(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0974]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
[0975]
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[0976]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide-
,
[0977]
(S)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[0978]
(2S,4R)-2-(3-chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[0979]
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-c-
hloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide,
[0980]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0981]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0982]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3--
hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0983]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3--
hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0984]
(3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0985]
(3R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0986]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[0987]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0988]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0989]
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0990]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0991]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0992]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[0993]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0994]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[0995]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0996]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0997]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-pheny-
l)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[0998]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[0999]
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1000]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1001]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1002]
(2R,3R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1003]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1004]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phen-
yl)-6-[2-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methy-
l-isobutyramide,
[1005]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[1006]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[1007]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[1008]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1009]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-
-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1010]
(3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(3,4-dihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1011]
(3S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrr-
olidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1012]
(3R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrr-
olidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1013]
(2R,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide,
[1014]
(2S,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide,
[1015]
(2R,5R)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide,
[1016]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1017]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1018]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1019]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1020]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-dimethylamino-ph-
enyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
[1021]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[1022]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1023]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1024]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1025]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1026]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-4-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1027]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1028]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1029]
(2S,4R)-N-[4-(2-amino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolid-
in-1-yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobuty-
ramide,
[1030]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[1031]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[1032]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1033]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
[1034]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methanesulfonyl-phenyl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1035]
(2S,4R)-2-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propiony-
l]-methyl-amino}-2-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-y-
l]-benzamide,
[1036]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1037]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1038]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1039]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[1040]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1041]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-
-isobutyramide,
[1042]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1043]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1044]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1045]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1046]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1047]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1048]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1049]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1050]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1051]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[1052]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1053]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1054]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1055]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[1056]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-cyano-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[1057]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[1058]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1059]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1060]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1061]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1062]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1063]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1064]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-pheny-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1065]
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1066]
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1067]
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1068]
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1069]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1070]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1071]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[1072]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1073]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1074]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1075]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1076]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-pheny-
l)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1077]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-
-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1078]
(2R,3S)-2-(3,5-,bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phen-
yl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1079]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-pheny-
l)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1080]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1081]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1082]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxy-
methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide,
[1083]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1084]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1085]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-difluoro-pheny-
l)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1086]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1087]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1088]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1089]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1090]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1091]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1092]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1093]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-
-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1094]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1095]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1096]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrol-
idin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1097]
(3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-
-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-me-
thyl-isobutyramide,
[1098]
(3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)--
3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isob-
utyramide,
[1099]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-
-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide,
[1100]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[1101]
(S)-2-(3,5-dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1102]
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-py-
rrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1103]
(S)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1104]
(2S,4R)-2-(3,5-dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[1105]
(2S,4R)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrroli-
din-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide,
[1106]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydrox-
ymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1107]
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[1108]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1109]
(S)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2--
hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1110]
(2S,4R)-2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1111]
(2S,4R)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl--
pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
and
[1112]
(2S,4R)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-is-
obutyramide.
[1113] Specific compounds of formula ID, encompassed by formula I,
which ring is substituted by one to three substituents, selected
from the group consisting of --NR'R",
--(CH.sub.2).sub.d--C(O)-lower alkyl, --CH.sub.2OH,
--(CH.sub.2).sub.d-pyrrolidinyl, --(CH.sub.2).sub.d--S(O).s-
ub.2-alkyl, .dbd.O, halogen or --(CH.sub.2).sub.dOC(O)NR'R", are
the followings
[1114]
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-c-
hloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide,
[1115]
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1116]
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1117]
(RS)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(2-chloro-phen-
yl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramid-
e,
[1118]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-2-
-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[1119]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3--
dimethylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1120]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-
-methanesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1121]
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide-
,
[1122]
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide-
,
[1123]
(R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-me-
thyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[1124]
(R)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-met-
hyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isob-
utyramide,
[1125]
(S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1126]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide,
[1127]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phen-
yl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-m-
ethyl-isobutyramide,
[1128]
(S)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfo-
nyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[1129]
(S)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-me-
thyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[1130]
(S)-N-[6-[3-(acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-met-
hyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isob-
utyramide,
[1131]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(3-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1132]
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(2-bromo-phenyl)-pyridin-
-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1133]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1134]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobu-
tyramide,
[1135]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1136]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
[1137]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1138]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide,
[1139]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1140]
(S)-N-[6-[2-(acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-met-
hyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isob-
utyramide or (S)-dimethyl-carbamic acid
1-[5-{[2-(3,5-bis-trifluoromethyl--
phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-2-yl]-pyrrolidin-2-ylmethyl ester.
[1141]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3-h-
ydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyrami-
de,
[1142]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hydrox-
y-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide,
[1143]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hydrox-
ymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyram-
ide,
[1144]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-(-
2-hydroxy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide,
[1145]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydr-
oxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1146]
N-[4-amino-4'-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyrid-
inyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1147]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methan-
esulfonylamino-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-iso-
butyramide,
[1148]
N-[4-acetylamino-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2-
H-[1,2']bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[1149]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-h-
ydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobu-
tyramide,
[1150]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-hy-
droxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobut-
yramide,
[1151]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-hy-
droxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobut-
yramide,
[1152]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(3-hydroxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1153]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-azetidin-1-yl)-4-
-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1154]
2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxymethyl-4'-o-tolyl-3,-
4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramide,
[1155]
(3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,5-dihydroxy-4'-o-to-
lyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramide,
[1156]
(3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)--
3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isob-
utyramide,
[1157]
(3S,5R)-5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3,5-d-
ihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyra-
mide,
[1158]
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4'-o--
tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramid-
e,
[1159]
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4'-o--
tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramid-
e,
[1160]
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-is-
obutyramide,
[1161]
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-3,4-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-is-
obutyramide,
[1162]
(2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-4-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-N-methyl-isobutyramide,
[1163]
(2RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-2-hydroxy-
methyl-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl)-N-methyl- -isobutyramide,
[1164]
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxy-
methyl-4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl--
isobutyramide,
[1165]
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxy-
methyl-4-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-i-
sobutyramide,
[1166]
(3RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide,
[1167]
(3RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-4-hydroxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide and
[1168]
(2RS,3RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl-
)-3-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide.
[1169] Other compounds of formula I are specific compounds of
formula IE 13
[1170] wherein
[1171] R.sup.1 is phenyl, unsubstituted or substituted by one or
more substituents selected from the group consisting of alkyl,
alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl
and --NR'S(O).sub.2-alkyl;
[1172] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[1173] R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with
[1174] --(CH.sub.2).sub.c--NR'--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[1175] by one or more substituents selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[1176] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R";
[1177] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl;
[1178] R" is hydrogen or alkyl;
[1179] b is 1 or 2;
[1180] c is 1, 2, or 3;
[1181] d is 0, 1, 2, or 3; and
[1182] e is 3, 4, or 5;
[1183] or a pharmaceutically active acid-addition salt thereof.
[1184] Examples of compounds of formula IE are
[1185]
N-[6-(4-acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2--
(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1186]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cycl-
opropanecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1187]
N-[6-(4-acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1188]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(5-oxo-diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1189]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(3-methanesulfonyl-imidazolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de,
[1190]
N-[6-(3-acetyl-imidazolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyri-
din-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1191]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazi-
n-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1192]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-meth-
anesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1193]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1194]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1195]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1196]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethanesulfonyl-piperazin-
-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1197]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-chloromethanesulfonyl-pi-
perazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyr-
amide,
[1198]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-dimethylsulfamoyl-pipera-
zin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
[1199]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1200]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1201]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4--
methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide,
[1202]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2-me-
thyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1203]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1204]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-4-
-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide,
[1205]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(-4-methanesulfonyl-3-m-
ethyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1206]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1207]
(2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methy-
l-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]--
N-methyl-isobutyramide,
[1208]
(2S,6R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-methanesulfonyl-2,6-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N--
methyl-isobutyramide,
[1209]
(3S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-methanesulfonyl-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N--
methyl-isobutyramide,
[1210]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[1211]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-formyl-2-hydroxymethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide,
[1212]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-cyclopropanecarbonyl-
-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl-
]-N-methyl-isobutyramide,
[1213]
(S)-N-[6-(4-acetyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-me-
thyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-iso-
butyramide,
[1214]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxymethy-
l-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isob-
utyramide,
[1215]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[1216]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-4-meth-
anesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide-
,
[1217]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide,
[1218]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1219]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-3,3-dime-
thyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1220]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl-
)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide,
[1221]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-2,2-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1222]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2,2-dime-
thyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1223]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperaz-
in-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
[1224]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide,
[1225]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-meth-
anesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1226]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1227]
2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-
-tolyl-pyridin-3-yl)-isobutyramide and
[1228]
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazi-
n-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
[1229] Additional compounds of formula I are compounds of formula
IF 14
[1230] wherein
[1231] R.sup.1 is phenyl, unsubstituted or substituted by one or
more substituents selected from the group consisting of alkyl,
alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl,
and --NR'S(O).sub.2-alkyl,
[1232] or is heteroaryl selected from the group consisting of
pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is
unsubstituted or substituted by alkyl, halogen or alkoxy;
[1233] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3; and
[1234] R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with
[1235] --(CH.sub.2).sub.c--O--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[1236] by one or more substituent selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O,
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.e, or
[1237] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R";
[1238] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl;
[1239] R" is hydrogen or alkyl;
[1240] b is 1 or 2;
[1241] c is 1, 2, or 3;
[1242] d is 0, 1, 2, or 3; and
[1243] e is 3, 4, or 5;
[1244] or a pharmaceutically active acid-addition salt thereof.
[1245] Compounds of formula IF include
[1246]
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e,
[1247]
(R)-(2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morph-
olin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1248]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-morph-
olin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide,
[1249]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide and
[1250]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-morpholin-4-yl-pyridin-3-yl]-N-methyl-isobutyramide.
[1251] Formula I also encompasses compounds of formula IG I 15
[1252] wherein
[1253] R.sup.1 is phenyl, unsubstituted or substituted by one or
more substituents selected from the group consisting of alkyl,
alkoxy, halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN,
S-alkyl, --S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl
and --NR'S(O).sub.2-alkyl;
[1254] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[1255] R.sup.4 and R.sup.5 form together with the N-atom to which
they are attached a ring with
[1256] --(CH.sub.2).sub.c--S(O).sub.f--(CH.sub.2).sub.2--, which is
unsubstituted or substituted
[1257] by one or more substituents selected from the group
consisting of lower alkyl, halogen, --(CR'R").sub.dOH, .dbd.O, and
--NR'R", wherein R' and R" may form together with the N-atom to
which they are attached a ring with --(CH.sub.2).sub.d, or
[1258] by --(CH.sub.2).sub.dNR'--C(O)-alkyl,
--(CH.sub.2).sub.d--C(O)-alky- l,
--(CH.sub.2).sub.d--C(O)-cycloalkyl, --(CH.sub.2).sub.dOC(O)NR'R",
--(CH.sub.2).sub.d--S(O).sub.2-alkyl,
--(CH.sub.2).sub.d-pyrrolidinyl or --C(O)NR'R";
[1259] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl;
[1260] R" is hydrogen or alkyl;
[1261] b is 1 or 2;
[1262] c is 1, 2, or 3;
[1263] d is 0, 1, 2, 3 or 4; and
[1264] e is 3, 4, or 5; and
[1265] f is 0, 1, or 2;
[1266] or a pharmaceutically active acid-addition salt thereof.
[1267] Examples of compounds of formula IG include
[1268]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide,
[1269]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-d-
ioxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl--
isobutyramide,
[1270]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-thiazolidin-3-yl-pyridin-3-yl]-N-methyl-isobutyramide,
[1271] (1RS,4RS)- or
(1RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4--
fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolid-
in-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric
racemate of Example 349),
[1272] (1RS,4SR)- or
(1RS,4RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4--
fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolid-
in-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric
racemate of Example 348),
[1273]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(4-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiazolidin-3-yl)-pyridi-
n-3-yl]-N-methyl-isobutyramide,
[1274]
(+)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-di-
oxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1275]
(-)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-di-
oxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-i-
sobutyramide,
[1276]
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(1-oxo-l.lambda..sup.4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl--
isobutyramide,
[1277]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6--
[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide and
[1278]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6--
[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide.
[1279] The invention relates also to compounds of formula I,
wherein R.sup.1 is unsubstituted or substituted phenyl as described
above and R.sup.4 and R.sup.5 form together with the N-atom to
which they are attached a ring with
--CH.sub.2CH.dbd.CH--CH.sub.2--, which is unsubstituted or
mono-substituted by --(CR'R").sub.dOH. An example of such a
compound
[1280]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide.
[1281] Other compounds of formula I are compounds of formula IH
16
[1282] wherein
[1283] R.sup.1 is heteroaryl selected from the group consisting of
pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is
unsubstituted or substituted by alkyl, halogen or alkoxy;
[1284] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[1285] and the other substituents are as described in formula I
above.
[1286] Examples for compounds of formula IH are
[1287]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(3,5-dimethyl-isoxa-
zol-4-yl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-me-
thyl-isobutyramide,
[1288]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-2,6-dimethoxy-[3,4']bipyridinyl-3'-yl]-N-methyl--
isobutyramide,
[1289]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-chloro-6'-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[1290]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[1291]
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6'-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[1292]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[2-chloro-6'-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[1293]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[1294]
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[3-chloro-6'-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[1295]
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(3-hydroxy-2-hydro-
xymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobu-
tyramide,
[1296]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(2-hydroxymethyl-pyrro-
lidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramide,
[1297] N-{6'
[bis-(2-hydroxy-ethyl)-amino]-2-methyl-[3,4']bipyridinyl-3'-y-
l}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide,
[1298]
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(2-hydroxymethyl-pyrro-
lidin-1-yl)-4-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramide,
[1299]
N-{6'-[bis-(2-hydroxy-ethyl)-amino]-4-methyl-[3,4']bipyridinyl-3'-y-
l}-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
and
[1300]
2-(3,5-bis-trifluoromethyl-phenyl)-N-{6'-[(2-hydroxy-ethyl)-methyl--
amino]-4-methyl-[3,4']bipyridinyl-3'-yl}-N-methyl-isobutyramide.
[1301] Also encompassed by formula I are compounds of compounds of
formula I J, 17
[1302] wherein
[1303] R.sup.1 is aryl, unsubstituted or substituted by one or more
substituents selected from the group consisting of alkyl, alkoxy,
halogen, --(CH.sub.2).sub.dOH, --C(O)H, CF.sub.3, CN, S-alkyl,
--S(O).sub.b-alkyl, --C(O)NR'R", --NR'R", --NR'C(O)-alkyl, and
--NR'S(O).sub.2-alkyl,
[1304] or is heteroaryl, selected from the group consisting of
pyridin-2-or 3-yl, imidazolyl and oxazolyl, each of which is
unsubstituted or substituted by alkyl, halogen or alkoxy;
[1305] R.sup.2 and R.sup.3 are each independently hydrogen,
halogen, alkyl, alkoxy, OCHF.sub.2, OCH.sub.2F, OCF.sub.3 or
CF.sub.3;
[1306] --NR.sup.4R.sup.5 are 18
[1307] R' is hydrogen, alkyl, --(CH.sub.2).sub.dOH, --C(O)H,
--C(O)-alkyl, --C(O)-cycloalkyl, --S(O).sub.2-alkyl,
--S(O).sub.2-halogen-alkyl, --S(O)-alkyl, --S-alkyl or
--S(O).sub.2--N-di-alkyl,
[1308] R" is hydrogen or alkyl;
[1309] b is 1 or 2;
[1310] d is 0, 1, 2, or 3; and
[1311] f is 0, 1, or 2;
[1312] or a pharmaceutically active acid-addition salt thereof.
[1313] Examples of such compounds are
[1314]
(1S,3R,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1315]
(1R,3S,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide,
[1316]
(rac)-(1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridi-
n-3-yl]-N-methyl-isobutyramide,
[1317]
(1R,3R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(3-methanesulfonyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide,
[1318]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide,
[1319]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4,4-dioxo-1-oxa-l.lambda..-
sup.6-thia-8-aza-spiro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin--
3-yl]-N-methyl-isobutyramide,
[1320]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1-oxa-5-thia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide,
[1321]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(5,5-dioxo-1-oxa-5.lambda..-
sup.6-thia-9-aza-spiro
[5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyrid-
in-3-yl]-N-methyl-isobutyramide,
[1322]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1,1,4,4-tetraoxo-l.lambda..sup.6,4.lambda..sup.6-dithia-8-aza-spiro[4.5-
]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1323]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1,1,5,5-tetraoxo-l.lambda..sup.6,5.lambda..sup.6-dithia-9-aza-spiro[5.5-
]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1324]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(1-oxa-8-aza-spiro
[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide,
[1325]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[(1S,5R)-4-(4-fluoro-2-methyl--
phenyl)-6-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-isobut-
yramide,
[1326]
(1S,5R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(8,8-dioxo-8%-thia--
3-aza-bicyclo
[3.2.1]oct-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]--
N-methyl-isobutyramide,
[1327]
(1S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-((1S,4S)-5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-py-
ridin-3-yl]-N-methyl-isobutyramide and
[1328]
(1R,5S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(8-methanesulfonyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide.
[1329] The present compounds of formula I and their
pharmaceutically acceptable salts can be prepared by methods known
in the art, described in schemes 1 to 14 and in specific examples 1
to 421 and, for example, by a process described below, which
process comprises
[1330] a) reacting a compound of formula 19
[1331] with a compound of formula
NHR.sup.4R.sup.5 III
[1332] to produce a compound of formula 20
[1333] wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have
the significances given above, or
[1334] b) reacting a compound of formula 21
[1335] with a compound of formula
R.sup.1--B(OH).sub.2 or 22
[1336] or
R.sup.1--ZnCl
[1337] to produce a compound of formula 23
[1338] wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have
the significances given above, and
[1339] if desired, modifying one or more substituents
R.sup.1-R.sup.5 within the definitions given above, and
[1340] if desired, converting the compound obtained into a
pharmaceutically acceptable acid addition salt.
[1341] In general, the compounds of formula I may be prepared as
follows:
[1342] a) To a solution of a compound of formula II, for example
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-m-
ethyl-isobutyramide and an amine of formula III, for example
L-prolinol in dimethyl sulfoxide, Na.sub.2CO.sub.3 or
K.sub.2CO.sub.3 is added, and the solution is stirred at
120-150.degree. C. for about 22 h. After cooling to ambient
temperature, the solution is worked up in conventional manner
or
[1343] b) A mixture of a compound of formula IV,
2-chlorophenylboronic acid, palladium(II)acetate,
triphenylphosphine, sodium carbonate and dimethoxyethane is heated
at about 80.degree. C. for 90 min. Then the reaction mixture is
cooled to room temperature, worked up and purified.
[1344] The salt formation is effected at room temperature in
accordance with methods which are known per se and which are
familiar to any person skilled in the art. Not only salts with
inorganic acids, but also salts with organic acids come into
consideration. Hydrochlorides, hydrobromides, sulphates, nitrates,
citrates, acetates, maleates, succinates, methan-sulphonates,
p-toluenesulphonates and the like are examples of such salts.
[1345] The following schemes 1-14 describe the processes for
preparation of compounds of formula I in more detail. The starting
materials are known compounds, described in EP 1035115, WO 02/08232
or WO 02/16324, or they may be prepared according to methods known
in the art. Furthermore, the preparation of intermediates 1, 2,
3A-3L, 4A-4L and 5A-5I are described in more detail in the
experimental part.
[1346] In the schemes the following abbreviations have been
used:
1 DMF N,N-dimethylformamide TFA trifluoroacetic acid DME ethylene
glycol dimethyl ether KHMDS potassium hexamethyldisilazide DMSO
di-methyl sulfoxide TBDMS tert-butyldimethylsilyl-protecting group
THF tetrahydrofuran Oxone potassium peroxymonosulfate DEAD diethyl
azodicarboxylate DIAD diisopropyl azodicarboxylate DMAP
4-(N,N-dimethylamine)pyridine RT room temperature DBU
1,8-diazabicyclo[5.4.0]undec-7-ene MW microwave MCPBA
3-chloroperbenzoic acid
[1347] 2425 2627
[1348] wherein R.sup.1, R.sup.2, R.sup.4 and R.sup.5 have the
meaning as described above. 28
[1349] wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have
the meaning as described above. 29
[1350] wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.5 have the
meaning as described above. 30
[1351] wherein R.sup.1, R.sup.2 and R.sup.3, have the meaning as
described above. 31
[1352] wherein R.sup.1, R.sup.2 and R.sup.3 have the meaning as
described above.
Method 7
[1353] The present compounds of formula I and their
pharmaceutically acceptable salts can be prepared by
[1354] reacting a compound of formula 32
[1355] wherein R.sup.4 or R.sup.5 contain an --OH substituent to
form a compound of formula I in which the absolute configuration at
the carbon center, to which the --OH group is attached, is
reversed. This is effected by reacting the compound of formula I
wherein R.sup.4 or R.sup.5 contain an --OH substituent with
triphenylphosphine, diethyl or diisopropyl azodicarboxylate and
benzoic acid in THF followed by treatment with sodium methylate or
sodium hydroxide in methanol. 33 34 35 36 37 38 39
Method 15
[1356] The present compounds of formula I and their
pharmaceutically acceptable salts can be prepared by
[1357] reacting a compound of formula 40
[1358] wherein R.sup.4 or R.sup.5 contain an --OH substituent to
form a compound of formula I in which the --OH group has been
transformed into an --S-alkyl, --S(O)-alkyl or S(O).sub.2-alkyl
group under inversion of the absolute configuration at the carbon
center to which the --OH group has been attached using the
following procedure:
[1359] The --OH group is first transformed into a
--OS(O).sub.2CH.sub.3 group by reaction with methanesulfonyl
chloride and triethylamine in dichloromethane. By treatment with
the salt of a thioalkane such as sodium methanethiolate in methanol
or DMF the --OS(O).sub.2CH.sub.3 group is further transformed into
the --S-alkyl group. The --S-alkyl group can be oxidized to an
--S(O)-alkyl group by treatment with Oxone in methanol or MCPBA in
dichloromethane. The compounds of formula I containing an
--S(O)-alkyl group can be isolated or oxidized further without
isolation to compounds containing an --S(O).sub.2-alkyl group by
treatment with Oxone in methanol or MCPBA in dichloromethane
(Examples 331 and 388).
Method 16
[1360] The present compounds of formula I and their
pharmaceutically acceptable salts can be prepared by
[1361] reacting a compound of formula 41
[1362] wherein R.sup.4 or R.sup.5 contain an --OH substituent to
form a compound of formula I in which the --OH group has been
transformed into an --S(O).sub.2--NR'R" group under inversion of
the absolute configuration at the carbon center to which the --OH
group has been attached using the following procedure:
[1363] The --OH group is transformed into a --SC(O)CH.sub.3 group
by reaction with triphenylphosphine, diethyl azodicarboxylate and
thioacetic acid in THF. The --SC(O)CH.sub.3 group is oxidized to an
--SO.sub.3H group by reaction with an aqueous solution of hydrogen
peroxide in acetic acid. Compounds containing the --SO.sub.3H are
treated consecutively with oxalyl chloride and a catalytic amount
of DMF in dichloromethane and an amine to form compounds of formula
I wherein R or R.sup.5 contain an --S(O).sub.2--NR'R" group.
[1364] As mentioned earlier, the compounds of formula I and their
pharmaceutically usable addition salts possess valuable
pharmacological properties. It has been found that the compounds of
the present invention are dual antagonists of the Neurokinin 1 and
3 receptors.
[1365] The compounds were investigated in accordance with the tests
given hereinafter.
NK.sub.1
[1366] The affinity of test compounds for the NK.sub.1 receptor was
evaluated at human NK.sub.1 receptors in CHO cells infected with
the human NK.sub.1 receptor (using the Semliki virus expression
system) and radiolabelled with [.sup.3H]substance P (final
concentration 0.6 nM). Binding assays were performed in HEPES
buffer (50 mM, pH 7.4) containing BSA (0.04%) leupeptin (16.8
.mu.g/ml), MnCl.sub.2 (3 mM) and phosphoramidon (2 .mu.M). Binding
assays consisted of 250 .mu.l of membrane suspension (approximately
1.5 .mu.g/well in a 96 well plate), 0.125 .mu.l of buffer of
displacing agent and 125 .mu.l of [.sup.3H]substance P.
Displacement curves were determined with at least seven
concentrations of the compound. The assay tubes were incubated for
60 min at room temperature after which time the tube contents were
rapidly filtered under vacuum through GF/C filters presoaked for 60
min with PEI (0.3%) with 3.times.1 ml washes of HEPES buffer (50
mM, pH 7.4). The radioactivity retained on the filters was measured
by scintillation counting. All assays were performed in duplicate
in at least 2 separate experiments.
NK.sub.3
[1367] Recombinant human NK.sub.3 (hNK.sub.3) receptor affinity was
determined in a 96 well plate assay, using [.sup.3H]SR142801 (final
concentration 0.3 nM) to radiolabel the hNK.sub.3 receptor in the
presence of 10 concentrations of competing compound or buffer. Non
specific binding was determined using 10 .mu.M SB222200. Assay
buffer consisted of Tris-HCl (50 mM, pH 7.4), BSA (0.1%),
MnCl.sub.2 (4 mM) and phosphoramidon (1 .mu.M). Membrane
preparations of hNK3 receptors (approximately 2.5 .mu.g/well in a
96 well plate) were used to initiate the incubation for 90 min at
room temperature. This assay was terminated by rapid filtration
under vacuum through GF/C filters, presoaked for 90 min with PEI
(0.3%), with 3.times.0.5 ml washes of ice-cold Tris buffer (50 mM,
pH 7.4) containing 0.1% BSA. The radioactivity retained on the
filters was measured by scintillation counting. All assays were
performed in duplicate in at least two separate experiments.
[1368] The activity of the present compounds is described in the
table below:
2 Subst. pKi on R.sup.1 R.sup.2/R.sup.3 R.sup.4 R.sup.5 R.sup.1
NK1/NK3 Expl. 2-Cl 3,5-di Cl --(CH.sub.2).sub.2OH H phenyl
8.56/8.05 1 2-Cl 3,5-di Cl are together with the N-atom phenyl
8.47/9.05 2 42 2-Cl 3,5-di Cl are together with the N-atom phenyl
8.85/9.06 3 43 2-Cl 3-F/5-CF.sub.3 are together with the N-atom
phenyl 8.35/8.81 4 44 2-Cl 3-F/5-CF.sub.3 are together with the
N-atom phenyl 8.81/8.76 5 45 2-Cl 3,5-di-F are together with the
N-atom phenyl 8.14/8.31 6 46 2-Cl 3-OCH.sub.3/ are together with
the N-atom phenyl 8.32/8.75 7 5-Cl 47 2-Cl 3-OCH.sub.3/ are
together with the N-atom phenyl 8.77/8.90 8 5-Cl 48 2-Cl 3,5-di-
are together with the N-atom phenyl 8.19/8.44 9 CH.sub.3 49 2-Cl
3,5-di- are together with the N-atom phenyl 8.67/8.44 10 50
2-CH.sub.3 3,5-di-Cl are together with the N-atom phenyl 8.75/8.96
11 51 2-CH.sub.3 3,5-di-Cl are together with the N-atom phenyl
8.95/8.86 12 52 2-CH.sub.3 3-CF.sub.3/ are together with the N-atom
phenyl 8.66/8.81 13 5-F 53 2-CH.sub.3 3-F/5-CF.sub.3 are together
with the N-atom phenyl 8.89/8.52 14 54 2-CH.sub.3 3,5-di-F are
together with the N atom phenyl 8.20/8.35 15 55 2-CH.sub.3 3,5-di-F
are together with the N-atom phenyl 8.58/8.39 16 56 2-CH.sub.3
3-OCH.sub.3/ are together with the N-atom phenyl 8.41/8.50 17 5-Cl
57 2-CH.sub.3 3-OCH.sub.3/ are together with the N-atom phenyl
8.93/8.60 18 5-Cl 58 2-CH.sub.3 3,5-di-CH.sub.3 are together with
the N-atom phenyl 8.53/8.29 19 59 2-CH.sub.3 3,5-di-CH.sub.3 are
together with the N-atom phenyl 8.94/8.21 20 60 2-CH.sub.3/4-F
3,5-di-Cl --(CH.sub.2).sub.2OH H phenyl 8.89/8.06 21 2-CH.sub.3/4-F
3,5-di-Cl are together with the N-atom phenyl 8.29/8.93 22 61
2-CH.sub.3/4-F 3,5-di-Cl are together with the N-atom phenyl
9.05/8.80 23 62 2-CH.sub.3/4-F 3-CF.sub.3/5-F are together with the
N-atom phenyl 8.88/9.05 24 63 2-CH.sub.3/4-F 3-CF.sub.3/5-F are
together with the N-atom phenyl 9.03/8.76 25 64 2-CH.sub.3/4-F
H/5-CF.sub.3 are together with the N-atom phenyl 8.52/8.24 26 65
2-CH.sub.3/4-F H/5-CF.sub.3 are together with the N-atom phenyl
8.82/7.97 27 66 2-CH.sub.3/4-F 3,5-di-F are together with the
N-atom phenyl 8.55/8.40 28 67 2-CH.sub.3/4-F 3,5-di-F are together
with the N-atom phenyl 8.81/8.45 29 68 2-CH.sub.3/4-F
3-OCH.sub.3/5-Cl are together with the N-atom phenyl 8.43/8.45 30
69 2-CH.sub.3/4-F 3-OCH.sub.3/5-Cl are together with the N-atom
phenyl 9.01/8.78 31 70 2-CH.sub.3/4-F 3,5-di-CH.sub.3 are together
with the N-atom phenyl 8.51/8.52 32 71 2-CH.sub.3/4-F
3,5-di-CH.sub.3 are together with the N-atom phenyl 8.93/8.52 33 72
2-Cl 3-OCHF.sub.2/ are together with the N-atom phenyl 8.41/9.08 34
5-Cl 73 2-Cl 3-OCHF.sub.2/ are together with the N-atom phenyl
8.71/9.26 35 5-Cl 74 2-CH.sub.3 3-OCHF.sub.2/ are together with the
N-atom phenyl 8.37/9.15 36 5-Cl 75 2-CH.sub.3 3-OCHF.sub.2/ are
together with the N-atom phenyl 8.92/9.21 37 5-Cl 76 2-CH.sub.3/4-F
3-OCHF.sub.2/ are together with the N-atom phenyl 8.45/8.65 38 77
2-CH.sub.3/4-F 3-OCHF.sub.2/ are together with the N-atom phenyl
8.98/8.89 39 78 2-Cl 3,5-di-CF.sub.3 are together with the N-atom
phenyl 9.19/8.99 40 79 2-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.97/8.12 41 80 2-Cl 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.78/9.08 42 81 2-Cl 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.62/7.45 43 82 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 9.20/7.81 44 83
2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl 8.64/8.70
45 84 2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
9.22/8.06 46 85 2-Cl 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.71/8.20 47 86 2-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 9.27/8.06 48 87 2-Cl 3,5-di-CF.sub.3 are together
with the N-atom phenyl 9.32/7.83 49 88 2-Cl 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.85/7.84 50 89 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 9.19/7.54 51 90
2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl 8.96/8.10
52 91 2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.60/7.61 53 92 2-Cl 3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH
--CH.sub.3 phenyl 9.00/8.57 54 2-Cl 3,5-di-CF.sub.3
--(CH.sub.2).sub.2OH --CH.sub.2CH.sub.3 phenyl 8.48/7.95 55 2-Cl
3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH --(CH.sub.2).sub.2CH.sub.3
phenyl 8.34/8.28 56 2-Cl 3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH
--(CH.sub.2).sub.3CH.sub.3 phenyl 8.00/7.56 57 2-Cl 3,5-di-CF.sub.3
--CH.sub.2CH(OH) CH.sub.3 phenyl 8.62/8.24 58 CH.sub.2OH 2-Cl
3,5-di-CF.sub.3 CH(CH.sub.2OH) H phenyl 8.49/8.31 59
CH.sub.2CH(CH.sub.3).sub.2 2-Cl 3,5-di-CF.sub.3 93 H phenyl
8.90/8.10 60 2-Cl 3,5-di-CF.sub.3 are together with the N-atom
phenyl 9.38/7.85 61 94 2-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.99/8.18 62 95 2-Cl 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.74/8.93 63 96 2-Cl 3,5-di-CF.sub.3 are
together with the N-atom phenyl 9.00/8.54 64 97 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.94/8.56 65 98
2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl 8.83/8.89
66 99 2-Cl 3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH H phenyl 9.14/7.94
67 2-CH.sub.3/4-F 3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH H phenyl
8.84/8.49 68 2-Cl/4-F 3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH H phenyl
8.95/7.84 69 2-Cl/4-Cl 3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH H
phenyl 8.70/8.39 70 2-Cl/4-Cl 3,5-di-CF.sub.3 100 H phenyl
8.69/8.04 71 2-Cl 3,5-di-CF.sub.3 101 H phenyl 9.14/7.58 72 2-Cl
3,5-di-CF.sub.3 102 H phenyl 9.06/8.13 73 2-Cl 3,5-di-CF.sub.3 103
H phenyl 9.06/8.24 74 2-Cl 3,5-di-CF.sub.3 104 H phenyl 8.77/7.91
75 2-Cl 3,5-di-CF.sub.3 105 H phenyl 8.80/7.97 76 2-CH.sub.3/4-F
3,5-di-CF.sub.3 106 H phenyl 9.19/8.32 77 2-Cl 3,5-di-CF.sub.3 107
H phenyl 8.55/8.21 78 2-Cl 3,5-di-CF.sub.3 108 H phenyl 8.87/7.98
79 2-Cl 3,5-di-CF.sub.3 109 H phenyl 8.90/8.05 80 2-Cl
3,5-di-CF.sub.3 110 H phenyl 8.68/8.25 81 2-Cl 3,5-di-CF.sub.3 111
112 phenyl 9.03/9.09 82 2-CH.sub.3 3,5-di-CF.sub.3 113 114 phenyl
8.93/8.96 83 2-CH.sub.3/4-F 3,5-di-CF.sub.3 115 116 phenyl
8.47/8.76 84 2-CH.sub.3/4-F 3,5-di-CF.sub.3 117 118 phenyl
8.63/8.64 85 2-Cl/4-Cl 3,5-di-CF.sub.3 119 120 phenyl 8.78/8.45 86
3-Cl/4-Cl 3,5-di-CF.sub.3 121 122 phenyl 8.80/8.02 87 4-F
3,5-di-CF.sub.3 123 124 phenyl 8.87/8.03 88 2-Cl 3,5-di-CF.sub.3
125 H phenyl 9.31/8.49 89 2-Cl 3,5-di-CF.sub.3 126 H phenyl
8.75/8.22 90 2-Cl/4-Cl 3,5-di-CF.sub.3 127 H phenyl 8.61/8.25 91
2-CH.sub.3/4-F 3,5-di-CF.sub.3 128 H phenyl 8.99/7.67 92
2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.95/8.13 93 129 2-Cl/4-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.37/7.83 94 130 3-Cl/4-Cl 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.42/8.03 95 131 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.16/7.84 96
132 2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
9.13/8.89 97 133 2-Cl 3,5-di-CF.sub.3 are together with the N-atom
phenyl 9.16/8.46 98 134 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together
with the N-atom phenyl 9.09/7.26 99 135 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.74/7.70 100
136 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.77/8.03 101 137 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.71/7.88 102 138 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.78/7.80 103
139 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.79/8.17 104 140 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.99/8.28 105 141 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 9.23/8.33 106
142 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.63/7.93 107 143 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are
together with the N atom phenyl 8.61/8.05 108 144 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N atom phenyl 8.69/7.87 109
145 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.58/7.86 110 146 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.68/8.39 111 147 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 9.25/8.26 112
148 2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.24/8.46 113 149 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 9.22/7.79 114 150 4-F 3,5-di-CF.sub.3
--(CH.sub.2).sub.2OH CH.sub.3 phenyl 8.73/7.52 115 4-F
3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH CH.sub.2CH.sub.3 phenyl
8.41/7.49 116 2-CH.sub.3 3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH
CH.sub.3 phenyl 8.68/8.51 117 2-CH.sub.3 3,5-di-CF.sub.3
--(CH.sub.2).sub.2OH CH.sub.2CH.sub.3 phenyl 8.44/8.34 118
2-CH.sub.3 3,5-di-CF.sub.3 --(CH.sub.2).sub.2OH
CH.sub.2CH.sub.2CH.sub.3 phenyl 8.40/8.64 119 2-CH.sub.3
3,5-di-CF.sub.3 151 H phenyl 8.86/8.00 120 2-CH.sub.3
3,5-di-CF.sub.3 152 153 phenyl 8.54/7.96 121 2-CH.sub.3
3,5-di-CF.sub.3 154 H phenyl 8.72/7.71 122 2-CH.sub.3
3,5-di-CF.sub.3 155 H phenyl 8.60/7.90 123 2-Cl 3,5-di-CF.sub.3 156
157 phenyl 8.58/7.86 124 2-Cl 3,5-di-CF.sub.3 158 H phenyl
8.55/7.86 125 2-Cl 3,5-di-CF.sub.3 159 H phenyl 8.60/8.11 126
2-CH.sub.3/3-F 3,5-di-CF.sub.3 160 161 phenyl 8.66/8.82 127
2-CH.sub.3/5-F 3,5-di-CF.sub.3 162 163 phenyl 8.58/8.25 128 2-Br
3,5-di-CF.sub.3 are together with the N-atom phenyl 9.07/8.58 129
164 2-Br 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.78/8.64 130 165 2-Br 3,5-di-CF.sub.3 166 H phenyl 8.97/8.37 131
2-Br 3,5-di-CF.sub.3 167 H phenyl 8.88/8.14 132 2-Br
3,5-di-CF.sub.3 are together with the N-atom phenyl 9.10/8.70 133
168 2-Br 3,5-di-CF.sub.3 169 170 phenyl 8.65/8.66 134 3,4-di-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.37/7.50 135
171 2,4-di-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.79/8.84 136 172 2,4-di-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.55/8.87 137 173 2-Cl 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.78/9.00 138 174 2-Cl 3,5-di-CF.sub.3 are
together with the N-atom phenyl 9.17/7.90 139 175 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 9.11/8.83 140
176 2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.19/7.73 141 177 2-CH.sub.3/4-F 3,5-di-CF.sub.3 178 H phenyl
8.89/8.59 142 2-CH.sub.3 3,5-di-CF.sub.3 179 H phenyl 8.52/8.44 143
2-Cl 3,5-di-CF.sub.3 180 H phenyl 8.44/8.92 144 2-Cl
3,5-di-CF.sub.3 181 H phenyl 9.08/8.10 145 2-Cl 3,5-di-CF.sub.3 182
H phenyl 9.05/7.93 146 2-Cl 3,5-di-CF.sub.3 183 H phenyl 9.14/7.98
147 2-Cl 3,5-di-CF.sub.3 (CH.sub.2).sub.2OH
(CH.sub.2).sub.5CH.sub.3 phenyl 8.68/7.92 148 2-Cl 3,5-di-CF.sub.3
(CH.sub.2).sub.2OH (CH.sub.2).sub.4CH.sub.3 phenyl 8.89/8.21 149
2-Cl 3,5-di-CF.sub.3 (CH.sub.2).sub.3OH (CH.sub.2).sub.2OH phenyl
8.88/9.01 150 2-Cl 3,5-di-CF.sub.3 184 H phenyl 8.94/7.56 151 2-Cl
3,5-di-CF.sub.3 185 H phenyl 9.12/8.11 152 2-Cl 3,5-di-CF.sub.3 186
H phenyl 9.31/8.39 153 2-CH.sub.3/4-F 3,5-di-CF.sub.3 187 H phenyl
8.50/8.24 154 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.76/9.06 155 188 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.76/8.80 156 189 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.60/8.80 157
190 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.78/9.02 158 191 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.75/8.02 159 192 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.69/7.52 160
193 2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
7.94/8.17 161 194 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 8.68/7.73 162 195 2-CH.sub.3 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.74/7.55 163 196 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.79/7.80 164
197 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.68/8.96 165 198 2-CH.sub.3/5-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.42/8.92 166 199 2-CH.sub.3/3-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.35/9.01 167
200 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.68/8.00 168 201 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 8.85/7.67 169 202 2-CH.sub.3/4-F 3,5-di-CF.sub.3
are together with the N-atom phenyl 8.71/8.04 170 203 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.43/7.61 171
204 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.15/7.89 172 205 2-CH.sub.3 3,5-di-CF.sub.3 206 H phenyl 8.72/8.73
173 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.78/8.59 174 207 2-CH.sub.3 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.79/8.67 175 208 2-CH.sub.3 3,5-di-CF.sub.3
are together with the N-atom phenyl 8.68/7.58 176 209
2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.92/8.58 177 210 2-CH.sub.3 3,5-di-CF.sub.3 are together with the
N-atom phenyl 9.03/8.46 178 211 2-CH.sub.3 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.82/8.39 179 212 2-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.79/8.49
180
213 2-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.70/8.47 181 214 2-Cl 3,5-di-CF.sub.3 are together with the N-atom
phenyl 9.03/7.49 182 215 2-CH.sub.3 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.96/7.57 183 216 2-CH.sub.3 3,5-di-CF.sub.3
are together with the N-atom phenyl 8.91/7.70 184 217 2-CH.sub.3
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.81/7.49 185
218 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.85/7.91 186 219 2-Cl 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.78/7.59 187 220 2-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.88/7.81 188 221 2-Cl 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.82/8.40 189 222 2-CH.sub.3 3,5-di-CF.sub.3
are together with the N-atom phenyl 8.80/8.39 190 223 2-CH.sub.3
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.69/7.61 191
224 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.52/7.46 192 225 2-Cl 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.84/7.92 193 226 2-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.78/7.76 194 227 2-Cl 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.74/7.54 195 228 2-CH.sub.3/4-F
3,5-di-CF.sub.3 229 CH.sub.3 phenyl 8.76/8.34 196 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.54/8.41 197
230 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.75/8.96 198 231 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.60/7.81 199 232 4-CH.sub.3
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.63/7.74 200
233 -- 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.83/8.06 201 234 4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.92/8.13 202 235 4-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.69/7.98 203 236 4-N(CH.sub.3).sub.2 3,5-di-CF.sub.3
are together with the N-atom phenyl 7.82/7.83 204 237 3-Br
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.71/8.07 205
238 3-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.73/7.80 206 239 3-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.86/8.33 207 240 3,5-di-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 8.87/8.21 208 241 3,4-di-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.87/8.46 209 242 3-F/4-CH.sub.3
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.64/7.86 210
243 3-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.78/7.81 211 244 3-Cl/4-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 9.09/8.60 212 245 2-NH.sub.2 3,5-di-CF.sub.3 are
together with the N-atom phenyl 9.18/8.49 213 246 2-OCH.sub.3
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.99/8.56 214
247 2-OH 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.99/8.35 215 248 2-CH.sub.3 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.87/9.10 216 249 2-SCH.sub.3 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.98/8.62 217 250
2-SO.sub.2CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.58/8.14 218 251 2-CONH.sub.2 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.84/7.69 219 252 2,4-di-F 3,5-di-CF.sub.3
are together with the N-atom phenyl 8.82/8.18 220 253 2-Cl/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 9.03/8.28 221
254 2-CHO/4-F 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.98/8.99 222 255 2-CH.sub.2OH/ 3,5-di-CF.sub.3 are together with
the N-atom phenyl 9.15/8.51 223 4-F 256 2-CHO 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.95/8.82 224 257 2-CH.sub.2OH
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.78/8.59 225
258 2,5-di-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.11/7.78 226 259 2-CH.sub.3/5-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 8.96/8.86 227 260 2-CH.sub.3/3-F 3,5-di-CF.sub.3
are together with the N-atom phenyl 8.93/8.85 228 261 2,3-di-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.53/8.73 229
262 3,5-di-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom
Isoxazol-4-yl 9.13/8.57 230 263 2,4-di-OCH.sub.3 3,5-di-CF.sub.3
are together with the N-atom Pyridin-3-yl 8.61/7.85 231 264 2-Cl
3,5-di-CF.sub.3 are together with the N-atom Pyridin-3-yl 9.24/8.87
232 265 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom
Pyridin-3-yl 9.37/8.41 233 266 3-Cl 3,5-di-CF.sub.3 are together
with the N-atom Pyridin-2-yl 8.66/7.96 234 267 2-Cl/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.78/8.90 235
268 2,4-di-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.75/8.75 236 269 2,4-di-F 3,5-di-CF.sub.3 are togethet with the
N-atom phenyl 8.99/8.11 237 270 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.91/8.99 238 271 2-CHO/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.79/8.83 239
272 2-CH.sub.2OH/ 3,5-di-CF.sub.3 are together with the N-atom
phenyl 9.10/8.52 240 4-F 273 2-CH.sub.3 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.84/8.79 241 274 2-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.88/8.16 242
275 2-CF.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.41/8.33 243 276 2-OCH.sub.3 3,5-di-CF.sub.3 are together with the
N-atom phenyl 9.00/8.15 244 277 2-CN 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.92/8.96 245 278 2-Br 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.72/8.83 246 279 --
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.82/7.80 247
280 3-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.66/7.56 248 281 2-CH.sub.3/3-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.70/8.99 249 282 2-CH.sub.3/5-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.71/8.70 250
283 3-F 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.88/8.05 251 284 3,4-di-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.78/8.21 252 285 2,3-di-Cl 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.54/8.50 253 286 2-Cl
3,5-di-CF.sub.3 are together with the N-atom Pyridin-3-yl 9.01/8.51
254 287 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom
Pyridin-3-yl 9.02/7.97 255 288 6-Cl 3,5-di-CF.sub.3 are together
with the N-atom Pyridin-2-yl 8.62/7.70 256 289 2CH.sub.3
3,5-di-CF.sub.3 are together with the N-atom phenyl 257 290
2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.70/8.00 258 291 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 8.78/7.82 259 292 2-CH.sub.3 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.85/7.75 260 293 2-CH.sub.3
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.89/9.04 261
294 2-CF.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.10/8.01 262 295 2-OCH.sub.3 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.99/8.87 263 296 2-F 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.83/8.67 264 297 -- 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.84/8.31 265 298 4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.92/8.42 266
299 4-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.44/7.54 267 300 3,4-di-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.64/8.62 268 301 3-Cl 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.73/8.45 269 302 2,5-di-Cl 3,5-di-CF.sub.3
are together with the N-atom phenyl 8.58/8.66 270 303 2,3-di-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.52/8.86 271
304 2-Cl/4-F 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.70/8.96 272 305 2-CHO/4-F 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.84/8.81 273 306 2-CH.sub.2OH/ 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.89/8.82 274 4-F 307
2-CH.sub.3/3-F 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.83/9.24 275 308 2-CH.sub.3/5-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 8.84/8.86 276 309 2,5-di-F 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.83/8.61 277 310 2-CH.sub.3
3,5-di-CF.sub.3 are together with the N-atom Pyridin-3-yl 9.09/8.57
278 311 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.55/8.93 279 312 2-OCH.sub.3 3,5-di-CF.sub.3 are together
with the N-atom phenyl 8.74/8.73 280 313 2-Br 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.46/8.74 281 314 2-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.51/8.65 282
315 2,4-di-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.55/8.83 283 316 2,5-di-Cl 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.83/8.84 284 317 2,3-di-Cl 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.80/8.73 285 318 3,4-di-Cl
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.87/8.43 286
319 4-Cl 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.20/8.13 287 320 4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.58/8.60 288 321 -- 3,5-di-CF.sub.3 are together with the
N-atom phenyl 8.52/8.30 289 322 2-CH.sub.3 3,5-di-CF.sub.3 are
together with the N-atom Pyridin-3-yl 8.84/8.75 290 323 2-CH.sub.3
3,5-di-CF.sub.3 324 325 Pyridin-3-yl 8.48/8.11 291 6-CH.sub.3
3,5-di-CF.sub.3 are together with the N-atom Pyridin-3-yl 8.44/9.11
292 326 6-CH.sub.3 3,5-di-CF.sub.3 327 328 Pyridin-3-yl 8.42/8.79
293 6-CH.sub.3 3,5-di-CF.sub.3 329 CH.sub.3 Pyridin-3-yl 8.29/8.37
294 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.81/8.78 295 330 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 8.60/8.76 296 331 2-CH.sub.3 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.54/8.88 297 332 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.81/915 298
333 2-CH.sub.3 3,5-di-CF.sub.3 are together with the N-atom phenyl
8.59/8.97 299 334 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with
the N-atom phenyl 9.02/9.31 300 335 2-CH.sub.3 3,5-di-CF.sub.3 are
together with the N-atom phenyl 8.67/8.64 301 336 2-CH.sub.3/4-F
3,5-di-CF.sub.3 are together with the N-atom phenyl 8.60/7.69 302
337 2-CH.sub.3/4-F 3,5-di-CF.sub.3 are together with the N-atom
phenyl 8.88/7.82 303 338 -CH.sub.3/4-F ,5-di-CF.sub.3 are together
with the N-atom phenyl .77/8.73 04 339 -Cl/H ,5-di-CF.sub.3 are
together with the N-atom phenyl .65/8.18 05 340 -CH.sub.3/H
,5-di-CF.sub.3 are together with the N-atom phenyl .76/7.92 06 341
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.06/7.66 07 342 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .65/8.25 08 343 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .67/7.88 09 344 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .83/7.70 10 345
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.93/7.94 11 346 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .65/8.18 12 347 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .93/8.32 13 348 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .90/8.14 14 349
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.99/8.51 15 350 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .88/7.76 16 351 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .97/8.40 17 352 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .11/8.50 18 353
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.12/8.34 19 354 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .90/7.80 20 355 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .81/7.98 21 356 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .75/7.61 22 357
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.15/8.07 23 358 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .67/7.93 24 359 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .05/8.05 25 360 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .87/8.58 26 361
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.91/7.89 27 362 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .70/8.34 28 363 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .63/7.70 29 364 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .92/7.83 30 365
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.02/8.60 31 366 -Cl/H ,5-di-CF.sub.3 are together with the N-atom
phenyl .70/8.04 32 367 -Cl/H ,5-di-CF.sub.3 are together with the
N-atom phenyl .82/8.06 33 368 -Cl/H ,5-di-CF.sub.3 are together
with the N-atom phenyl .01/8.56 34 369 -CH.sub.3/4-F ,5-di-CF.sub.3
are together with the N-atom phenyl .59/8.25 35 370 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .00/8.67 36 371
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.79/7.99 37 372 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .05/8.74
38 373 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom
phenyl .97/7.98 39 374 -CH.sub.3/4-F ,5-di-CF.sub.3 are together
with the N-atom phenyl .88/7.81 40 375 -CH.sub.3/4-F ,5-di-CF.sub.3
are together with the N-atom phenyl .92/8.18 41 376 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .65/8.93 42 377
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.78/7.70 43 378 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .99/7.69 44 379 -CH.sub.3/4-F ,5-di-CF.sub.3
--(CH.sub.2).sub.2SCH.sub.3 phenyl .00/7.95 45 -CH.sub.3/4-F
,5-di-CF.sub.3 --(CH.sub.2).sub.2S(O).su- b.2 phenyl .81/8.08 46
CH.sub.3 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom
phenyl .93/7.93 47 380 -CH.sub.3/4-F ,5-di-CF.sub.3 are together
with the N-atom phenyl .97/8.55 48 381 -CH.sub.3/4-F ,5-di-CF.sub.3
are together with the N-atom phenyl .85/.65 49 382 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .80/8.31 50 383
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.39/8.27 51 384 -CH.sub.3/H ,5-di-CF.sub.3 are together with the
N-atom phenyl .07/8.33 52 385 -CH.sub.3/H ,5-di-CF.sub.3 are
together with the N-atom phenyl .08/8.81 53 386 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .65/7.70 54 387
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.63/7.72 55 388 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .95/7.92 56 389 -CH.sub.3/4-F ,5-di-CF.sub.3
--(CH.sub.2).sub.2NH.sub.2 phenyl .74/7.65 57 -CH.sub.3/4-F
,5-di-CF.sub.3 --(CH.sub.2).sub.2 phenyl .47/7.77 58
NHS(O).sub.2CH.sub.3 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with
the N-atom phenyl .90/8.00 59 390 -CH.sub.3/4-F ,5-di-CF.sub.3
--(CH.sub.2).sub.2 phenyl .78/7.84 60 NHC(O).sub.2CH.sub.3
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.42/7.89 61 391 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .03/8.32 62 392 -Cl/H ,5-di-CF.sub.3 are together
with the N-atom phenyl .13/8.57 63 393 -CH.sub.3/3-Cl
,5-di-CF.sub.3 are together with the N-atom phenyl .15/7.78 64 394
-CH.sub.3/3-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.03/8.42 65 395 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .22/8.67 66 396 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .11/8.44 67 397 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .98/8.39 68 398
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.16/8.67 69 399 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .03/8.55 70 400 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .03/8.91 71 401 -Cl/H
,5-di-CF.sub.3 are together with the N-atom phenyl .05/8.68 72 402
-CH.sub.3/H ,5-di-CF.sub.3 are together with the N-atom phenyl
.16/8.80 73 403 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .21/9.22 74 404 -Cl/H ,5-di-CF.sub.3 are together
with the N-atom phenyl .09/8.95 75 405 -CH.sub.3/H ,5-di-CF.sub.3
are together with the N-atom phenyl .14/9.06 76 406 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .93/8.44 77 407
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.24/8.76 78 408 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .79/8.32 79 409 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .06/8.67 80 410 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .01/7.90 81 411
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.07/7.96 82 412 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .89/9.31 83 413 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .74/8.99 84 414 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .84/9.19 85 415
-CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom phenyl
.77/9.18 86 416 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the
N-atom phenyl .58/8.67 87 417 -Cl/H ,5-di-CF.sub.3
--(CH.sub.2).sub.2 phenyl .65/8.04 88 S(O).sub.2NHCH.sub.3 -Cl/H
,5-di-CF.sub.3 are together with the N-atom phenyl .03/8.13 89 418
-Cl/H ,5-di-CF.sub.3 are together with the N-atom phenyl .09/8.22
90 419 -CH.sub.3/4-F ,5-di-CF.sub.3 are together with the N-atom
phenyl .85/8.26 91 420 -CH.sub.3/H ,5-di-CF.sub.3 are together with
the N-atom phenyl .72/8.77 92 421 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .79/8.90 93 422 -CH.sub.3/4-F
,5-di-CF.sub.3 are together with the N-atom phenyl .22/8.64 94 423
-CH.sub.3/H ,5-di-CF.sub.3 are together with the N-atom phenyl
.12/8.31 95 424 -CH.sub.2OH/H ,5-di-CF.sub.3 are together with the
N-atom phenyl .85/8.04 96 425 -CH.sub.3/4-F ,5-di-CF.sub.3 are
together with the N-atom phenyl .26/8.24 97 426 -CH.sub.3/H
,5-di-CF.sub.3 are together with the N-atom phenyl .85/7.73 98 427
-CH.sub.3/H ,5-di-OCH.sub.3 are together with the N-atom phenyl
.05/8.15 99 428 -CH.sub.3/H ,5-di-OCH.sub.3 are together with the
N-atom phenyl .48/8.22 00 429 -CH.sub.3/4-F ,5-di-OCH.sub.3
--(CH.sub.2).sub.2OH phenyl .59/7.70 01 -CH.sub.3/4-F
,5-di-OCH.sub.3 are together with the N-atom phenyl .44/8.33 02 430
-CH.sub.3/4-F ,5-di-OCH.sub.3 are together with the N-atom phenyl
.82/8.24 03 431 -Cl/H ,5-di-OCH.sub.3 are together with the N-atom
phenyl .40/8.28 04 432 -CH.sub.3/H ,5-di-OCHF.sub.2
--(CH.sub.2).sub.2OH phenyl .72/8.30 05 -CH.sub.3/H
,5-di-OCHF.sub.2 are together with the N-atom phenyl .98/9.04 06
433 -CH.sub.3/H ,5-di-OCHF.sub.2 are together with the N-atom
phenyl .53/9.06 07 434 -CH.sub.3/4-F ,5-di-OCHF.sub.2
--(CH.sub.2).sub.2OH phenyl .71/8.25 08 -CH.sub.3/4-F
,5-di-OCHF.sub.2 are together with the N-atom phenyl .51/8.99 09
435 -Cl/H ,5-di-OCHF.sub.2 are together with the N-atom phenyl
.86/9.14 10 436 -Cl/H ,5-di-OCHF.sub.2 are together with the N-atom
phenyl .46/9.17 11 437 -Cl/H ,5-di-OCHF.sub.2 --(CH.sub.2).sub.2OH
phenyl .59/8.41 12 -CH.sub.3/4-F ,5-di-OCHF.sub.2 are together with
the N-atom phenyl .05/9.05 13 438 -CH.sub.3/H -OCF.sub.3 are
together with the N-atom phenyl .10/8.23 14 439 -CH.sub.3/4-F
-OCF.sub.3 are together with the N-atom phenyl .39/8.24 15 440
-Cl/H ,5-di-OCHF.sub.2 are together with the N-atom phenyl .83/7.64
16 441 -CH.sub.3/4-F ,5-di-OCHF.sub.2 are together with the N-atom
phenyl .13/7.63 17 442 -Cl/H ,5-di-OCHF.sub.2 are together with the
N-atom phenyl .01/8.45 18 443 -CH.sub.3/4-F ,5-di-OCHF.sub.2 are
together with the N-atom phenyl .18/8.42 19 444 -CH.sub.3/H
,5-di-OCHF.sub.2 are together with the N-atom phenyl .13/8.49 20
445 -CH.sub.3/H ,5-di-OCHF.sub.2 are together with the N-atom
phenyl .10/7.61 21 446
[1369] The present invention also provides pharmaceutical
compositions containing compounds of formula I or pharmaceutically
usable acid addition salts thereof and a pharmaceutically
acceptable carrier. Such pharmaceutical compositions can be in the
form of tablets, coated tablets, drages, hard and soft gelatine
capsules, solutions, emulsions or suspensions. The pharmaceutical
compositions also can be in the form of suppositories or injectable
solutions.
[1370] The pharmaceutical compositions of the invention, in
addition to one or more compounds of formula I or a
pharmaceutically usable acid addition salt thereof, contain a
pharmaceutically acceptable excipient. Suitable pharmaceutically
inert excipients include pharmaceutically inert, inorganic or
organic excipients for the production of tablets, coated tablets,
drages and hard gelatine capsules. Lactose, corn starch or
derivatives thereof, talc, stearic acid or its salts etc. can be
used as such excipients e.g. for tablets, drages and hard gelatine
capsules.
[1371] Suitable excipients for soft gelatine capsules are e.g.
vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
[1372] Suitable excipients for the manufacture of solutions and
syrups are e.g. water, polyols, saccharose, invert sugar, glucose
etc.
[1373] Suitable excipients for injection solutions are e.g. water,
alcohols, polyols, glycerol, vegetable oils etc.
[1374] Suitable excipients for suppositories are e.g. natural or
hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
[1375] Moreover, the pharmaceutical compositions of the invention
can contain preservatives, solubilizers, stabilizers, wetting
agents, emulsifiers, sweeteners, colorants, flavorants, salts for
varying the osmotic pressure, buffers, masking agents or
antioxidants. They can also contain still other therapeutically
valuable substances.
[1376] Compounds of the present invention are dual NK-1/NK-3
antagonists. Therefore, the present invention also provides a
method for the treatment of schizophrenia. Such method includes
administering a therapeutically effective amount of a compound of
formula I, or a pharmaceutically acceptable addition salt thereof,
to an individual. In particular, such method includes administering
a therapeutically effective amount of a compound of formula I-1, or
a pharmaceutically acceptable acid addition salt thereof, to an
individual.
[1377] In individual embodiments, the present invention provides
methods for the treatment of schizophrenia which comprise
administering to an individual an effective amount of a compound of
formula IA, IB, IC, ID, IE, IF, IG, IH, IJ, or a pharmaceutically
acceptable acid addition salt of any one or more of these
compounds.
[1378] The compounds and compositions of the invention can be
administered in a conventional manner, for example, orally,
rectally, or parenterally. The pharmaceutical compositions of the
invention can be administered orally, for example, in the form of
tablets, coated tablets, drages, hard and soft gelatine capsules,
solutions, emulsions or suspensions. The pharmaceutical
compositions also can be administered rectally, for example, in the
form of suppositories or parenterally, for example, in the form of
injectable solutions.
[1379] The dosage at which the compound of the invention is
administered can vary within wide limits and will, of course, be
fitted to the individual requirements in each particular case. In
general, in the case of oral administration a daily dosage of about
10 to 1000 mg per person of a compound of general formula I should
be appropriate, although the above upper limit can also be exceeded
when necessary.
[1380] The following Examples illustrate the present invention
without limiting it. All temperatures are given in degrees
Celsius.
Intermediate 1
(6-Chloro-4-iodo-pyridin-3-yl)-methyl-carbamic acid tert-butyl
ester
[1381] 447
[1382] To a solution of 1.00 g (2.82 mmol)
(6-chloro-4-iodo-pyridin-3-yl)-- carbamic acid tert-butyl ester in
10 ml DMF were added 0.12 g (3.1 mmol) sodium hydride (60% in
mineral oil) at -10.degree. C. (The preparation of
(6-chloro-4-iodo-pyridin-3-yl)-carbamic acid tert-butyl ester has
been described in US 2002/0022624 A1.) The reaction mixture was
allowed to warm to room temperature. After 1 h, the mixture was
cooled back to -10.degree. C., and 0.44 ml (7.1 mmol) iodomethane
were added during 5 min. The reaction mixture was allowed to warm
to room temperature. After 2.5 h at room temperature, the reaction
was quenched by addition of 10 ml of a saturated aqueous solution
of NaHCO.sub.3 and the mixture was extracted with ethyl acetate.
The combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude product was
purified by column chromatography (silica gel, hexanes/ethyl
acetate=4:1) to give 1.06 g (100%) of the title compound as a
colorless oil.
[1383] MS m/e (%): 368 (M.sup.+, 1)
Intermediate 2
(6-Chloro-4-iodo-pyridin-3-yl)-methyl-amine
[1384] 448
[1385] To a solution of 8.65 g (19.6 mmol)
(6-chloro-4-iodo-pyridin-3-yl)-- methyl-carbamic acid tert-butyl
ester in 20 ml dichloromethane were added 20.0 ml (261 mmol)
trifluoroacetic acid at 0.degree. C. After stirring for 2 h at room
temperature the reaction mixture was concentrated in vacuo. The
residue was treated with 50 ml saturated sodium carbonate solution
and extracted three times with 75 ml ethyl acetate. The combined
organic layers were washed with 50 ml brine, dried over sodium
sulfate and concentrated in vacuo to give 6.1 g (87%) of the title
compound as a light brown solid.
[1386] MS m/e (%): 268 (M.sup.+, 1)
Intermediate 3A
[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine
[1387] 449
[1388] A mixture of 6.05 g (19.3 mmol)
(6-chloro-4-iodo-pyridin-3-yl)-meth- yl-amine, 23.6 g (23.6 mmol)
2-chlorophenylboronic acid, 441 mg (1.96 mmol) palladium(II)
acetate, 1.03 g (3.93 mmol) triphenylphosphine, 47.1 ml 2 N sodium
carbonate solution and 50 ml 1,2-dimethoxyethane was heated at
80.degree. C. for 90 min. The reaction mixture was cooled to room
temperature and diluted with 100 ml ethyl acetate. The aqueous
layer was separated and extracted with 100 ml ethyl acetate. The
combined organic layers were dried over sodium sulfate,
concentrated in vacuo and purified by flash chromatography to give
4.1 g (83%) of the title compound as a light brown solid.
[1389] MS m/e (%): 253 (M+H.sup.+, 100)
Intermediate 3B
[4-(2-Bromo-phenyl)-6-chloro-pyridin-3-yl]-methyl-amine
[1390] 450
[1391] The title compound was obtained as a brown solid in 86%
yield after flash chromatography according to the procedure
described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using
2-bromophenylboronic acid instead of 2-chlorophenylboronic
acid.
[1392] MS m/e (%): 297 (M+H.sup.+, 85)
Intermediate 3C
[6-Chloro-4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-methyl-amine
[1393] 451
[1394] The title compound was obtained as a light brown solid in
69% yield after flash chromatography according to the procedure
described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-ami- ne using
2-chloro-4-fluorophenylboronic acid instead of
2-chlorophenylboronic acid.
[1395] MS m/e (%): 271 (M+H.sup.+, 100)
Intermediate 3D
[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
[1396] 452
[1397] The title compound was obtained as a orange solid in 80%
yield after flash chromatography according to the procedure
described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-ami- ne using
4-fluoro-2-methyl-phenylboronic acid instead of
2-chlorophenylboronic acid.
[1398] MS m/e (%): 251 (M+H.sup.+, 100)
Intermediate 3E
[6-Chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
[1399] 453
[1400] The title compound was obtained as an off-white solid in
comparable yield after flash chromatography according to the
procedure described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-- methyl-amine using
3-fluoro-2-methyl-phenylboronic acid instead of
2-chlorophenylboronic acid.
[1401] MS m/e (%): 251 (M+H.sup.+, 100)
Intermediate 3F
[6-Chloro-4-(5-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
[1402] 454
[1403] The title compound was obtained as an off-white solid in
comparable yield after flash chromatography according to the
procedure described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-- methyl-amine using
5-fluoro-2-methyl-phenylboronic acid instead of
2-chlorophenylboronic acid.
[1404] MS m/e (%): 251 (M+H.sup.+, 100)
Intermediate 3G
(6-Chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine
[1405] 455
[1406] The title compound was obtained as a light brown solid in
92% yield after flash chromatography according to the procedure
described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-ami- ne using
o-tolylboronic acid instead of 2-chlorophenylboronic acid.
[1407] MS m/e (%): 233 (M+H.sup.+, 100)
Intermediate 3H
[6-Chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine
[1408] 456
[1409] The title compound was obtained as a light brown solid in
70% yield after flash chromatography according to the procedure
described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-ami- ne using
2,4-dichlorophenylboronic acid instead of 2-chlorophenylboronic
acid.
[1410] MS m/e (%): 287 (M+H.sup.+, 100)
Intermediate 31
[6-Chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine
[1411] 457
[1412] The title compound was obtained as a light brown solid in
68% yield after flash chromatography according to the procedure
described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-ami- ne using
3,4-dichlorophenylboronic acid instead of 2-chlorophenylboronic
acid.
[1413] MS m/e (%): 287 (M+H.sup.+, 100)
Intermediate 3J
[6-Chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-methyl-amine
[1414] 458
[1415] The title compound was obtained as an off-white solid in
comparable yield according to the procedure described above for the
preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using
4-fluorophenylboronic acid instead of 2-chlorophenylboronic
acid.
[1416] MS m/e (%): 237 (M+H.sup.+, 100)
Intermediate 3K
[6-Chloro-4-(3-chloro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
[1417] a) 3-Chloro-2-methyl-phenylboronic acid 459
[1418] To a solution of 10.0 g (48.7 mmol) 2-bromo-6-chlorotoluene
and 11.3 ml (48.7 mmol) triisopropyl borate in 90 ml dry THF were
added dropwise 30 ml (49 mmol) of a 1.6 M solution on
n-butyllithium in hexanes at -78.degree. C. under argon. After 45
min the reaction mixture was allowed to warm to room temperature.
The reaction was quenched by addition of 5 ml water and the solvent
was evaporated in vacuo. Addition of 1 M aqueous hydrochloric acid
solution was followed by extraction with four portions of
dichloromethane. The combined organic extracts were dried over
sodium sulfate and concentrated in vacuo. Crystallisation from
heptane gave 5.08 g (61%) of the title compound as a white
solid.
[1419] b)
[6-Chloro-4-(3-chloro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amin- e
460
[1420] The title compound was obtained as an off-white solid in
comparable yield after flash chromatography according to the
procedure described above for the preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-- methyl-amine
(Intermediate 3A) using 3-chloro-2-methyl-phenylboronic acid
instead of 2-chlorophenylboronic acid.
Intermediate 3L
{4-[2-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-pyridin-3-yl-
}-methyl-amine
[1421] a) [2-(2-Chloro-5-methylamino-pyridin-4-yl)-phenyl]-methanol
461
[1422] The title compound was obtained as a yellow oil in
comparable yield according to the procedure described above for the
preparation of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine using
2-(hydroxymethyl)benzeneboronic acid instead of
2-chlorophenylboronic acid.
[1423] MS m/e (%): 249 (M+H.sup.+, 100)
[1424] b)
[4-[2-(tert-Butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-py-
ridin-3-yl]-methyl-amine 462
[1425] The crude title compound was obtained as a yellow oil in
quantitative yield after extraction according to the procedure
described above for the preparation of
(S)-4-benzyl-3-(tert-butyl-dimethyl-silanylo- xymethyl)-morpholine
(Example 174 a)) using [2-(2-chloro-5-methylamino-pyr-
idin-4-yl)-phenyl]-methanol instead of
(R)-(4-benzyl-morpholin-3-yl)-metha- nol.
[1426] MS m/e (%): 363 (M+H.sup.+, 100)
Intermediate 4A
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-
-3-yl]-N-methyl-isobutyramide
[1427] 463
[1428] To a solution of 20 g (79 mmol)
[6-chloro-4-(2-chloro-phenyl)-pyrid- in-3-yl]-methyl-amine in 200
ml tetrahydrofuran were added dropwise at 0.degree. C. 113 ml (94.8
mmol) of a 0.91 M solution of potassium bis(trimethylsilyl)amide in
tetrahydrofuran. The reaction mixture was stirred at room
temperature for 30 min. After cooling to 0.degree. C. 27.7 g (86.9
mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl
chloride were added dropwise. The reaction mixture was allowed to
warm to room temperature and stirred at room temperature for 1 h.
The reaction mixture was treated with 220 ml 1 N sodium
hydrogencarbonate solution and extracted with three 200-ml portions
of ethyl acetate. The combined organic layers were dried over
sodium sulfate and triturated with 150 ml diethylether to give 34.6
g (82%) of the title compound as a white solid.
[1429] MS m/e (%): 535 (M+H.sup.+, 100)
Intermediate 4B
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin--
3-yl]-N-methyl-isobutyramide
[1430] 464
[1431] The title compound was obtained as a light yellow solid in
68% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chlo-
ro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-methyl-amine instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1432] MS m/e (%): 579 (M+H.sup.+, 98)
Intermediate 4C
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-4-fluoro-phenyl-
)-pyridin-3-yl]-N-methyl-isobutyramide
[1433] 465
[1434] The title compound was obtained as a white foam in 52% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-
-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
[6-chloro-4-(2-chloro-4-fluoro-phenyl)-pyridin-3-yl]-methyl-amine
instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1435] MS m/e (%): 553 (M+H.sup.+, 100)
Intermediate 4D
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl-
)-pyridin-3-yl]-N-methyl-isobutyramide
[1436] 466
[1437] The title compound was obtained as a light yellow foam in
87% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-ch-
loro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1438] MS m/e (%): 533 (M+H.sup.+, 100)
Intermediate 4E
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-fluoro-2-methyl-phenyl-
)-pyridin-3-yl]-N-methyl-isobutyramide
[1439] 467
[1440] The title compound was obtained as a light brown solid in
78% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-ch-
loro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
[6-chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1441] MS m/e (%): 533 (M+H.sup.+, 100)
Intermediate 4F
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(5-fluoro-2-methyl-phenyl-
)-pyridin-3-yl]-N-methyl-isobutyramide
[1442] 468
[1443] The title compound was obtained as a light yellow solid in
comparable yield after flash chromatography according to the
procedure described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
using
[6-chloro-4-(3-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1444] MS m/e (%): 533 (M+H.sup.+, 100)
Intermediate 4G
2-(3,5-Bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-m-
ethyl-isobutyramide
[1445] 469
[1446] The title compound was obtained as a white solid in 78%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-
-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
(6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1447] MS m/e (%): 514 (M.sup.+, 5)
Intermediate 4H
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-pyr-
idin-3-yl]-N-methyl-isobutyramide
[1448] 470
[1449] The title compound was obtained as a light yellow foam in
57% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-ch-
loro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
[6-chloro-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine
instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1450] MS m/e (%): 569 (M+H.sup.+, 100)
Intermediate 41
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3,4-dichloro-phenyl)-pyr-
idin-3-yl]-N-methyl-isobutyramide
[1451] 471
[1452] The title compound was obtained as a light yellow foam in
45% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-ch-
loro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
[6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine
instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1453] MS m/e (%): 569 (M+H.sup.+, 100)
Intermediate 4J
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-
-3-yl]-N-methyl-isobutyramide
[1454] 472
[1455] The title compound was obtained as a light brown solid in
92% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-ch-
loro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
[6-chloro-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-methyl-amine
instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1456] MS m/e (%): 519 (M+H.sup.+, 100)
Intermediate 4K
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-chloro-2-methyl-phenyl-
)-pyridin-3-yl]-N-methyl-isobutyramide
[1457] 473
[1458] The title compound was obtained as a white solid in 49%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-
-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4A)
using
[6-chloro-4-(3-chloro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-methyl-amine.
[1459] MS m/e (%): 549 (M+H.sup.+, 100)
Intermediate 4L
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-[2-(tert-butyl-dimethyl-silanyloxy-
methyl)-phenyl]-6-chloro-pyridin-3-yl}-N-methyl-isobutyramide
[1460] 474
[1461] The title compound was obtained as a light yellow oil in 76%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-ch-
loro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide using
{4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-chloro-pyridin-3-y-
l}-methyl-amine instead of
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-met- hyl-amine.
[1462] MS m/e (%): 645 (M+H.sup.+, 100)
Intermediate 5A
2-(3,5-Dichloro-phenyl)-2-methyl-propionyl chloride
[1463] a) 2-(3,5-Dichloro-phenyl)-2-methyl-propionic acid methyl
ester
[1464] A solution of 18.2 g (82.8 mmol)
(3,5-dichloro-phenyl)-acetic acid methyl ester in 15 ml THF was
added to a solution of lithium diisopropylamide in THF (obtained by
adding 49.7 ml (99.4 mmol) of a 2 M solution of lithium
diispropylamide in THF/heptane/ethylbenzene to 125 ml THF at
-20.degree. C. After stirring for 45 min. 6.3 ml (99.4 mmol) methyl
iodide in 12 ml THF was added at the same temperature over a period
of 30 min. To this solution another 49.7 ml (99.4 mmol) lithium
diisopropylamide solution (2 M) in THF/heptane/ethylbenzene was
added at -20.degree. C. followed by 6.3 ml (99.4 mmol) methyl
iodide in 12 ml THF. After stirring for 2 h at ambient temperature
the solution was poured into 500 ml 2 N hydrochloric acid solution
and extracted three times with 300 ml CH.sub.2Cl.sub.2. The
combined organic layers were dried (Na.sub.2SO.sub.4), filtered and
evaporated. The residue was purified by flash-chromatography
(SiO.sub.2, CH.sub.2Cl.sub.2/hexanes 1:2) to yield 17.0 g (83%)
2-(3,5-dichloro-phenyl)-2-methyl-propionic acid methyl ester as a
light yellow oil.
[1465] MS m/e (%): 246 (M.sup.+, 38), 187 (100).
[1466] b) 2-(3,5-Dichloro-phenyl)-2-methyl-propionic acid
[1467] To a solution of 9.0 g (36 mmol)
2-(3,5-dichloro-phenyl)-2-methyl-p- ropionic acid methyl ester in
40 ml ethanol 40 ml 2 N sodium hydroxide solution was added. After
stirring for 4 hrs at RT 150 ml water was added and the solution
washed twice with 200 ml Et.sub.2O. The aqueous phase was acidified
with 25% hydrochloric acid solution and three times extracted with
150 ml CH.sub.2Cl.sub.2. The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered and evaporated to yield 8.3 g (97%)
2-(3,5-dichloro-phenyl)-2-methyl-propionic acid as a off-white
solid.
[1468] MS m/e (%): 232 (M.sup.+, 28), 187 (100).
[1469] c) 2-(3,5-Dichloro-phenyl)-2-methyl-propionyl chloride
[1470] To a solution of 8.3 g (35.6 mmol)
2-(3,5-dichloro-phenyl)-2-methyl- -propionic acid in 80 ml
CH.sub.2Cl.sub.2 and 4 drops DMF 6.1 ml (71.2 mmol) oxalyl chloride
was added at 0.degree. C. and the resulting mixture stirred for 12
h After evaporation of the solvent 8.3 g (93%)
2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride was obtained as
a light yellow oil, which was used without further
purification.
Intermediate 5B
2-(3-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-propionyl
chloride
[1471] The title compound was obtained as a yellow oil in an
analogous manner to that described for
2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using
(3-fluoro-5-trifluoromethyl-phenyl)-acetic acid methyl ester in
step a).
Intermediate 5C
2-Methyl-2-(3-trifluoromethyl-phenyl)-propionyl chloride
[1472] The title compound was obtained as a yellow oil in an
analogous manner to that described for
2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using
(3-trifluoromethyl-phenyl)-acetic acid methyl ester in step a).
Intermediate 5D
2-(3,5-Difluoro-phenyl)-2-methyl-propionyl chloride
[1473] The title compound was obtained as a yellow oil in analogous
manner to that described for
2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using
(3,5-difluoro-phenyl)-acetic acid methyl ester in step a).
Intermediate 5E
2-(3-Chloro-5-methoxy-phenyl)-2-methyl-propionyl chloride
[1474] The title compound was obtained as a yellow oil in an
analogous manner to that described for
2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using
(3-chloro-5-methoxy-phenyl)-acetic acid methyl ester in step
a).
Intermediate 5F
2-(3,5-Dimethyl-phenyl)-2-methyl-propionyl chloride
[1475] The title compound was obtained as a yellow oil in an
analogous manner to that described for
2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using
(3,5-dimethyl-phenyl)-acetic acid methyl ester in step a).
Intermediate 5G
2-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride
[1476] The title compound is obtained according to the procedure
described in WO 0279134 A1.
Intermediate 5H
2-(3,5-Dimethoxy-phenyl)-2-methyl-propionyl chloride
[1477] The title compound was obtained as a light red oil in an
analogous manner to that described for
2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride using
(3,5-dimethoxy-phenyl)-acetic acid ethyl ester in step a).
Intermediate 5I
2-Methyl-2-(3-trifluoromethoxy-phenyl)-propionyl chloride
[1478] The title compound was obtained as a light yellow oil in an
analogous manner to that described for
2-(3,5-dichloro-phenyl)-2-methyl-p- ropionyl chloride using
(3-trifluoromethoxy-phenyl)-acetic acid ethyl ester in step a).
EXAMPLE 1
N-[4-(2-Chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2-(3,5-dichl-
oro-phenyl)-N-methyl-isobutyramide
[1479] a)
N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dichloro-ph-
enyl)-N-methyl-isobutyramide
[1480] To a solution of 1.20 g (4.74 mmol)
[6-chloro-4-(2-chloro-phenyl)-p- yridin-3-yl]-methyl-amine and 1.43
g (5.68 mmol) 2-(3,5-dichloro-phenyl)-2- -methyl-propionyl chloride
in 20 ml toluene 1.27 g (10.42 mmol) 4-dimethylaminopyridine was
added and the resulting solution stirred at 120.degree. for 48 h.
After cooling to ambient temperature, the solution was poured into
100 ml 0.5 N NaHCO.sub.3-solution and extracted three times with 50
ml CH.sub.2Cl.sub.2. The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered and evaporated. The residue was
purified by flash-chromatography (SiO.sub.2, hexanes/ethyl acetate
4:1) to give 1.90 g (85%) of the title compound as a white
solid.
[1481] MS m/e (%): 469.1 (M+H.sup.+, 100).
[1482] b)
N-[4-(2-Chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-2--
(3,5-dichloro-phenyl)-N-methyl-isobutyramide
[1483] A solution of 0.14 g (0.29 mmol)
N-[6-chloro-4-(2-chloro-phenyl)-py-
ridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and 4 ml
ethanolamine was stirred at 0.130.degree. for 9 h. After cooling to
ambient temperature, the solution was poured into 20 ml 0.5N
NaHCO.sub.3-solution and extracted three times with 30 ml
CH.sub.2Cl.sub.2. The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered and evaporated. The residue was
purified by flash-chromatography (SiO.sub.2, CH.sub.2Cl.sub.2/ethyl
acetate 1:3) to give 0.08 g (54%) of the title
[1484] compound as a white foam.
[1485] MS m/e (%): 492.2 (M+H.sup.+, 100).
EXAMPLE 2
(S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
[1486] To a solution of 0.15 g (0.32 mmol)
N-[6-chloro-4-(2-chloro-phenyl)-
-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and
0.25 g (2.47 mmol) L-prolinol in 2 ml dimethyl sulfoxide 0.2 g
(1.55 mmol) Na.sub.2CO.sub.3 was added and the solution was stirred
at 130.degree. C. for 22 h. After cooling to ambient temperature,
the solution was poured into 20 ml 0.5 N NaHCO.sub.3-solution and
extracted three times with 30 ml CH.sub.2Cl.sub.2. The combined
organic layers were dried (Na.sub.2SO.sub.4), filtered and
evaporated. The residue was purified by flash-chromatography
(SiO.sub.2, CH.sub.2Cl.sub.2/ethyl acetate 1:2) to give 0.15 g
(87%) of the title compound as a white foam.
[1487] MS m/e (%): 532.2 (M+H.sup.+, 100).
EXAMPLE 3
(2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide
[1488] To a solution of 0.15 g (0.32 mmol)
N-[6-chloro-4-(2-chloro-phenyl)-
-pyridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and
0.25 g (2.13 mmol) (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine in
2 ml dimethyl sulfoxide 0.2 g (1.55 mmol) Na.sub.2CO.sub.3 was
added and the solution was stirred at 130.degree. C. for 9 h After
cooling to ambient temperature, the solution was poured into 20 ml
0.5 N NaHCO.sub.3-solution and extracted three times with 30 ml
CH.sub.2Cl.sub.2. The combined organic layers were dried
(Na.sub.2SO.sub.4), filtered and evaporated. The residue was
purified by flash-chromatography (SiO.sub.2, CH.sub.2Cl.sub.2/ethyl
acetate 1:2) to give 0.05 g (31%) of the title compound as a white
foam.
[1489] MS m/e (%): 548.3 (M+H.sup.+, 100).
EXAMPLE 4
(S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1490] a)
N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-fluoro-5-trif-
luoromethyl-phenyl)-N-methyl-isobutyramide
[1491] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]- -methyl-amine and
2-(3-fluoro-5-trifluoromethyl-phenyl)-2-methyl-propionyl chloride
as a white solid.
[1492] MS m/e (%): 485.3 (M+H.sup.+, 100).
[1493] b)
(S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-p-
yridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1494] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and
L-prolinol as a white foam.
[1495] MS m/e (%): 550.3 (M+H.sup.+, 100).
EXAMPLE 5
(2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyram-
ide
[1496] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[1497] MS m/e (%): 566.3 (M+H.sup.+, 100).
EXAMPLE 6
(2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide
[1498] a)
N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-difluoro-ph-
enyl)-N-methyl-isobutyramide
[1499] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]- -methyl-amine and
2-(3,5-difluoro-phenyl)-2-methyl-propionyl chloride as a light
yellow solid.
[1500] MS m/e (%): 435.2 (M+H.sup.+, 100).
[1501] b)
(2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrr-
olidin-1-yl)-pyridin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide
[1502] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[1503] MS m/e (%): 516.3 (M+H.sup.+, 100).
EXAMPLE 7
(S)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1504] a)
N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-meth-
oxy-phenyl)-N-methyl-isobutyramide
[1505] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]- -methyl-amine and
2-(3-chloro-5-methoxy-phenyl)-2-methyl-propionyl chloride as a
light yellow solid.
[1506] MS m/e (%): 463.2 (M+H.sup.+, 100).
[1507] b)
(S)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1508] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide and
L-prolinol as a white foam.
[1509] MS m/e (%): 528.2 (M+H.sup.+, 100).
EXAMPLE 8
(2S,4R)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydroxy--
2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1510] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[1511] MS m/e (%): 544.3 (M+H.sup.+, 100).
EXAMPLE 9
(S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
[1512] a)
N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dimethyl-ph-
enyl)-N-methyl-isobutyramide
[1513] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]- -methyl-amine and
2-(3,5-dimethyl-phenyl)-2-methyl-propionyl chloride as a white
solid.
[1514] MS m/e (%): 427.1 (M+H.sup.+, 100).
[1515] b)
(S)-N-[4-(2-Chloro-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-p-
yridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
[1516] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and L-prolinol as
a white foam.
[1517] MS m/e (%): 492.3 (M+H.sup.+, 100).
EXAMPLE 10
(2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide
[1518] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[1519] MS m/e (%): 508.3 (M+H.sup.+, 100).
EXAMPLE 11
(S)-2-(3,5-Dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-6-tol-
yl-pyridin-3-yl]-N-methyl-isobutyramide
[1520] a)
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dichloro-phenyl)-N-me-
thyl-isobutyramide
[1521] The title compound was obtained in an analogous manner to
that described in example 1a) from
(6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-am- ine and
2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride as a white
solid. MS m/e (%): 449.2 (M+H.sup.+, 100).
[1522] b)
(S)-2-(3,5-Dichloro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-y-
l)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1523] The title compound was obtained in an analogous manner to
that described in example 2) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-d-
ichloro-phenyl)-N-methyl-isobutyramide and L-prolinol as a white
foam.
[1524] MS m/e (%): 512.4 (M+H.sup.+, 100).
EXAMPLE 12
(2S,4R)-2-(3,5-Dichloro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1525] The title compound was obtained in an analogous manner to
that described in example 3) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-d-
ichloro-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymeth- yl-pyrrolidine as a white
foam.
[1526] MS m/e (%): 528.3 (M+H.sup.+, 100).
EXAMPLE 13
(S)-2-(3-Fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-
-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1527] a)
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3-fluoro-5-trifluoromethy-
l-phenyl)-N-methyl-isobutyramide
[1528] The title compound was obtained in an analougous manner to
that described in Example 1a) from
(6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-am- ine and
2-(3-fluoro-5-trifluoromethyl-phenyl)-2-methyl-propionyl chloride
as a white foam.
[1529] MS m/e (%): 465.2 (M+H.sup.+, 100).
[1530] b)
(S)-2-(3-Fluoro-5-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1531] The title compound was obtained in an analogous manner to
that described in example 2) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3-flu-
oro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and L-prolinol
as a white foam.
[1532] MS m/e (%): 530.2 (M+H.sup.+, 100).
EXAMPLE 14
(2R,4S)-2-(3-Fluoro-5-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymet-
hyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1533] The title compound was obtained in an analogous manner to
that described in example 3) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3-flu-
oro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a orange foam.
[1534] MS m/e (%): 546.3 (M+H.sup.+, 100).
EXAMPLE 15
(S)-2-(3,5-Difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tol-
yl-pyridin-3-yl]-N-methyl-isobutyramide
[1535] a)
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-difluoro-phenyl)-N-me-
thyl-isobutyramide
[1536] The title compound was obtained in an analogous manner to
that described in example 1a) from
(6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-am- ine and
2-(3,5-difluoro-phenyl)-2-methyl-propionyl chloride as a light
yellow solid.
[1537] MS m/e (%): 415.2 (M+H.sup.+, 100).
[1538] b)
(S)-2-(3,5-Difluoro-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-y-
l)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1539] The title compound was obtained in an analogous manner to
that described in example 2) from
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-d-
ifluoro-phenyl)-N-methyl-isobutyramide and L-prolinol as a light
yellow foam.
[1540] MS m/e (%): 480.2 (M+H.sup.+, 100).
EXAMPLE 16
(2S,4R)-2-(3,5-Difluoro-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1541] The title compound was obtained in an analogous manner to
that described in example 3) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-d-
ifluoro-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymeth- yl-pyrrolidine as a orange
foam.
[1542] MS m/e (%): 496.4 (M+H.sup.+, 100).
EXAMPLE 17
(S)-2-(3-Chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-
-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1543]
a)2-(3-Chloro-5-methoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-
-N-methyl-isobutyramide
[1544] The title compound was obtained in an analogous manner to
that described in example 1a) from
(6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-am- ine and
2-(3-chloro-5-methoxy-phenyl)-2-methyl-propionyl chloride as a
light yellow solid.
[1545] MS m/e (%): 443.1 (M+H.sup.+, 100).
[1546] b)
(S)-2-(3-Chloro-5-methoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolid-
in-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1547] The title compound was obtained in an analogous manner to
that described in example 2) from
2-(3-chloro-5-methoxy-phenyl)-N-(6-chloro-4--
o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and L-prolinol as a
white foam.
[1548] MS m/e (%): 508.2 (M+H.sup.+, 100).
EXAMPLE 18
(2S,4R)-2-(3-Chloro-5-methoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrr-
olidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1549] The title compound was obtained in an analogous manner to
that described in example 3) from
2-(3-chloro-5-methoxy-phenyl)-N-(6-chloro-4--
o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydro- xymethyl-pyrrolidine as a white
foam.
[1550] MS m/e (%): 524.3 (M+H.sup.+, 100).
EXAMPLE 19
(S)-2-(3,5-Dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tol-
yl-pyridin-3-yl]-N-methyl-isobutyramide
[1551] a)
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethyl-phenyl)-N-me-
thyl-isobutyramide
[1552] The title compound was obtained to that described in example
1a) from (6-Chloro-4-o-tolyl-pyridin-3-yl)-methyl-amine and
2-(3,5-dimethyl-phenyl)-2-methyl-propionyl chloride as a light
yellow foam.
[1553] MS m/e (%): 407.1 (M+H.sup.+, 100).
[1554] b)
(S)-2-(3,5-Dimethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-y-
l)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1555] The title compound was obtained in an analogous manner to
that described in example 2) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-d-
imethyl-phenyl)-N-methyl-isobutyramide and L-prolinol as a white
foam.
[1556] MS m/e (%): 472.3 (M+H.sup.+, 100).
EXAMPLE 20
(2S,4R)-2-(3,5-Dimethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1557] The title compound was obtained in an analogous manner to
that described in example 3) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-d-
imethyl-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymeth- yl-pyrrolidine as a light yellow
foam.
[1558] MS m/e (%): 488.3 (M+H.sup.+, 100)
EXAMPLE 21
2-(3,5-Dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethyl-
amino)-pyridin-3-yl]-N-methyl-isobutyramide
[1559] a)
N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-di-
chloro-phenyl)-N-methyl-isobutyramide
[1560] The title compound was obtained to that described in example
1a) from
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-methyl-amine
and 2-(3,5-dichloro-phenyl)-2-methyl-propionyl chloride as a white
foam.
[1561] MS m/e (%): 464.1 (M.sup.+, 5).
[1562] b)
2-(3,5-Dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hyd-
roxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1563] The title compound was obtained in an analogous manner to
that described in example 1b) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-py-
ridin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and
ethanolamine as a white foam.
[1564] MS m/e (%): 490.2 (M+H.sup.+, 100).
EXAMPLE 22
(S)-2-(3,5-Dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxyme-
thyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1565] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and
L-prolinol as a white foam.
[1566] MS m/e (%): 530.2 (M+H.sup.+, 100).
EXAMPLE 23
(2S,4R)-2-(3,5-Dichloro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydro-
xy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1567] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-dichloro-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
[1568] MS m/e (%): 546.2 (M+H.sup.+, 100).
EXAMPLE 24
(S)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-py-
ridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1569] a)
N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-fluo-
ro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1570] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyri- din-3-yl]-methyl-amine
and 2-(3-fluoro-5-trifluoromethyl-phenyl)-2-methyl-- propionyl
chloride as a white foam.
[1571] MS m/e (%): 483.2 (M+H.sup.+, 100).
[1572] b)
(S)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidi-
n-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobu-
tyramide
[1573] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
and L-prolinol as a white foam.
[1574] MS m/e (%): 548.4 (M+H.sup.+, 100).
EXAMPLE 25
(2S,4R)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrro-
lidin-1-yl)-pyridin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide
[1575] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3-fluoro-5-trifluoromethyl-phenyl)-N-methyl-isobutyramide
and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white
foam.
[1576] MS m/e (%): 564.4 (M+H.sup.+, 100).
EXAMPLE 26
(S)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-py-
ridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide
[1577] a)
N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl--
2-(3-trifluoromethyl-phenyl)-isobutyramide
[1578] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyri- din-3-yl]-methyl-amine
and 2-methyl-2-(3-trifluoromethyl-phenyl)-propionyl chloride as a
white solid.
[1579] MS m/e (%): 465.4 (M+H.sup.+, 100).
[1580] b)
(S)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidi-
n-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide
[1581] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide and
L-prolinol as a white foam.
[1582] MS m/e (%): 530.3 (M+H.sup.+, 100).
EXAMPLE 27
(2S,4R)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrro-
lidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyram-
ide
[1583] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-N-methyl-2-(3-trifluoromethyl-phenyl)-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
[1584] MS m/e (%): 546.3 (M+H.sup.+, 100).
EXAMPLE 28
(S)-2-(3,5-Difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxyme-
thyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1585] a)
N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-di-
fluoro-phenyl)-N-methyl-isobutyramide
[1586] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyri- din-3-yl]-methyl-amine
and 2-(3,5-difluoro-phenyl)-2-methyl-propionyl chloride as a white
solid.
[1587] MS m/e (%): 433.3 (M+H.sup.+, 100).
[1588] b)
(S)-2-(3,5-Difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-
-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1589] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide and
L-prolinol as a light yellow foam.
[1590] MS m/e (%): 498.3 (M+H.sup.+, 100).
EXAMPLE 29
(2S,4R)-2-(3,5-Difluoro-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydro-
xy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1591] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-difluoro-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[1592] MS m/e (%): 513.2 (M+), 482.2 (100).
EXAMPLE 30
(S)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hyd-
roxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1593] a)
N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3-chlo-
ro-5-methoxy-phenyl)-N-methyl-isobutyramide
[1594] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyri- din-3-yl]-methyl-amine
and 2-(3-chloro-5-methoxy-phenyl)-2-methyl-propiony- l chloride as
a waxy solid.
[1595] MS m/e (%): 461.1 (M+H.sup.+, 100).
[1596] b)
(S)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1597] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide and
L-prolinol as a white foam.
[1598] MS m/e (%): 526.2 (M+H.sup.+, 100).
EXAMPLE 31
(2S,4R)-2-(3-Chloro-5-methoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[1599] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[1600] MS m/e (%): 542.2 (M+H.sup.+, 100).
EXAMPLE 32
(S)-(3,5-Dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1601] a)
N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-di-
methyl-phenyl)-N-methyl-isobutyramide
[1602] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyri- din-3-yl]-methyl-amine
and 2-(3,5-dimethyl-phenyl)-2-methyl-propionyl chloride as a white
foam.
[1603] MS m/e (%): 425.2 (M+H.sup.+, 100).
[1604] b)
(S)-(3,5-Dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-h-
ydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1605] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and
L-prolinol as a white foam.
[1606] MS m/e (%): 490.4 (M+H.sup.+, 100).
EXAMPLE 33
(2S,4R)-2-(3,5-Dimethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydro-
xy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1607] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-dimethyl-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[1608] MS m/e (%): 506.3 (M+H.sup.+, 100).
EXAMPLE 34
(S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydr-
oxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1609] a)
N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-hydr-
oxy-phenyl)-N-methyl-isobutyramide
[1610] To a solution of 1.10 g (2.37 mmol)
N-[6-chloro-4-(2-chloro-phenyl)-
-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide
in 20 ml CH.sub.2Cl.sub.2 4.74 ml (4.74 mmol) BBr.sub.3 (1 M in
CH.sub.2Cl.sub.2) was added at 0.degree. C. The reaction mixture
was allowed to reach ambient temperature and stirred for 6 h After
addition of 50 ml water the mixture was extracted three times with
60 ml CH.sub.2Cl.sub.2. The combined organic solvents were dried
(Na.sub.2SO.sub.4), filtered and evaporated. The residue was
purified by flash-chromatography (SiO.sub.2, CH.sub.2Cl.sub.2/ethyl
acetate 4:1) to give 0.70 g (65%) of the title compound as a white
foam.
[1611] MS m/e (%): 449.1 (M+H.sup.+, 100).
[1612] b)
N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-chloro-5-difl-
uoromethoxy-phenyl)-N-methyl-isobutyramide
[1613] To a solution of 0.700 g (1.56 mmol)
N-[6-chloro-4-(2-chloro-phenyl-
)-pyridin-3-yl]-2-(3-chloro-5-hydroxy-phenyl)-N-methyl-isobutyramide
in 10 ml N,N-Dimethylformamide 0.215 g (1.56 mmol) K.sub.2CO.sub.3
and 0.2 ml (1.56 mmol) ethyl chlordifluoroacetate was added and the
resulting suspension heated at 65.degree. C. for 15 h. After
cooling to ambient temperature, the reaction mixture was poured
into 75 ml water and extracted three times with 80 ml
CH.sub.2Cl.sub.2. The combined organic solvents were dried
(Na.sub.2SO.sub.4), filtered and evaporated. The residue was
purified by flash-chromatography (SiO.sub.2, CH.sub.2Cl.sub.2/ethyl
acetate 4:1) to give 0.38 g (49%) of the title compound as a white
solid.
[1614] MS m/e (%): 499.1 (M+H.sup.+, 100).
[1615] c)
(S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-
-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1616] The title compound was obtained in an analogous manner to
that described in example 2 from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-
-2-(3-chloro-5-difluoromethoxy-phenyl)-N-methyl-isobutyramide and
L-prolinol as a white foam.
[1617] MS m/e (%): 564.2 (M+H.sup.+, 100).
EXAMPLE 35
(2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4--
hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide
[1618] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3-chloro-5-difluoromethoxy-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
[1619] MS m/e (%): 580.5 (M+H.sup.+, 100).
EXAMPLE 36
(S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-
-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1620]
a)2-(3-Chloro-5-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyrid-
in-3-yl)-N-methyl-isobutyramide
[1621] The title compound was obtained in an analogous manner to
that described in example 34a), b) from
2-(3-chloro-5-methoxy-phenyl)-N-(6-chl-
oro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide as a white
foam.
[1622] MS m/e (%): 479.1 (M+H.sup.+, 100).
[1623] b)
(S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl--
pyrrolidin 1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1624] The title compound was obtained in an analogous manner to
that described in example 2) from
2-(3-chloro-5-difluoromethoxy-phenyl)-N-(6-c-
hloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and L-prolinol
as a white foam.
[1625] MS m/e (%): 544.3 (M+H.sup.+, 100).
EXAMPLE 37
(2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymet-
hyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1626] The title compound was obtained in an analogous manner to
that described in example 3) from
2-(3-chloro-5-difluoromethoxy-phenyl)-N-(6-c-
hloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[1627] MS m/e (%): 560.3 (M+H.sup.+, 100).
EXAMPLE 38
(S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)--
6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1628]
a)2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-m-
ethyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[1629] The title compound was obtained in an analogous manner to
that described in example 34a), b) from
N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-2-(3-chloro-5-methoxy-phenyl)-N-methyl-isobutyramide
as a white foam.
[1630] MS m/e (%): 497.1 (M+H.sup.+, 100).
[1631] b)
(S)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methy-
l-phenyl)-6-(2S-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[1632] The title compound was obtained in an analogous manner to
that described in example 2) from
2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-c-
hloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and L-prolinol as a white foam.
[1633] MS m/e (%): 562.2 (M+H.sup.+, 100).
EXAMPLE 39
(2S,4R)-2-(3-Chloro-5-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide
[1634] The title compound was obtained in an analogous manner to
that described in example 3) from
2-(3-chloro-5-difluoromethoxy-phenyl)-N-[6-c-
hloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light brown
foam.
[1635] MS m/e (%): 578.3 (M+H.sup.+, 100).
EXAMPLE 40
(2S,4S)-N-[6-(4-Acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chloro-p-
henyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyra-
mide
[1636] A mixture of 30 mg (0.056 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
200 mg (1.27 mmol)
(2S,4S)-4-acetylamino-2-hydroxymethyl-pyrrolidine and 0.2 ml
dimethyl sulfoxide was heated at 130.degree. C. for 24 h. After
cooling to room temperature, 22 mg (59%) of the title compound were
isolated as a white solid by automated, preparative HPLC (YMC
CombiPrep C18 column 50.times.20 mm, solvent gradient 5-95%
CH.sub.3CN in 0.1% TFA(aq) over 6.0 min, .lambda.=230 nm, flow rate
40 ml/min). (2S,4S)-4-Acetylamino-2-hydroxymethyl-pyrrolidine can
be obtained by the method described by Terry Rosen, Daniel T. W.
Chu, Isabella M. Lico, Isabella M. Lico, Prabhavathi B. Fernandes,
Kennan Marsh, Linus Shen, Valerie G. Cepa, Andr G. Pernet, J. Med.
Chem. 1988, 31, 1598.
[1637] MS m/e (%): 657 (M+H.sup.+)
EXAMPLE 41
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-
methyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1638] The title compound was obtained from D-prolinol as a light
grey solid in 8% yield according to to the procedure described
above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-y-
l)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N--
methyl-isobutyramide.
[1639] MS m/e (%): 600 (M+H.sup.+)
EXAMPLE 42
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-
methyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1640] The title compound was obtained from L-prolinol as a white
solid in 49% yield according to the procedure described above for
the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chlo-
ro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobu-
tyramide.
[1641] MS m/e (%): 600 (M+H.sup.+)
EXAMPLE 43
(S)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-
-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1642] The title compound was obtained from
(S)-3-acetamidopyrrolidine as a white solid in 42% yield according
to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1643] MS m/e (%): 627 (M+H.sup.+)
EXAMPLE 44
(R)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-
-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1644] The title compound was obtained from
(R)-3-acetamidopyrrolidine as a white solid in 56% yield according
to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1645] MS m/e (%): 627 (M+H.sup.+)
EXAMPLE 45
(RS)-N-[6-[3-(Acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(2-chloro-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1646] The title compound was obtained from
(RS)-3-(N-acetyl-N-ethylamino)- pyrrolidine as a white solid in 54%
yield according to the procedure described above for the
preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydr-
oxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-tr-
ifluoromethyl-phenyl)-N-methyl-isobutyramide.
[1647] MS m/e (%): 655 (M+H.sup.+)
EXAMPLE 46
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-
-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1648] The title compound was obtained from (S)-3-pyrrolidinol as a
light grey solid in 7% yield according to the procedure described
above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-y-
l)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N--
methyl-isobutyramide.
[1649] MS m/e (%): 586 (M+H.sup.+)
EXAMPLE 47
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-
-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1650] The title compound was obtained from (R)-3-pyrrolidinol as
an off-white solid in 30% yield according to the procedure
described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrol-
idin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-ph-
enyl)-N-methyl-isobutyramide.
[1651] MS m/e (%): 586 (M+H.sup.+)
EXAMPLE 48
(3R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-d-
ihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1652] The title compound was obtained from
(3R,4S)-pyrrolidin-3,4-diol as a white solid in 47% yield according
to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide. 3R,4S)-Pyrrolidine-3,4-diol can be
obtained by the method described by Albert Defoin, Joaquim Pires,
Jaques Streith, Helv. Chim. Acta 1991, 74, 1653.
[1653] MS m/e (%): 602 (M+H.sup.+)
EXAMPLE 49
(3R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-d-
ihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1654] The title compound was obtained from
(3R,4R)-pyrrolidin-3,4-diol as a white solid in 61% yield according
to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1655] MS m/e (%): 602 (M+H.sup.+)
EXAMPLE 50
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3-hydroxy--
3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
[1656] The title compound was obtained from (RS)-3-piperidinol as a
white solid in 55% yield according to the procedure described above
for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-y-
l)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N--
methyl-isobutyramide.
[1657] MS m/e (%): 600 (M+H.sup.+)
EXAMPLE 51
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hydroxy-3,4,5-
,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-N-methyl-isobutyramide
[1658] The title compound was obtained from 4-hydroxypiperidine as
a white solid in 47% yield according to the procedure described
above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-y-
l)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N--
methyl-isobutyramide.
[1659] MS m/e (%): 600 (M+H.sup.+)
EXAMPLE 52
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hydroxymethyl-
-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
[1660] The title compound was obtained from
4-(hydroxmethyl)-piperidine as a white foam in 43% yield according
to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1661] MS m/e (%): 614 (M+H.sup.+)
EXAMPLE 53
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-(2-hydro-
xy-ethyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyr-
amide
[1662] The title compound was obtained from
(RS)-2-piperidin-2-yl-ethanol as a light yellow solid in 5% yield
according to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl--
pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-methyl-isobutyramide.
[1663] MS m/e (%): 628 (M+H.sup.+)
EXAMPLE 54
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2-hydroxy-et-
hyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
[1664] The title compound was obtained from N-methylethanolamine as
a white solid in 54% yield according to the procedure described
above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1665] MS m/e (%): 574 (M+H.sup.+)
EXAMPLE 55
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[ethyl-(2-hydr-
oxy-ethyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide
[1666] The title compound was obtained from 2-ethylamino-ethanol as
a white solid in 50% yield according to the procedure described
above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1667] MS m/e (%): 588 (M+H.sup.+)
EXAMPLE 56
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2-hydroxy-et-
hyl)-propyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
[1668] The title compound was obtained from N-propylethanolamine as
a white solid in 34% yield according to the procedure described
above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1669] MS m/e (%): 602 (M+H.sup.+)
EXAMPLE 57
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[butyl-(2-hydroxy-ethyl)-amino]-4--
(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[1670] The title compound was obtained from N-butylethanolamine as
a colorless waxy solid in 37% yield according to the procedure
described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl--
pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-methyl-isobutyramide.
[1671] MS m/e (%): 616 (M+H.sup.+)
EXAMPLE 58
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2,3-dih-
ydroxy-propyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
[1672] The title compound was obtained from
(RS)-2,3-dihydroxy-N-methylpro- pylamine as a white solid in 48%
yield according to the procedure described above for the
preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydr-
oxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-tr-
ifluoromethyl-phenyl)-N-methyl-isobutyramide.
[1673] MS m/e (%): 604 (M+H.sup.+)
EXAMPLE 59
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(1-hydroxy-
methyl-3-methyl-butylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1674] The title compound was obtained from L-leucinol as a white
solid in 42% yield according to the procedure described above for
the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-chlo-
ro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobu-
tyramide.
[1675] MS m/e (%): 616 (M+H.sup.+)
EXAMPLE 60
trans-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hydro-
xy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1676] The title compound was obtained from
trans-4-aminocyclohexanol as a white solid in 42% yield according
to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1677] MS m/e (%): 614 (M+H.sup.+)
EXAMPLE 61
N-[6-(4-Acetyl-piperazin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bi-
s-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1678] The title compound was obtained from 1-acetylpiperazine as a
white solid in 52% yield according to the procedure described above
for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-1-y-
l)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N--
methyl-isobutyramide.
[1679] MS m/e (%): 627 (M+H.sup.+)
EXAMPLE 62
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-cyclopropan-
ecarbonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1680] The title compound was obtained from
1-cyclopropylcarbonylpiperazin- e as a white solid in 32% yield
according to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrol-
idin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-ph-
enyl)-N-methyl-isobutyramide.
[1681] MS m/e (%): 653 (M+H.sup.+)
EXAMPLE 63
N-[6-(4-Acetyl-[1,4]diazepan-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,-
5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1682] The title compound was obtained from 1-acetylhomopiperazine
as a white solid in 50% yield according to the procedure described
above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl-pyrrolidin-
-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1683] MS m/e (%): 641 (M+H.sup.+)
EXAMPLE 64
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-2-pyrrol-
idin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1684] The title compound was obtained from
(S)-(+)-1-(2-pyrrolidinyl-meth- yl)pyrrolidine as a white solid in
54% yield according to the procedure described above for the
preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydr-
oxymethyl-pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-tr-
ifluoromethyl-phenyl)-N-methyl-isobutyramide.
[1685] MS m/e (%): 653 (M+H.sup.+)
EXAMPLE 65
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-dimethy-
lamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1686] The title compound was obtained from
(S)-(-)-3-(dimethylamino)pyrro- lidine as a white solid in 56%
yield according to the procedure described above for the
preparation of (2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl--
pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-methyl-isobutyramide.
[1687] MS m/e (%): 613 (M+H.sup.+)
EXAMPLE 66
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-methan-
esulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1688] The title compound was obtained from
(RS)-3-methylsulfonylpyrrolidi- ne as a white solid in 57% yield
according to the procedure described above for the preparation of
(2S,4S)-N-[6-(4-acetylamino-2-hydroxymethyl--
pyrrolidin-1-yl)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-methyl-isobutyramide.
[1689] MS m/e (%): 648 (M+H.sup.+)
EXAMPLE 67
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-eth-
ylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1690] A mixture of 28.6 g (56 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)-N--
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide,
50 ml dimethyl sulfoxide and 50 ml (830 mmol) ethanolamine was
stirred at 140.degree. C. for 24 h. The reaction mixture was cooled
to room temperature, diluted with 200 ml ethyl acetate and washed
with 200 ml 1 N sodium carbonate solution and 100 ml water. The
aqueous layers were extracted with two 200-ml portions of ethyl
acetate. The combined organic layers were dried over sodium sulfate
and concentrated in vacuo. The residue was crystallized from a
mixture of 150 ml diisopropyl ether and 150 ml heptane to give 29.1
g (93%) of the title compound as white crystals. M.p.
117-118.degree. C.
[1691] MS m/e (%): 560 (M+H.sup.+, 100)
EXAMPLE 68
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1692] The title compound was obtained as a white foam in 28% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide.
[1693] MS m/e (%): 558 (M+H.sup.+, 100)
EXAMPLE 69
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-6-(2-hy-
droxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1694] The title compound was obtained as a white foam in 48% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-4-fluoro-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide.
[1695] MS m/e (%): 578 (M+H.sup.+, 100)
EXAMPLE 70
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hydroxy-
-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1696] The title compound was obtained as a light yellow foam in
91% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-py-
ridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e.
[1697] MS m/e (%): 594 (M+H.sup.+, 100)
EXAMPLE 71
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hyd-
roxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1698] The title compound was obtained as a light yellow foam in
78% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-py-
ridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e and (S)-1-amino-2-propanol instead of ethanolamine.
[1699] MS m/e (%): 608 (M+H.sup.+, 100)
EXAMPLE 72
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-
-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1700] The title compound was obtained as an off-white foam in 65%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using (S)-1-amino-2-propanol instead of ethanolamine.
[1701] MS m/e (%): 574 (M+H.sup.+, 100)
EXAMPLE 73
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-
-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1702] The title compound was obtained as a white foam in 84% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
(R)-1-amino-2-propanol instead of ethanolamine.
[1703] MS m/e (%): 574 (M+H.sup.+, 100)
EXAMPLE 74
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydrox-
y-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1704] The title compound was obtained as a light brown foam in 79%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using (RS)-1-amino-2-propanol instead of ethanolamine.
[1705] MS m/e (%): 574 (M+H.sup.+, 100)
EXAMPLE 75
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-2-m-
ethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1706]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-ox-
o-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1707] To a solution of 457 mg (3.60 mmol) oxalyl chloride in 17 ml
dichloromethane was added dropwise during 5 minutes at -75.degree.
C. a solution of 562 mg (7.20 mmol) dimethyl sulfoxide in 5 ml
dichloromethane. After stirring for 5 minutes a solution of 1.72 g
(3.00 mmol)
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-
-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide in 5 ml
dichloromethane was added dropwise at -65.degree. C. Stirring was
continued at -70.degree. C. for 1 h, followed by addition of 2.6 ml
(15 mmol) ethyldiisopropylamine. After stirring at room temperature
for 3 h the reaction mixture was diluted with 20 ml dichloromethane
and washed with 20 ml water, 20 ml 1 N hydrochloric acid solution
and 20 ml saturated sodium carbonate solution. The combined organic
layers were dried over sodium sulfate, concentrated in vacuo and
purified by flash chromatography to give 1.45 g (85%) of the title
compound as a white foam.
[1708] MS m/e (%): 572 (M+H.sup.+, 100)
[1709] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-h-
ydroxy-2-methyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1710] To a solution of 100 mg (0.175 mmol)
2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-i-
sobutyramide in 1 ml tetrahydrofuran was added a 3 N solution of
methylmagnesium bromide in diethyl ether at room temperature. The
reaction mixture was stirred at room temperature for 1 h and at
65.degree. C. for 3 h. After cooling to room temperature few drops
of a 1 N aqueous solution of hydrochloric acid were added to the
reaction mixture, followed by extraction with dichloromethane and
washing with saturated sodium carbonate solution. The combined
organic layers were dried over sodium sulfate, concentrated in
vacuo and purified by flash chromatography to give 51 mg (50%) of
the title compound as a white foam.
[1711] MS m/e (%): 588 (M+H.sup.+, 100)
EXAMPLE 76
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-but-
ylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1712] The title compound was obtained as a yellow foam in 55%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
1-amino-2-butanol instead of ethanolamine.
[1713] MS m/e (%): 588 (M+H.sup.+, 100)
EXAMPLE 77
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1714] The title compound was obtained as a white foam in 59% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
(S)-1-amino-2-propanol instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide
[1715] MS m/e (%): 572 (M+H.sup.+, 100)
EXAMPLE 78
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihy-
droxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1716] The title compound was obtained as a white solid in 100%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using (RS)-3-amino-1,2-propandiol instead of ethanolamine.
[1717] MS m/e (%): 590 (M+H.sup.+, 100)
EXAMPLE 79
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-
-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1718] The title compound was obtained as a light yellow solid in
14% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-c-
hloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e using L-alaninol instead of ethanolamine.
[1719] MS m/e (%): 574 (M+H.sup.+, 100)
EXAMPLE 80
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-
-1-methyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1720] The title compound was obtained as a white foam in 24% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
(R)-2-amino-1-propanol instead of ethanolamine.
[1721] MS m/e (%): 574 (M+H.sup.+, 100)
EXAMPLE 81
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-1-h-
ydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1722] The title compound was obtained as a white foam in 34% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
2-amino-1,3-propandiol instead of ethanolamine.
[1723] MS m/e (%): 590 (M+H.sup.+, 100)
EXAMPLE 82
N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,-
5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1724] The title compound was obtained as a white solid in 41%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
diethanolamine instead of ethanolamine.
[1725] MS m/e (%): 604 (M+H.sup.+, 100)
EXAMPLE 83
N-{6-[Bis-(2-hydroxy-ethyl)-amino]-4-o-tolyl-pyridin-3-yl}-2-(3,5-bis-trif-
luoromethyl-phenyl)-N-methyl-isobutyramide
[1726] The title compound was obtained as a white solid in 55%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
diethanolamine instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide.
[1727] MS m/e (%): 584 (M+H.sup.+, 100)
EXAMPLE 84
N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3--
yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1728] The title compound was obtained as a white solid in 52%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
diethanolamine instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-ch-
loro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
[1729] MS m/e (%): 602 (M+H.sup.+, 100)
EXAMPLE 85
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(2-h-
ydroxy-ethyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl}-N-methyl-isobutyrami-
de
[1730] The title compound was obtained as a light brown solid in
15% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using 3-(2-hydroxyethylamino)-1-propanol instead of ethanolamine
and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide.
[1731] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 86
N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(2,4-dichloro-phenyl)-pyridin-3-yl]-2-
-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1732] The title compound was obtained as a light yellow foam in
48% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-py-
ridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e. and diethanolamine instead of ethanolamine.
[1733] MS m/e (%): 638 (M+H.sup.+, 100)
EXAMPLE 87
N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(3,4-dichloro-phenyl)-pyridin-3-yl]-2-
-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1734] The title compound was obtained as a yellow foam in 65%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3,4-dichloro-phenyl)-py-
ridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e and diethanolamine instead of ethanolamine.
[1735] MS m/e (%): 638 (M+H.sup.+, 100)
EXAMPLE 88
N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(4-fluoro-phenyl)-pyridin-3-yl]-2-(3,-
5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1736] The title compound was obtained as a white solid in 68%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
diethanolamine instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phe-
nyl)-pyridin-3-yl]-N-methyl-isobutyramide.
[1737] MS m/e (%): 588 (M+H.sup.+, 100)
EXAMPLE 89
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methanesulf-
onyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1738]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-me-
thylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1739] The title compound was obtained as a white foam in 30% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
2-(methylthio)ethylamine instead of ethanolamine.
[1740] MS m/e (%): 590 (M+H.sup.+, 100)
[1741] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-m-
ethanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1742] A mixture of 50 mg (0.087 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[4-(2-chloro-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-met-
hyl-isobutyramide and 130 mg (0.212 mmol) potassium monopersulfate
triple salt in 1 ml methanol was stirred at room temperature for 3
days. The reaction was quenched with 1 ml sodium hydrogen sulfite
solution 38%. The mixture was treated with 3 ml saturated sodium
carbonate solution and extracted with three 5-ml portions of ethyl
acetate. The combined organic layers were dried over sodium
sulfate, concentrated in vacuo and purified by flash chromatography
to give 29 mg (55%) of the title compound as a white foam.
[1743] MS m/e (%): 622 (M+H.sup.+, 100)
EXAMPLE 90
N-[6-(2-Acetylamino-ethylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-b-
is-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1744] The title compound was obtained as a white foam in 65% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
N-acetylethylenediamine instead of ethanolamine.
[1745] MS m/e (%): 601 (M+H.sup.+, 100)
EXAMPLE 91
trans-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-h-
ydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1746] The title compound was obtained as a light yellow foam in
42% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-py-
ridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e and trans-4-aminocyclohexanol instead of ethanolamine.
[1747] MS m/e (%): 648 (M+H.sup.+, 100)
EXAMPLE 92
trans-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(4-hydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1748] The title compound was obtained as a light brown foam in 23%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using trans-4-aminocyclohexanol instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide
[1749] MS m/e (%): 612 (M+H.sup.+, 100).
EXAMPLE 93
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1750] The title compound was obtained as a white foam in 58% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
D-prolinol instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyra-
mide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-
-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[1751] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 94
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hyd-
roxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1752] The title compound was obtained as a light yellow foam in
96% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,4-dichloro-phenyl)-py-
ridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e. and D-prolinol instead of ethanolamine.
[1753] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 95
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hyd-
roxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1754] The title compound was obtained as a yellow foam in 97%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3,4-dichloro-phenyl)-py-
ridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e and D-prolinol instead of ethanolamine.
[1755] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 96
(2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1756] The title compound was obtained as a white foam in 76% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
(2R,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of
ethanolamine.
[1757] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 97
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1758] The title compound was obtained as an off-white foam in 62%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of
ethanolamine.
[1759] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 98
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydroxy-aze-
tidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1760] The title compound was obtained as a light yellow foam in
23% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using azetidin-3-ol instead of ethanolamine.
[1761] MS m/e (%): 572 (M+H.sup.+, 100)
EXAMPLE 99
(S)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyri-
din-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1762] The title compound was obtained as a white foam in 58% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
(S)-3-acetamidopyrrolidine instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide.
[1763] MS m/e (%): 625 (M+H.sup.+, 100)
EXAMPLE 100
(R)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyri-
din-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1764] The title compound was obtained as an off-white foam in 75%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using (R)-3-acetamidopyrrolidine instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide.
[1765] MS m/e (%): 625 (M+H.sup.+, 100)
EXAMPLE 101
(R)-N-[6-[3-(Acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-ph-
enyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyram-
ide
[1766] To a solution of 146 mg (0.234 mmol)
(R)-N-[6-(3-acetylamino-pyrrol-
idin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoro-
methyl-phenyl)-N-methyl-isobutyramide in 5 ml tetrahydrofuran were
added dropwise at room temperature 0.31 ml (0.28 mmol) of a 0.91 N
potassium bis(trimethylsilyl)amide solution in tetrahydrofuran.
After stirring at room temperature for 30 min. 43 mg (30 mmol)
iodomethane were added. The reaction mixture was stirred at room
temperature for 18 h, followed by dilution with 10 ml ethyl acetate
and washing with 10 ml saturated sodium carbonate solution. The
combined organic layers were dried over sodium sulfate,
concentrated in vacuo and purified by flash chromatography to give
130 mg (87%) of the title compound as a white foam.
[1767] MS m/e (%): 639 (M+H.sup.+, 100)
EXAMPLE 102
(R)-N-[6-[3-(Acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phe-
nyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyrami-
de
[1768] The title compound was obtained as a white foam in 41% yield
after flash chromatography according to the procedure described
above for the preparation of
(R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fl-
uoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide using iodoethane instead of iodomethane.
[1769] MS m/e (%): 653 (M+H.sup.+, 100)
EXAMPLE 103
(S)-N-[6-(3-Amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3--
yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1770] A mixture of 975 mg (1.83 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 1.26 g (9.15 mmol) potassium carbonate and 800 mg (3.66 mmol)
(S)-3-(trifluoro-acetamido)pyrrolidine hydrochloride in 10 ml
dimethyl sulfoxide was stirred at 130.degree. C. for 52 h. After
cooling to room temperature the reaction mixture was diluted with
30 ml tert-butyl methyl ether and washed with 20 ml of water and 10
ml of a saturated aqueous solution of sodium carbonate. The
combined organic layers were dried over sodium sulfate and
concentrated. The residue was dissolved in 25 ml of a 2 N solution
of ammonia in ethanol. The solution was stirred at room temperature
for 18 h. The reaction mixture was concentrated and purified by
flash chromatography to give 640 mg (60%) of the title compound as
a light brown foam.
[1771] MS m/e (%): 583 (M+H.sup.+, 100)
EXAMPLE 104
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de
[1772] To a solution of 600 mg (1.03 mmol)
(S)-N-[6-(3-amino-pyrrolidin-1--
yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl--
phenyl)-N-methyl-isobutyramide in 6 ml dichloromethane were added 6
mg (0.05 mmol) 4-(N,N-dimethylamino)pyridine, 266 mg (2.06 mmol)
N,N-diisopropylethylamine and 153 mg (1.34 mmol) methanesulfonyl
chloride. After stirring at room temperature for 18 h the reaction
mixture was diluted with 20 ml dichloromethane and washed with 20
ml of a saturated aqueous solution of sodium carbonate. The
combined organic layers were dried over sodium sulfate,
concentrated and purified by flash chromatography to give 553 mg
(81%) of the title compound as an off-white foam.
[1773] MS m/e (%): 659 ([M-H+]-, 100)
EXAMPLE 105
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[-
3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-i-
sobutyramide
[1774] The title compound was obtained as an off-white foam in 48%
yield after flash chromatography according to the procedure
described above for the preparation of
(R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(-
4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-
-N-methyl-isobutyramide using
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide instead of
(R)-N-[6-(3-acetylamino-pyrrol-
idin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoro-
methyl-phenyl)-N-methyl-isobutyramide.
[1775] MS m/e (%): 675 (M+H.sup.+, 100)
EXAMPLE 106
(S)-(2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfonyl-ami-
no)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide
[1776] To a solution of 150 mg (0.227 mmol)
(S)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrroli-
din-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in 1 ml
dimethylformamide were added 14 mg (0.35 mmol) sodium hydride (60%
dispersion in mineral oil). After stirring at room temperature for
30 min. 22 mg (0.27 mmol) iodoethane were added. The reaction
mixture was stirred at room temperature for 18 h, followed by
dilution with 10 ml tert-butyl methyl ether and washing with 20 ml
water and with 10 ml of a saturated aqueous solution of sodium
carbonate. The combined organic layers were dried over sodium
sulfate, concentrated and purified by flash chromatography to give
86 mg (55%) of the title compound as an off-white foam.
[1777] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 107
(S)-N-[6-[3-(Acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-ph-
enyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyram-
ide
[1778] The title compound was obtained as a white foam in 62% yield
after flash chromatography according to the procedure described
above for the preparation of
(R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fl-
uoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide using
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fl-
uoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide instead of
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4--
(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide.
[1779] MS m/e (%): 639 (M+H.sup.+, 100)
EXAMPLE 108
(S)-N-[6-[3-(Acetyl-ethyl-amino)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phe-
nyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyrami-
de
[1780] The title compound was obtained as a white foam in 59% yield
after flash chromatography according to the procedure described
above for the preparation of
(R)-N-[6-[3-(acetyl-methyl-amino)-pyrrolidin-1-yl]-4-(4-fl-
uoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide using
(S)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4-(4-fl-
uoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide instead of
(R)-N-[6-(3-acetylamino-pyrrolidin-1-yl)-4--
(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide and iodoethane instead of iodomethane.
[1781] MS m/e (%): 639 (M+H.sup.+, 100)
EXAMPLE 109
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1782] The title compound was obtained as a white foam in 62% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
(S)-3-hydroxypyrrolidine instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide
[1783] MS m/e (%): 584 (M+H.sup.+, 100)
EXAMPLE 110
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1784] The title compound was obtained as an off-white foam in 73%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using (RS)-3-pyrrolidinol instead of ethanolamine and
2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl--
isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4--
(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[1785] MS m/e (%): 584 (M+H.sup.+, 100)
EXAMPLE 111
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-ox-
o-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1786] The title compound was obtained as a off-white foam in 73%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(3-hydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
[1787] MS m/e (%): 582 (M+H.sup.+, 100)
EXAMPLE 112
N-[4-Amino-4'-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-
-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1788]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-oxo--
3,4,5,6-tetrahydro-2H-1,2' 1
bipyridinyl-5'-yl]-N-methyl-isobutyramide
[1789] The title compound was obtained as a white foam in 72% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hydroxy-3,4,-
5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
instead of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hy-
droxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
[1790] MS m/e (%): 598 (M+H.sup.+, 100)
[1791] b)
N-[4-Amino-4'-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipy-
ridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1792] To a solution of 752 mg (1.26 mmol)
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4'-(2-chloro-phenyl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl--
5'-yl]-N-methyl-isobutyramide in 7 ml methanol 970 mg (12.6 mmol)
ammonium acetate were added at room temperature. The mixture was
stirred 5 minutes at this temperature, cooled to 0.degree. C. and
treated with 119 mg (1.89 mmol) sodium cyanoborohydride. The
reaction mixture was allowed to slowly warm to room temperature
during 5 h, followed by dilution with 20 ml ethyl acetate, washing
with 10 ml brine and extraction with 20 ml ethyl acetate. The
combined organic layers were dried over sodium sulfate,
concentrated in vacuo and purified by flash chromatography to give
480 mg (64%) of the title compound as a white foam.
[1793] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 113
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methanesulfon-
ylamino-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyram-
ide
[1794] The title compound was obtained as a white foam in 16% yield
after flash chromatography according to the procedure described
above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-me-
thyl-isobutyramide using
N-[4-amino-4'-(2-chloro-phenyl)-3,4,5,6-tetrahydr-
o-2H-[1,2']bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl--
isobutyramide instead of
(S)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide.
[1795] MS m/e (%): 677 (M+H.sup.+, 100)
EXAMPLE 114
N-[4-Acetylamino-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyra-
mide
[1796]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-pheny-
l)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobu-
tyramide
[1797] The title compound was obtained as a light yellow foam in
93% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide and 4-hydroxy-piperidine instead of ethanolamine.
[1798] MS m/e (%): 598 (M+H.sup.+, 100)
[1799] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phen-
yl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyr-
amide
[1800] The title compound was obtained as a white foam in 96% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-hyd-
roxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
instead of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-
-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1801] MS m/e (%): 596 (M+H.sup.+, 100)
[1802] c)
N-[4-Amino-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[-
1,2']bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobut-
yramide
[1803] The title compound was obtained as a white foam in 45% yield
after flash chromatography according to the procedure described
above for the preparation of
N-[4-amino-4'-(2-chloro-phenyl)-3,4,5,6-tetrahydro-2H-[1,2-
']bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyra-
mide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phe-
nyl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobuty-
ramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-pheny-
l)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyra-
mide.
[1804] MS m/e (%): 597 (M+H.sup.+, 100)
[1805] d)
N-[4-Acetylamino-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydr-
o-2H-[1,2']bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl--
isobutyramide
[1806] To a solution of 80 mg (0.13 mmol)
N-[4-amino-4'-(4-fluoro-2-methyl-
-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-2-(3,5-bis-trifluo-
romethyl-phenyl)-N-methyl-isobutyramide and 26 mg (0.20 mmol)
N,N-diisopropylethylamine in 3 ml dichloromethane were added 12 mg
(0.15 mmol) acetyl chloride at 0.degree. C. The reaction mixture
was stirred at room temperature for 18 h. The mixture was diluted
with 10 ml dichloromethane and washed with 10 ml of a saturated
aqueous solution of sodium carbonate. The combined organic layers
were dried over sodium sulfate, concentrated and purified by flash
chromatography to give 82 mg (95%) of the title compound as a white
foam.
[1807] MS m/e (%): 639 (M+H.sup.+, 100)
EXAMPLE 115
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)-6-[(2-hydroxy-et-
hyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
[1808] A mixture of 0.10 g (0.20 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and 0.45 g (6.0 mmol) 2-(methylamino)ethanol was stirred 6 h at
140.degree. C. After cooling to room temperature the reaction
mixture was partitioned between water and tert-butyl methyl ether
and extracted with three portions of tert-butyl methyl ether. The
combined organic extracts were washed with a saturated aqueous
solution of ammonium chloride and water, dried over sodium sulfate
and concentrated in vacuo. Flash column chromatography gave 87 mg
(78%) of the title compound as a light yellow solid.
[1809] MS m/e (%): 558 (M+H.sup.+, 100)
EXAMPLE 116
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[ethyl-(2-hydroxy-ethyl)-amino]-4--
(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[1810] The title compound was obtained as a white solid in 23%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using 2-(ethylamino)ethanol instead of 2-(methylamino)ethanol.
[1811] MS m/e (%): 572 (M+H.sup.+, 100)
EXAMPLE 117
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{6-[(2-hydroxy-ethyl)-methyl-amino]-4-
-o-tolyl-pyridin-3-yl}-N-methyl-isobutyramide
[1812] The title compound was obtained as a white solid in 87%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3--
yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
[1813] MS m/e (%): 554 (M+H.sup.+, 100)
EXAMPLE 118
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{6-[ethyl-(2-hydroxy-ethyl)-amino]-4--
o-tolyl-pyridin-3-yl}-N-methyl-isobutyramide
[1814] The title compound was obtained as a white solid in 91%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3--
yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and 2-(ethylamino)ethanol instead of 2-(methylamino)ethanol.
[1815] MS m/e (%): 568 (M+H.sup.+, 100)
EXAMPLE 119
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{6-[(2-hydroxy-ethyl)-propyl-amino]-4-
-o-tolyl-pyridin-3-yl}-N-methyl-isobutyramide
[1816] The title compound was obtained as a white solid in 72%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3--
yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and 2-(propylamino)ethanol instead of 2-(methylamino)ethanol.
[1817] MS m/e (%): 568 (M+H.sup.+, 100)
EXAMPLE 120
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-to-
lyl-pyridin-3-yl]-N-methyl-isobutyramide
[1818] The title compound was obtained as a light yellow solid in
55% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-f-
luoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-is-
obutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-
-pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyra-
mide and (S)-1-amino-2-propanol instead of
2-(methylamino)ethanol.
[1819] MS m/e (%): 554 (M+H.sup.+, 100)
EXAMPLE 121
N-{6-[Bis-(2-hydroxy-propyl)-amino]-4-o-tolyl-pyridin-3-yl}-2-(3,5-bis-tri-
fluoromethyl-phenyl)-N-methyl-isobutyramide
[1820] The title compound was obtained as a white solid in 51%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3--
yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and bis-(2-hydroxypropyl)amine instead of
2-(methylamino)ethanol.
[1821] MS m/e (%): 612 (M+H.sup.+, 100)
EXAMPLE 122
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4--
o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1822] The title compound was obtained as a white solid in 76%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3--
yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and (S)-3-amino-1,2-propandiol instead of
2-(methylamino)ethanol.
[1823] MS m/e (%): 570 (M+H.sup.+, 100)
EXAMPLE 123
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2,3-dihydroxy-propylamino)-4--
o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1824] The title compound was obtained as a white solid in 74%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3--
yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and (R)-3-amino-1,2-propandiol instead of
2-(methylamino)ethanol.
[1825] MS m/e (%): 570 (M+H.sup.+, 100)
EXAMPLE 124
N-[6-[Bis-(2-hydroxy-propyl)-amino]-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3-
,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1826] The title compound was obtained as a white solid in 71%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)--
pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide and bis-(2-hydroxypropyl)amine instead of
2-(methylamino)ethanol.
[1827] MS m/e (%): 632 (M+H.sup.+, 100)
EXAMPLE 125
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihyd-
roxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1828] The title compound was obtained as a white solid in 73%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)--
pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide and (S)-3-amino-1,2-propandiol instead of
2-(methylamino)ethanol.
[1829] MS m/e (%): 590 (M+H.sup.+, 100)
EXAMPLE 126
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2,3-dihyd-
roxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1830] The title compound was obtained as a white solid in 65%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)--
pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide and (R)-3-amino-1,2-propandiol instead of
2-(methylamino)ethanol.
[1831] MS m/e (%): 590 (M+H.sup.+, 100)
EXAMPLE 127
N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(3-fluoro-2-methyl-phenyl)-pyridin-3--
yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1832] The title compound was obtained as a light yellow solid in
34% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-f-
luoro-phenyl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-is-
obutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-fluo-
ro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide and 2-(2-hydroxy-ethylamino)-ethanol
instead of 2-(methylamino)ethanol.
[1833] MS m/e (%): 602 (M+H.sup.+, 100)
EXAMPLE 128
N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(5-fluoro-2-methyl-phenyl)-pyridin-3--
yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1834] The title compound was obtained as a light yellow solid in
9% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phen-
yl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramid-
e using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(5-fluoro-2-methy-
l-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide and 2-(2-hydroxy-ethylamino)-ethanol
instead of 2-(methylamino)ethanol.
[1835] MS m/e (%): 602 (M+H.sup.+, 100)
EXAMPLE 129
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1836] A mixture of 800 mg (1.38 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[4-(2-bromo-phenyl)-6-chloro-pyridin-3-yl]-N-methyl-isobutyramide,
4 ml dimethyl sulfoxide and 1.15 g (6.9 mmol)
(2S,4R)-2-(hydroxymethyl)-4-hydr- oxypyrrolidine was stirred at
130.degree. C. for 24 h. The reaction mixture was cooled to room
temperature, diluted with 100 ml ethyl acetate and washed with 200
ml 1 N sodium carbonate solution and 100 ml water. The combined
aqueous layers were extracted twice with 100 ml ethyl acetate. The
combined organic layers were dried over sodium sulfate and
evaporated. Purification by flash chromatography gave 434 mg (48%)
of the title compound as a yellow foam.
[1837] MS m/e (%): 660 (M+H.sup.+, 100)
EXAMPLE 130
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(3-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1838] The title compound was obtained as a yellow foam in 27%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1839] MS m/e (%): 660 (M+H.sup.+, 100)
EXAMPLE 131
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxy--
propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1840] The title compound was obtained as a white foam in 52% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using (S)-1-amino-2-propanol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1841] MS m/e (%): 618 (M+H.sup.+, 89)
EXAMPLE 132
trans-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydrox-
y-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1842] The title compound was obtained as a white foam in 39% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using trans-4-aminocyclohexanol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1843] MS m/e (%): 658 (M+H.sup.+, 83)
EXAMPLE 133
(S)-N-[6-(3-Acetylamino-pyrrolidin-1-yl)-4-(2-bromo-phenyl)-pyridin-3-yl]--
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1844] The title compound was obtained as a white foam in 67% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using (S)-acetamidopyrrolidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1845] MS m/e (%): 671 (M+H.sup.+, 100)
EXAMPLE 134
N-[6-[Bis-(2-hydroxy-ethyl)-amino]-4-(2-bromo-phenyl)-pyridin-3-yl]-2-(3,5-
-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1846] The title compound was obtained as a light yellow foam in
23% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using diethanolamine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1847] MS m/e (%): 648 (M+H.sup.+, 100)
EXAMPLE 135
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[1848] The title compound was obtained as a yellow foam in 61%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3,-
4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide.
[1849] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 136
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[1850] The title compound was obtained as a yellow foam in 50%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,-
4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide.
[1851] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 137
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[1852] The title compound was obtained as a yellow foam in 45%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2,-
4-dichloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and
(2R,3S)-2-hydroxymethyl-pyrrolidin-3-ol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1853] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 138
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1854] The title compound was obtained as an off-white foam in 26%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-
-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrro- lidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1855] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 139
(2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1856] The title compound was obtained as an off-white foam in 67%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-
-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and
(2R,4S)-2-(hydroxymethyl)-4-hydroxypyrro- lidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1857] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 140
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1858] The title compound was obtained as a white foam in 50% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2--
chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and
(2S,4S)-2-(hydroxymethyl)-4-hydroxypyrro- lidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1859] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 141
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-hydroxym-
ethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramid-
e
[1860] The title compound was obtained as a white foam in 45% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2--
chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and (RS)-2-piperidinemethanol instead
of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1861] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 142
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxy
1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1862] The title compound was obtained as a light yellow solid in
23% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[-
6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chl-
oro-pyridin-3-yl]-N-methyl-isobutyramide and 5 mol-%
4-(N,N-dimethylamino)pyridine and 2-amino-1,3-propandiol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1863] MS m/e (%): 588 (M+H.sup.+, 100)
EXAMPLE 143
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-1-hydroxymethyl-ethylam-
ino)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1864] The title compound was obtained as an off-white solid in 55%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-
-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and 2-amino-1,3-propandiol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1865] MS m/e (%): 570 (M+H.sup.+, 100)
EXAMPLE 144
(1R,2R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hyd-
roxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1866] The title compound was obtained as an off-white solid in 32%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-
-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and 5 mol-%
4-(N,N-dimethylamino)pyridine and L-threoninol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidin- e.
[1867] MS m/e (%): 604 (M+H.sup.+, 100)
EXAMPLE 145
(1R,2S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hyd-
roxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1868] The title compound was obtained as an off-white solid in 23%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-
-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and 5 mol-%
4-(N,N-dimethylamino)pyridine and L-allo-threoninol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrro- lidine.
[1869] MS m/e (%): 604 (M+H.sup.+, 100)
EXAMPLE 146
(1S,2R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hyd-
roxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1870] The title compound was obtained as an off-white solid in 18%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-
-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and 5 mol-%
4-(N,N-dimethylamino)pyridine and D-allo-threoninol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrro- lidine.
[1871] MS m/e (%): 604 (M+H.sup.+, 100)
EXAMPLE 147
(1S,2S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hyd-
roxy-1-hydroxymethyl-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1872] The title compound was obtained as an off-white solid in 4%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-
-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and 5 mol-%
4-(N,N-dimethylamino)pyridine and D-threoninol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidin- e.
[1873] MS m/e (%): 604 (M+H.sup.+, 100)
EXAMPLE 148
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[hexyl-(2-hydr-
oxy-ethyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide
[1874] The title compound was obtained as a light yellow solid in
39% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[-
6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyri-
din-3-yl]-N-methyl-isobutyramide and 2-(hexylamino)ethanol instead
of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1875] MS m/e (%): 644 (M+H.sup.+, 100)
EXAMPLE 149
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2-hydroxy-et-
hyl)-pentyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
[1876] The title compound was obtained as a light yellow solid in
38% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[4-(2-bromo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[-
6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyri-
din-3-yl]-N-methyl-isobutyramide and 2-(N-amylamino)ethanol instead
of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1877] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 150
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(2-chloro-phenyl)-6-[(2-hydroxy-et-
hyl)-(3-hydroxy-propyl)-amino]-pyridin-3-yl}-N-methyl-isobutyramide
[1878] The title compound was obtained as an off-white solid in 26%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-
-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and 3-(hydroxyethylamino)-1-propanol
instead of (2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1879] MS m/e (%): 618 (M+H.sup.+, 100)
EXAMPLE 151
(1RS,2RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-h-
ydroxy-cyclohexylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1880] The title compound was obtained as a light brown solid in
46% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bro-
mo-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-
-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and 5 mol-%
4-(N,N-dimethylamino)pyridine and (1RS,2RS)-2-aminocyclohexanol
instead of (2S,4R)-2-(hydroxymethyl)-4-- hydroxypyrrolidine.
[1881] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 152
(1R,2R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hyd-
roxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1882]
a)(1R,2R)-N-[6-(2-Benzyloxy-cyclopentylamino)-4-(2-chloro-phenyl)-p-
yridin-3-yl-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[1883] The title compound was obtained as a brown solid in 58%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-p-
henyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2--
chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-chloro-pyridin-
-3-yl]-N-methyl-isobutyramide and 5 mol-%
4-(N,N-dimethylamino)pyridine and
(1R,2R)-2-benzyloxy-cyclopentylamine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[1884] b)
(1R,2R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl-
)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1885] To a solution of 0.15 g (0.22 mmol)
(1R,2R)-N-[6-(2-benzyloxy-cyclo-
pentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl--
phenyl)-N-methyl-isobutyramide in 2 ml dichloromethane were added
0.87 ml (0.87 mmol) of a 1 M boron trichloride solution in
dichloromethane at room temperature. After 2 h the reaction was
quenched by addition of 2 ml of a 1 M aqueous hydrochloric acid
solution. Neutralisation with 1 M aqueous NaOH solution was
followed by extraction with 3 portions of tert-butyl methyl ether.
The combined organic layers were dried over sodium sulfate and
concentrated in vacuo. Flash column chromatography gave 60 mg (46%)
of the title compound as an off-white solid.
[1886] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 153
(1S,2S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hyd-
roxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1887] The title compound was obtained as an off-white solid in 8%
yield over two steps according to the procedures described above
for the preparation of
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro--
phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e using (1S,2S)-2-benzyloxy-cyclopentylamine instead of
(1R,2R)-2-benzyloxy-cyclopentylamine in step a).
[1888] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 154
(1S,2S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[1889] The title compound was obtained as a light brown solid in
15% yield over two steps according to the procedures described
above for the preparation of
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro--
phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methy-
l-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide and
(1S,2S)-2-benzyloxy-cyclopentylamine instead of
(1R,2R)-2-benzyloxy-cyclopentylamine in step a).
[1890] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 155
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[1891] A mixture of 11.0 g (20.6 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 14.3 g (103 mmol) potassium carbonate and 12.2 g (75.7 mmol)
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine in 110 ml dimethyl
sulfoxide was stirred at 130.degree. C. for 68 h. The reaction
mixture was diluted with 800 ml ethyl acetate and washed with 800
ml saturated sodium carbonate solution, 500 ml water and 750 ml
brine. The combined aqueous layers were extracted with two 800-ml
portions of ethyl acetate. The combined organic layers were dried
over sodium sulfate and concentrated in vacuo. Purification by
flash chromatography gave 8.48 g (67%) of the title compound as a
light yellow foam.
[1892] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 156
(2R,3R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide and
EXAMPLE 157
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide
[1893] To a solution of 400 mg (0.65 mmol)
(2R,3S)-2-(3,5-bis-trifluoromet-
hyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-p-
yrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in 6.5 ml
tetrahydrofuran were added at 0.degree. C. 0.67 ml (3.26 mmol)
diisopropyl azodicarboxylate and 398 mg (3.26 mmol) benzoic acid.
The reaction mixture was cooled to -78.degree. C., followed by
addition of 855 mg (3.26 mmol) triphenylphosphine. The reaction
mixture was allowed to slowly warm to room temperature over night.
Addition of 75 ml of a saturated sodium carbonate solution was
followed by extraction with two 75-ml portions of tert-butyl methyl
ether. The organic layers were washed with 75 ml brine, dried over
sodium sulfate, concentrated in vacuo and purified by flash
chromatography. The residue was dissolved in 20 ml methanol and
treated with 0.1 ml of a 5.5 M sodium methylate solution in
methanol. After stirring 3 h at room temperature the reaction
mixture was concentrated in vacuo. The residue was dissolved in 75
ml dichloromethane and washed with 60 ml water, dried over sodium
sulfate and purified by flash chromatography to give 117 mg (29%)
of (2R,3R)-2-(3,5-bis-trifluoro-
methyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide as a white
foam and 155 mg (40%) of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-
-2-methyl-phenyl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide as a white foam.
[1894]
(2R,3R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide:
[1895] MS m/e (%): 614 (M+H.sup.+, 100)
[1896]
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(2-hydroxymethyl-2,5-dihydro-pyrrol-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide:
[1897] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 158
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[1898] The title compound was obtained as an off-white foam in 66%
yield after flash chromatography according to the procedure
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-flu-
oro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyr- rolidine instead of
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
[1899] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 159
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[-
2-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-isobu-
tyramide
[1900] The title compound was obtained as a light brown amorphous
material in 36% yield after flash chromatography according to the
procedure described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrr-
olidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using
(S)-2-pyrrolidin-2-yl-propan-2-ol instead of
(2R,3S)-2-(hydroxymethyl)-3-- hydroxypyrrolidine.
[1901] MS m/e (%): 626 (M+H.sup.+, 100)
EXAMPLE 160
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-hydroxyme-
thyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
[1902] The title compound was obtained as a light brown gum in 14%
yield after flash chromatography according to the procedure
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-flu-
oro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[-
6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-ph-
enyl)-pyridin-3-yl]-N-methyl-isobutyramide and
(R)-piperidine-2-ylmethanol instead of
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
[1903] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 161
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-2-hydroxyme-
thyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
[1904] The title compound was obtained as a light brown oil in 15%
yield after flash chromatography according to the procedure
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-flu-
oro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using (S)-piperidine-2-yl-methanol
instead of (2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-pheny-
l)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide.
[1905] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 162
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hy-
droxy-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1906] The title compound was obtained as a light yellow foam in
65% yield after flash chromatography according to the procedure
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-flu-
oro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using azetidin-3-ol instead of
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
[1907] MS m/e (%): 570 (M+H.sup.+, 100)
EXAMPLE 163
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-azetidin-1-yl)-4-o-toly-
l-pyridin-3-yl]-N-methyl-isobutyramide
[1908] The title compound was obtained as a light yellow foam in
62% yield after flash chromatography according to the procedure
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-flu-
oro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using azetidin-3-ol instead of
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-ch-
loro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
[1909] MS m/e (%): 552 (M+H.sup.+, 100)
EXAMPLE 164
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(5-ox-
o-diazepan-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1910] The title compound was obtained as a light yellow solid in
36% yield after flash chromatography according to the procedure
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-N-methyl-isobutyramide using
2,3,6,7-tetrahydro-(1H)-1,4-- diazepin-5-(4H)-one instead of
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolid- ine.
[1911] MS m/e (%): 611 (M+H.sup.+, 100)
EXAMPLE 165
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1912] A mixture of 0.20 g (0.38 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 0.23 g (2.3 mmol) L-prolinol and 0.15 g (1.1 mmol) potassium
carbonate in 0.5 ml dimethyl sulfoxide was heated at 180.degree. C.
under microwave irradiation for 30 min. in a sealed tube. After
cooling to room temperature the reaction mixture was diluted with
water and extracted with three portions of tert-butyl methyl ether.
The combined organic extracts were washed with water and brine,
dried over sodium sulfate and concentrated in vacuo. Flash column
chromatography gave 0.18 g (78%) of the title compound as an
off-white solid.
[1913] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 166
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1914] The title compound was obtained as a white solid in 47%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(5-fluo-
ro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide.
[1915] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 167
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1916] The title compound was obtained as a white solid in 40%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-fluo-
ro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide.
[1917] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 168
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1--
yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1918] The title compound was obtained as a white solid in 45%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-
-pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl--
isobutyramide and D-prolinol instead of L-prolinol.
[1919] MS m/e (%): 580 (M+H.sup.+, 100)
EXAMPLE 169
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide
[1920] The title compound was obtained as an off-white solid in 57%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using (S)-(+)-1-(2-pyrrolidinylmethyl)pyrrolidine
instead of L-prolinol.
[1921] MS m/e (%): 651 (M+H.sup.+, 100)
EXAMPLE 170
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-methanesulfonyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1922] The title compound was obtained as a light yellow solid in
48% yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide using 3-(methylsulfonyl)pyrrolidine
instead of L-prolinol.
[1923] MS m/e (%): 646 (M+H.sup.+, 100)
EXAMPLE 171
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3-hydrox-
ymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1924] The title compound was obtained as an off-white solid in 84%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2--
chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide and
(RS)-pyrrolidin-3-yl-methanol instead of L-prolinol.
[1925] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 172
2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-hydroxymethyl-4'-o-tolyl-3,4,5,6-t-
etrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramide
[1926] The title compound was obtained as a light yellow solid in
54% yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-ch-
loro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide and
4-(hydroxymethyl)piperidine instead of L-prolinol.
[1927] MS m/e (%): 594 (M+H.sup.+, 100)
EXAMPLE 173
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-propylamino)-4-o-to-
lyl-pyridin-3-yl]-N-methyl-isobutyramide
[1928] The title compound was obtained as an off-white solid in 30%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-t-
olyl-pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide and (R)-1-amino-2-propanol
instead of L-prolinol.
[1929] MS m/e (%): 554 (M+H.sup.+, 100)
EXAMPLE 174
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1930]
a)(S)-4-Benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine
[1931] A solution of 1.00 g (4.82 mmol)
(R)-(4-benzyl-morpholin-3-yl)-meth- anol, 0.80 g (5.3 mmol)
tert-butyl-chloro-dimethyl-silane and 0.72 g (0.11 mmol) imidazole
in 10 ml N,N-dimethylformamide was stirred at room temperature for
90 min. Consecutive addition of water and 1 M aqueous sodium
hydroxide solution was followed by extraction with three portions
of tert-butyl methyl ether. The combined organic layers were washed
with 1 M aqueous sodium hydroxide solution, dried over sodium
sulphate and concentrated in vacuo to give 1.54 g (99.3%) of the
crude title compound as a colorless oil.
[1932] MS m/e (%): 322 (M+H.sup.+, 100)
[1933] b)
(S)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-morpholine
[1934] A solution of 1.54 g (4.79 mmol)
(S)-4-benzyl-3-(tert-butyl-dimethy- l-silanyloxymethyl)-morpholine
in 24 ml ethanol was deoxygenated by three cycles of evacuation and
flushing with argon. After addition of 0.5 g palladium on charcoal
(10%) the reaction vessel was evacuated and filled with hydrogen
gas. The reaction mixture was stirred at room temperature under an
atmosphere of hydrogen over night. Filtration over decalite and
evaporation of the solvent in vacuo gave 1.08 g (97.4%) of the
crude title compound as a colorless oil.
[1935] MS m/e (%): 232 (M+H.sup.+, 100)
[1936] c)
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[1937] A mixture of 0.30 g (0.56 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 0.17 g (0.73 mmol)
(S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morph- oline, 0.01 g
(0.03 mmol) cetyltrimethylammonium bromide, 0.029 g (0.056 mmol)
bis(tri-t-butylphosphine)palladium(0), 0.07 ml NaOH 50% and 3 ml
toluene was degassed by two freeze-thaw cycles. The reaction
mixture was heated under argon at 90.degree. C. for 3 h. After
cooling to room temperature the mixture was diluted with water and
extracted with three portions of toluene. The combined organic
layers were dried over sodium sulphate and concentrated in vacuo.
The residue was dissolved in a mixture of 10 ml methanol and 0.5 ml
concentrated aqueous hydrochloric acid solution. After stirring at
room temperature for 90 min. the reaction mixture was neturalized
with 0.5 M aqueous sodium hydroxide solution and extracted with
three portions of tert-butyl methyl ether. The combined organic
layers were dried over sodium sulfate and concentrated in vacuo.
Flash column chromatography gave 0.10 g (30%) of the title compound
as an off-white solid.
[1938] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 175
(R)-(2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-morpholin-4--
yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1939] The title compound was obtained as a white solid in 61%
yield after flash chromatography according to the procedure
described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl--
pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide.
[1940] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 176
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-morpholin-4--
yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1941] The title compound was obtained as a light brown solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-py-
ridin-3-yl]-N-methyl-isobutyramide using
(RS)-(4-benzyl-morpholin-2-yl)-me- thanol instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-ch-
loro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in step c).
[1942] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 177
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide
[1943]
a)(RS)-3-(tert-Butyl-dimethyl-silanyloxymethyl)-thiomorpholine
[1944] The crude title compound was obtained as an orange oil in
92% yield according to the procedure described above for the
preparation of
(S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine
using (RS)-thiomorpholin-3-yl-methanol instead of
(R)-(4-benzyl-morpholin-3-yl)- -methanol.
[1945] MS m/e (%): 248 (M+H.sup.+, 100)
[1946] b)
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxymethyl-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[1947] The title compound was obtained as an off-white solid in 55%
yield after flash chromatography according to step c) of the
procedure described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-py-
ridin-3-yl]-N-methyl-isobutyramide using
(RS)-3-(tert-butyl-dimethyl-silan- yloxymethyl)-thiomorpholine
instead of (S)-3-(tert-butyl-dimethyl-silanylo-
xymethyl)-morpholine.
[1948] MS m/e (%): 630 (M+H.sup.+, 100)
[1949] c)
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide
[1950] The title compound was obtained as a white solid in 80%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)--
6-(2-methanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(3-hydroxymethyl-thiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl-
)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
[1951] MS m/e (%): 662 (M+H.sup.+, 100)
EXAMPLE 178
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-l.-
lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide
[1952] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-t-
hiomorpholin-4-yl)-pyridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-ch-
loro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in step b).
[1953] MS m/e (%): 644 (M+H.sup.+, 100)
EXAMPLE 179
(3R,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(3,5-dihydroxy-4'-o-tolyl-3,4-
,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramide
[1954] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using (3R,5R)-1-benzyl-piperidine-3,5-diol
instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-ch-
loro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in step c).
[1955] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 180
(3R,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3,5-dih-
ydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyrami-
de
[1956] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide, using
(3R,5R)-1-benzyl-piperidine-3,5-diol instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-pheny-
l)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide in step c).
[1957] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 181
(3S,5R)-5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3,5-dihydrox-
y-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
[1958]
a)(3R,5R)-1-Benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-o-
l
[1959] The title compound was obtained as a light brown oil in 38%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-- morpholine
using (3R,5R)-1-benzyl-piperidine-3,5-diol instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol.
[1960] MS m/e (%): 322 (M+H.sup.+, 100)
[1961] b)
(3S,5R)-1-Benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3--
ol
[1962] To a solution of 1.8 g (5.6 mmol)
(3R,5R)-1-benzyl-5-(tert-butyl-di-
methyl-silanyloxy)-piperidin-3-ol in 50 ml tetrahydrofuran were
added at 0.degree. C. 0.97 ml (6.2 mmol) diethyl azodicarboxylate
and 0.75 g (6.2 mmol) benzoic acid. The reaction mixture was cooled
to 0.degree. C., followed by addition of 1.6 g (6.2 mmol)
triphenylphosphine. The reaction mixture was stirred at 0.degree.
C. for 6 h. Addition of a saturated sodium carbonate solution was
followed by extraction with three portions of tert-butyl methyl
ether. The combined organic layers were washed with saturated
sodium carbonate solution and brine, dried over sodium sulfate,
concentrated in vacuo and purified by flash chromatography. The
residue was dissolved in a mixture of 50 ml dioxane and 18 ml 1 N
aqueous sodium hydroxide solution. After stirring at 70.degree. C.
for 5 h the reaction mixture was diluted with tert-butyl methyl
ether. The layers were separated and the organic layer was washed
with a saturation aqueous sodium carbonate solution. The combined
aqueous layers were extracted with two portions of tert-butyl
methyl ether. The combined organic layers were washed with brine,
dried over sodium sulfate and concentrated in vacuo. Flash
chromatography gave 0.1 g (6%) of the title compound as a light
brown oil.
[1963] MS m/e (%): 322 (M+H.sup.+, 100)
[1964] c)
(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidine
[1965] The title compound was obtained as a white solid in
comparable yields according to the procedures described above for
the preparation of
(S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine using
(3S,5R)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol
instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
[1966] MS m/e (%): 346 (M+H.sup.+, 100)
[1967] d)
(3S,5R)-5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3,-
5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobut-
yramide
[1968] The title compound was obtained as a white solid in
comparable yield after flash chromatography according to the
procedure described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
(3S,5R)-3,5-bis-(tert-butyl-dimethyl-silany- loxy)-piperidine
instead of (S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-m-
orpholine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-p-
henyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide.
[1969] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 182
(3S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(3,4-d-
ihydroxy-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[1970] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
(3S,4S)-1-benzyl-pyrrolidine-3,4-diol instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-pheny-
l)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide in step c).
[1971] MS m/e (%): 602 (M+H.sup.+, 100)
EXAMPLE 183
(3S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin--
1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1972] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
(3S,4S)-1-benzyl-pyrrolidine-3,4-diol instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-ch-
loro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in step c).
[1973] MS m/e (%): 582 (M+H.sup.+, 100)
EXAMPLE 184
(3R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3,4-dihydroxy-pyrrolidin--
1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[1974] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
(3R,4S)-3,4-dihydroxy-pyrrolidine-1-carboxy- lic acid benzyl ester
instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyri-
din-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide in step c).
[1975] MS m/e (%): 582 (M+H.sup.+, 100)
EXAMPLE 185
(3RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4'-o-tolyl-3-
,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramide
[1976] The title compound was obtained as an off-white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3
hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
(3RS,4SR)-3,4-dihydroxy-piperidine-1-carbox- ylic acid benzyl ester
instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-p-
yridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl--
phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-is-
obutyramide in step c).
[1977] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 186
(3RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(3,4-dihydroxy-4'-o-tolyl-3-
,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobutyramide
[1978] The title compound was obtained as an off-white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
(3RS,4SR)-3,4-dihydroxy-piperidine-1-carbox- ylic acid benzyl ester
instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-p-
yridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl--
phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-is-
obutyramide in step c).
[1979] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 187
(3RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3,4-d-
ihydroxy-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-N-methyl-isobutyr- amide
[1980] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
(3RS,4SR)-3,4-dihydroxy-piperidine-1-carbox- ylic acid benzyl ester
instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-
-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
[1981] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 188
(3RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3,4-d-
ihydroxy-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-N-methyl-isobutyr- amide
[1982] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
(3RS,4SR)-3,4-dihydroxy-piperidine-1-carbox- ylic acid benzyl ester
instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-
-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
[1983] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 189
(2RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hyd-
roxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-meth-
yl-isobutyramide
[1984] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chl-
oro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and
(2RS,4SR)-1-benzyl-2-hydroxymethyl-piperidin-4-ol instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
(2RS,4SR)-1-Benzyl-2-hydroxymethyl-piperidin-4-ol is obtained by
reduction of
(1RS,5SR)-2-benzyl-6-oxa-2-aza-bicyclo[3.2.1]octan-7-one with
lithium aluminum hydride in tetrahydrofuran at room temperature for
1 h.
[1985] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 190
(2RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-hydroxy-2-hydroxymethyl--
4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobuty-
ramide
[1986] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chl-
oro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and
(2RS,4SR)-1-benzyl-2-hydroxymethyl-piperidin-4-ol instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
[1987] MS m/e (%): 610 (M+H.sup.+, 100)
EXAMPLE 191
(3RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl--
4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobuty-
ramide
[1988] The title compound was obtained as a light yellow solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-py-
ridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl-
)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and
1-benzyl-3-hydroxymethyl-piperidin-4-ol as a mixture of racemic
diastereomers (Gueller, Rolf; Binggeli, Alfred; Breu, Volker; Bur,
Daniel; Fischli, Walter; et al.; Bioorg. Med. Chem. Lett.
1999,9,1403-1408.) instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
(3RS,4SR)-1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-bu-
tyl-dimethyl-silanyloxymethyl)-piperidine was separated from
(3RS,4RS)-1-benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimet-
hyl-silanyloxymethyl)-piperidine by flash column chromatography and
used in step b).
[1989] MS m/e (%): 610 (M+H.sup.+, 100)
EXAMPLE 192
(3RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-(4-hydroxy-3-hydroxymethyl--
4'-o-tolyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl)-N-methyl-isobuty-
ramide
[1990] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chl-
oro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and
1-benzyl-3-hydroxymethyl-piperidin-4-ol as a mixture of racemic
diastereomers (Gueller, Rolf; Binggeli, Alfred; Breu, Volker; Bur,
Daniel; Fischli, Walter; et al.; Bioorg. Med. Chem. Lett.
1999,9,1403-1408.) instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
(3RS,4RS)-1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-bu-
tyl-dimethyl-silanyloxymethyl)-piperidine was separated from
(3RS,4SR)-1-benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimet-
hyl-silanyloxymethyl)-piperidine by flash column chromatography and
used in step b).
[1991] MS m/e (%): 610 (M+H.sup.+, 100)
EXAMPLE 193
(3RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hyd-
roxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-meth-
yl-isobutyramide
[1992] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chl-
oro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and
1-benzyl-3-hydroxymethyl-piperidin-4-ol as a mixture of racemic
diastereomers (Gueller, Rolf; Binggeli, Alfred; Breu, Volker; Bur,
Daniel; Fischli, Walter; et al.; Bioorg. Med. Chem. Lett.
1999,9,1403-1408.) instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a). (3RS,
4SR)-1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-b-
utyl-dimethyl-silanyloxymethyl)-piperidine was separated from
(3RS,4RS)-1-benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimet-
hyl-silanyloxymethyl)-piperidine by flash column chromatography and
used in step b).
[1993] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 194
(3RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-hyd-
roxy-3-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-meth-
yl-isobutyramide
[1994] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chl-
oro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and
1-benzyl-3-hydroxymethyl-piperidin-4-ol as a mixture of racemic
diastereomers (Gueller, Rolf; Binggeli, Alfred; Breu, Volker; Bur,
Daniel; Fischli, Walter; et al.; Bioorg. Med. Chem. Lett.
1999,9,1403-1408.) instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
(3RS,4RS)-1-Benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-bu-
tyl-dimethyl-silanyloxymethyl)-piperidine was separated from
(3RS,4SR)-1-benzyl-4-(tert-butyl-dimethyl-silanyloxy)-3-(tert-butyl-dimet-
hyl-silanyloxymethyl)-piperidine by flash column chromatography and
used in step b).
[1995] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 195
(2RS,3RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3-hyd-
roxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-meth-
yl-isobutyramide
[1996]
a)(2RS,3RS)-3-Hydroxy-2-hydroxymethyl-piperidine-1-carboxylic acid
benzyl ester
[1997] A mixture of 20.0 g (105 mmol)
3-hydroxy-2-(hydroxymethyl)-pyridine hydrochloride, 4.0 g (18 mmol)
platinum(IV) oxide, 4 g charcoal (Norit SX1) and 300 ml acetic acid
was stirred at room temperature for 20 h under a hydrogen pressure
of 10 bar in an autoclave. The catalyst was filtered off and washed
with acetic acid. The filtrate was concentrated in vacuo,
redissolved in isopropanol and treated with 29.0 g (210 mmol)
potassium carbonate. After stirring for 30 min. the mixture was
filtered, and the solvent was evaporated in vacuo to give 15.7 g of
crude (2RS,3RS)-2-hydroxymethyl-piperidin-3-ol. A portion of 2.0 g
of the crude intermediate was dissolved in 50 ml dichloromethane
and treated with 5.2 ml (30 mmol) N,N-diisopropylethylamine and 2.4
ml (16 mmol) benzyl chloroformate at 0.degree. C. After 45 min.
water and saturated ammonium chloride solution were added. The
mixture was extracted with four portions of dichloromethane. The
combined organic layers were dried over sodium sulfate and
concentrated in vacuo. Flash chromatography gave 0.82 g (23% based
on 3-hydroxy-2-(hydroxymethyl)-pyridine hydrochloride) of the title
compound as an off-white oil.
[1998] MS m/e (%): 266 (M+H.sup.+, 92)
[1999] b)
(2RS,3RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phe-
nyl)-3-hydroxy-2-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'--
yl]-N-methyl-isobutyramide
[2000] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chl-
oro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c) and
(2RS,3RS)-3-hydroxy-2-hydroxymethyl-piperidine-1-carboxylic acid
benzyl ester instead of (R)-(4-benzyl-morpholin-3-yl)-methanol in
step a).
[2001] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 196
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(2-h-
ydroxy-1-hydroxymethyl-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobuty-
ramide
[2002]
a)[2-(tert-Butyl-dimethyl-silanyloxy)-1-(tert-butyl-dimethyl-silany-
loxymethyl)-ethyl]-methyl-amine
[2003] To 26 ml (0.21 mmol) of a 8 M solution of methylamine in
ethanol were added dropwise at 0.degree. C. 31 ml (0.11 mmol)
titanium(IV) isopropoxide. The mixture was allowed to warm to room
temperature over a period of 15 min. A solution of 17 g (0.52 mmol)
1,3-bis-(tert-butyl-dime- thyl-silanyloxy)-propan-2-one in 10 ml
ethanol was added. The reaction mixture was stirred at room
temperature over night, followed by addition of 6.6 g (0.11 mmol)
sodium cyanoborohydride. After stirring for 24 h the reaction was
quenched by the addition of silica gel. The mixture was
concentrated in vacuo, and the residue was transfered to a silica
gel chromatography column. Flash chromatography and Kugelrohr
distillation (120.degree. C./2 mbar) gave 5.2 g (30%) of the title
compound as a light yellow viscous oil.
[2004] MS m/e (%): 334 (M+H.sup.+, 100)
[2005] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-[(2-hydroxy-1-hydroxymethyl-ethyl)-methyl-amino
1-pyridin-3-yl]-N-methyl-isobutyramide
[2006] The title compound was obtained as a light yellow solid in
comparable yield after flash chromatography according to the
procedure described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-py-
ridin-3-yl]-N-methyl-isobutyramide using
[2-(tert-butyl-dimethyl-silanylox-
y)-1-(tert-butyl-dimethyl-silanyloxymethyl)-ethyl]-methyl-amine
instead of (S)-3-(tert-butyl-dimethyl-silanyloxymethyl)-morpholine
in step c).
[2007] MS m/e (%): 602 (M+H.sup.+, 100)
EXAMPLE 197
(2R,5S)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl--
phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide and
EXAMPLE 198
(2S,5S)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl--
phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide
[2008] A mixture of 0.30 g (0.56 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 0.11 g (0.68 mmol)
(2S,5S)-(-)-2,5-bis(methoxymethyl)pyrrolidine, 5 mg (0.01 mmol)
cetyltrimethylammonium bromide, 0.014 g (0.027 mmol)
bis(tri-t-butylphosphine)palladium(0), 0.07 ml NaOH 50% and 2 ml
toluene was degassed by two freeze-thaw cycles. The reaction
mixture was heated under argon at 90.degree. C. over night. After
cooling to room temperature the mixture was diluted with water and
extracted with three portions of tert-butyl methyl ether. The
combined organic layers were dried over sodium sulphate and
concentrated in vacuo. Flash column chromatography gave 0.09 g of
the crude coupling product. This material was dissolved in 2 ml
dichloromethane and treated with 1.1 ml (1.1 mmol) of a 1 M
solution of boron tribromide in dichloromethane at 0.degree. C.
After 15 min. the reaction was quenched by the addition of water,
followed by extraction with three portions of dichloromethane. The
combined organic layers were dried over sodium sulphate and
concentrated in vacuo. Flash column chromatography gave 7 mg (2%)
of
(2R,5S)-N-[6-(2,5-bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-
-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobuty-
ramide as a light brown solid and 6 mg (2%) of
(2S,5S)-N-[6-(2,5-bis-hydro-
xymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,-
5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide as a light
brown solid.
[2009]
(2R,5S)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide
[2010] MS m/e (%): 628 (M+H.sup.+, 100)
[2011]
(2S,5S)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide
[2012] MS m/e (%): 628 (M+H.sup.+, 100)
EXAMPLE 199
(2R,5R)-N-[6-(2,5-Bis-hydroxymethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl--
phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide
[2013] The title compound was obtained as a light brown solid in
comparable yield after flash chromatography according to the
procedure described above for the preparation of
(2S,5S)-N-[6-(2,5-bis-hydroxymethy-
l-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-t-
rifluoromethyl-phenyl)-N-methyl-isobutyramide using
(2R,5R)-(+)-2,5-bis(methoxymethyl)pyrrolidine instead of
(2S,5S)-(-)-2,5-bis(methoxymethyl)pyrrolidine.
[2014] MS m/e (%): 628 (M+H.sup.+, 100)
EXAMPLE 200
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2015]
a)(2S,4R)-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyr-
idin-3-yl]-methyl-carbamic acid tert-butyl ester
[2016] A mixture of 26.5 g (71.8 mmol)
(6-chloro-4-iodo-pyridin-3-yl)-meth- yl-carbamic acid tert-butyl
ester and 25.4 g (144 mmol)
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine in 260 ml dimethyl
sulfoxide was stirred at 130.degree. C. for 32 h. The reaction
mixture was concentrated in vacuo, treated with 200 ml 2 N sodium
carbonate solution and extracted with three 200-ml portions of
ethyl acetate. The organic layers were washed with 200 ml 2 N
sodium carbonate solution and 200 ml brine and dried over sodium
sulfate. Flash chromatography gave 15.5 g (48%) of the title
compound as a white foam.
[2017] MS m/e (%): 450 (M+H.sup.+, 100)
[2018] b)
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
[2019] To a solution of 8.94 g (19.9 mmol)
(2S,4R)-[6-(4-hydroxy-2-hydroxy-
methyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic acid
tert-butyl ester in 85 ml dichloromethane were added 50 ml of a 2 M
solution of hydrogen chloride in diethylether at 0.degree. C. The
reaction mixture was stirred at room temperature for 22 h and
concentrated in vacuo. The residue was re-dissolved in 85 ml
dichloromethane and treated with 17 ml (99.4 mmol)
N-ethyldiisopropylamine. At 0.degree. C. 19.0 g (59.7 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride were
added dropwise. The reaction mixture was stirred at room
temperature for 4 h and concentrated in vacuo. After addition of
250 ml methanol and 70 ml 3 N potassium hydroxide solution the
mixture was stirred at room temperature for 2 h. The mixture was
concentrated to remove methanol and extracted with four 750
ml-portions of dichloromethane. The combined organic layers were
washed with 500 ml 1 N sodium hydroxide solution and 500 ml brine,
dried over sodium sulfate and evaporated. Flash-chromatography gave
11 g (87%) of the title compound as a light yellow foam.
[2020] MS m/e (%): 632 (M+H.sup.+, 100)
[2021] c)
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2022] A mixture of 150 mg (0.238 mmol)
(2S,4R)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-
-yl]-N-methyl-isobutyramide, 38.7 mg (0.284 mmol) 4-tolylboronic
acid, 0.75 ml 2 N sodium carbonate solution, 5.3 mg (0.024 mmol)
palladium acetate and 12 mg (0.048 mmol) triphenylphosphine in 1.5
ml 1,2-dimethoxyethane was stirred at 80.degree. C. for 2 h. The
reaction mixture was treated with 10 ml 2 N sodium carbonate
solution and extracted with two 15-ml portions of ethyl acetate.
The combined organic layers were dried over sodium sulfate and
evaporated. Flash chromatography gave 112 mg (79%) of the title
compound as a yellow foam.
[2023] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 201
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide
[2024] The title compound was obtained as a white foam in 72% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using phenylboronic acid instead of 4-tolylboronic acid in
step c).
[2025] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 202
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2026] The title compound was obtained as a brown foam in 62% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 4-fluorophenylboronic acid instead of 4-tolylboronic
acid in step c).
[2027] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 203
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2028] The title compound was obtained as a white foam in 41% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 4-chlorophenylboronic acid instead of 4-tolylboronic
acid in step c).
[2029] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 204
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-dimethylamino-phenyl)-6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide
[2030] The title compound was obtained as a brown foam in 76% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 4-dimethylaminophenylboronic acid instead of
4-tolylboronic acid in step c).
[2031] MS m/e (%): 625 (M+H.sup.+, 73)
EXAMPLE 205
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-bromo-phenyl)-6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2032] The title compound was obtained as a brown foam in 59% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 3-bromophenylboronic acid instead of 4-tolylboronic
acid in step c).
[2033] MS m/e (%): 660 (M+H.sup.+, 45)
EXAMPLE 206
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2034] The title compound was obtained as a brown foam in 68% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 3-chlorophenylboronic acid instead of 4-tolylboronic
acid in step c).
[2035] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 207
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2036] The title compound was obtained as a light brown foam in 97%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 3-fluorophenylboronic acid instead of
4-tolylboronic acid in step c).
[2037] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 208
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,5-difluoro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2038] The title compound was obtained as a white foam in 74% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 3,5-difluorophenylboronic acid instead of
4-tolylboronic acid in step c).
[2039] MS m/e (%): 618 (M+H.sup.+, 100)
EXAMPLE 209
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-difluoro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2040] The title compound was obtained as a solid in 85% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 3,4-difluorophenylboronic acid instead of
4-tolylboronic acid in step c).
[2041] MS m/e (%): 618 (M+H.sup.+, 100)
EXAMPLE 210
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-4-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2042] The title compound was obtained as a yellow foam in 60%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 3-fluoro-4-methylphenylboronic acid instead of
4-tolylboronic acid in step c).
[2043] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 211
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2044] The title compound was obtained as a brown foam in 60% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 4-fluoro-3-methylphenylboronic acid instead of
4-tolylboronic acid in step c).
[2045] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 212
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-4-fluoro-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2046] The title compound was obtained as a light brown foam in 97%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 3-chloro-4-fluorophenylboronic acid instead of
4-tolylboronic acid in step c).
[2047] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 213
(2S,4R)-N-[4-(2-Amino-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl-
)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[2048] The title compound was obtained as a brown foam in 82% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
instead of 4-tolylboronic acid in step c).
[2049] MS m/e (%): 597 (M+H.sup.+, 100)
EXAMPLE 214
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e
[2050] The title compound was obtained as a brown foam in 88% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-methoxyphenylboronic acid instead of 4-tolylboronic
acid in step c).
[2051] MS m/e (%): 612 (M+H.sup.+, 100)
EXAMPLE 215
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-hydroxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e
[2052] The title compound was obtained as a brown foam in 61% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
instead of 4-tolylboronic acid in step c).
[2053] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 216
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2054] The title compound was obtained as a brown foam in 79% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-tolylboronic acid instead of 4-tolylboronic acid in
step c).
[2055] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 217
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-methylsulfanyl-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide
[2056] The title compound was obtained as a brown foam in 86% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using (2-methylthio)phenylboronic acid instead of
4-tolylboronic acid in step c).
[2057] MS m/e (%): 628 (M+H.sup.+, 100)
EXAMPLE 218
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-methanesulfonyl-phenyl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2058] To a solution of 150 mg (0.239 mmol)
(2S,4R)-2-(3,5-bis-trifluorome-
thyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-(2-methyls-
ulfanyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide in 1.5 ml
methanol were added 250 mg (0.406 mmol) potassium monopersulfate
triple salt. The reaction mixture was stirred at room temperature
for 24 h. The reaction mixture was treated with 0.5 ml sodium
hydrogen sulfite solution (38%) and stirred for 30 minutes.
Addition of 5 ml 2 N sodium carbonate solution was followed by
extraction with two 10-ml portions of dichloromethane. The combined
organic layers were dried over sodium sulfate and purified by flash
chromatography to give 131 mg (83%) of the title compound as a
white foam.
[2059] MS m/e (%): 660 (M+H.sup.+, 100)
EXAMPLE 219
(2S,4R)-2-[5-{[2-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-meth-
yl-amino}-2-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-yl]-benz-
amide
[2060] The title compound was obtained as a light brown foam in 33%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using (2-aminocarbonyl)phenylboronic acid instead of
4-tolylboronic acid in step c).
[2061] MS m/e (%): 625 (M+H.sup.+, 100)
EXAMPLE 220
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2062] The title compound was obtained as a brown foam in 78% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2,4-difluorophenylboronic acid instead of
4-tolylboronic acid in step c).
[2063] MS m/e (%): 618 (M+H.sup.+, 100)
EXAMPLE 221
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2064] The title compound was obtained as a light brown foam in 76%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 2-chloro-4-fluorophenylboronic acid instead of
4-tolylboronic acid in step c).
[2065] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 222
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2066] a)2-(2-Bromo-5-fluoro-phenyl)-[1,3]dioxolane
[2067] To a solution of 2.0 g (9.9 mmol)
2-bromo-5-fluorobenzaldehyde in 20 ml toluene were added 0.722 ml
(13.0 mmol) ethane-1,2-diol and 5 mg (0.03 mmol) toluene-4-sulfonic
acid monohydrate. The reaction mixture was heated in a rotary
evaporator at 60.degree. C. and 200 mbar during 4 h. After
evaporation of the solvent and flash chromatography 2.32 g (95%) of
the title compound were obtained as a colorless liquid.
[2068] MS m/e (%): 246 (M.sup.+, 13)
[2069] b) 4-Fluoro-2-formylphenylboronic acid
[2070] To a solution of 2.30 g (9.31 mmol)
2-(2-bromo-5-fluoro-phenyl)-[1,- 3]dioxolane in 15 ml
tetrahydrofuran was added dropwise at -70.degree. C. 6.11 ml (9.77
mmol) of a 1.6 M solution of n-butyllithium in hexane. The reaction
mixture was stirred at -74.degree. C. for 1 h. After dropwise
addition of 2.65 ml (11.2 mmol) triisopropyl borate at -70.degree.
C. the reaction mixture was allowed to warm to 15.degree. C. during
a period of 2 h. Water (7 ml) was added, and the mixture was
acidified to pH 1 by addition of 37% hydrochloric acid solution.
After heating at 60.degree. C. for 1 h, the mixture was cooled to
room temperature and extracted with three 50-ml portions of diethyl
ether. The combined organic layers were washed with 50 ml brine,
dried over sodium sulfate and concentrated. Flash chromatography
gave 1.2 g (77%) of the title compound as a light yellow
liquid.
[2071] MS m/e (%): 167 (M.sup.+, 1)
[2072] c)
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-form-
yl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide
[2073] The title compound was obtained as a light brown foam in 80%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 4-fluoro-2-formylphenylboronic acid instead of
4-tolylboronic acid in step c).
[2074] MS m/e (%): 628 (M+H.sup.+, 100)
EXAMPLE 223
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide
[2075] To a solution of 24 mg (0.637 mmol) sodium borohydride in 1
ml methanol were added 100 mg (0.159 mmol)
(2S,4R)-2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyr-
rolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide at room
temperature. After stirring for 1 h the reaction mixture was
concentrated in vacuo and partitioned between ethyl acetate and
saturated sodium carbonate solution. The layers were separated and
the aqueous layer was extracted with ethyl acetate. The combined
organic layers were dried over sodium sulfate, concentrated in
vacuo and purified by flash chromatography to give 78 mg (78%) of
the title compound as a white foam.
[2076] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 224
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-formyl-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2077] The title compound was obtained as a white foam in 68% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-formylphenylboronic acid instead of 4-tolylboronic
acid in step c).
[2078] MS m/e (%): 610 (M+H.sup.+, 100)
EXAMPLE 225
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-hydroxymethyl-phenyl)-pyridin-3-yl]-N-methyl-isobut-
yramide
[2079] The title compound was obtained as a white foam in 52% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide using
(2S,4R)-2-(3,5-bis-trifluoromethyl--
phenyl)-N-[4-(2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-N-methyl-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trif-
luoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxy-
methyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide.
[2080] MS m/e (%): 612 (M+H.sup.+, 100)
EXAMPLE 226
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2081] The title compound was obtained as a light brown foam in 60%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 2,5-dichlorophenylboronic acid instead of
4-tolylboronic acid in step c).
[2082] MS m/e (%): 650 (M+H.sup.+, 49)
EXAMPLE 227
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2083] The title compound was obtained as a brown foam in 67% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 5-fluoro-2-methylphenylboronic acid instead of
4-tolylboronic acid in step c).
[2084] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 228
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2085] The title compound was obtained as a brown foam in 100%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 3-fluoro-2-methylphenylboronic acid instead of
4-tolylboronic acid in step c).
[2086] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 229
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2087] The title compound was obtained as a white foam in 20% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2,3-dichlorophenylboronic acid instead of
4-tolylboronic acid in step c).
[2088] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 230
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,5-dimethyl-isoxazol-4-y-
l)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide
[2089] The title compound was obtained as a light brown foam in 80%
yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 3,5-dimethylisoxazole-4-boronic acid instead
of 4-tolylboronic acid in step c).
[2090] MS m/e (%): 601 (M+H.sup.+, 100)
EXAMPLE 231
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-2,6-dimethoxy-[3,4']bipyridinyl-3'-yl]-N-methyl-isobuty-
ramide
[2091] The title compound was obtained as a brown foam in 67% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using
2,6-dimethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
pyridine instead of 4-tolylboronic acid in step c).
[2092] MS m/e (%): 643 (M+H.sup.+, 100)
EXAMPLE 232
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-chloro-6'-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramid-
e
[2093] The title compound was obtained as a light brown solid in
49% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using (2-chloro-3-pyridyl)boronic acid instead of
4-tolylboronic acid in step c).
[2094] MS m/e (%): 617 (M+H.sup.+, 100)
EXAMPLE 233
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridilyl-3'-yl]-N-methyl-isobutyramid-
e
[2095] A mixture of 0.12 g (0.48 mmol) trifluoro-methanesulfonic
acid 2-methyl-pyridin-3-yl ester, 0.13 g (0.52 mmol)
bis(pinacolato)diboron, 0.14 g (1.4 mmol) potassium acetate and
0.02 g (0.02 mmol) dichloro[1,1'-bis(diphenylphosphino)
ferrocene]palladium(II) dichloromethane adduct in 2.5 ml
N,N-dimethylformamide was heated at 80.degree. C. over night under
argon. After cooling to room temperature 0.10 g (0.16 mmol)
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobut-
yramide and 1.3 ml of a deoxygenated 2 M aqueous solution of sodium
carbonate were added. The reaction mixture was heated at 80.degree.
C. for 6 h. After cooling to room temperature the mixture was
diluted with water and extracted with three portions of tert-butyl
methyl ether. The combined organic layers were dried over sodium
sulfate and concentrated in vacuo. Flash column chromatography gave
37 mg (39%) of the title compound as an off-white solid.
[2096] MS m/e (%): 597 (M+H.sup.+, 100)
EXAMPLE 234
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[3-chloro-6'-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-[2,4']bipyridinyl-3'-yl]-N-methyl-isobutyramid-
e
[2097] To a solution of 0.500 g (2.09 mmol)
3-chloro-2-iodo-pyridine in 6 ml tetrahydrofuran 1.04 ml (2.09
mmol) of a 2 M solution of isopropylmagnesium chloride in
tetrahydrofuran was added dropwise at -40.degree. C. under an
atmosphere of argon. After 30 min. 2.3 ml (4.2 mmol) of an
anhydrous 1.8 M solution of zinc chloride in tetrahydrofuran was
added slowly. The cooling bath was removed after completed
addition, and the reaction mixture was stirred at room temperature
for 90 min. A portion of 1.6 ml of this solution was added to a
solution of 0.15 g (0.24 mmol)
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2--
hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
and 14 mg (0.012 mmol) tetrakis(triphenylphosphine)palladium(0) in
1 ml tetrahydrofuran. The mixture was heated at 100.degree. C.
under microwave irradiation for 30 min. After cooling to room
temperature a 0.5 M solution of sodium hydroxide was added, and the
mixture was extracted with three portions of dichloromethane. The
combined organic layers were dried over sodium sulfate and
concentrated in vacuo. Flash column chromatography gave 58 mg (40%)
of the title compound as a light yellow solid.
[2098] MS m/e (%): 617 (M+H.sup.+, 100)
EXAMPLE 235
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2099]
a)(2S,4S)-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyr-
idin-3-yl]-methyl-carbamic acid tert-butyl ester
[2100] The title compound was obtained as a light yellow foam in
60% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-
-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using
(2S,4S)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[2101] MS m/e (%): 450 (M+H.sup.+, 100)
[2102] b)
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
[2103] The title compound was obtained as a light yellow foam in
87% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobut-
yramide using
(2S,4S)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iod-
o-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-y-
l]-methyl-carbamic acid tert-butyl ester.
[2104] MS m/e (%): 632 (M+H.sup.+, 100)
[2105] c)
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluo-
ro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide
[2106] The title compound was obtained as a brown foam in 58% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-chloro-4-fluorophenylboronic acid instead of
4-tolylboronic acid and
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-h-
ydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
[2107] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 236
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2108] The title compound was obtained as a light yellow foam in
56% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide using 2,4-dichlorophenylboronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2109] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 237
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-difluoro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2110] The title compound was obtained as a light yellow foam in
78% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide using 2,4-difluorophenylboronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2111] MS m/e (%): 618 (M+H.sup.+, 100)
EXAMPLE 238
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2112] The title compound was obtained as a brown foam in 84% yield
after flash chromatography according to the procedures described
above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro--
4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide using 4-fluoro-2-methylphenylboronic acid
instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2113] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 239
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2114] The title compound was obtained as a light yellow foam in
71% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide using
4-fluoro-2-formylphenylboronic acid instead of
2-chloro-4-fluorophenylboronic acid in step c).
[2115] MS m/e (%): 628 (M+H.sup.+, 100)
EXAMPLE 240
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl--
phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide
[2116] The title compound was obtained as a white foam in 47% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide using
(2S,4S)-2-(3,5-bis-trifluoromethyl--
phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrro-
lidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide.
[2117] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 241
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2118] The title compound was obtained as a light yellow foam in
90% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using 2-tolylboronic acid instead of
2-chloro-4-fluorophenylboronic acid in step c).
[2119] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 242
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2120] The title compound was obtained as a light yellow foam in
47% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using 2-fluorophenylboronic acid
instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2121] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 243
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2122] The title compound was obtained as a light yellow foam in
79% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using 2-trifluoromethylphenylboronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2123] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 244
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e
[2124] The title compound was obtained as a light yellow foam in
84% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using 2-methoxyphenylboronic acid
instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2125] MS m/e (%): 612 (M+H.sup.+, 100)
EXAMPLE 245
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-cyano-phenyl)-6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2126] The title compound was obtained as a light yellow foam in
10% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using
2-(4,4,5,5-tetramethyl-1,3,2-dioxaboro- lan-2-yl)benzonitrile
instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2127] MS m/e (%): 607 (M+H.sup.+, 100)
EXAMPLE 246
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2128] The title compound was obtained as a light yellow foam in
68% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using 2-bromophenylboronic acid
instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2129] MS m/e (%): 660 (M+H.sup.+, 100)
EXAMPLE 247
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide
[2130] The title compound was obtained as a light yellow foam in
80% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using phenylboronic acid instead of
2-chloro-4-fluorophenylboronic acid in step c).
[2131] MS m/e (%): 582 (M+H.sup.+, 100)
EXAMPLE 248
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-3-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2132] The title compound was obtained as a light yellow foam in
92% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using 4-fluoro-3-methylphenylboronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2133] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 249
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl-N-methyl-isobu-
tyramide
[2134] The title compound was obtained as a light brown foam in 87%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using 3-fluoro-2-methylphenylboronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2135] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 250
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2136] The title compound was obtained as a light brown foam in 48%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chl-
oro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide using 5-fluoro-2-methylphenylboronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2137] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 251
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2138] The title compound was obtained as a light yellow foam in
87% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide using 3-fluorophenylboronic acid
instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2139] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 252
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2140] The title compound was obtained as a light yellow foam in
64% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide using 3,4-dichlorophenylboronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2141] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 253
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2142] The title compound was obtained as a light yellow foam in
77% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide using 2,3-dichlorophenylboronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2143] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 254
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-chloro-6'-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramid-
e
[2144] The title compound was obtained as a light brown solid in
48% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
-chloro-4-fluoro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide using (2-chloro-3-pyridyl)boronic
acid instead of 2-chloro-4-fluorophenylboronic acid in step c).
[2145] MS m/e (%): 617 (M+H.sup.+, 100)
EXAMPLE 255
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6'-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramid-
e
[2146] The title compound was obtained as a light brown solid in
48% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(4-hy-
droxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-
-methyl-isobutyramide using
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[-
6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methy-
l-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-
-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-
-isobutyramide.
[2147] MS m/e (%): 597 (M+H.sup.+, 100)
EXAMPLE 256
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[3-chloro-6'-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-[2,4']bipyridinyl-3'-yl-N-methyl-isobutyramide
[2148] The title compound was obtained as a light yellow solid in
24% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[3-chloro-6'-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4']bipyridiny-
l-3'-yl]-N-methyl-isobutyramide using
(2S,4S)-2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-y-
l]-N-methyl-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-ph-
enyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl-
]-N-methyl-isobutyramide.
[2149] MS m/e (%): 617 (M+H.sup.+, 100)
EXAMPLE 257
(2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2150]
a)(2R,4R)-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyr-
idin-3-yl]-methyl-carbamic acid tert-butyl ester
[2151] The title compound was obtained as a light brown foam in 28%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-
-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using
(2R,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[2152] MS m/e (%): 450 (M+H.sup.+, 100)
[2153] b)
(2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
[2154] The title compound was obtained as a light brown foam in 82%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobut-
yramide using
(2R,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iod-
o-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-y-
l]-methyl-carbamic acid tert-butyl ester.
[2155] MS m/e (%): 632 (M+H.sup.+, 100)
[2156] c)
(2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2157] The title compound was obtained as a light yellow foam in
78% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-iso-
butyramide using 2-tolylboronic acid instead of 4-tolylboronic acid
and
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
[2158] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 258
(2R,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2159] The title compound was obtained as a light yellow foam in
85% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 4-fluoro-2-methylphenylboronic acid instead of
2-tolylboronic acid in step c).
[2160] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 259
(2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2161]
a)(2R,4S)-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyr-
idin-3-yl]-methyl-carbamic acid tert-butyl ester
[2162] The title compound was obtained as a light brown foam in 14%
yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-
-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using
(2R,4S)-2-(hydroxymethyl)-4-hydroxypyrrolidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[2163] MS m/e (%): 450 (M+H.sup.+, 100)
[2164] b)
(2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
[2165] The title compound was obtained as a light yellow foam in
71% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobut-
yramide using
(2R,4S)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iod-
o-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-y-
l]-methyl-carbamic acid tert-butyl ester.
[2166] MS m/e (%): 632 (M+H.sup.+, 100)
[2167] c)
(2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-m-
ethyl-isobutyramide
[2168] The title compound was obtained as a light yellow foam in
78% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-iso-
butyramide using 4-fluoro-2-methylphenylboronic acid instead of
4-tolylboronic acid and
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-i-
sobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-is-
obutyramide.
[2169] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 260
(2R,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2170] The title compound was obtained as a light yellow foam in
94% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-
-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide using 2-tolylboronic acid instead
of 4-fluoro-2-methylphenylboronic acid in step c).
[2171] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 261
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2172]
a)(2R,3S)-[6-(3-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyr-
idin-3-yl]-methyl-carbamic acid tert-butyl ester
[2173] The title compound was obtained as a light yellow foam in
29% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-
-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[2174] MS m/e (%): 450 (M+H.sup.+, 100)
[2175] b)
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
[2176] The title compound was obtained as a light yellow foam in
53% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobut-
yramide using
(2R,3S)-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iod-
o-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester instead of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-y-
l]-methyl-carbamic acid tert-butyl ester.
[2177] MS m/e (%): 632 (M+H.sup.+, 100)
[2178] c)
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2179] The title compound was obtained as a brown foam in 85% yield
after flash chromatography according to the procedure described
above for the preparation of (2S,
4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydrox-
y-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobut-
yramide using 2-tolylboronic acid instead of 4-tolylboronic acid
and
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
[2180] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 262
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-trifluoromethyl-phenyl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2181] The title compound was obtained as a light yellow foam in
58% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 2-(trifluoromethyl)phenylboronic acid instead
of 2-tolylboronic acid in step c).
[2182] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 263
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e
[2183] The title compound was obtained as a brown foam in 89% yield
after flash chromatography according to the procedures described
above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-methoxyphenylboronic acid instead of 2-tolylboronic
acid in step c).
[2184] MS m/e (%): 612 (M+H.sup.+, 100)
EXAMPLE 264
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(3-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2185] The title compound was obtained as a brown foam in 70% yield
after flash chromatography according to the procedures described
above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-fluorophenylboronic acid instead of 2-tolylboronic
acid in step c).
[2186] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 265
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide
[2187] The title compound was obtained as a brown foam in 79% yield
after flash chromatography according to the procedures described
above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using phenylboronic acid instead of 2-tolylboronic acid in
step c).
[2188] MS m/e (%): 582 (M+H.sup.+, 100)
EXAMPLE 266
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(3-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2189] The title compound was obtained as a light yellow foam in
77% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 4-fluorophenylboronic acid instead of
2-tolylboronic acid in step c).
[2190] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 267
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2191] The title compound was obtained as a light yellow foam in
53% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 4-tolylboronic acid instead of 2-tolylboronic
acid in step c).
[2192] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 268
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2193] The title compound was obtained as a light yellow foam in
45% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 3,4-dichlorophenylboronic acid instead of
2-tolylboronic acid in step c).
[2194] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 269
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-phenyl)-6-(3-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2195] The title compound was obtained as a light yellow foam in
79% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 3-chlorophenylboronic acid instead of
2-tolylboronic acid in step c).
[2196] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 270
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2197] The title compound was obtained as a light yellow foam in
50% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 2,5 dichlorophenylboronic acid instead of
2-tolylboronic acid in step c).
[2198] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 271
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2199] The title compound was obtained as a light yellow foam in
54% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 2,3-dichlorophenylboronic acid instead of
2-tolylboronic acid in step c).
[2200] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 272
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-4-fluoro-phenyl)-
-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2201] The title compound was obtained as a light yellow foam in
77% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 2-chloro-4-fluorobenzeneboronic acid instead
of 2-tolylboronic acid in step c).
[2202] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 273
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-
-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2203] The title compound was obtained as a light yellow foam in
60% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 4-fluoro-2-formylphenylboronic acid instead of
2-tolylboronic acid in step c).
[2204] MS m/e (%): 628 (M+H.sup.+, 100)
EXAMPLE 274
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-hydroxymethyl--
phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide
[2205] The title compound was obtained as a white foam in 48% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-hydroxymethyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide using
(2R,3S)-2-(3,5-bis-trifluoromethyl--
phenyl)-N-[4-(4-fluoro-2-formyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrro-
lidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-formyl-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide.
[2206] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 275
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-
-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2207] The title compound was obtained as a off white foam in 78%
yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 3-fluoro-2-methylphenylboronic acid instead of
2-tolylboronic acid in step c).
[2208] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 276
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(5-fluoro-2-methyl-phenyl)-
-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2209] The title compound was obtained as a light yellow foam in
83% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 5-fluoro-2-methylphenylboronic acid instead of
2-tolylboronic acid in step c).
[2210] MS m/e (%): 614 (M+H.sup.+, 100)
EXAMPLE 277
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,5-difluoro-phenyl)-6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2211] The title compound was obtained as a light yellow foam in
52% yield after flash chromatography according to the procedures
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-
-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-
-isobutyramide using 2,5-difluorophenylboronic acid instead of
2-tolylboronic acid in step c).
[2212] MS m/e (%): 618 (M+H.sup.+, 100)
EXAMPLE 278
(2R,3S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6'-(3-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramid-
e
[2213] The title compound was obtained as a light brown solid in
46% yield after flash chromatography according to the procedures
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6'-(-
4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-y-
l]-N-methyl-isobutyramide using
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-m-
ethyl-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-me-
thyl-isobutyramide.
[2214] MS m/e (%): 597 (M+H.sup.+, 100)
EXAMPLE 279
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1--
yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2215]
a)(S)-[6-(2-Hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-met-
hyl-carbamic acid tert-butyl ester
[2216] The title compound was obtained as a light yellow foam in
15% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-
-4-iodo-pyridin-3-yl]-methyl-carbamic acid tert-butyl ester using
L-prolinol instead of
(2S,4R)-2-(hydroxymethyl)-4-hydroxypyrrolidine.
[2217] MS m/e (%): 434 (M+H.sup.+, 100)
[2218] b)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyr-
rolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide
[2219] The title compound was obtained as a white foam in 74% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyram-
ide using
(S)-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-me-
thyl-carbamic acid tert-butyl ester instead of
(2S,4R)-[6-(4-hydroxy-2-hyd-
roxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-methyl-carbamic
acid tert-butyl ester.
[2220] MS m/e (%): 616 (M+H.sup.+, 100)
[2221] c)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyr-
rolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2222] The title compound was obtained as a white foam in 43% yield
after flash chromatography according to the procedure described
above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-
-2-hydroxymethyl-pyrrolidin-1-yl)-4-p-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide using 2-tolylboronic acid instead of 4-tolylboronic acid and
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-
-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide.
[2223] MS m/e (%): 580 (M+H.sup.+, 100)
EXAMPLE 280
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1--
yl)-4-(2-methoxy-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[2224] The title compound was obtained as a yellow foam in 28%
yield after flash chromatography according to the procedures
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 2-methoxyphenylboronic acid instead of 2-tolylboronic acid in
step c).
[2225] MS m/e (%): 596 (M+H.sup.+, 100)
EXAMPLE 281
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-bromo-phenyl)-6-(2-hydroxym-
ethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2226] The title compound was obtained as a white foam in 23% yield
after flash chromatography according to the procedures described
above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 2-bromophenylboronic acid instead of 2-tolylboronic acid in
step c).
[2227] MS m/e (%): 644 (M+H.sup.+, 100)
EXAMPLE 282
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-fluoro-phenyl)-6-(2-hydroxy-
methyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2228] The title compound was obtained as a yellow foam in 68%
yield after flash chromatography according to the procedures
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 2-fluorophenylboronic acid instead of 2-tolylboronic acid in
step c).
[2229] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 283
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,4-dichloro-phenyl)-6-(2-hyd-
roxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2230] The title compound was obtained as a white foam in 29% yield
after flash chromatography according to the procedures described
above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 2,4-dichlorophenylboronic acid instead of 2-tolylboronic acid
in step c).
[2231] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 284
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,5-dichloro-phenyl)-6-(2-hyd-
roxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2232] The title compound was obtained as a yellow foam in 32%
yield after flash chromatography according to the procedures
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 2,5-dichlorophenylboronic acid instead of 2-tolylboronic acid
in step c).
[2233] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 285
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2,3-dichloro-phenyl)-6-(2-hyd-
roxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2234] The title compound was obtained as a white foam in 18% yield
after flash chromatography according to the procedures described
above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 2,3-dichlorophenylboronic acid instead of 2-tolylboronic acid
in step c).
[2235] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 286
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3,4-dichloro-phenyl)-6-(2-hyd-
roxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2236] The title compound was obtained as a orange foam in 34%
yield after flash chromatography according to the procedures
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 3,4-dichlorophenylboronic acid instead of 2-tolylboronic acid
in step c).
[2237] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 287
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-chloro-phenyl)-6-(2-hydroxy-
methyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2238] The title compound was obtained as a yellow oil in 50% yield
after flash chromatography according to the procedures described
above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 4-chlorophenylboronic acid instead of 2-tolylboronic acid in
step c).
[2239] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 288
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-phenyl)-6-(2-hydroxy-
methyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2240] The title compound was obtained as a white foam in 45% yield
after flash chromatography according to the procedures described
above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using 4-fluorophenylboronic acid instead of 2-tolylboronic acid in
step c).
[2241] MS m/e (%): 644 (M+H.sup.+, 100)
EXAMPLE 289
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1--
yl)-4-phenyl-pyridin-3-yl]-N-methyl-isobutyramide
[2242] The title compound was obtained as a white foam in 48% yield
after flash chromatography according to the procedures described
above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using phenylboronic acid instead of 2-tolylboronic acid in step
c).
[2243] MS m/e (%): 566 (M+H.sup.+, 100)
EXAMPLE 290
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6'-(2-hydroxymethyl-pyrrolidin-1-
-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramide
[2244]
a)(6'-Chloro-2-methyl-[3,4']bipyridinyl-3'-yl)-methyl-amine
[2245] The title compound was obtained as a light yellow solid in
60% yield after flash chromatography according to the procedure
described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6'-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-2-methyl-[3,4']bipyridiny-
l-3'-yl]-N-methyl-isobutyramide using
(6-chloro-4-iodo-pyridin-3-yl)-methy- l-amine instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobuty-
ramide.
[2246] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-(6'-chloro-2-methyl-[3,4]bi-
pyridinyl-3'-yl)-N-methyl-isobutyramide
[2247] To a solution of 2.77 g (11.9 mmol)
(6'-chloro-2-methyl-[3,4']bipyr- idinyl-3'-yl)-methyl-amine in 120
ml tetrahydrofuran 7.8 ml (12 mmol) of a 1.6 M solution of
n-butyllithium in hexanes was added dropwise at -78.degree. C.
After 30 min. 4.2 g (13 mmol) 2-(3,5-bis-trifluoromethyl-p-
henyl)-2-methyl-propionyl chloride were added. The reaction mixture
was stirred at -78.degree. C. for 5 min. and allowed to warm to
room temperature during a period of 1 h. Dilution with 2 M aqueous
sodium carbonate solution was followed by extraction with three
portions of tert-butyl methyl ether. The combined organic layers
were washed with 2 M aqueous sodium carbonate solution and brine,
dried over sodium sulfate and concentrated in vacuo. Flash column
chromatography gave 4.8 g (78%) of the title compound as an
off-white solid.
[2248] MS m/e (%): 516 (M+H.sup.+, 100)
[2249] c)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6'-(2-hydroxymethyl-py-
rrolidin-1-yl)-2-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramide
[2250] The title compound was obtained as a white solid in 65%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6'-chloro-2-methyl-
-[3,4']bipyridinyl-3'-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide.
[2251] MS m/e (%): 581 (M+H.sup.+, 100)
EXAMPLE 291
N-{6'-[Bis-(2-hydroxy-ethyl)-amino]-2-methyl-[3,4']bipyridinyl-3'-yl}-2-(3-
,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[2252] The title compound was obtained as an off-white solid in 43%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using diethanolamine instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-(6'-chloro-2-methyl-[3,4']bipyridinyl-3'-yl)-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phe-
nyl)-pyridin-3-yl]-N-methyl-isobutyramide.
[2253] MS m/e (%): 585 (M+H.sup.+, 100)
EXAMPLE 292
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6'-(2-hydroxymethyl-pyrrolidin-1-
-yl)-4-methyl-[3,4']bipyridinyl-3'-yl]-N-methyl-isobutyramide
[2254]
a)(6'-Chloro-4-methyl-[3,4']bipyridinyl-3'-yl)-methyl-amine
[2255] The title compound was obtained as a light yellow solid in
comparable yield after flash chromatography according to the
procedure described above for the preparation of
(2S,4R)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[3-chloro-6'-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-[2,4']-
bipyridinyl-3'-yl]-N-methyl-isobutyramide using
(6-chloro-4-iodo-pyridin-3- -yl)-methyl-carbamic acid tert-butyl
ester instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-iodo-pyridin-3-yl]-N-methyl-isobutyramide and
3-bromo-4-methylpyridine instead of 3-chloro-2-iodo-pyridine.
[2256] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-(6'-chloro-4-methyl-[3,4']b-
ipyridinyl-3'-yl)-N-methyl-isobutyramide
[2257] The title compound was obtained as a light yellow solid in
65% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6'-chl-
oro-2-methyl-[3,4']bipyridinyl-3'-yl)-N-methyl-isobutyramide using
(6'-chloro-4-methyl-[3,4']bipyridinyl-3'-yl)-methyl-amine instead
of (6'-chloro-2-methyl-[3,4']bipyridinyl-3'-yl)-methyl-amine.
[2258] MS m/e (%): 585 (M+H.sup.+, 100)
[2259] c)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6'-(2-hydroxymethyl-py-
rrolidin-1-yl)-4-methyl-[3,4'bipyridinyl-3'-yl]-N-methyl-isobutyramide
[2260] The title compound was obtained as a light yellow solid in
39% yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6'-c-
hloro-4-methyl-[3,4']bipyridinyl-3'-yl)-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide.
[2261] MS m/e (%): 581 (M+H.sup.+, 100)
EXAMPLE 293
N-{6'-[Bis-(2-hydroxy-ethyl)-amino]-4-methyl-[3,4']bipyridinyl-3'-yl}-2-(3-
,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[2262] The title compound was obtained as an off-white solid in 34%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phen-
yl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
using diethanolamine instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-(6'-chloro-4-methyl-[3,4']bipyridinyl-3'-yl)-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phe-
nyl)-pyridin-3-yl]-N-methyl-isobutyramide.
[2263] MS m/e (%): 585 (M+H.sup.+, 100)
EXAMPLE 294
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{6'-[(2-hydroxy-ethyl)-methyl-amino]--
4-methyl-[3,4']bipyridinyl-3'-yl}-N-methyl-isobutyramide
[2264] The title compound was obtained as a light yellow solid in
66% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-c-
hloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e using 2-(methylamino)ethanol instead of ethanolamine and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6'-chloro-4-methyl-[3,4']bipyridiny-
l-3'-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.
[2265] MS m/e (%): 555 (M+H.sup.+, 100)
EXAMPLE 295
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-oxo-pyrroli-
din-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2266] a)(2S,4R)-Acetic acid
1-(5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-me-
thyl-propionyl]-methyl-amino
1-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidi- n-2-ylmethyl
ester
[2267] To a solution of 1.5 g (2.4 mmol)
(2S,4R)-2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyrid-
in-3-yl]-N-methyl-isobutyramide and 0.4 ml (5 mmol) pyridine in 24
ml dichloromethane were added dropwise at room temperature 0.22 ml
(2.4 mmol) acetic anhydride. After stirring at room temperature for
20 h the reaction mixture was diluted with a 0.1 M aqueous
hydrochloric acid solution and extracted with 3 portions of
dichloromethane. The combined organic extracts were washed with a 2
M aqueous sodium carbonate solution, dried over sodium sulfate and
concentrated in vacuo. Flash column chromatography gave 1.1 g (71%)
of the title compound as an off-white solid.
[2268] MS m/e (%): 638 (M+H.sup.+, 100)
[2269] b) (S)-Acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-meth-
yl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylm-
ethyl ester
[2270] To a solution of 0.08 ml (0.9 mmol) oxalyl chloride in 2 ml
dichloromethane were added dropwise at -78.degree. C. 0.13 ml (1.9
mmol) dimethyl sulfoxide and after a period of 3 min. a solution of
0.50 g (0.78 mmol) (2S,4R)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-
-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrro-
lidin-2-ylmethyl ester in 2 ml dichloromethane. After stirring at
-78.degree. C. for 30 min. 0.7 ml (4 mmol)
N,N-diisopropylethylamine were added. The reaction mixture was
allowed to warm to room temperature during 1 h, diluted with
tert-butyl methyl ether and washed with an aqueous ammonium
chloride solution. The aqueous layer was extracted with two
portions of tert-butyl methyl ether. The combined organic extracts
were dried over sodium sulfate and concentrated in vacuo. Flash
column chromatography gave 0.47 g (94%) of the title compound as a
white solid.
[2271] MS m/e (%): 636 (M+H.sup.+, 100)
[2272] c)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymethyl-4-o-
xo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2273] A solution of 60 mg (0.094 mmol) (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amin-
o}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester and a
catalytic amount of sodium methylate in 2 ml methanol was stirred
at room temperature for 30 min. The reaction mixture was diluted
with water and brine and extracted with three portions of
dichloromethane. The combined organic extracts were dried over
sodium sulfate and concentrated in vacuo. Flash column
chromatography gave 13 mg (23%) of the title compound as a light
brown solid.
[2274] MS m/e (%): 594 (M+H.sup.+, 100)
EXAMPLE 296
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e
[2275] a)(2S,4R)-Acetic acid
1-[5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-me-
thyl-propionyl]-methyl-amino
1-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]--
4-hydroxy-pyrrolidin-2-ylmethyl ester
[2276] The title compound was obtained as a white solid in 52%
yield after flash chromatography according to the procedure
described above for the preparation of (2S,4R)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phen-
yl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-py-
rrolidin-2-ylmethyl ester using
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-
-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-hydroxy-2-hydroxymethy-
l-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide.
[2277] MS m/e (%): 656 (M+H.sup.+, 100)
[2278] b) (S)-Acetic acid
1-[5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methy-
l-propionyl]-methyl-amino
1-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-o-
xo-pyrrolidin-2-ylmethyl ester
[2279] The title compound was obtained as a white solid in 77%
yield after flash chromatography according to the procedure
described above for the preparation of (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)--
2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-
-2-ylmethyl ester using (2S,4R)-acetic acid
1-[5-{[2-(3,5-bis-trifluoromet-
hyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-
-pyridin-2-yl]-4-hydroxy-pyrrolidin-2-ylmethyl ester instead of
(2S,4R)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-pr-
opionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylme-
thyl ester.
[2280] MS m/e (%): 654 (M+H.sup.+, 100)
[2281] c)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide
[2282] The title compound was obtained as a light yellow solid in
37% yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6--
(2-hydroxymethyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-i-
sobutyramide using (S)-acetic acid
1-[5-{[2-(3,5-bis-trifluoromethyl-pheny-
l)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin--
2-yl]-4-oxo-pyrrolidin-2-ylmethyl ester instead of (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amin-
o}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester.
[2283] MS m/e (%): 612 (M+H.sup.+, 100)
EXAMPLE 297
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2284] a)(2S,4S)-Acetic acid
1-(5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-me-
thyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin--
2-ylmethyl ester
[2285] To a solution of 0.14 g (0.21 mmol) (2S,4R)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amin-
o}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester in
2 ml dichloromethane were added dropwise at 0.degree. C. 0.03 ml
(0.2 mmol) (diethylamino)sulfur trifluoride. After 1 h the reaction
mixture was diluted with a 0.5 M aqueous sodium hydroxide solution
and extracted with four portions of dichloromethane. The combined
organic extracts were dried over sodium sulfate and concentrated in
vacuo. Flash column chromatography gave 47 mg (35%) of the title
compound as a white solid.
[2286] MS m/e (%): 640 (M+H.sup.+, 100)
[2287] b)
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydr-
oxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2288] The title compound was obtained as an off-white solid in 91%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxy-
methyl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyrami-
de using (2S,4S)-acetic acid
1-(5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-me-
thyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin--
2-ylmethyl ester instead of (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromet-
hyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-ox-
o-pyrrolidin-2-ylmethyl ester.
[2289] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 298
(2S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl--
pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide
[2290] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-m-
ethyl-isobutyramide using (2S,4R)-acetic acid
1-[5-{[2-(3,5-bis-trifluorom-
ethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-2-yl]-4-hydroxy-pyrrolidin-2-ylmethyl ester instead of
(2S,4R)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-pr-
opionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylme-
thyl ester in step a).
[2291] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 299
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2292] a)(S)-Acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methy-
l-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4,4-difluoro-pyrrolidin-
-2-ylmethyl ester
[2293] To a solution of 0.20 g (0.31 mmol) (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amin-
o}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolidin-2-ylmethyl ester in 3
ml dichloromethane were added at room temperature 0.19 ml (1.5
mmol) (diethylamino)sulfur trifluoride. After 36 h the reaction
mixture was partitioned between water and tert-butyl methyl ether.
The layers were separated and the organic layer was washed with 0.5
M aqueous sodium hydroxide solution. The combined aqueous layers
were extracted with three portions of tert-butyl methyl ether. The
combined organic extracts were dried over sodium sulfate and
concentrated in vacuo. Flash column chromatography gave 93 mg (45%)
of the title compound as an off-white solid.
[2294] MS m/e (%): 658 (M+H.sup.+, 100)
[2295] b)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydr-
oxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2296] The title compound was obtained as a white solid in 83%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl--
propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4,4-difluoro-pyrrolidin-2-
-ylmethyl ester instead of (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluorometh-
yl-phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-
-pyrrolidin-2-ylmethyl ester.
[2297] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 300
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4,4-difluoro-2-hydroxymethyl--
pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobu-
tyramide
[2298] The title compound was obtained as a light yellow solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[6-(4,4-difluoro-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-
-3-yl]-N-methyl-isobutyramide using (S)-acetic acid
1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amin-
o}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-4-oxo-pyrrolidin-2-ylmethyl
ester instead of (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl-
)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-oxo-pyrrolid-
in-2-ylmethyl ester in step a).
[2299] MS m/e (%): 634 (M+H.sup.+, 100)
EXAMPLE 301
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydroxymethyl--
pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2300] a)(2S,4S)-Acetic acid 1-(5-f
[2-(3,5-bis-trifluoromethyl-phenyl)-2--
methyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolid-
in-2-ylmethyl ester
[2301] The title compound was obtained as a white solid in 60%
yield after flash chromatography according to the procedure
described above for the preparation of (2S,4R)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phen-
yl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-py-
rrolidin-2-ylmethyl ester using
(2S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]--
N-methyl-isobutyramide instead of
(2S,4R)-2-(3,5-bis-trifluoromethyl-pheny-
l)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl-
]-N-methyl-isobutyramide.
[2302] MS m/e (%): 638 (M+H.sup.+, 100)
[2303] b) (2S,4R)-Acetic acid
1-(5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-m-
ethyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin-
-2-ylmethyl ester
[2304] The title compound was obtained as an off-white solid in 69%
yield after flash chromatography according to the procedure
described above for the preparation of (2S,4S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl--
phenyl)-2-methyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-fluoro-
-pyrrolidin-2-ylmethyl ester using (2S,4S)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amin-
o}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-ylmethyl ester
instead of (2S,4R)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-
-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-hydroxy-pyrrolidin-2-y-
lmethyl ester.
[2305] MS m/e (%): 640 (M+H.sup.+, 100)
[2306] c)
(2S,4R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-fluoro-2-hydr-
oxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2307] The title compound was obtained as a white solid in 78%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2-hydroxymeth-
yl-4-oxo-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using (2S,4R)-acetic acid
1-(5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-met-
hyl-propionyl]-methyl-amino}-4-o-tolyl-pyridin-2-yl)-4-fluoro-pyrrolidin-2-
-ylmethyl ester instead of (S)-acetic acid
1-(5-{[2-(3,5-bis-trifluorometh-
yl-phenyl)-2-methyl-propionyl]-methyl-amino]-4-o-tolyl-pyridin-2-yl)-4-oxo-
-pyrrolidin-2-ylmethyl ester.
[2308] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 302
(S)-N-[6-[2-(Acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phe-
nyl)-pyridin-3-yl-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramid-
e
[2309]
a)(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[2-(1,3-dioxo-1,3-dih-
ydro-isoindol-2-ylmethyl)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-py-
ridin-3-yl]-N-methyl-isobutyramide
[2310] To a solution of 0.20 g (0.33 mmol)
(S)-2-(3,5-bis-trifluoromethyl--
phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl-
)-pyridin-3-yl]-N-methyl-isobutyramide and 54 mg (0.37 mmol)
phthalimide in 3 ml tetrahydrofuran were added 71 mg (0.37 mmol)
diethyl azodicarboxylate (90%) and 97 mg (0.37 mmol)
triphenylphosphine at 0.degree. C. After stirring for 90 min. the
reaction mixture was allowed to warm to room temperature over
night. The mixture was diluted with a 0.1 M aqueous sodium
hydroxide solution and extracted with three portions of tert-butyl
methyl ether. The combined organic extracts were dried over sodium
sulphate and concentrated. Flash column chromatography gave 70 mg
(29%) of the title compound as a light yellow solid.
[2311] MS m/e (%): 727 (M+H.sup.+, 100)
[2312] b)
(S)-N-[6-[2-(Acetylamino-methyl)-pyrrolidin-1-yl]-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide
[2313] A solution of 65 mg (0.089 mmol)
(S)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[6-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-pyrrolidin-1-yl]--
4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and 7.0 mg (0.14 mmol) hydrazine hydrate in 1 ml ethanol was
stirred at room temperature over night. The reaction mixture was
diluted with a 1 M aqueous sodium hydroxide solution and extracted
with three portions of tert-butyl methyl ether. The combined
organic extracts were dried over sodium sulphate and concentrated
to give 55 mg of crude
(S)-N-[6-(2-aminomethyl-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
This material was dissolved in 2 ml dichloromethane, followed by
the addition of 0.013 ml (0.092 mmol) triethylamine and 0.009 ml
(0.09 mmol) acetic anhydride at 0.degree. C. The cooling bath was
removed 5 min. after completed addition, and stirring was continued
at room temperature over night. The reaction mixture was diluted
with a 0.5 M aqueous sodium hydroxide solution and extracted with
three portions of tert-butyl methyl ether. The combined organic
extracts were dried over sodium sulphate and concentrated. Flash
chromatography gave 44 mg (77%) of the title compound as an
off-white solid.
[2314] MS m/e (%): 639 (M+H.sup.+, 100)
EXAMPLE 303
(S)-Dimethyl-carbamic acid
1-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-met-
hyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-yl]-py-
rrolidin-2-ylmethyl ester
[2315] To a solution of 44 mg (0.33 mmol)
1,1,3,3-tetramethyl-2-thiourea in 1.5 ml N,N-dimethylformamide were
added 0.027 ml iodomethane at room temperature. After stirring for
50 min. 0.20 g (0.33 mmol)
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
and a suspension of 45 mg (0.90 mmol) sodium hydride (ca. 50%
dispersion in mineral oil) in 0.5 ml n-hexane were added. After
stirring at room temperature for 1 h the reaction mixture was
diluted with water and extracted with three portions of tert-butyl
methyl ether. The combined organic extracts were dried over sodium
sulphate and concentrated. Flash column chromatography gave 90 mg
(40%) of the title compound as an off-white solid.
[2316] MS m/e (%): 669 (M+H.sup.+, 100)
EXAMPLE 304
(3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl-
)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-is-
obutyramide
[2317]
a)(5R,3S)-1-Benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-o-
l
[2318] To a solution of 1.8 g (5.6 mmol)
(3R,5R)-1-benzyl-5-(tert-butyl-di-
methyl-silanyloxy)-piperidin-3-ol in 50 ml THF were consecutively
added 0.75 g (6.2 mmol) benzoic acid, 1.1 g (6.2 mmol) diethyl
azodicarboxylate and 1.6 g (6.2 mmol) triphenylphosphine at
0.degree. C. After 6 h the reaction mixture was diluted with
tert-butyl methyl ether washed with a 2N aqueous solution of sodium
carbonate. The aqueous layer was extracted with 3 portions of
tert-butyl methyl ether. The combined organic extracts were washed
with a 2N aqueous solution of sodium carbonate and brine and dried
over sodium sulfate. Flash chromatography gave 0.80 g
(3S,5R)-benzoic acid
1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidi- n-3-yl ester
as a light brown oil. The ester was dissolved in a mixture of 50 ml
dioxane and 18 ml 1N aqueous sodium hydroxide solution. The
reaction mixture was heated at 70.degree. C. for 5 h. After cooling
to room temperature the mixture was extracted with tert-butyl
methyl ether. The organic extract was washed with a 2N aqueous
solution of sodium carbonate. The combined aqueous layers were
extracted with two portions of tert-butyl methyl ether. The
combined organic extracts were washed with brine and dried over
sodium sulfate. Flash chromatography gave 0.10 g (17%) of the title
compound as a light brown oil.
[2319] MS m/e (%): 322 (M+H.sup.+, 100)
[2320] b)
(3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-met-
hyl-phenyl)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-
-methyl-isobutyramide
[2321] The title compound was obtained as a light yellow solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-py-
ridin-3-yl]-N-methyl-isobutyramide using
(5R,3S)-1-benzyl-5-(tert-butyl-di-
methyl-silanyloxy)-piperidin-3-ol instead of
(R)-(4-benzyl-morpholin-3-yl)- -methanol in step a).
[2322] MS m/e (%): 614.7 (M+H.sup.+, 100)
EXAMPLE 305
(3S,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-3,5-dih-
ydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyrami-
de
[2323]
a)(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidine
[2324] The title compound was obtained as a light brown solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(S)-3-(tert-butyl-dimethyl-silanyl- oxymethyl)-morpholine (Example
174b)) using (3R,5R)-1-benzyl-piperidine-3,- 5-diol instead of
(R)-(4-benzyl-morpholin-3-yl)-methanol in step a).
[2325] MS m/e (%): 346 (M+H.sup.+, 100)
[2326] b)
(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidine-1-ca-
rboxylic acid benzyl ester
[2327] To a solution of 0.50 g (1.4 mmol)
(3R,5R)-3,5-bis-(tert-butyl-dime- thyl-silanyloxy)-piperidine and
0.15 g (1.5 mmol) triethylamine in 30 ml of THF was added dropwise
a solution of 0.26 g (1.5 mmol) benzyl chloroformate in 2 ml of THF
at 0.degree. C. After completed addition, the mixture was allowed
to warm to room temperature during 30 min. Quenching with a
saturated aqueous solution of sodium hydrogencarbonate was followed
by extraction with three portions of dichloromethane. The combined
organic extracts were washed with brine and dried over sodium
sulfate. Flash chromatography gave 0.62 g (90%) of the title
compound as a colorless oil.
[2328] MS m/e (%): 480 (M+H.sup.+, 100)
[2329] c)
(3R,5R)-3-(tert-Butyl-dimethyl-silanyloxy)-5-hydroxy-piperidine--
1-carboxylic acid benzyl ester
[2330] To a solution of 8.7 g (18 mmol)
(3R,5R)-3,5-bis-(tert-butyl-dimeth-
yl-silanyloxy)-piperidine-1-carboxylic acid benzyl ester in 200 ml
THF were added 18 ml (18 mmol) of a 1M solution of tetrabutyl
ammoniumfluoride in THF at 0.degree. C. After completed addition,
the mixture was allowed to warm to room temperature over night.
Addition of water was followed by extraction with three portions of
tert-butyl methyl ether. The combined organic extracts were dried
over sodium sulfate. Flash chromatography gave 1.1 g (16%) of the
title compound as a pale yellow oil.
[2331] MS m/e (%): 366 (M+H.sup.+, 98)
[2332] d)
(3S,5R)-3-Benzoyloxy-5-(tert-butyl-dimethyl-silanyloxy)-piperidi-
ne-1-carboxylic acid benzyl ester
[2333] To a solution of 2.8 g (7.8 mmol)
(3R,5R)-3-(tert-butyl-dimethyl-si-
lanyloxy)-5-hydroxy-piperidine-1-carboxylic acid benzyl ester in 70
ml dry THF were consecutively added 1.0 g (8.5 mmol) benzoic acid,
1.7 g (8.5 mmol) diethyl azodicarboxylate and 2.2 g (8.5 mmol)
triphenylphosiphine at 0.degree. C. After 6 h the reaction mixture
was diluted with tert-butyl methyl ether washed with a 2N aqueous
solution of sodium carbonate. The aqueous layer was extracted with
3 portions of tert-butyl methyl ether. The combined organic
extracts were washed with a 2N aqueous solution of sodium carbonate
and brine and dried over sodium sulfate. Flash chromatography gave
2.8 g (78%) of the title compound as a yellow oil.
[2334] MS m/e (%): 470 (M+H.sup.+, 100)
[2335] e) (3S,5R)-3-Benzoyloxy-5-hydroxy-piperidine-1-carboxylic
acid benzyl ester
[2336] To a solution of 2.3 g (5.0 mmol)
(3S,5R)-3-benzoyloxy-5-(tert-buty-
l-dimethyl-silanyloxy)-piperidine-1-carboxylic acid benzyl ester in
20 ml dry THF were added 5.5 ml (5.5 mmol) of a 1M solution of
tetrabutyl ammoniumfluoride in THF at 0.degree. C. After completed
addition, the mixture was allowed to warm to room temperature over
30 min. Addition of water was followed by extraction with three
portions of tert-butyl methyl ether. The combined organic extracts
were dried over sodium sulfate. Kugelrohr distillation gave 1.7 g
(95%) of the title compound as a light yellow oil.
[2337] MS m/e (%): 356 (M+H.sup.+, 100)
[2338] f) (3S,5S)-3,5-Dihydroxy-piperidine-1-carboxylic acid benzyl
ester
[2339] The title compound was obtained as a light brown oil in 4%
yield after flash chromatography according to the procedure
described above for the preparation of
(5R,3S)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-pi-
peridin-3-ol (Example 304a)) using
(3S,5R)-3-benzoyloxy-5-hydroxy-piperidi- ne-1-carboxylic acid
benzyl ester instead of (3R,5R)-1-benzyl-5-(tert-buty-
l-dimethyl-silanyloxy)-piperidin-3-ol.
[2340] MS m/e (%): 252 (M+H.sup.+, 63)
[2341] g)
(3S,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-pheny-
l)-3,5-dihydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide
[2342] The title compound was obtained as a light brown solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-morpholin-4-yl)-py-
ridin-3-yl]-N-methyl-isobutyramide using
(3S,5S)-3,5-dihydroxy-piperidine-- 1-carboxylic acid benzyl ester
instead of (R)-(4-benzyl-morpholin-3-yl)-me- thanol in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2--
chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step c).
[2343] MS m/e (%): 616 (M+H.sup.+, 100)
EXAMPLE 306
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2-formyl-pyrrolidin-1-yl)-4-o-
-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2344] The title compound was obtained as a colorless viscous oil
in comparable yields after flash chromatography according to the
procedures described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[4-(2-chloro-phenyl)-6-(2-oxo-propylamino)-pyridin-3-yl]-N-methyl-isobu-
tyramide (Example 75a)) using
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6--
(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobuty-
ramide instead of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-p-
henyl)-6-(2-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
[2345] MS m/e (%): 578 (M+H.sup.+, 100)
EXAMPLE 307
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide
[2346] a)(S)-2-Methanesulfonylmethyl-pyrrolidine-1-carboxylic acid
benzyl ester
[2347] To a suspension of 1.81 g (25.8 mmol) sodium methanethiolate
in 25 ml methanol was added a solution of 1.35 g (4.31 mmol)
2-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid benzyl
ester in 25 ml methanol. Conversion was monitored by thin layer
chromatography. After complete consumption of the starting material
the reaction mixture was diluted with ethyl acetate and washed with
two portions of water. The organic layer was dried over sodium
sulfate. Flash chromatography gave 0.89 g (3.4 mmol, 78%)
(S)-2-methylsulfanylmethyl-pyrrolidine-1-carboxyli- c acid benzyl
ester as a light yellow oil.
[2348] This material was dissolved in 25 ml of methanol and treated
with 3.1 g (5.1 mmol) Oxone at room temperature. Conversion was
monitored by thin layer chromatography. After complete consumption
of the starting material the reaction mixture was diluted with
water and extracted with three portions of ethyl acetate. The
combined organic extracts were dried over sodium sulfate and
concentrated in vacuo to give 0.86 g (86%) of the crude title
compound as a colorless oil.
[2349] MS m/e (%): 297 (M.sup.+, 3)
[2350] b) (S)-2-Methanesulfonylmethyl-pyrrolidine
[2351] A solution of 0.86 g (2.9 mmol)
(S)-2-methanesulfonylmethyl-pyrroli- dine-1-carboxylic acid benzyl
ester in 15 ml ethanol was deoxygenated by three cycles of
evacuation and flushing with argon. After addition of 0.15 g
palladium on charcoal (10%) the reaction vessel was evacuated and
filled with hydrogen gas. The reaction mixture was stirred at room
temperature under an atmosphere of hydrogen over night. Filtration
over decalite and evaporation of the solvent in vacuo gave 0.44 g
(93%) of the crude title compound as a light yellow oil.
[2352] MS m/e (%): 164 (M+H.sup.+, 100)
[2353] c)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(2
methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl--
isobutyramide
[2354] The title compound was obtained as an off-white solid after
preparative thin layer chromatography according to the procedure
described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide using
(S)-2-methanesulfonylmethyl-pyrr- olidine instead of
L-prolinol.
[2355] MS m/e (%): 660 (M+H.sup.+, 100)
EXAMPLE 308
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-hydr-
oxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyr-
amide
[2356] A mixture of 0.50 g (0.94 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 0.32 g (2.8 mmol) 4-(hydroxymethyl)piperidine, 0.12 g (2.8
mmol) lithium chloride and 0.39 g (2.8 mmol) potassium carbonate in
5 ml DMSO was heated at 140.degree. C. for 24 h. After cooling to
room temperature the reaction mixture was diluted with water and
extracted with three portions of dichloromethane. The combined
organic extracts were dried over sodium sulphate and concentrated.
Flash column chromatography gave 0.42 g (74%) of the title compound
as a white solid.
[2357] MS m/e (%): 612 (M+H.sup.+, 100)
EXAMPLE 309
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-meth-
ylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide
[2358] a) Methanesulfonic acid 5'-f
[2-(3,5-bis-trifluoromethyl-phenyl)-2--
methyl-propionyl]-methyl-amino]-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetr-
ahydro-2H-[1,2']bipyridinyl-4-ylmethyl ester
[2359] To a solution of 0.42 g (0.69 mmol)
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-
-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide in 7 ml
dichloromethane were added 83 mg (0.72 mmol) methanesulfonyl
chloride and 73 mg (0.72 mmol) triethylamine at 0.degree. C. After
30 min the reaction mixture was diluted with water and extracted
with three portions of dichloromethane. The combined organic
extracts were dried over sodium sulphate and concentrated. Flash
column chromatography gave 0.29 g (63%) of the title compound as a
white solid.
[2360] MS m/e (%): 690 (M+H.sup.+, 100)
[2361] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phen-
yl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]--
N-methyl-isobutyramide
[2362] A solution of 0.29 g (0.42 mmol) methanesulfonic acid
5'-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-
-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-y-
lmethyl ester and 44 mg (0.63 mmol) sodium methanethiolate in 8 ml
DMF was heated at 80.degree. C. for 30 min. After cooling to room
temperature the reaction mixture was treated with a 1 N aqueous
sodium hydroxide solution and extracted with three portions of
tert-butyl methyl ether. The combined organic extracts were dried
over sodium sulphate and concentrated. Flash column chromatography
gave 0.25 g (92%) of the title compound as a white solid.
[2363] MS m/e (%): 642 (M+H.sup.+, 100)
EXAMPLE 310
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-
-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-me-
thyl-isobutyramide
[2364] To a solution of 0.25 g (0.39 mmol)
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrah-
ydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide in 10 ml
dichloromethane were added 95 mg (70%, 0.39 mmol)
3-chloroperbenzoic acid at 0.degree. C. After completed addition,
the reaction mixture was allowed to warm to room temperature and
stirred over night. An aqueous solution of sodium hydrogensulfite
was added and the mixture was stirred for 10 min. Basification with
1 N aqueous sodium hydroxide solution was followed by extraction
with three portions of dichloromethane. The combined organic
extracts were dried over sodium sulphate and concentrated. Flash
column chromatography gave 0.23 g (89%) of the title compound as a
white solid.
[2365] MS m/e (%): 658 (M+H.sup.+, 100)
EXAMPLE 311
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-meth-
anesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl--
isobutyramide
[2366] To a solution of 0.22 g (0.33 mmol)
(RS)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6--
tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide in 5
ml dichloromethane were added 142 mg (70%, 0.58 mmol)
3-chloroperbenzoic acid at 0.degree. C. After completed addition,
the reaction mixture was allowed to warm to room temperature and
stirred over night. An aqueous solution of sodium hydrogensulfite
was added and the mixture was stirred for 10 min. Basification with
1 N aqueous sodium hydroxide solution was followed by extraction
with three portions of dichloromethane. The combined organic
extracts were dried over sodium sulphate and concentrated. Flash
column chromatography gave 0.13 g (55%) of the title compound as a
white solid.
[2367] MS m/e (%): 674 (M+H.sup.+, 100)
EXAMPLE 312
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2368] The title compound was obtained as a white solid in 70%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-
-methyl-isobutyramide using (RS)-3-(hydroxymethyl)pyrrolidine
instead of 4-(hydroxymethyl)piperidine.
[2369] MS m/e (%): 598 (M+H.sup.+, 100)
EXAMPLE 313
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-methylsulfanylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide
[2370] The title compound was obtained as a white solid in 66%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5-
'-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3--
yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[4'-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2-
']bipyridinyl-5'-yl]-N-methyl-isobutyramide in step a).
[2371] MS m/e (%): 628 (M+H.sup.+, 100)
EXAMPLE 314
2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[(RS)-
-3-((RS)-methanesulfinylmethyl)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-is-
obutyramide
[2372] The title compound was obtained as a white solid in 86%
yield after flash chromatography according to the procedure
described above for the preparation of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2--
methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrid-
inyl-5'-yl]-N-methyl-isobutyramide using
(RS)-2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanylmethyl-pyrrolidi-
n-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-met-
hylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl--
isobutyramide.
[2373] MS m/e (%): 644 (M+H.sup.+, 100)
EXAMPLE 315
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-methanesulfonylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2374] The title compound was obtained as a white solid in 31%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl--
5'-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-{-
4-(4-fluoro-2-methyl-phenyl)-6-[(RS)-3-((RS)-methanesulfinylmethyl)-pyrrol-
idin-1-yl]-pyridin-3-yl}-N-methyl-isobutyramide instead of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)--
4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-m-
ethyl-isobutyramide.
[2375] MS m/e (%): 660 (M+H.sup.+, 100)
EXAMPLE 316
(R)-N-[6-(3-Amino-pyrrolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3--
yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[2376] A mixture of 939 mg (1.76 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 1.22 g (8.81 mmol) potassium carbonate and 770 mg (3.52 mmol)
(R)-3-(trifluoro-acetamido)pyrrolidine hydrochloride in 20 ml
dimethyl sulfoxide was stirred at 130.degree. C. for 52 h. After
cooling to room temperature the reaction mixture was diluted with
30 ml tert-butyl methyl ether and washed with 20 ml of water and 10
ml of a saturated aqueous solution of sodium carbonate. The
combined organic layers were dried over sodium sulfate,
concentrated and dissolved in 25 ml of a 2 N solution of ammonia in
ethanol. The solution was stirred at room temperature for 18 h. The
reaction mixture was concentrated and purified by flash
chromatography to give 670 mg (65%) of the title compound as a
light brown foam.
[2377] MS m/e (%): 583 (M+H.sup.+, 100)
EXAMPLE 317
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de
[2378] To a solution of 620 mg (1.06 mmol)
(R)-N-[6-(3-amino-pyrrolidin-1--
yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl--
phenyl)-N-methyl-isobutyramide in 6 ml dichloromethane were added 7
mg (0.05 mmol) 4-(N,N-dimethylamino)pyridine, 275 mg (2.13 mmol)
N,N-diisopropylethylamine and 158 mg (1.38 mmol) methanesulfonyl
chloride at room temperature. After stirring for 18 h the reaction
mixture was diluted with 20 ml dichloromethane and washed with 20
ml of a saturated aqueous solution of sodium carbonate. The
combined organic layers were dried over sodium sulfate,
concentrated and purified by flash chromatography to give 618 mg
(88%) of the title compound as an off-white foam.
[2379] MS m/e (%): 659 (M+H.sup.+, 66)
EXAMPLE 318
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-methyl-phenyl)-6-[-
3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin-3-yl}-N-methyl-i-
sobutyramide
[2380] To a solution of 150 mg (0.227 mmol)
(R)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfonylamino-pyrroli-
din-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide in 1 ml
dimethylformamide were added 15 mg (0.34 mmol) sodium hydride (55%
dispersion in mineral oil) at room temperature. After stirring at
room temperature for 30 min 39 mg (27 mmol) iodomethane were added.
The reaction mixture was stirred at room temperature for 18 h,
followed by dilution with 10 ml ethyl acetate and washing with 10
ml saturated sodium carbonate solution. The combined organic layers
were dried over sodium sulfate, concentrated in vacuo and purified
by flash chromatography to give 120 mg (78%) of the title compound
as a white foam.
[2381] MS m/e (%): 675 (M+H.sup.+, 100)
EXAMPLE 319
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[3-(ethyl-methanesulfonyl-amin-
o)-pyrrolidin-1-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-is-
obutyramide
[2382] The title compound was obtained as a white foam in 84% yield
after flash chromatography according to the procedure described
above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-me-
thyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin--
3-yl}-N-methyl-isobutyramide using iodoethane instead of
iodomethane.
[2383] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 320
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-meth-
anesulfonylamino-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-N-methyl-- isobutyramide
[2384] The title compound was obtained as a white foam in 93% yield
after flash chromatography according to the procedure described
above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-me-
thyl-isobutyramide using
N-[4-amino-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6--
tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-2-(3,5-bis-trifluoromethyl-phenyl)--
N-methyl-isobutyramide (Example 114c)) instead of
(R)-N-[6-(3-amino-pyrrol-
idin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoro-
methyl-phenyl)-N-methyl-isobutyramide.
[2385] MS m/e (%): 673 ([M-H.sup.+].sup.-, 90)
EXAMPLE 321
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-(met-
hanesulfonyl-methyl-amino)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]--
N-methyl-isobutyramide
[2386] The title compound was obtained as a white foam in 98% yield
after flash chromatography according to the procedure described
above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-me-
thyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin--
3-yl}-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
'-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H--
[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide instead of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide.
[2387] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 322
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(ethyl-methanesulfonyl-amino)-4'-(-
4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-
-methyl-isobutyramide
[2388] The title compound was obtained as a white foam in 95% yield
after flash chromatography according to the procedure described
above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-2-me-
thyl-phenyl)-6-[3-(methanesulfonyl-methyl-amino)-pyrrolidin-1-yl]-pyridin--
3-yl}-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
'-(4-fluoro-2-methyl-phenyl)-4-methanesulfonylamino-3,4,5,6-tetrahydro-2H--
[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide instead of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide and iodoethane instead of iodomethane.
[2389] MS m/e (%): 703 (M+H.sup.+, 100)
EXAMPLE 323
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-trif-
luoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobut-
yramide
[2390] A mixture of 150 mg (0.28 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide and 0.16 g (0.84 mmol) 4-(trifluoromethyl)piperidine
hydrochloride in 2 ml 1,8-diazabicyclo[5.4.0]undec-7-ene was heated
at 140.degree. C. for 20 h. After cooling to room temperature the
reaction mixture was diluted with water and extracted with three
portions of tert-butyl methyl ether. The combined organic layers
were dried over sodium sulfate, concentrated in vacuo and purified
by flash chromatography to give 62 mg (34%) of the title compound
as a light yellow solid.
[2391] MS m/e (%): 650 (M+H.sup.+, 100)
EXAMPLE 324
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-me-
thanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2392]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2393] The title compound was obtained as a white solid in 38%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5-
'-yl]-N-methyl-isobutyramide (Example 309) using
2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide (Example 162) instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-hyd-
roxymethyl-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-N-methyl-isobut- yramide in step a).
[2394] MS m/e (%): 600 (M+H.sup.+, 100)
[2395] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramid-
e
[2396] To a solution of 0.25 g (0.42 mmol)
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide in 10 ml dichloromethane were
added 206 mg (70%, 0.84 mmol) 3-chloroperbenzoic acid at 0.degree.
C. After completed addition, the reaction mixture was allowed to
warm to room temperature and stirred for 2 h. An aqueous solution
of sodium hydrogensulfite was added and the mixture was stirred for
10 min. Basification with 1 N aqueous sodium hydroxide solution was
followed by extraction with three portions of dichloromethane. The
combined organic extracts were dried over sodium sulphate and
concentrated. Flash column chromatography gave 0.16 g (60%) of the
title compound as a white solid.
[2397] MS m/e (%): 632 (M+H.sup.+, 100)
EXAMPLE 325
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-3-
-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-i-
sobutyramide
[2398]
a)(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl--
phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl--
isobutyramide
[2399] The title compound was obtained as a white solid in 60%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-
-methyl-isobutyramide using (RS)-3-hydroxypiperidine instead of
4-(hydroxymethyl)piperidine.
[2400] MS m/e (%): 598 (M+H.sup.+, 100)
[2401] b)
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-
-phenyl)-3-methanesulfonyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]--
N-methyl-isobutyramide
[2402] The title compound was obtained as a white solid in 5% yield
after flash chromatography according to the procedures described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide (Example 324) using
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'--
(4-fluoro-2-methyl-phenyl)-3-hydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridin-
yl-5'-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phe-
nyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyridin-3-
-yl]-N-methyl-isobutyramide in step a).
[2403] MS m/e (%): 660 (M+H.sup.+, 100)
EXAMPLE 326
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-meth-
anesulfonyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobut-
yramide
[2404] The title compound was obtained as a white solid in 35%
yield after flash column chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-
-methyl-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-
-methyl-isobutyramide (Example 114a)) instead of
2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-azetidin-1-yl)-pyri-
din-3-yl]-N-methyl-isobutyramide in step a).
[2405] MS m/e (%): 660 (M+H.sup.+, 100)
EXAMPLE 327
(1S,3R,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2406] The title compound was obtained as a light brown solid in
57% yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-m-
ethyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-y-
l]-N-methyl-isobutyramide using nortropine instead of
4-(hydroxymethyl)piperidine.
[2407] MS m/e (%): 624 (M+H.sup.+, 100)
EXAMPLE 328
(1R,3S,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2408] The title compound was obtained as a white solid in 37%
yield after flash chromatography according to the procedure
described above for the preparation of
(5R,3S)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperi-
din-3-ol (Example 304a)) using
(1S,3R,5R)-2-(3,5-bis-trifluoromethyl-pheny-
l)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oct-8--
yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
(3R,5R)-1-benzyl-5-(tert-butyl-dimethyl-silanyloxy)-piperidin-3-ol.
[2409] MS m/e (%): 624 (M+H.sup.+, 100)
EXAMPLE 329
(rac)-(1R,3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methy-
l-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide
[2410]
a)(1R,3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(3-methylsulfanyl-8-aza-bicylo[3.2.1]oct-8-yl)-pyridin-3-yl-
]-N-methyl-isobutyramide
[2411] The title compound was obtained as a white solid in 45%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5-
'-yl]-N-methyl-isobutyramide using
(1R,3S,5S)-2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-8-aza-bicyclo[3.2.1]oc-
t-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-hyd-
roxymethyl-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-N-methyl-isobut- yramide in step a).
[2412] MS m/e (%): 654 (M+H.sup.+, 100)
[2413] b)
(rac)-(1R,3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluo-
ro-2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyr-
idin-3-yl]-N-methyl-isobutyramide
[2414] The title compound was obtained as a white solid in 78%
yield after flash chromatography according to the procedure
described above for the preparation of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2--
methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2'
]bipyridinyl-5'-yl]-N-methyl-isobutyramide using
(1R,3R,5S)-2-(3,5-bis-tr-
ifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methylsulfanyl--
8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4--
methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-meth-
yl-isobutyramide.
[2415] MS m/e (%): 670 (M+H.sup.+, 100)
EXAMPLE 330
(1R,3R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-methanesulfonyl-8-aza-bicyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-met-
hyl-isobutyramide
[2416] The title compound was obtained as a white solid in 60%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl--
5'-yl]-N-methyl-isobutyramide using
(rac)-(1R,3R,5S)-2-(3,5-bis-trifluorom-
ethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-methanesulfinyl-8-aza-b-
icyclo[3.2.1]oct-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide instead
of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)--
4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-m-
ethyl-isobutyramide.
[2417] MS m/e (%): 686 (M+H.sup.+, 100)
EXAMPLE 331
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-dimethylsulfamoyl-4'-(4-fluoro-2-m-
ethyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isob-
utyramide
[2418] a) Thioacetic acid
5'-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-
-propionyl]-methyl-amino}-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-
-2H-[1,2']bipyridinyl-4-yl ester
[2419] A solution of 0.22 g (0.84 mmol) triphenylphosphine and 0.15
g (0.84 mmol) diethyl azodicarboxylate in 3.33 ml THF was stirred
for 15 min at 0.degree. C. This solution was added to a solution of
0.25 g (0.42 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-
-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobuty-
ramide and 64 mg (0.84 mmol) thoacetic acid in 10 ml THF at
0.degree. C. Conversion was monitored by thin layer chromatography.
After complete consumption of the starting material a 2 N aqueous
solution of sodium carbonate was added. The mixture was extracted
with three portions of tert-butyl methyl ether. The combined
organic extracts were dried over sodium sulphate and concentrated.
Flash column chromatography gave 0.16 g (59%) of the title compound
as a white solid.
[2420] MS m/e (%): 656 (M+H.sup.+, 100)
[2421] b)
5'-[2-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methy-
l-amino
1-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyri-
dinyl-4-sulfonic acid
[2422] To a suspension of 0.16 g (0.24 mmol) thioacetic acid
5'-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amino}-
-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-y-
l ester in 1 ml acetic acid were added 0.12 ml (1.2 mmol) of a 30%
aqueous solution of hydrogen peroxide at room temperature. After
heating to 60.degree. C., a clear solution was obtained. Stirring
was continued at this temperature for 20 h. After cooling to room
temperature an aqueous solution of sodium hydrogensulfite was added
and the mixture was stirred for 10 min. Acidifcation with 1 N
aqueous hydrochloride solution to pH 1 was followed by extraction
with three portions of dichloromethane. The combined organic
extracts were dried over sodium sulphate and concentrated. Flash
column chromatography gave 0.13 g (83%) of the title compound as a
light yellow solid.
[2423] MS m/e (%): 660 ([M-H.sup.+].sup.-, 100)
[2424] c)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-dimethylsulfamoyl-4'-(4--
fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-5'-yl]-N-me-
thyl-isobutyramide
[2425] To a solution of 0.13 g (0.19 mmol)
5'-{[2-(3,5-bis-trifluoromethyl-
-phenyl)-2-methyl-propionyl]-methyl-amino}-4'-(4-fluoro-2-methyl-phenyl)-3-
,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-sulfonic acid in 2 ml
dichloromethane were added 0.33 ml (0.39 mmol) oxalyl chloride and
one drop of DMF at 0.degree. C. After 30 min the reaction mixture
was allowed to warm to room temperature during 2 h. To the yellow
reaction mixture were added 1.8 ml (20 mmol) of an aqueous solution
of dimethylamine (60%). After 1 h the reaction mixture was diluted
with water and extracted with three portions of dichloromethane.
The combined organic extracts were dried over sodium sulphate and
concentrated. Flash column chromatography gave 92 mg (69%) of the
title compound as a white solid.
[2426] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 332
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methylsulfany-
l-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
[2427] The title compound was obtained as a white solid in 59%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-methylsulfanylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5-
'-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-
'-(2-chloro-phenyl)-4-hydroxy-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-y-
l]-N-methyl-isobutyramide (Example 51) instead of
2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-hydroxymethyl-3,4,5,6-tetrah-
ydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide in step
a).
[2428] MS m/e (%): 630 (M+H.sup.+, 100)
EXAMPLE 333
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methanes-
ulfinyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyram-
ide
[2429] The title compound was obtained as a white solid in 84%
yield after flash chromatography according to the procedure
described above for the preparation of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2--
methyl-phenyl)-4-methanesulfinylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyrid-
inyl-5'-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-phenyl-
)-N-[4'-(2-chloro-phenyl)-4-methylsulfanyl-3,4,5,6-tetrahydro-2H-[1,2']bip-
yridinyl-5'-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-methylsulfanylmethyl-3,4,5,6-
-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide.
[2430] MS m/e (%): 646 (M+H.sup.+, 100)
EXAMPLE 334
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4'-(2-chloro-phenyl)-4-methanesulfon-
yl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide
[2431] The title compound was obtained as a white solid in 86%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-methanesulfonylmethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl--
5'-yl]-N-methyl-isobutyramide using
(RS)-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-[4'-(2-chloro-phenyl)-4-methanesulfinyl-3,4,5,6-tetrahydro-2H-[1,2']bi-
pyridinyl-5'-yl]-N-methyl-isobutyramide instead of
(RS)-2-(3,5-bis-trifluo-
romethyl-phenyl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-methanesulfinylmethyl--
3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide.
[2432] MS m/e (%): 662 (M+H.sup.+, 100)
EXAMPLE 335
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-ox-
a-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2433] To a solution of 0.20 g (0.34 mmol)
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4'-(4-fluoro-2-methyl-phenyl)-4-oxo-3,4,5,6-tetrahydro-2H-[1,2']bip-
yridinyl-5'-yl]-N-methyl-isobutyramide in 5 ml dichloromethane were
added 0.03 g (0.4 mmol) 2-mercaptoethanol and 0.11 g (0.34 mmol)
boron trifluoride etherate at 0.degree. C. After 1 h the reaction
mixture was allowed to warm to room temperature and stirred over
night. Dilution with a 2 N aqueous sodium hydroxide solution was
followed by extraction with 3 portions of dichloromethane. The
combined organic extracts were dried over sodium sulfate and
concentrated in vacuo. Flash column chromatography gave 0.22 g
(98%) of the title compound as a white solid.
[2434] MS m/e (%): 656 (M+H.sup.+, 100)
EXAMPLE 336
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4,4-dioxo-1-oxa-4%6-thia-8-aza-sp-
iro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2435] The title compound was obtained as a white solid in 55%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(1-oxa-4-thia-8-aza-spiro
[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-i- sobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-
-isobutyramide.
[2436] MS m/e (%): 688 (M+H.sup.+, 100)
EXAMPLE 337
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-ox-
a-5-thia-9-aza-spiro[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2437] The title compound was obtained as a white solid in 84%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl--
isobutyramide using 3-mercapto-1-propanol instead of
2-mercaptoethanol.
[2438] MS m/e (%): 670 (M+H.sup.+, 100)
EXAMPLE 338
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(5,5-dioxo-1-oxa-5.lambda..sup.6-t-
hia-9-aza-spiro
[5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl-
]-N-methyl-isobutyramide
[2439] The title compound was obtained as a white solid in 70%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(1-oxa-5-thia-9-aza-spiro
[5.5]undec-9-yl)-pyridin-3-yl]-N-methyl- -isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluor-
o-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-meth-
yl-isobutyramide.
[2440] MS m/e (%): 702 (M+H.sup.+, 100)
EXAMPLE 339
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,-
4,4-tetraoxo-l.lambda..sup.6,4.lambda..sup.6-dithia-8-aza-spiro[4.5]dec-8--
yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2441]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,4-dithia-8-aza-spiro[4-
.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2442] The title compound was obtained as a white solid in 41%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl--
isobutyramide using 1,2-ethanedithiol instead of
2-mercaptoethanol.
[2443] MS m/e (%): 672 (M+H.sup.+, 100)
[2444] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(1,1,4,4-tetraoxo-l.lambda..sup.6,4.lambda..sup.6-dithia-8-aza-spiro[-
4.51 dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2445] The title compound was obtained as a white solid in 33%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,4-dithia-8-aza-sp-
iro[4.5]dec-8-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isob-
utyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-m-
ethyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide and 4 instead of 2 equivalents of 3-chloroperbenzoic
acid.
[2446] MS m/e (%): 736 (M+H.sup.+, 100)
EXAMPLE 340
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1,1,-
5,5-tetraoxo-l.lambda..sup.6,5.lambda..sup.6-dithia-9-aza-spiro[5.5]undec--
9-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2447]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,5-dithia-9-aza-spiro[5-
.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide
[2448] The title compound was obtained as a white solid in 41%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(1-oxa-4-thia-8-aza-spiro[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl--
isobutyramide using 1,3-propanedithiol instead of
2-mercaptoethanol.
[2449] MS m/e (%): 686 (M+H.sup.+, 100)
[2450] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(1,1,5,5-tetraoxo-l.lambda..sup.6,5.lambda..sup.6-dithia-9-aza-spiro[-
5.5]undec-9-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2451] The title compound was obtained as an off-white solid in 4%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-is-
obutyramide using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,5-dithia-9-az-
a-spiro[5.5]undec-9-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluo-
ro-2-methyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-met-
hyl-isobutyramide and 4 instead of 2 equivalents of
3-chloroperbenzoic acid.
[2452] MS m/e (%): 750 (M+H.sup.+, 100)
EXAMPLE 341
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(1-ox-
a-8-aza-spiro
[4.5]dec-8-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2453] The title compound was obtained as an off-white solid in 12%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-m-
ethyl-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-
-yl]-N-methyl-isobutyramide using 1-oxa-8-azaspiro[4.5]decane
trifluoroacetic acid salt instead of 4-(trifluoromethyl)piperidine
hydrochloride.
[2454] MS m/e (%): 638 (M+H.sup.+, 100)
EXAMPLE 342
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2455] A mixture of 0.10 g (0.17 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-p-
yridin-3-yl]-N-methyl-isobutyramide (Example 142), 12 mg (0.39
mmol) paraformaldehyde and 61 mg (0.51 mmol) magnesium sulfate in 2
ml 1,2-dichloromethane was heated at 85.degree. C. until complete
consumption of starting material. After cooling to room temperature
the reaction mixture was diluted with water and extracted with 3
portions of tert-butyl methyl ether. The combined organic extracts
were dried over sodium sulfate and concentrated in vacuo. Flash
column chromatography gave 60 mg (59%) of the title compound as an
off-white solid.
[2456] MS m/e (%): 600 (M+H.sup.+, 100)
EXAMPLE 343
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-morph-
olin-4-yl-pyridin-3-yl]-N-methyl-isobutyramide
[2457] The title compound was obtained as an off-white solid in 67%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phen-
yl)-6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramid-
e (Example 115) using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4--
fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide and morpholine instead of
2-(methylamino)ethanol.
[2458] MS m/e (%): 584 (M+H.sup.+, 100)
EXAMPLE 344
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[(1S,5R)-4-(4-fluoro-2-methyl-phenyl)-
-6-8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-isobutyramide
[2459] A mixture of 0.15 g (0.28 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 0.13 g (0.84 mmol) 8-oxa-3-aza-bicyclo[3.2.1]octane
hydrochloride and 0.20 g (1.4 mmol) potassium carbonate in 1 ml
dimethyl sulfoxide was heated at 150.degree. C. under microwave
irradiation in a sealed tube for 30 min. Another portion of 0.06 g
(0.4 mmol) 8-oxa-3-aza-bicyclo[3.2.1]oc- tane hydrochloride was
added and the reaction mixture was heated at 150.degree. C. under
microwave irradiation in a sealed tube for 30 more minutes. After
cooling to room temperature the reaction mixture was diluted with
water and extracted with four portions of tert-butyl methyl ether.
The combined organic extracts were dried over sodium sulfate and
concentrated. Flash column chromatography gave 32 mg (18%) of the
title compound as a light yellow solid.
[2460] MS m/e (%): 610 (M+H.sup.+, 100)
EXAMPLE 345
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-me-
thylsulfanyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2461] The title compound was obtained as light orange foam in 19%
yield after flash chromatography according to the procedure
described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-flu-
oro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide (Example 155) using
2-(methylthio)ethylamine instead of
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
[2462] MS m/e (%): 588 (M+H.sup.+, 100)
EXAMPLE 346
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-me-
thanesulfonyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2463] The title compound was obtained as a white foam in 54% yield
after flash chromatography according to the procedure described
above for the preparation of
(S)-2-methanesulfonylmethyl-pyrrolidine-1-carboxylic acid benzyl
ester (Example 307a)) using 2-(3,5-bis-trifluoromethyl-phenyl)-N-[-
4-(4-fluoro-2-methyl-phenyl)-6-(2-methylsulfanyl-ethylamino)-pyridin-3-yl]-
-N-methyl-isobutyramide instead of
(S)-2-methylsulfanylmethyl-pyrrolidine-- 1-carboxylic acid benzyl
ester.
[2464] MS m/e (%): 620 (M+H.sup.+, 100)
EXAMPLE 347
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-thiaz-
olidin-3-yl-pyridin-3-yl]-N-methyl-isobutyramide
[2465] A mixture of 0.25 g (0.47 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide and 0.59 g (6.6 mmol) thiazolidine was heated three times at
180.degree. C. for 30 minutes and once at 250.degree. C. for 15
minutes under microwave irradiation in a sealed tube. The reaction
mixture was diluted with a 0.2 M aqueous solution of sodium
hydroxide and extracted with three portions of tert-butyl methyl
ether. The combined organic extracts were dried over sodium sulfate
and concentrated in vacuo. Flash column chromatography and drying
in high vacuo (70-90.degree. C./1-2 mbar) for three hours gave 33
mg (12%) of the title compound as a yellow oil.
[2466] MS m/e (%): 586 (M+H.sup.+, 100)
EXAMPLE 348
(1RS,4RS)- or
(1RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolidin-3-yl-
)-pyridin-3-yl]-N-methyl-isobutyramide (Diastereomeric racemate of
Example 349) and
EXAMPLE 349
(1RS,4SR)- or
(1RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-1%4-thiazolidin-3-yl)-pyridin-3--
yl]-N-methyl-isobutyramide (Diastereomeric racemate of Example
348)
[2467] a)
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dime-
thyl-silanyloxy)-1-hydroxymethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)--
pyridin-3-yl]-N-methyl-isobutyramide
[2468] The title compound was obtained as a white solid in 42%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-4-benzyl-3-(tert-butyl-dimethyl-silanyloxymethyl)-morp- holine
(Example 174a)) using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fl-
uoro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-y-
l]-N-methyl-isobutyramide (Example 142) instead of
(R)-(4-benzyl-morpholin- -3-yl)-methanol.
[2469] MS m/e (%): 702 (M+H.sup.+, 100)
[2470] b) (RS)-Thioacetic acid 2-[5-f
[2-(3,5-bis-trifluoromethyl-phenyl)--
2-methyl-propionyl]-methyl-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-y-
lamino]-3-(tert-butyl-dimethyl-silanyloxy)-propyl ester
[2471] To a solution of 0.19 mg (0.71 mmol) triphenylphosphine in
10 ml dry THF were added 0.12 g (0.71 mmol) diethyl
azodicarboxylate at 0.degree. C. under argon. After 30 min a
solution of 0.50 g (0.71 mmol)
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dimethyl-sila-
nyloxy)-1-hydroxymethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-
-yl]-N-methyl-isobutyramide in 5 ml dry THF and 0.06 g (0.9 mmol)
thioacetic acid were added. The reaction mixture was allowed to
warm to room temperature over night. Dilution with a saturated
aqueous solution of sodium hydrogencarbonate was followed by
extraction with three portions of tert-butyl methyl ether. The
combined organic extracts were dried over sodium sulfate and
concentrated in vacuo. Flash column chromatography gave 0.28 g
(52%) of the title compound as a white solid.
[2472] MS m/e (%): 760 (M+H.sup.+, 100)
[2473] c)
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(2-hydroxy-1-mercaptomethyl-ethylamino)-pyridin-3-yl]-N-methyl-i-
sobutyramide
[2474] A mixture of 0.28 mg (0.37 mmol) (RS)-thioacetic acid
2-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amin-
o}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-3-(tert-butyl-dimethyl--
silanyloxy)-propyl ester in 10 ml ethanol and 4 ml of a 2 N
solution of ammonia in ethanol was heated at reflux for 4 h. After
cooling to room temperature the reaction mixture was concentrated
in vacuo to give 0.22 g of the crude title compound as a light
brown amorphous residue, which was used in the next step without
any further purification.
[2475] d)
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dime-
thyl-silanyloxy)-1-mercaptomethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)-
-pyridin-3-yl]-N-methyl-isobutyramide
[2476] The crude title compound was obtained as a light brown
amorphous residue in quantitative yield after extraction according
to the procedure described above for the preparation of
(S)-4-benzyl-3-(tert-butyl-dimethy- l-silanyloxymethyl)-morpholine
(Example 174a)) using
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-
-(2-hydroxy-1-mercaptomethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyram-
ide instead of (R)-(4-benzyl-morpholin-3-yl)-methanol.
[2477] e)
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-[4-(tert-butyl-dime-
thyl-silanyloxymethyl)-thiazolidin-3-yl]-4-(4-fluoro-2-methyl-phenyl)-pyri-
din-3-yl]-N-methyl-isobutyramide
[2478] The title compound was obtained as a white solid in 39%
yield after flash chromatography according to the procedure
described above for the preparation of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-m-
ethyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide (Example 342) using
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[6-[2-(tert-butyl-dimethyl-silanyloxy)-1-mercaptomethyl-ethylamino]-4-(4--
fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-h-
ydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide.
[2479] MS m/e (%): 730 (M+H.sup.+, 100)
[2480] f)
(1RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda.4-thiazolidin-3-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide and
[2481]
(1RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methy-
l-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda.4-thiazolidin-3-yl)-pyridin-3--
yl]-N-methyl-isobutyramide
[2482] To a solution of 50 mg (0.069 mmol)
(RS)-2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[6-[4-(tert-butyl-dimethyl-silanyloxymethyl)-thiazolidin-3-yl]--
4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in 2 ml dichloromethane were added 17 mg (70%, 0.069 mmol)
3-chloroperbenzoic acid at 0.degree. C. After completed addition,
the reaction mixture was allowed to warm to room temperature during
3 h. A saturated aqueous solution of sodium carbonate was added and
the mixture was extracted with three portions of dichloromethane.
The combined organic extracts were dried over sodium sulphate and
concentrated. The residue, 80 mg of a brown oil, was dissolved in 2
ml THF and treated with 0.07 ml (0.07 mmol) of a 1 M solution of
tetrabutylammonium fluoride in THF at room temperature. After
stirring at room temperature over night the reaction mixture was
diluted with a 2 N aqueous solution of sodium carbonate and
extracted with three portions of tert-butyl methyl ether. The
combined organic extracts were dried over sodium sulphate and
concentrated. Preparative thin layer chromatography gave 24 mg
(55%) of one diastereomeric racemate of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-flu-
oro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolidin--
3-yl)-pyridin-3-yl]-N-methyl-isobutyramide as a white solid and 11
mg (25%) of the second diastereomeric racemate of
2-(3,5-bis-trifluoromethyl-
-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda-
..sup.4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide as a
white solid. The assignement of the relative configuration of the
two diastereomeric racemates was not possible.
[2483] (3RS,4RS)- or
(1RS,4SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4--
fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolid-
in-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2484] MS m/e (%): 632 (M+H.sup.+, 100)
[2485] (1RS,4SR)- or
(1RS,4RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4--
fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolid-
in-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2486] MS m/e (%): 632 (M+H.sup.+, 100)
EXAMPLE 350
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(4-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiazolidin-3-yl)-pyridin-3-yl]-
-N-methyl-isobutyramide
[2487] The title compound was obtained as an off-white solid in 83%
yield from
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[4-(tert-butyl-dimethyl-
-silanyloxymethyl)-thiazolidin-3-yl]-4-(4-fluoro-2-methyl-phenyl)-pyridin--
3-yl]-N-methyl-isobutyramide after flash chromatography according
to the procedure described above for the preparation of
(1RS,4RS)-2-(3,5-bis-tri-
fluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydroxymethyl-1--
oxo-l.lambda..sup.4-thiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyramide
and
(1RS,4SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(4-hydroxymethyl-1-oxo-l.lambda..sup.4-thiazolidin-3-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide (step f)) using two instead of one
molar equivalents of 3-chloroperbenzoic acid.
[2488] MS m/e (%): 648 (M+H.sup.+, 100)
EXAMPLE 351
(1S,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(8,8-dioxo-8.lambda..sup.6-
-thia-3-aza-bicyclo
[3.2.1]oct-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin--
3-yl]-N-methyl-isobutyramide
[2489]
a)(1S,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methy-
l-phenyl)-6-8-thia-3-aza-bicyclo[3.2.1]oct-3-yl-pyridin-3-yl]-N-methyl-iso-
butyramide
[2490] The title compound was obtained as a light yellow viscous
oil in 22% yield after flash chromatography according to the
procedure described above for the preparation of
(2R,3S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[4-(4-fluoro-2-methyl-phenyl)-6-(3-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-N-methyl-isobutyramide (Example 155) using
(1S,5R)-8-thia-3-azabicyclo[3.2.1]octane hydrochloride instead of
(2R,3S)-2-(hydroxymethyl)-3-hydroxypyrrolidine.
[2491] MS m/e (%): 626 (M+H.sup.+, 100)
[2492] b)
(1S,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(8,8-dioxo-8.lam-
bda..sup.6-thia-3-aza-bicyclo
[3.2.1]oct-3-yl)-4-(4-fluoro-2-methyl-phenyl-
)-pyridin-3-yl]-N-methyl-isobutyramide
[2493] The title compound was obtained as an off-white solid in 42%
yield after flash chromatography according to the procedure
described above for the preparation of
(S)-2-methanesulfonylmethyl-pyrrolidine-1-carboxylic acid benzyl
ester (Example 307a)) using (1S,5R)-2-(3,5-bis-trifluoromethy-
l-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-8-thia-3-aza-bicyclo[3.2.1]oct-
-3-yl-pyridin-3-yl]-N-methyl-isobutyramide instead of
(S)-2-methylsulfanylmethyl-pyrrolidine-1-carboxylic acid benzyl
ester.
[2494] MS m/e (%): 658 (M+H.sup.+, 100)
EXAMPLE 352
(+)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-l.l-
ambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2495] The title compound was obtained as a white solid by
preparative HPLC separation of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(3-hydrox-
ymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3--
yl]-N-methyl-isobutyramide (Example 178) on a Chiralpak AD column
(heptane/ethanol 85:15).
[2496] MS m/e (%): 644 (M+H.sup.+, 100)
EXAMPLE 353
(-)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-l.lambda..sup-
.6-dioxo-l.lambda..sup.6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-met-
hyl-isobutyramide
[2497] The title compound was obtained in 81% enantiomeric excess
as a white solid by preparative HPLC separation of
(RS)-2-(3,5-bis-trifluorome-
thyl-phenyl)-N-[6-(3-hydroxymethyl-1,1-dioxo-l.lambda..sup.6-thiomorpholin-
-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide (Example 178)
on a Chiralpak AD column (heptane/ethanol 85:15).
[2498] MS m/e (%): 644 (M+H.sup.+, 100)
EXAMPLE 354
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6--
(1-oxo-l.lambda..sup.4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl-isobuty-
ramide and
EXAMPLE 355
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6-[1,4]th-
iazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2499]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-[1,4]thiazepan-4-yl-pyridin-3-yl]-N-methyl-isobutyramide
[2500] The title compound was obtained as a white solid in 41%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-methy-
l-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-yl]-
-N-methyl-isobutyramide (Example 323) using [1,4]thiazepane
hydrochloride instead of 4-(trifluoromethyl)piperidine
hydrochloride.
[2501] MS m/e (%): 614 (M+H.sup.+, 100)
[2502] b)
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-(1-oxo-l.lambda..sup.4-11,41
thiazepan-4-yl)-pyridin-3-yl]-N-met- hyl-isobutyramide and
[2503]
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6--
[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide
[2504] To a solution of 0.11 g (0.18 mmol)
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-[1,4]thiazepan-4-yl-pyridin-3-yl]-N--
methyl-isobutyramide in 2 ml dichloromethane were added 63 mg (70%,
0.27 mmol) 3-chloroperbenzoic acid at room temperature. The
reaction mixture was stirred over night. Dilution with a 2 M
aqueous solution of sodium carbonate was followed by extraction
with three portions of dichloromethane. The combined organic
extracts were dried over sodium sulphate and concentrated. Flash
column chromatography gave 71 mg (66%) of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(1-oxo-l.lambda..sup.4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide as a white solid and 32 mg (29%) of
2-(3,5-bis-trifluoromethyl--
phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6-[1,4]thiazepan-4-yl)-4-(4-fluoro-2-
-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide as a white
solid.
[2505]
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phe-
nyl)-6-(1-oxo-l.lambda..sup.4-[1,4]thiazepan-4-yl)-pyridin-3-yl]-N-methyl--
isobutyramide: MS m/e (%): 630 (M+H.sup.+, 100)
[2506]
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6--
[1,4]thiazepan-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide: MS m/e (%): 646 (M+H.sup.+, 100)
EXAMPLE 356
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup.6-[1,3]th-
iazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2507]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl-
)-6-(3-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2508] A mixture of 2.0 g (3.8 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)-N--
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e and 5.6 g (75 mmol) 3-amino-1-propanol was heated at 180.degree.
C. under microwave irradiation for 40 min. Dilution with water was
followed by extraction with three portions of tert-butyl methyl
ether. The combined organic extracts were dried over sodium sulfate
and concentrated in vacuo. Flash chromatography gave 1.9 g (87%) of
the title compound as a white solid.
[2509] MS m/e (%): 572 (M+H.sup.+, 100)
[2510] b) Thioacetic acid
3-[5-[2-(3,5-bis-trifluoromethyl-phenyl)-2-methy-
l-propionyl]-methyl-amino]-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamino
1-propyl ester
[2511] The title compound was obtained as a white solid in 69%
yield after flash chromatography according to the procedure
described above for the preparation of (RS)-thioacetic acid
2-[5-{[2-(3,5-bis-trifluoromethyl-phe-
nyl)-2-methyl-propionyl]-methyl-amino}-4-(4-fluoro-2-methyl-phenyl)-pyridi-
n-2-ylamino]-3-(tert-butyl-dimethyl-silanyloxy)-propyl ester
(Example 349 b)) using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phen-
yl)-6-(3-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
instead of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-[2-(tert-butyl-dimethyl-s-
ilanyloxy)-1-hydroxymethyl-ethylamino]-4-(4-fluoro-2-methyl-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide.
[2512] MS m/e (%): 630 (M+H.sup.+, 100)
[2513] c)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(3-mercapto-propylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2514] To a solution of 1.3 g (2.0 mmol) thioacetic acid
3-[5-{[2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-methyl-amin-
o}-4-(4-fluoro-2-methyl-phenyl)-pyridin-2-ylamino]-propyl ester in
20 ml methanol were added 5 ml of a 25% aqueous solution of
ammonium hydroxide. The reaction mixture was heated at 50.degree.
C. for 1 h. After cooling to room temperature the mixture was
acidified with 1 N aqueous hydrochloric acid solution and extracted
with three portions of tert-butyl methyl ether. The combined
organic layers were dried over sodium sulfate and concentrated in
vacuo to give the crude title compound in quantitative yield as a
light yellow solid.
[2515] MS m/e (%): 588 (M+H.sup.+, 100)
[2516] d)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-[1,3]thiazinan-3-yl-pyridin-3-yl]-N-methyl-isobutyramide
[2517] The title compound was obtained as a white solid in 68%
yield after flash chromatography according to the procedure
described above for the preparation of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-m-
ethyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide (Example 342) using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(-
4-fluoro-2-methyl-phenyl)-6-(3-mercapto-propylamino)-pyridin-3-yl]-N-methy-
l-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluo-
ro-2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-
-N-methyl-isobutyramide.
[2518] MS m/e (%): 600 (M+H.sup.+, 100)
[2519] e)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-l.lambda..sup-
.6-[1,3]thiazinan-3-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methy-
l-isobutyramide
[2520] The title compound was obtained as a white solid in 73%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-
-phenyl)-6-(3-methanesulfonyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-isobut-
yramide (Example 324 b)) using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4--
fluoro-2-methyl-phenyl)-6-[1,3]thiazinan-3-yl-pyridin-3-yl]-N-methyl-isobu-
tyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(3-methylsulfanyl-azetidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide.
[2521] MS m/e (%): 632 (M+H.sup.+, 100)
EXAMPLE 357
N-[6-(2-Amino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,-
5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[2522] A mixture of 1.0 g (1.9 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)-N--
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e and 5.0 ml (75 mmol) ethylenediamine was heated at 130.degree. C.
for 6 h. After cooling to room temperature the reaction mixture was
diluted with 20 ml tert-butyl methyl ether and washed with 20 ml of
a saturated aqueous solution of sodium carbonate, 20 ml of water
and 20 ml of a saturated aqueous solution of sodium carbonate. The
combined organic layers were dried over sodium sulfate,
concentrated in vacuo and purified by flash chromatography to give
0.92 g (88%) of the title compound as a white foam.
[2523] MS m/e (%): 557 (M+H.sup.+, 100)
EXAMPLE 358
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-me-
thanesulfonylamino-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2524] The title compound was obtained as a white foam in 89% yield
after flash chromatography according to the procedure described
above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(3-methanesulfonylamino-pyrrolidin-1-yl)-pyridin-3-yl]-N-me-
thyl-isobutyramide (Example 317) using
N-[6-(2-amino-ethylamino)-4-(4-fluo-
ro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-met-
hyl-isobutyramide instead of
(R)-N-[6-(3-amino-pyrrolidin-1-yl)-4-(4-fluor-
o-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-meth-
yl-isobutyramide.
[2525] MS m/e (%): 633 ([M-H.sup.+].sup.-, 74)
EXAMPLE 359
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(3-me-
thanesulfonyl-imidazolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2526] To a solution of 0.20 g (0.36 mmol)
N-[6-(2-amino-ethylamino)-4-(4--
fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-methyl-isobutyramide in 2 ml 1,2-dichloroethane were added 42 mg
(0.48 mmol) paraformaldehyde and 0.13 g (1.1 mmol) magnesium
sulfate. After stirring at room temperature for 18 h 0.14 g (1.1
mmol) N,N-diisopropylethylamine, 2 mg (0.02 mmol)
4-(N,N-dimethylamino)pyridine and 62 mg (0.54 mmol) methanesulfonyl
chloride were added. The reaction mixture was heated to 80.degree.
C. and kept at this temperature for 4 h. After cooling to room
temperature the reaction mixture was diluted with 20 ml tert-butyl
methyl ether and washed with two 20-ml portions of a saturated
aqueous solution of sodium carbonate. The combined organic layers
were dried over sodium sulfate, concentrated in vacuo and purified
by flash chromatography to give 93 mg (40%) of the title compound
as a white foam.
[2527] MS m/e (%): 647 (M+H.sup.+, 100)
EXAMPLE 360
N-[6-(2-Acetylamino-ethylamino)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-
-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[2528] The title compound was obtained as an off-white solid in 48%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(3-hydroxy-propylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e (Example 356a)) using N-acetylethylenediamine instead of
3-amino-1-propanol.
[2529] MS m/e (%): 599 (M+H.sup.+, 100)
EXAMPLE 361
N-[6-(3-Acetyl-imidazolidin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-y-
l]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide
[2530] To a solution of 50 mg (0.090 mmol)
N-[6-(2-amino-ethylamino)-4-(4--
fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-methyl-isobutyramide in 2 ml 1,2-dichloroethane were added 3 mg
(0.1 mmol) paraformaldehyde and 32 mg (0.27 mmol) magnesium
sulfate. After stirring at room temperature over night another 3 mg
(0.1 mmol) paraformaldehyde were added and the reaction mixture was
heated to 85.degree. C. After 1 h the reaction mixture was cooled
to room temperature and treated with 14 mg (0.13 mmol)
triethylamine and 11 mg (0.13 mmol) acetyl chloride. Conversion was
monitored by thin layer chromatography. After complete consumption
of the starting material the reaction mixture was diluted with
water and extracted with three portions of dichloromethane. The
combined organic layers were dried over sodium sulfate,
concentrated in vacuo and purified by flash chromatography to give
40 mg (73%) of the title compound as an off-white solid.
[2531] MS m/e (%): 611 (M+H.sup.+, 100)
EXAMPLE 362
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2532]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-
-o-tolyl-pyridin-3-yl)-isobutyramide
[2533] The crude title compound was obtained as an off-white solid
in 98% yield after extraction according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-(4-fluoro-phenyl)--
6-[(2-hydroxy-ethyl)-methyl-amino]-pyridin-3-yl}-N-methyl-isobutyramide
(Example 115) using
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-to-
lyl-pyridin-3-yl)-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide and piperazine instead of
2-(methylamino)ethanol.
[2534] MS m/e (%): 565 (M+H.sup.+, 100)
[2535] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-piper-
azin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2536] To a solution of 0.16 g (0.31 mmol)
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
and 38 mg (0.38 mmol) triethylamine in 4 ml dichloromethane were
added 38 mg (0.33 mmol) methanesulfonyl chloride at 0.degree. C.
After completed addition the reaction mixture was allowed to warm
to room temperature. Conversion was monitored by thin layer
chromatography. After complete consumption of the starting material
the reaction mixture was diluted with water and extracted with
three portions of tert-butyl methyl ether. The combined organic
layers were dried over sodium sulfate and concentrated in vacuo.
Flash cholumn chromatography gave 0.15 g (75%) of the title
compound as a white solid.
[2537] MS m/e (%): 643 (M+H.sup.+, 100)
EXAMPLE 363
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulf-
onyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2538] The title compound was obtained as a white solid in 73%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-pheny-
l)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide in
step a).
[2539] MS m/e (%): 663 (M+H.sup.+, 100)
EXAMPLE 364
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-chloro-2-methyl-phenyl)-6-(4-me-
thanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2540] The title compound was obtained as a white solid in 79%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-chloro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4K) instead
of
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide in step a).
[2541] MS m/e (%): 677 (M+H.sup.+, 100)
EXAMPLE 365
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(3-fluoro-2-methyl-phenyl)-6-(4-me-
thanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2542] The title compound was obtained as a white solid in 77%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(3-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4E) instead
of
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide in step a).
[2543] MS m/e (%): 661 (M+H.sup.+, 100)
EXAMPLE 366
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-me-
thanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2544] The title compound was obtained as a white solid in 83%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4D) instead
of
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide in step a).
[2545] MS m/e (%): 661 (M+H.sup.+, 100)
EXAMPLE 367
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-ethanesulfonyl-piperazin-1-yl)--
4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[2546] The title compound was obtained as a white solid in 78%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4D) instead
of
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide in step a) and ethanesulfonyl chloride instead
of methanesulfonyl chloride in step b).
[2547] MS m/e (%): 675 (M+H.sup.+, 100)
EXAMPLE 368
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-chloromethanesulfonyl-piperazin-
-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[2548] The title compound was obtained as a white solid in 84%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4D) instead
of
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide in step a) and chloromethylsulfonyl chloride
instead of methanesulfonyl chloride in step b).
[2549] MS m/e (%): 695 (M+H.sup.+, 100)
EXAMPLE 369
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-dimethylsulfamoyl-piperazin-1-y-
l)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[2550] The title compound was obtained as a white solid in 84%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide (Intermediate 4D) instead
of
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide in step a) and dimethylsulfamoyl chloride
instead of methanesulfonyl chloride in step b).
[2551] MS m/e (%): 695 (M+H.sup.+, 100)
EXAMPLE 370
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2552]
a)(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-ph-
enyl)-6-(3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2553] A mixture of 0.20 g (0.38 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 0.11 g (1.1 mmol) (R)-2-methylpiperazine and 0.10 g (0.72
mmol) potassium carbonate in 0.3 ml dimethyl sulfoxide was heated
at 180.degree. C. under microwave irradiation in a sealed tube for
30 min. After cooling to room temperature the reaction mixture was
diluted with a 0.3 M aqueous solution of sodium hydroxide and
extracted with three portions of tert-butyl methyl ether. The
combined organic extracts were dried over sodium sulfate and
concentrated. Flash column chromatography gave 0.12 g (51%) of the
title compound as an off-white solid.
[2554] MS m/e (%): 597 (M+H.sup.+, 100)
[2555] b)
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide
[2556] The title compound was obtained as a white solid in 87%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
(Example 362 b)) using
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-met-
hyl-phenyl)-6-(3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-
-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
[2557] MS m/e (%): 675 (M+H.sup.+, 100)
EXAMPLE 371
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2558] a)(R)-1-Benzyl-3-methyl-piperazine
[2559] A mixture of 1.0 g (10 mmol) (R)-2-methylpiperazine, 1.3 g
(10 mmol) benzyl chloride and 4.1 g (30 mmol) potassium carbonate
in 10 ml ethanol was heated at reflux over night. After cooling to
room temperature the reaction mixture was diluted with a 0.5 M
aqueous solution of sodium hydroxide and extracted with three
portions of dichloromethane. The combined organic extracts were
dried over sodium sulfate and concentrated. Flash column
chromatography gave 0.93 g (49%) of the title compound as an
off-white solid.
[2560] MS m/e (%): 191 (M+H.sup.+, 100)
[2561] b)
(R)-N-[6-(4-Benzyl-2-methyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-
-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobuty-
ramide
[2562] A mixture of 0.20 g (0.38 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 93 mg (0.49 mmol) (R)-1-benzyl-3-methyl-piperazine, 0.01 g
(0.03 mmol) cetyltrimethyl-ammonium bromide, 0.038 g (0.074 mmol)
bis(tri-t-butylphosphine)palladium(0), 0.05 ml NaOH 50% and 2 ml
toluene was degassed by two freeze-thaw cycles. The reaction
mixture was heated under argon at 90.degree. C. for 48 h. After
cooling to room temperature the mixture was diluted with water and
brine and extracted with three portions of tert-butyl methyl ether.
The combined organic layers were dried over sodium sulphate and
concentrated in vacuo. Flash column chromatography gave 95 mg (37%)
of the title compound as a light yellow solid.
[2563] MS m/e (%): 687 (M+H.sup.+, 100)
[2564] c)
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2565] A solution of 0.11 g (0.17 mmol)
(R)-N-[6-(4-benzyl-2-methyl-pipera-
zin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluorom-
ethyl-phenyl)-N-methyl-isobutyramide in 3 ml acetic acid was
deoxygenated by three cycles of evacuation and flushing with argon.
After addition of 0.02 g palladium on charcoal (10%) the reaction
vessel was evacuated and filled with hydrogen gas. The reaction
mixture was stirred at room temperature under an atmosphere of
hydrogen for 3 h. The reaction mixture was filtered over decalite
followed by washing with tert-butyl methyl ether. The filtrate was
washed with a 2 M aqueous solution of sodium hydroxide. The aqueous
layer was extracted with three portions of tert-butyl methyl ether.
The combined organic layers were dried over sodium sulfate and
concentrated in vacuo to give 98 mg (98%) of the crude title
compound as an off-white solid, which was used in the next step
without further purification.
[2566] MS m/e (%): 597 (M+H.sup.+, 100)
[2567] d)
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide
[2568] The title compound was obtained as a white solid in 87%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
(Example 362 b)) using
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-met-
hyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyrami-
de instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-
-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
[2569] MS m/e (%): 675 (M+H.sup.+, 100)
EXAMPLE 372
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methane-
sulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2570] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-pheny-
l)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
(Intermediate 4A) instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chlo-
ro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in step b).
[2571] MS m/e (%): 677 (M+H.sup.+, 100)
EXAMPLE 373
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2-methyl-pi-
perazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2572] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-pheny-
l)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide
(Intermediate 4G) instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chlo-
ro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in step b).
[2573] MS m/e (%): 657 (M+H.sup.+, 100)
EXAMPLE 374
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2574] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide (Example 370) using
(S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step
a).
[2575] MS m/e (%): 675 (M+H.sup.+, 100)
EXAMPLE 375
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(-4-methan-
esulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2576] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide (Example 370) using
(S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step a)
and
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridi-
n-3-yl]-N-methyl-isobutyramide (Intermediate 4A) instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-pheny-
l)-pyridin-3-yl]-N-methyl-isobutyramide in step b).
[2577] MS m/e (%): 677 (M+H.sup.+, 100)
EXAMPLE 376
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(-4-methanesulfonyl-3-methyl-p-
iperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2578] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide (Example 370) using
(S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step a)
and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide (Intermediate 4G) instead of
2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-
-isobutyramide in step b).
[2579] MS m/e (%): 657 (M+H.sup.+, 100)
EXAMPLE 377
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2580] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide using (S)-2-methylpiperazine
instead of (R)-2-methylpiperazine in step a).
[2581] MS m/e (%): 675 (M+H.sup.+, 100)
EXAMPLE 378
(2RS,5SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide
[2582]
a)(2RS,5SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(2,5-dimethyl-p-
iperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobuty-
ramide
[2583] A mixture of 0.20 g (0.38 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)--
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyram-
ide, 87 mg (0.75 mmol) (2RS,5SR)-dimethyl-piperazine, 0.01 g (0.03
mmol) cetyltrimethyl-ammonium bromide, 0.01 g (0.02 mmol)
bis(tri-t-butylphosphine)palladium(0), 0.075 ml NaOH 50% and 3 ml
toluene was degassed by two freeze-thaw cycles. The reaction
mixture was heated under argon at 90.degree. C. for 48 h. After
cooling to room temperature the mixture was diluted with water and
brine and extracted with three portions of tert-butyl methyl ether.
The combined organic layers were dried over sodium sulphate and
concentrated in vacuo. Flash column chromatography gave 96 mg (42%)
of the title compound as a light yellow solid.
[2584] MS m/e (%): 611 (M+H.sup.+, 100)
[2585] b)
(2RS,5SR)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide
[2586] The title compound was obtained as a white solid in 69%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
(Example 362 b)) using
(2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(2,5-dime-
thyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-p-
iperazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
[2587] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 379
(2S,6R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(4-methanesulfonyl-2,6-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl--
isobutyramide
[2588] The title compound was obtained as a white solid in 1%
overall yield after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide using
cis-2,6-dimethyl-piperazine instead of (R)-2-methylpiperazine in
step a).
[2589] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 380
(3S,5R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(4-methanesulfonyl-3,5-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl--
isobutyramide
[2590] The title compound was obtained as a white solid in 56%
yield after flash chromatography according to the procedures
described above for the preparation of
(2RS,5SR)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluor-
o-2-methyl-phenyl)-6-(4-methanesulfonyl-2,5-dimethyl-piperazin-1-yl)-pyrid-
in-3-yl]-N-methyl-isobutyramide using cis-2,6-dimethyl-piperazine
instead of (2RS,5SR)-dimethyl-piperazine in step a).
[2591] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 381
(1S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-((1S,4S)-5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-pyridin-3-
-yl]-N-methyl-isobutyramide
[2592]
a)(1S,4S)-N-l.lambda..sup.6-(5-Benzyl-2,5-diaza-bicyclo[2.2.11
hept-2-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluor-
omethyl-phenyl)-N-methyl-isobutyramide
[2593] The title compound was obtained as an off-white solid in 85%
yield after flash chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4'-(4-fluoro-2-m-
ethyl-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-
-yl]-N-methyl-isobutyramide using
(1S,4S)-(+)-2-benzyl-2,5-diazabicyclo[2.- 2.1]heptane
dihydrobromide instead of 4-(trifluoromethyl)piperidine
hydrochloride.
[2594] MS m/e (%): 685 (M+H.sup.+, 100)
[2595] b)
(1S,4S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-meth-
yl-phenyl)-6-(5-methanesulfonyl-2,5-diaza-bicyclo[2.2.1]hept-2-yl)-pyridin-
-3-yl]-N-methyl-isobutyramide
[2596] The title compound was obtained as a white solid in 80%
yield after flash chromatography according to the procedures
described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-
-methyl-isobutyramide (Example 371 steps c) and d)) using
(1S,4S)-N-[6-(5-benzyl-2,5-diaza-bicyclo
[2.2.1]hept-2-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide instead of
(R)-N-[6-(4-benzyl-2-methyl-piperazin-1-yl)-4-(4-f-
luoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N--
methyl-isobutyramide in step c).
[2597] MS m/e (%): 673 (M+H.sup.+, 100)
EXAMPLE 382
(1R,5S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(8-methanesulfonyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-yl]-N-me-
thyl-isobutyramide
[2598] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(1S,4S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-
-[4-(4-fluoro-2-methyl-phenyl)-6-(5-methanesulfonyl-2,5-diaza-bicyclo[2.2.-
1]hept-2-yl)-pyridin-3-yl]-N-methyl-isobutyramide using
(1R,5S)-8-benzyl-3,8-diazabicyclo[3.2.1]octane dihydrochloride
instead of (1S,4S)-(+)-2-benzyl-2,5-diazabicyclo[2.2.1]heptane
dihydrobromide in step a).
[2599] MS m/e (%): 687 (M+H.sup.+, 100)
EXAMPLE 383
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide
[2600]
a)(S)-N-[6-(2-Benzyloxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl--
phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyr-
amide
[2601] The title compound was obtained as a light brown solid in
comparable yields according to the procedures described above for
the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide (Example 371c)) using
(S)-1-benzyl-3-(benzyloxymethyl)piperazine (prepared as described
in WO2001009111) instead of (R)-1-benzyl-3-methyl-piperazine in
step b).
[2602] MS m/e (%): 703 (M+H.sup.+, 100)
[2603] b)
(S)-N-[6-(2-Benzyloxymethyl-4-methanesulfonyl-piperazin-1-yl)-4--
(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide
[2604] The title compound was obtained as a white solid in 89%
yield after flash chromatography according to the procedures
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
(Example 362 b)) using
(S)-N-[6-(2-benzyloxymethyl-piperazin-1-yl)-4-(4-fluoro-2-m-
ethyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-is-
obutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-pi-
perazin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
[2605] MS m/e (%): 781 (M+H.sup.+, 100)
[2606] c)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]--
N-methyl-isobutyramide
[2607] The title compound was obtained as an off-white solid in 72%
yield after flash chromatography according to the procedures
described above for the preparation of
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-
-chloro-phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isob-
utyramide (Example 152 b)) using
(S)-N-[6-(2-benzyloxymethyl-4-methanesulf-
onyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-
-trifluoromethyl-phenyl)-N-methyl-isobutyramide instead of
(1R,2R)-N-[6-(2-benzyloxy-cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-
-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide.
[2608] MS m/e (%): 691 (M+H.sup.+, 100)
EXAMPLE 384
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
4-formyl-2-hydroxymethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide
[2609] A mixture of 0.35 ml (3.7 mmol) acetic anhydride and 0.17 ml
(4.6 mmol) formic acid was heated at 50.degree. C. for 2 h. After
cooling to room temperature a portion of 0.08 ml of this mixture
was added to 0.5 ml THF. A solution of 0.10 g (0.14 mmol)
(S)-N-[6-(2-benzyloxymethyl-piperaz-
in-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluorome-
thyl-phenyl)-N-methyl-isobutyramide (Example 383a)) in 1 ml THF was
added dropwise at 0.degree. C. Conversion was monitored by thin
layer chromatography. After complete consumption of the starting
material the reaction mixture was diluted with water and extracted
with three portions of dichloromethane. The combined organic
extracts were dried over sodium sulfate and concentrated in vacuo
to give 0.11 g of crude
(S)-N-[6-(2-benzyloxymethyl-4-formyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-
-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobuty-
ramide as a light yellow solid.
[2610] The title compound was obtained as a white solid in 58%
yield after flash chromatography according to the procedure
described above for the preparation of
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro--
phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e (Example 152 b)) using crude
(S)-N-[6-(2-benzyloxymethyl-4-formyl-pipera-
zin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluorom-
ethyl-phenyl)-N-methyl-isobutyramide instead of
(1R,2R)-N-[6-(2-benzyloxy--
cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluorome-
thyl-phenyl)-N-methyl-isobutyramide.
[2611] MS m/e (%): 641 (M+H.sup.+, 100)
EXAMPLE 385
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-cyclopropanecarbonyl-2-hydr-
oxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-met-
hyl-isobutyramide
[2612] The title compound was obtained as an off-white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin--
1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using
cyclopropanecarboxylic acid chloride instead of methanesulfonyl
chloride in step b).
[2613] MS m/e (%): 681 (M+H.sup.+, 100)
EXAMPLE 386
(S)-N-[6-(4-Acetyl-2-hydroxymethyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-ph-
enyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyram-
ide
[2614] The title compound was obtained as an off-white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-4-methanesulfonyl-piperazin--
1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using acetic anhydride
instead of methanesulfonyl chloride in step b).
[2615] MS m/e (%): 655 (M+H.sup.+, 100)
EXAMPLE 387
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxymethyl-piper-
azin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyrami-
de
[2616]
a)(S)-N-[6-(2-Benzyloxymethyl-4-ethyl-piperazin-1-yl)-4-(4-fluoro-2-
-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl--
isobutyramide
[2617] The title compound was obtained as a light brown solid in 5%
yield in step c) according to the procedures described above for
the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide (Example 371c)) using
(S)-1-benzyl-3-(benzyloxymethyl)piperazine (prepared as described
in WO2001009111) instead of (R)-1-benzyl-3-methyl-piperazine in
step b) and ethanol instead of acetic acid as a solvent in step
c).
[2618] MS m/e (%): 731 (M+H.sup.+, 100)
[2619] b)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-ethyl-2-hydroxyme-
thyl-piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-i-
sobutyramide
[2620] The title compound was obtained as a white solid in 58%
yield after flash chromatography according to the procedure
described above for the preparation of
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro--
phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e (Example 152 b)) using
(S)-N-[6-(2-benzyloxymethyl-4-ethyl-piperazin-1-y-
l)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-p-
henyl)-N-methyl-isobutyramide instead of
(1R,2R)-N-[6-(2-benzyloxy-cyclope-
ntylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-ph-
enyl)-N-methyl-isobutyramide.
[2621] MS m/e (%): 641 (M+H.sup.+, 100)
EXAMPLE 388
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methylsulfa-
moyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2622]
a)2-[5-{[2-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-propionyl]-met-
hyl-amino}-4-(2-chloro-phenyl)-pyridin-2-ylamino]-ethanesulfonic
acid
[2623] The title compound was obtained as a light brown solid in
49% yield after flash column chromatography according to the
procedure described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-y-
l]-N-methyl-isobutyramide (Example 165) using
2-(3,5-bis-trifluoromethyl-p-
henyl)-N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramid-
e (Intermediate 4A) instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chl-
oro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and taurine instead of L-prolinol.
[2624] MS m/e (%): 622 ([M-H+].sup.-, 100)
[2625] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-m-
ethylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2626] The title compound was obtained as a white solid in 77%
yield after flash column chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-dimethylsu-
lfamoyl-4'-(4-fluoro-2-methyl-phenyl)-3,4,5,6-tetrahydro-2H-[1,2']bipyridi-
nyl-5'-yl]-N-methyl-isobutyramide (Example 331 step c)) using a 12
M aqueous solution of N-methylamine instead of a solution of
dimethylamine.
[2627] MS m/e (%): 637 (M+H.sup.+, 100)
EXAMPLE 389
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-methyl-1,1--
dioxo-l.lambda..sup.6-thiadiazinan-4-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide
[2628] The title compound was obtained as a white solid in 31%
yield after flash chromatography according to the procedure
described above for the preparation of
(RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-m-
ethyl-phenyl)-6-(4-hydroxymethyl-oxazolidin-3-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide (Example 342) using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(-
2-chloro-phenyl)-6-(2-methylsulfamoyl-ethylamino)-pyridin-3-yl]-N-methyl-i-
sobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro--
2-methyl-phenyl)-6-(2-hydroxy-1-hydroxymethyl-ethylamino)-pyridin-3-yl]-N--
methyl-isobutyramide.
[2629] MS m/e (%): 649 (M+H.sup.+, 100)
EXAMPLE 390
(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-oxo-2.-
lambda..sup.4-[1,2,3]oxathiazolidin-3-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2630] To a solution of 0.20 g (0.36 mmol)
2-(3,5-bis-trifluoromethyl-phen-
yl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-
-isobutyramide in a 5 ml dichloromethane were added consecutively
0.11 g (1.1 mmol) triethylamine and 0.05 g (0.4 mmol) thionyl
chloride at room temperature. After 1 h the reaction mixture was
diluted with water and extracted with three portions of
dichloromethane. The combined organic extracts were dried over
sodium sulfate and concentrated in vacuo. Flash column
chromatography gave 0.17 g (77%) of the title compound as a white
solid.
[2631] MS m/e (%): 606 (M+H.sup.+, 100)
EXAMPLE 391
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide
[2632]
a)(S)-4-Benzyl-2-benzyloxymethyl-1-methanesulfonyl-piperazine
[2633] The crude title compound was obtained as a light brown oil
in quantitative yield after extraction according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-m-
ethanesulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyram-
ide (Example 362 b)) using
(S)-1-benzyl-3-(benzyloxymethyl)piperazine instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-y-
l-4-o-tolyl-pyridin-3-yl)-isobutyramide.
[2634] MS m/e (%): 375 (M+H.sup.+, 100)
[2635] b) (S)-2-Benzyloxymethyl-1-methanesulfonyl-piperazine
[2636] The crude title compound was obtained as a light brown oil
in 60% yield after extraction according to the procedure described
above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-me-
thyl-phenyl)-6-(2-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyram-
ide (Example 371c)) using
(S)-4-benzyl-2-benzyloxymethyl-1-methanesulfonyl- -piperazine
instead of (R)-N-[6-(4-benzyl-2-methyl-piperazin-1-yl)-4-(4-fl-
uoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-m-
ethyl-isobutyramide.
[2637] MS m/e (%): 285 (M+H.sup.+, 100)
[2638] c)
(S)-N-[6-(3-Benzyloxymethyl-4-methanesulfonyl-piperazin-1-yl)-4--
(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl-
)-N-methyl-isobutyramide
[2639] The title compound was obtained as a white solid in 55%
yield after flash chromatography according to the procedure
described above for the preparation of
(R)-N-[6-(4-benzyl-2-methyl-piperazin-1-yl)-4-(4-fluoro-2--
methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-i-
sobutyramide (Example 371 b)) using
(S)-2-benzyloxymethyl-1-methanesulfony- l-piperazine instead of
(R)-1-benzyl-3-methyl-piperazine.
[2640] MS m/e (%): 781 (M+H.sup.+, 100)
[2641] d)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-p-
henyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]--
N-methyl-isobutyramide
[2642] The title compound was obtained as a white solid in 96%
yield after flash chromatography according to the procedure
described above for the preparation of
(1R,2R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(2-chloro--
phenyl)-6-(2-hydroxy-cyclopentylamino)-pyridin-3-yl]-N-methyl-isobutyramid-
e (Example 152 b)) using
(S)-N-[6-(3-benzyloxymethyl-4-methanesulfonyl-pip-
erazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluo-
romethyl-phenyl)-N-methyl-isobutyramide instead of
(1R,2R)-N-[6-(2-benzylo-
xy-cyclopentylamino)-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-bis-trifluor-
omethyl-phenyl)-N-methyl-isobutyramide.
[2643] MS m/e (%): 691 (M+H.sup.+, 100)
EXAMPLE 392
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3-hydroxymethyl-4-methanesulf-
onyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2644] The title compound was obtained as white solid in comparable
yields after flash column chromatography according to the
procedures described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin--
1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (R)- instead of
(S)-1-benzyl-3-(benzyloxymethyl)piperazine in step a) and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide (Intermediate 4G) instead of
2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-
-isobutyramide in step c).
[2645] MS m/e (%): 673 (M+H.sup.+, 100)
EXAMPLE 393
(R)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
3-hydroxymethyl-4-methanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-i-
sobutyramide
[2646] The title compound was obtained as white solid in comparable
yields after flash column chromatography according to the
procedures described above for the preparation of
(S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(3-hydroxymethyl-4-methanesulfonyl-piperazin--
1-yl)-pyridin-3-yl]-N-methyl-isobutyramide using (R)- instead of
(S)-1-benzyl-3-(benzyloxymethyl)piperazine in step a).
[2647] MS m/e (%): 691 (M+H.sup.+, 100)
EXAMPLE 394
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-me-
thanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2648]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(3,3-dimethyl-piperazin-1-
-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[2649] The title compound was obtained as a light brown amorphous
resin in 27% yield after flash column chromatography according to
the procedure described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[4'-(4-fluoro-2-methyl-phenyl)-4-trifluoromethyl-3,4,5,6-tetrahydro-2H--
[1,2']bipyridinyl-5'-yl]-N-methyl-isobutyramide (Example 323) using
2,2-dimethyl-piperazine di-acetic acid salt instead of
4-(trifluoromethyl)piperidine hydrochloride.
[2650] MS m/e (%): 611 (M+H.sup.+, 100)
[2651] b)
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methy-
l-isobutyramide
[2652] The title compound was obtained as a white solid in 69%
yield after flash column chromatography according to the procedure
described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methane-
sulfonyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
(Example 362 b)) using
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(dimethyl--
piperazin-1-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobut-
yramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-pipera-
zin-1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide.
[2653] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 395
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-3,3-dimethyl-pi-
perazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2654] The title compound was obtained as white solid in comparable
yields after flash column chromatography according to the
procedures described above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-(4-f-
luoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3,3-dimethyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide using
2-(3,5-bis-trifluoromethyl-pheny-
l)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide
(Intermediate 4G) instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chlo-
ro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in step a).
[2655] MS m/e (%): 671 (M+H.sup.+, 100)
EXAMPLE 396
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phenyl)-6-(-4-
-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyra-
mide
[2656]
a)2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-[2-(tert-butyl-dimethyl-s-
ilanyloxymethyl)-phenyl]-6-((S)-4-methanesulfonyl-3-methyl-piperazin-1-yl)-
-pyridin-3-yl]-N-methyl-isobutyramide
[2657] The title compound was obtained as a white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-3-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide (Example 370) using
(S)-2-methylpiperazine instead of (R)-2-methylpiperazine in step a)
and
2-(3,5-bis-trifluoromethyl-phenyl)-N-{4-[2-(tert-butyl-dimethyl-silanylox-
ymethyl)-phenyl]-6-chloro-pyridin-3-yl}-N-methyl-isobutyramide
(Intermediate 4L) instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-chlo-
ro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
in step b).
[2658] MS m/e (%): 787 (M+H.sup.+, 100)
[2659] b)
(S)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(2-hydroxymethyl-phe-
nyl)-6-(-4-methanesulfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-
-isobutyramide
[2660] A solution of 73 mg (0.093 mmol)
2-(3,5-bis-trifluoromethyl-phenyl)-
-N-[4-[2-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-6-((S)-4-methanesu-
lfonyl-3-methyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
in 5 ml of a 1 M solution of hydrochloric acid in methanol was
stirred at room temperature. Conversion was monitored by thin layer
chromatography. After complete consumption of the starting material
the reaction mixture was diluted with a 1 M aqueous solution of
sodium hydroxide and extracted with three portions of tert-butyl
methyl ether. The combined organic extracts were dried over sodium
sulfate and concentrated in vacuo. Flash column chromatography gave
62 mg (quantitative) of the title compound as a light yellow
solid.
[2661] MS m/e (%): 673 (M+H.sup.+, 100)
EXAMPLE 397
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-me-
thanesulfonyl-2,2-dimethyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyr-
amide
[2662] The title compound was obtained as an off-white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide using 2,2-dimethyl-piperazine
di-acetic acid salt instead of (R)-2-methyl-piperazine in step
a).
[2663] MS m/e (%): 689 (M+H.sup.+, 100)
EXAMPLE 398
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-2,2-dimethyl-pi-
perazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2664] The title compound was obtained as an off-white solid in
comparable yields after flash chromatography according to the
procedures described above for the preparation of
(R)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4--
(4-fluoro-2-methyl-phenyl)-6-(4-methanesulfonyl-2-methyl-piperazin-1-yl)-p-
yridin-3-yl]-N-methyl-isobutyramide using 2,2-dimethyl-piperazine
di-acetic acid salt instead of (R)-2-methyl-piperazine in step a)
and
2-(3,5-bis-trifluoromethyl-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N--
methyl-isobutyramide (Intermediate 4G) instead of
2-(3,5-bis-trifluorometh-
yl-phenyl)-N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-
-isobutyramide in step b).
[2665] MS m/e (%): 671 (M+H.sup.+, 100)
EXAMPLE 399
(S)-2-(3,5-Dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1-yl)-4-o-to-
lyl-pyridin-3-yl]-N-methyl-isobutyramide
[2666] a)
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dimethoxy-phenyl)-N-m-
ethyl-isobutyramide
[2667] The title compound was obtained in an analogous manner to
that described in example 1a) from
(6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-am- ine and
2-(3,5-dimethoxy-phenyl)-2-methyl-propionyl chloride as a white
solid.
[2668] MS m/e (%): 439 (M+H.sup.+, 100).
[2669] b)
(S)-2-(3,5-Dimethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1--
yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2670] The title compound was obtained in an analogous manner to
that described in example 2) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-d-
imethoxy-phenyl)-N-methyl-isobutyramide and L-prolinol as a light
yellow foam.
[2671] MS m/e (%): 504 (M+H.sup.+, 100).
EXAMPLE 400
(2S,4R)-2-(3,5-Dimethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-pyrrolidi-
n-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2672] The title compound was obtained in an analogous manner to
that described in example 3) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-d-
imethoxy-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymet- hyl-pyrrolidine as a light yellow
foam.
[2673] MS m/e (%): 520 (M+H.sup.+, 100).
EXAMPLE 401
2-(3,5-Dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxy-ethy-
lamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2674] a)
N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-2-(3,5-di-
methoxy-phenyl)-N-methyl-isobutyramide
[2675] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyri- din-3-yl]-methyl-amine
and 2-(3,5-dimethoxy-phenyl)-2-methyl-propionyl chloride as a white
solid.
[2676] MS m/e (%): 457 (M+H.sup.+, 100).
[2677] b)
2-(3,5-Dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2678] The title compound was obtained in an analogous manner to
that described in example 1b) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-py-
ridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and
ethanolamine as an off-white foam.
[2679] MS m/e (%): 482 (M+H.sup.+, 100).
EXAMPLE 402
(S)-2-(3,5-Dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hydroxym-
ethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2680] The title compound was obtained in an analogous manner to
that described in example 2) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and
L-prolinol as a white foam.
[2681] MS m/e (%): 522 (M+H.sup.+, 100).
EXAMPLE 403
(2S,4R)-2-(3,5-Dimethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-hydr-
oxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2682] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
[2683] MS m/e (%): 538 (M+H.sup.+, 100).
EXAMPLE 404
(2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-y-
l)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide
[2684] a)
N-[6-Chloro-4-(2-chloro-phenyl)-pyridin-3-yl]-2-(3,5-dimethoxy-p-
henyl)-N-methyl-isobutyramide
[2685] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl]- -methyl-amine and
2-(3,5-dimethoxy-phenyl)-2-methyl-propionyl chloride as a light
yellow solid.
[2686] MS m/e (%): 459 (M+H.sup.+, 100).
[2687] b)
(2S,4R)-N-[4-(2-Chloro-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrr-
olidin-1-yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide
[2688] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(2-chloro-phenyl)-pyridin-3-yl-
]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[2689] MS m/e (%): 540 (M+H.sup.+, 100).
EXAMPLE 405
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxy-ethylamino)-4-o-tolyl-p-
yridin-3-yl]-N-methyl-isobutyramide
[2690] a)
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-2-(3,5-dihydroxy-phenyl)-N-m-
ethyl-isobutyramide
[2691] To a solution of 2.8 g (6.4 mmol)
N-(6-chloro-4-o-tolyl-pyridin-3-y-
l)-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide in 70 ml
CH.sub.2Cl.sub.2 19 ml (19 mmol) BBr.sub.3 (1 M in
CH.sub.2Cl.sub.2) were added at 0.degree. C. The reaction mixture
was allowed to reach ambient temperature and stirred for 15 h After
addition of 50 ml water the mixture was extracted with three
portions of dichloromethane. The combined organic extracts were
dried (Na.sub.2SO.sub.4), filtered and evaporated. The residue was
purified by flash-chromatography (SiO.sub.2,
CH.sub.2Cl.sub.2/methanol) to give 2.5 g (95%) of the title
compound as a white foam.
[2692] MS m/e (%): 409 (M+H.sup.+, 87).
[2693] b)
2-(3,5-Bis-difluoromethoxy-phenyl)-N-(6-chloro-4-o-tolyl-pyridin-
-3-yl)-N-methyl-isobutyramide
[2694] To a solution of 2.5 g (6.1 mmol)
N-(6-chloro-4-o-tolyl-pyridin-3-y-
l)-2-(3,5-dihydroxy-phenyl)-N-methyl-isobutyramide in 60 ml DMF 1.7
g (12 mmol) K.sub.2CO.sub.3 and 1.5 ml (12 mmol) ethyl
chlordifluoroacetate were added and the resulting suspension heated
at 65.degree. C. for 15 h. After cooling to ambient temperature,
the reaction mixture was poured into 250 ml water and extracted
with three portions of CH.sub.2Cl.sub.2. The combined organic
extracts were dried (Na.sub.2SO.sub.4), filtered and evaporated.
The residue was purified by flash-chromatography (SiO.sub.2,
CH.sub.2Cl.sub.2/ethyl acetate) to give 0.71 g (23%) of the title
compound as a colorless viscous oil.
[2695] MS m/e (%): 511 (M+H.sup.+, 100).
[2696] c)
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxy-ethylamino)-4-
-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2697] The title compound was obtained in an analogous manner to
that described in example 1b) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-(6-chl-
oro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and ethanolamine
as an off-white foam.
[2698] MS m/e (%): 536 (M+H.sup.+, 100).
EXAMPLE 406
(2S,4R)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(4-hydroxy-2-hydroxymethyl-
-pyrrolidin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2699] The title compound was obtained in an analogous manner to
that described in example 3) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-(6-chlo-
ro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[2700] MS m/e (%): 592 (M+H.sup.+, 100).
EXAMPLE 407
(S)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(2-hydroxymethyl-pyrrolidin-1--
yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2701] The title compound was obtained in an analogous manner to
that described in example 2) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-(6-chlo-
ro-4-o-tolyl-pyridin-3-yl)-N-methyl-isobutyramide and L-prolinol as
a white foam.
[2702] MS m/e (%): 576 (M+H.sup.+, 100).
EXAMPLE 408
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(2-hy-
droxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2703]
a)2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(4-fluoro-2-meth-
yl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
[2704] The title compound was obtained in an analogous manner to
that described in example 406a), b) from
N-[6-chloro-4-(4-fluoro-2-methyl-phen-
yl)-pyridin-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide
as a colorless oil.
[2705] MS m/e (%): 529 (M+H.sup.+, 100).
[2706] b)
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-pheny-
l)-6-(2-hydroxy-ethylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2707] The title compound was obtained in an analogous manner to
that described in example 1b) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chl-
oro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and ethanolamine as a white foam.
[2708] MS m/e (%): 554 (M+H.sup.+, 100).
EXAMPLE 409
(S)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(-
2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2709] The title compound was obtained in an analogous manner to
that described in example 2) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chlo-
ro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and L-prolinol as a light brown foam.
[2710] MS m/e (%): 594 (M+H.sup.+, 100).
EXAMPLE 410
(2S,4R)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-hyd-
roxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2711]
a)2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-chloro-4-(2-chloro-phenyl-
)-pyridin-3-yl]-N-methyl-isobutyramide
[2712] The title compound was obtained in an analogous manner to
that described in example 406a), b) from
N-[6-chloro-4-(2-chloro-phenyl)-pyrid-
in-3-yl]-2-(3,5-dimethoxy-phenyl)-N-methyl-isobutyramide as a
colorless oil.
[2713] MS m/e (%): 531 (M+H.sup.+, 100).
[2714] b)
(2S,4R)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl-
)-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-iso-
butyramide
[2715] The title compound was obtained in an analogous manner to
that described in example 3) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chlo-
ro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[2716] MS m/e (%): 612 (M+H.sup.+, 100).
EXAMPLE 411
(S)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-
methyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2717] The title compound was obtained in an analogous manner to
that described in example 2) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chlo-
ro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and
L-prolinol as a white foam.
[2718] MS m/e (%): 596 (M+H.sup.+, 100).
EXAMPLE 412
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(2-hydroxy-eth-
ylamino)-pyridin-3-yl]-N-methyl-isobutyramide
[2719] The title compound was obtained in an analogous manner to
that described in example 1b) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chl-
oro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and
ethanolamine as a white foam.
[2720] MS m/e (%): 556 (M+H.sup.+, 100).
EXAMPLE 413
(2S,4R)-2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-
-6-(4-hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-isob-
utyramide
[2721] The title compound was obtained in an analogous manner to
that described in example 3) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chlo-
ro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and (2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a light yellow
foam.
[2722] MS m/e (%): 610 (M+H.sup.+, 100).
EXAMPLE 414
(2S,4R)-N-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tolyl-pyridin-
-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
[2723] a)
N-(6-Chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-2-(3-trifluorometho-
xy-phenyl)-isobutyramide
[2724] The title compound was obtained in an analogous manner to
that described in example 1a) from
(6-chloro-4-o-tolyl-pyridin-3-yl)-methyl-am- ine and
2-methyl-2-(3-trifluoromethoxy-phenyl)-propionyl chloride
(Intermediate 5I) as a light yellow oil.
[2725] MS m/e (%): 462 (M.sup.+, 8).
[2726] b)
(2S,4R)-N-[6-(4-Hydroxy-2-hydroxymethyl-pyrrolidin-1-yl)-4-o-tol-
yl-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide
[2727] The title compound was obtained in an analogous manner to
that described in example 3) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-
-2-(3-trifluoromethoxy-phenyl)-isobutyramide and
(2S,4R)-4-hydroxy-2-hydro- xymethyl-pyrrolidine as a white
foam.
[2728] MS m/e (%): 544 (M+H.sup.+, 100).
EXAMPLE 415
(2S,4R)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxymethyl-pyrro-
lidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyra-
mide
[2729] a)
N-[6-Chloro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl--
2-(3-trifluoromethoxy-phenyl)-isobutyramide
[2730] The title compound was obtained in an analogous manner to
that described in example 1a) from
[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyri- din-3-yl]-methyl-amine
and 2-methyl-2-(3-trifluoromethoxy-phenyl)-propiony- l chloride
(Intermediate 5I) as white solid.
[2731] MS m/e (%): 481 (M+H.sup.+, 100).
[2732] b)
(2S,4R)-N-[4-(4-Fluoro-2-methyl-phenyl)-6-(4-hydroxy-2-hydroxyme-
thyl-pyrrolidin-1-yl)-pyridin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-
-isobutyramide
[2733] The title compound was obtained in an analogous manner to
that described in example 3) from
N-[6-chloro-4-(4-fluoro-2-methyl-phenyl)-pyr-
idin-3-yl]-N-methyl-2-(3-trifluoromethoxy-phenyl)-isobutyramide and
(2S,4R)-4-hydroxy-2-hydroxymethyl-pyrrolidine as a white foam.
[2734] MS m/e (%): 562 (M+H.sup.+, 100).
EXAMPLE 416
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-piperazin-1-yl-
-pyridin-3-yl]-N-methyl-isobutyramide
[2735] The title compound was obtained in an analogous manner to
that described in example 2) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chlo-
ro-4-(2-chloro-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide and
piperazine instead of L-prolinol as a light yellow foam.
[2736] MS m/e (%): 581 (M+H.sup.+, 100).
EXAMPLE 417
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-piper-
azin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide
[2737] The title compound was obtained in an analogous manner to
that described in example 2) from
2-(3,5-bis-difluoromethoxy-phenyl)-N-[6-chlo-
ro-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide
and piperazine instead of L-prolinol as an off-white foam.
[2738] MS m/e (%): 579 (M+H.sup.+, 100).
EXAMPLE 418
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-(4-methanesulf-
onyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2739] The title compound was obtained as a white foam in 84% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
(Example 362 b)) using
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(2-chloro-phenyl)-6-
-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-
-pyridin-3-yl)-isobutyramide.
[2740] MS m/e (%): 659 (M+H.sup.+, 100)
EXAMPLE 419
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl-phenyl)-6-(4-me-
thanesulfonyl-piperazin-1-yl)-pyridin-3-yl]-N-methyl-isobutyramide
[2741] The title compound was obtained as a white foam in 88% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
(Example 362 b)) using
2-(3,5-bis-difluoromethoxy-phenyl)-N-[4-(4-fluoro-2-methyl--
phenyl)-6-piperazin-1-yl-pyridin-3-yl]-N-methyl-isobutyramide
instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-
-pyridin-3-yl)-isobutyramide.
[2742] MS m/e (%): 657 (M+H.sup.+, 100)
EXAMPLE 420
2-(3,5-Bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl--
pyridin-3-yl)-isobutyramide
[2743] The title compound was obtained in an analogous manner to
that described in example 2) from
N-(6-chloro-4-o-tolyl-pyridin-3-yl)-N-methyl-
-2-(3-trifluoromethoxy-phenyl)-isobutyramide and piperazine instead
of L-prolinol as a light yellow foam.
[2744] MS m/e (%): 561 (M+H.sup.+, 100).
EXAMPLE 421
2-(3,5-Bis-difluoromethoxy-phenyl)-N-[6-(4-methanesulfonyl-piperazin-1-yl)-
-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
[2745] The title compound was obtained as a white foam in 61% yield
after flash chromatography according to the procedure described
above for the preparation of
2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(4-methanesulfonyl-
-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide
(Example 362 b)) using
2-(3,5-bis-difluoromethoxy-phenyl)-N-methyl-N-(6-piperazin--
1-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide instead of
2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-piperazin-1-yl-4-o-tolyl-
-pyridin-3-yl)-isobutyramide.
[2746] MS m/e (%): 639 (M+H.sup.+, 100)
EXAMPLE A
[2747] Tablets of the following composition are manufactured in the
usual manner:
3 mg/tablet Active substance 5 Lactose 45 Corn starch 15
Microcrystalline cellulose 34 Magnesium stearate 1 Tablet weight
100
EXAMPLE B
[2748] Capsules of the following composition are manufactured:
4 mg/capsule Active substance 10 Lactose 155 Corn starch 30 Talc 5
Capsule fill weight 200
[2749] The active substance, lactose and corn starch are firstly
mixed in a mixer and then in a comminuting machine. The mixture is
returned to the mixer, the talc is added thereto and mixed
thoroughly. The mixture is filled by machine into hard gelatine
capsules.
EXAMPLE C
[2750] Suppositories of the following composition are
manufactured:
5 mg/supp. Active substance 15 Suppository mass 1285 Total 1300
[2751] The suppository mass is melted in a glass or steel vessel,
mixed thoroughly and cooled to 45.degree. C. Thereupon, the finely
powdered active substance is added thereto and stirred until it has
dispersed completely. The mixture is poured into suppository moulds
of suitable size, left to cool, the suppositories are then removed
from the moulds and packed individually in wax paper or metal
foil.
* * * * *